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Abstract 
Leishmaniasis is a parasitic vector-borne disease caused by the Leishmania 
parasite, which resides in female sandflies. African sleeping sickness or African 
trypanosomiasis is also a parasitic disease but it is spread by the tsetse fly 
(Glossina species). Chagas disease or American trypanosomiasis is a tropical 
disease caused by Trypanosoma cruzi and spread by insects called kissing bugs, 
Triatominae. Drug resistance has been one of the most important obstacles to 
the treatment of leishmaniasis and trypanosomiasis. For example, there has 
been evidence of resistance to melarsoprol and pentamidine for gHAT, and 
eflornithine for late stage HAT particularly in the T. b. rhodesiense, and 
pentavalent antimonials for leishmaniasis. This has limited the treatment 
options for these diseases. This has limited the treatment options for these 
diseases. Recent evidence has shown that pyrimidine metabolism is an excellent 
anti-protozoan drug development target, with multiple enzymes that are 
genetically essential. Pyrimidine nucleobase and nucleoside analogues have 
shown promising activity against Leishmania and Trypanosoma spp. Drugs like 5-
fluorouracil and 5-fluoro-2’deoxyuridine are rapidly metabolized by the parasites 
into metabolic intermediates such as 5F-UDP-glucose, 5F-2’dUMP, 5F-UDP-
galactose and 5F-UDP-N-acetylglucosamine, and incorporated into RNA. 
Pyrimidine analogue 5-FU was found to be a good inhibitor of high-affinity uracil 
transporters in T. b. brucei (TbU1 and TbU3) and Leishmania (LmajU1 and 
LmexU1). 
Although the transporters for therapeutically active nucleobase allopurinol and 
antiparasitic nucleoside analogues have been identified, the transporter for 5-FU 
is still unknown. However, following the exclusion method, it is concluded that 
the 5-FU transporter is not an ENT transporter in Trypanosoma and Leishmania 
spps as their ENT transporters have all been cloned and characterised. Hence, 
our main interest is identifying the transporter gene (family) of kinetoplastids 
for pyrimidine nucleobases, using the antimetabolite 5-FU as a probe. It is 
expected that the 5-FU transporter is not of a gene family that has been 
previously associated with that activity. Resistance to 5-FU was generated in 
both T. b. brucei s427-wild type BSF and L. mexicana promastigotes, producing 
clonal lines Tbb-5FURes and Lmex-5FURes, respectively. RNA-seq and RIT-seq 
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analyses of 5-FU resistant cell lines have identified candidate genes for 
pyrimidine transporters, including genes annotated as cation transporters (Tbb-
CAT1-4), fatty acid desaturase (Tbb-FAD and Lmex-FAD) and glucose 
transporters. Apart from some of the glucose transporters, none of these 
potential transport genes have been previously characterised in protozoa and as 
such they are of interest in their own right as well. 
Using the Alamar blue assay, the sensitivity to 5-FU in a single knockout of Tbb-
CAT1-4 genes in T. b. brucei s427 WT cells was determined, and found to have 
no significant difference. Also, the results showed that [3H]-uracil uptake in T. 
b. brucei s427 WT + Tbb-CAT1-4+/- was almost the same as in wild type cells. 
Further, according to our results, the overexpression of Lmex-FAD gene in Lmex-
5FURes and Tbb-FAD gene in Tbb-5FURes did not cause increased sensitivity to 5-
FU in vitro, and similarly, did not change the rate of transport of [3H]-uracil. 
Following a full knockout of glucose transporter genes, their sensitivity to 5-FU 
was determined, revealing a significantly reduced sensitivity of the LmexGT1-3 
double knockout genes in L. mexicana to 5-FU, in comparison to the wild type 
cell lines. Our results also revealed that the Lmex-GT1-3 KO cells do not 
accumulate 5-FU and uracil. In the re-expression of single LmexGT in Lmex-GT1-
3 KO cells, the sensitivity to 5-FU increased significantly, but not quite back to 
the level of wild-type cells. After the introduction of the glucose transporter 
genes, all the three genes did appear to have a very similar ability of functioning 
with regards to the (regulation of) uptake of 5-FU and uracil, restoring uptake to 
~50% of 5-FU and ~30% of uracil uptake of wild type, respectively. It was also 
discovered that 5-FU and uracil did not have any measurable effects on the 
transport of glucose by LmexGT1, LmexGT2 and LmexGT3, an indication that 
none of them inhibits the transport of 0.1 μM of [3H]-2-deoxy-D-glucose up to 2.5 
mM and therefore, the GTs are not themselves transporting uracil. 
We successfully expressed and characterized the FurD transporter in the 5-FU 
resistant cell lines (Tbb-5FURes and Lmex-5FURes) in order to investigate 
whether the sensitivity to 5-FU in vitro resistant strains could be restored by the 
introduction of a confirmed uracil/5-FU transporter. This would allow a 
functional screening of potential transporter genes. However, we found that the 
EC50 values of 5-FU of the 5-FU resistant cell lines and the FurD-expressing cell 
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lines were not significantly different, although the expression of FurD in Lmex-
5FURes induced a very high level of [3H]-uracil/5-FU uptake, even much above 
the wild type activity. We also characterised the transport activity of FurD in 
Lmex-5FURes promastigotes, and found FurD to be a highly selective and high-
affinity transporter for uracil with Km of 0.97 ± 0.17 μM. Interestingly, our results 
confirmed that the anticancer drug 5-FU was as good a substrate as uracil for 
FurD in Lmex-5FURes, with a Ki of 0.76 ± 0.25 μM. 
Using a targeted CRISPR-Cas9 gene knockout strategy, we show that deletion of 
the LmexNT1 locus in L. mexicana-Cas9 promastigotes completely abolished 
adenosine and thymidine uptake. Moreover, it became highly resistant to 
tubercidin (and its analogues) and to 5-fluoro-2’-deoxyuridine. We also tested 
the possibility of using L. mexicana-Cas9ΔNT1 promastigotes as a surrogate system 
for the expression of TcrNT2 and TcrNB2 transporters of T. cruzi. We found 
TcrNT2 to be a high-affinity thymidine transporter with a Km 0.156 ± 0.017 μM, 
while TcrNB2 could not be characterised despite our efforts.  
To conclude, the results obtained in this study provide significant contributions 
to the identification of the pyrimidine transporter genes. The results also 
increase our understanding of the cytotoxic activity of 5-FU in kinetoplastid 
parasites, gaining insight into the complex pyrimidine metabolism that occurs in 
these parasites. In addition, the study shows that pyrimidine transport 
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1 General Introduction 
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Kinetoplastida is a widespread order of flagellated protozoan pathogens and the 
defining feature of these parasites is the presence of a large mitochondrial DNA 
region known as the kinetoplast (Stuart et al., 2008). Members of this order have 
the potential to parasitise virtually every animal group as well as several plant 
groups (Maslov et al., 2001). The taxonomic hierarchy of Kinetoplastida is: 
Phylum Euglenozoa, order Kinetoplastida, suborder Trypanosomatina and family 
Trypanosomatidae. The order Kinetoplastida may be biflagellate Bodonidae or 
uniflagellate Trypanosomatidina. Bodonidae includes free living species whilst 
the latter are extremely parasitic. Trypanosomatidae family consists of parasitic 
flagellated protozoans which have the potential to cause pathologies in both 
humans and animals. The most important genus of the Trypanosomatidae family 
are Trypanosoma and Leishmania. The most important species of these two 
genera are Trypanosoma brucei, Trypanosoma cruzi, Trypanosoma congolense, 
Leishmania mexicana, Leishmania major, Leishmania donovani and Leishmania 
infantum (Figure 1.1) (Lukeš et al., 2014; Maslov et al., 2001; Maslov et al., 
2013; Dolezel et al., 2000). Some kinetoplastida can cause common parasitic 
diseases in humans. These include Trypanosoma brucei which causes sleeping 
sickness (or Human African trypanosomiasis, HAT), Trypanosoma cruzi which 
causes Chagas’ disease (or American trypanosomiasis), and Leishmania spp. 
which causes leishmaniasis. These all have a major global impact on health 
(Maslov et al., 2001; Barrett and Croft, 2012). 
 
Figure 1.1: Classification of the kinetoplastids. 
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 Leishmania and leishmaniasis 
The protozoan parasites belonging to genus Leishmania cause infections that 
lead to a group of diseases known as leishmaniasis. More than 90 species of 
female phlebotomine sandflies (the genus of Phlebotomus in the old world and 
Lutzomyia in the new world) bites transmit the leishmaniasis infection (Desjeux, 
1996; Boelaert and Sundar, 2014; W.H.O., 2020c). Charles Donovan and William 
Leishman in 1903 independently described the Leishmania parasites. However, 
they had previously been observed by Peter Borovosky in 1898 and David D. 
Cuningham in 1885. It was easy to mistake these parasites for other protozoa, 
but James Wright proposed Leishmania in 1903 (Vannier-Santos et al., 2002). 
Leishmania species are digenetic parasitic protozoans belonging to the order 
Kinetoplastida and the family Trypanosomatidae (Van der Auwera and Dujardin, 
2015). There are two subgenera of the genus Leishmania, Leishmania and 
Viannia based on how they are developed in the sandfly vector. A number of 
factors determine how the subgenera are specified like the geographical 
distribution, clinical presentation and the epidemiology of the animal reservoir 
and the vector (Marfurt et al., 2003; Leprohon et al., 2015). According to the 
World Health Organization (WHO), one of the most Neglected Tropical Diseases 
(NTD) is human leishmaniasis, caused by twenty species of the obligate 
intracellular protozoan Leishmania (W.H.O., 2020c). 
 Morphology and life cycle 
Morphology of protozoan parasites like Leishmania are often directly connected 
to the pathogenicity and evolutionary pressures that establish, maintain and 
transmit an infection within the host organism (Lipa, 2012). It has crosslinked 
sub pellicular microtubules with a single copy of each organelle like 
mitochondrion and Golgi apparatus. The kinetoplast or mitochondrial DNA is 
directly associated with the basal body from which the flagellum arises (Neto et 
al., 2011). Leishmania exists in two basic body forms: promastigote form 
(infective stage) and amastigote form (vertebrate tissue stage) (Figure 1.2). 
Promastigotes are extracellular forms in the sandfly vector, elongated and 
motile, with dimensions ranging from 15 to 20 μm in length and 1.5 to 3.5 μm in 
width. The kinetoplast is elongated and perpendicular to the nucleus. In 
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contrast, amastigotes are intracellular forms in the vertebrate host, oval or 
rounded shape, no free flagellum, with dimensions ranging from 2.5 to 6.5 μm in 
length and 1.5 to 3 μm in width (Ambit et al., 2011; Rodriguez et al., 2018; 
Akpunarlieva and Burchmore, 2017). 
 
Figure 1.2: Schematic representation of promastigotes (left) and amastigotes (right) of 
Leishmania parasites (Besteiro et al., 2007). 
Leishmania parasite undergo a complex life cycle which includes being hosted by 
both vertebrates and invertebrates in addition to two developmental stages 
which are: promastigotes, this is the proliferative type present in the lumen of 
the sandfly, and amastigotes which represent the proliferative form present in a 
number of mammalian host cells (Teixeira et al., 2013). The bite of an infected 
female phlebotomine sandfly on the skin of a mammalian host is where the 
lifecycle of leishmania transmits infective metacyclic promastigote forms. 
Phagocytes are mostly macrophages and some mononuclear phagocytic cells. 
The differentiation process (amastigogenesis) of the parasite happens inside the 
host cell. This leads to the emergence and multiplication of rounded amastigotes 
inside a parasitophorous vacuole (PV) which may continue to infect other 
phagocytic cells even after death of the host cell. The blood meal of the sandfly 
is when the amastigotes are ingested and changed in its midgut to procyclic 
promastigotes that multiply through binary fission. There is then migration of 
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procyclic-derived forms towards the anterior midgut where they differentiate to 
metacyclic forms (metacyclogenesis), which then has capacity to infect another 
mammalian host (Figure 1.3) (Bates, 2007; De Pablos et al., 2016). 
 
Figure 1.3: Life cycle of Leishmania parasites. Image taken from . 
 Geographical distribution 
Leishmaniasis is a vector-borne disease caused by the parasite Leishmania, 
which lives in a variety of sand fly species. This insect is most active in warm 
and humid environments. Thus, the parasite is found in tropical and subtropical 
regions such as the rainforests of Central and South America, some parts of 
Mexico, the Mediterranean basin, deserts of Western Asia and the Middle East 
(Pratlong et al., 2009). Though environment and climate are one of the 
determining factors of spreading of the disease, according to WHO, poverty also 
heavily influences the spreading of leishmaniasis. In addition to poverty, socio-
economic factors like malnutrition, lack of financial resources, famine, 
migration of people in large numbers caused by urbanisation, emergency 
situations such as war, etc. influence the disease’s epidemiology (Peterson and 
Shaw, 2003; W.H.O., 2020b). Thus, leishmaniasis is found in the countries where 
the above-mentioned conditions are common. WHO classifies leishmaniasis as an 
NTD, and out of the 200 countries and territories that report to WHO, 98 
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countries and territories are endemic for this disease and over 350 million 
people are at the risk of getting infected with the disease. In 2014, over 90 
percent of all cases that were reported to WHO, were from six countries: Brazil, 
Ethiopia, India, Somalia, South Sudan and Sudan. This disease is found in people 
of almost every continent in the world except Australia and Antarctica. 
Cutaneous leishmaniasis occurs mostly in Afghanistan, Brazil, Iran, Peru and 
Saudi Arabia (90 percent of total cases) (Figure 1.4B)   (W.H.O., 2020b; Tiuman 
et al., 2011). The muco-cutaneous form occurs in Brazil, Bolivia and Peru, which 
account for more than 90 percent of the total cases. India, Bangladesh, Brazil, 
Nepal and Sudan account for 90 percent of global incidence of visceral 
leishmaniasis (Figure 1.4A). Leishmaniasis is predominantly found in developing 
countries rather than in developed countries and is more likely to occur in rural 
areas than in urban areas but can be found in the outskirts of some cities 
(Chakravarty and Sundar, 2010). 
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Figure 1.4: Worldwide geographic distribution of leishmaniasis. A) Visceral leishmaniasis 
and B) Cutaneous leishmaniasis (Image taken from (W.H.O., 2020b). 
 The genome 
 L. major, L. infantum and L. donovani have their genetic information in 36 
chromosomes (Figure 1.5). However, L. mexicana has 34 chromosomes while L. 
braziliensis possesses 35 chromosomes. Leishmania species have unique gene 
distributions as a consequence of chromosome fusion events. Leishmania 
commonly have genetic variation resulting from single gene expansion during 
multi-copy array or whole genome replication (Llanes et al., 2015; Fiebig et al., 
2015; Rogers et al., 2011; Real et al., 2013). A study from Zhang et al. (2008b) 
demonstrated that the genetic variation and their expression levels affects the 
virulence and tissue tropism of the organism. The structure of the chromosome 
is similar to that of other pathogenic protozoa. It has a central conserved core 
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with a single or low copy number sequences and extensive repeated telomeric 
and sub-telomeric sequences. The sizes of telomeric and sub-telomeric 
sequences are highly diverse even among the homologous chromosomes which 
make every other isolate of Leishmania distinct from each other. The 36 
chromosomes contain 32,816,678 bp of DNA. 8272 genes within the genome code 
for proteins, 911 for RNA and 39 genes are pseudo genes (Llanes et al., 2015; 
Real et al., 2013). Apart from the nuclear chromosomes the independently 
replicating mitochondrial genome is present within the kinetoplast. . In 1998, 
RNA interference (RNAi) was discovered and accepted as a critical element of 
studying the functions of genes and anatomise the biological processes of 
organisms that carry them (Fire et al., 1998). From the discovery, T. brucei was 
identified as the first protozoan parasite to have a functional RNAi system  
(Oberholzer et al., 2007). Nonetheless, T. cruzi and most Leishmania species do 
not have the RNAi pathway (Peacock et al., 2007; Downing et al., 2011; Fire et 
al., 1998). 
 
Figure 1.5: The genomic distribution of 36 chromosomes that have been assembly from L. 
donovani (Lypaczewski et al., 2018). 
 Pathology and clinical manifestation 
The leishmaniases are known to affect the poorest people and are commonly 
linked with lack of financial resources, weak immune system, poor housing, 
population displacement and malnutrition. There are approximately 700,000 to 1 
million new cases every year in addition to around 20,000 to 30,000 death occur 
annually (W.H.O., 2020c). Amastigotes are the obligate intracellular stage of the 
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parasites inside macrophages and they multiply and survive within a 
compartment known as the phagolysosome. Human leishmaniasis exists in three 
main forms (Reithinger et al., 2007). 
 Visceral leishmaniasis 
Visceral leishmaniasis (VL), also known as kala azar, is the most deadly form of 
leishmaniasis (Elarabi et al., 2020). Visceral leishmaniasis is caused by two 
Leishmania species, L. infantum and L. donovani, based on the respective 
geographical region. Children and immunosuppressed individuals are the ones 
mostly affected by L. infantum whereas L. donovani can infect any age group. 
VL has an incubation period of between 2 and 6 months. Symptoms reported by 
visceral leishmaniasis patients include persistent systematic infection (loss of 
appetite, weight loss, weakness, fatigue and fever), reticulo-endothelial system 
and parasitic invasion of the blood which causes enlargement of lymph nodes, 
liver and spleen (Chappuis et al., 2007; Desjeux, 2004). This parasitic disease 
has attracted increased attention with the emergence of Leishmania/HIV co-
infection in many areas of the world (Vannier-Santos et al., 2002). The potential 
origin of the rise of anti-leishmanial drug resistance is the HIV/VL co-infected 
patients. The reason is these patients have a weak immune response and high 
parasite burden, making it hard to clear the infection with standard drug 
dosages. In addition, it can be fatal if there is delayed diagnosis of visceral 
leishmaniasis (Singh, 2014). 
 Cutaneous leishmaniasis 
Cutaneous leishmaniasis (CL) is the most common form of the disease. Cutaneous 
leishmaniasis is common in more than seventy countries in the world (Desjeux, 
2004). Multiple species of Leishmania produce cutaneous leishmaniasis in adults 
and children such as L. tropica, L. major and L. (L) aethiopica (Old World); L. 
chagasi and L. infantum (Mediterranean and Caspian Sea Regions); and L. (V) 
guyanensis, L. (V) peruviana, L. (V) panamensis, L. braziliensis, L. (L) 
amazonenesis and L. mexicana (New World). The sandfly bite is where the 
papule begins; it then grows to a nodule and ulcerates for almost 3 months 
(Dowlati, 1996; Magill, 2005). Cutaneous leishmaniasis patients often have more 
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than one lesion on the skin, usually without fever. L. major infections are 
characterized by superficial satellite papules found in the periphery of the main 
lesion, usually healing after 4 - 6 months in an estimated 50 - 70% of the cases. 
L. tropica is characterised by the dry form of its ulcers on the skin which take a 
year or longer to heal. HIV-linked cutaneous leishmaniasis is not that common, 
but prevalence might increase in the future (Wajihullah and Zakai, 2014; 
Couppie et al., 2004; Romero et al., 2005). 
 Mucocutaneous leishmaniasis 
Mucocutaneous leishmaniasis (MCL) is most common in the new world relative to 
the old world. Most 90% cases of mucocutaneous leishmaniasis are reported in 
Peru, Brazil and Bolivia. Mucocutaneous leishmaniasis is referred to as espundia 
in Latin America and is as a result of several Viannia Leishmania subgenera such 
as panamensis, braziliensis and sometimes (but rare) guyanensis and 
amazonensis. Most cases of mucocutaneous leishmaniasis are attributed to L. 
braziliensis (Chappuis et al., 2007; Chakravarty and Sundar, 2010; Crovetto-
Martínez et al., 2015). Mucocutaneous leishmaniasis is not that common in the 
old world. It is caused by L. tropica, L. major and L. infantum, which normally 
affects immunosuppressed patients and older adults. Mucocutaneous 
leishmaniasis causes patients to go through progressive destructive ulcerations of 
the mucosa which extends from the nose, mouth to the pharynx and larynx. The 
lesions do not heal on their own and can remain for months or years after 
colonization of the macrophages of the naso-oropharyngeal mucosa. The 
metastatic spread is not common and is vulnerable to parasitic factors, 
geographic factors and the immune status of the host (Chappuis et al., 2007; 
Crovetto-Martínez et al., 2015). 
 Diagnosis 
Several laboratory methods are used to diagnose leishmaniasis to detect the 
parasite and identify its species. The diagnosis of the visceral form is done by 
performing a physical examination to look for enlarged spleen or liver followed 
by a bone marrow biopsy or blood sample examination. Also, visceral 
leishmaniasis is diagnosed through PCR to detect the parasite DNA in the blood, 
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which is highly specific and sensitive. Serological testing can provide supportive 
evidence for the diagnosis (Chakravarty and Sundar, 2010; Handler et al., 2015; 
Reithinger et al., 2007). For diagnosis of cutaneous leishmaniasis, skin biopsy is 
done from the lesion area to look for the DNA of the parasite (Sundar and Rai, 
2002). Diagnosis is based on the production of antibodies by cutaneous 
leishmaniasis patients against Leishmania antigens that are detected though 
normal serologic approaches like the immunoenzymatic assay (ELISA) and the 
indirect immunofluorescent assay (IFA) (Couppie et al., 2004; Romero et al., 
2005). A variety of specialised tests that are available only in reference 
laboratories, are also performed. It is necessary to mention here that since the 
manifestations take years in some cases, the condition becomes hard to 
diagnose. In such cases, a history of living or travelling to an area where 
leishmaniasis is highly endemic is helpful for the diagnosis. 
 Treatment and control of leishmaniases 
The approach to treatment of leishmaniasis partly depends on the host and 
parasite species and partly on the geographical region. Some treatment 
approaches are effective against a particular species of Leishmania in a 
particular geographical region. In fact, the data from a well-conducted clinical 
trial in a particular setting cannot always be generalised to other settings. All 
cases of visceral and muco-cutaneous leishmaniasis require treatment, however 
not all cases of the cutaneous form require treatment (Khare et al., 2016). 
Antileishmanial effects have been established for approximately 25 compounds; 
however only a few of them are used as antileishmanial drugs for humans and 
these are mostly parenteral. Urea-stibamine was the initial effective drug, which 
was discovered in 1912. Brahmchari of India first reported it as effective against 
L. donovani in 1922. Millions of poor lives in India were saved by this discovery 
which led to the nomination of Prof Brahmchari for a Nobel Prize in 1929 (Singh 
and Sivakumar, 2004; Papadopoulou et al., 1998). 
Anti-parasitic drugs such as pentavalent antimonials (sodium stibogluconate and 
meglumine antimonate), amphotericin B, paromomycin, pentamidine, 
miltefosine, and orally administered ‘azoles’ (ketoconazole, itraconazole, and 
fluconazole) are effective for the treatment of all three clinical forms of 
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leishmaniasis (Khare et al., 2016). In some settings, local therapies such as 
cryotherapy, thermotherapy, intralesional administration of Sbv, and topical 
application of particular paromomycin formulations are used as effective 
treatment approaches. Different medications and dosages may be needed for 
young children, pregnant or lactating women, elderly persons, and persons who 
have a compromised immune system or other co-morbidities. There is no 
available vaccine or prophylactic medication to prevent the disease. The best 
way of prevention is to protect oneself from sand fly bites. Protective measures 
include wearing clothes that cover as much skin as possible, application of insect 
repellent on exposed skin, spraying of insecticides, reducing nocturnal activities 
and the use of bed nets tucked into the mattress (Kobets et al., 2012). In 
general, the preventive measures must be tailored to the geographical area one 
lives in and, though difficult, must be sustained for the effective control of 
leishmaniasis (Otranto and Dantas-Torres, 2013). 
 Pentavalent antimonials 
Pentavalent antimonials (SbVs) are a group of compounds used extensively for 
more than 50 years as a treatment for parasitic leishmaniasis. Although they are 
still the first line of drugs often used for the disease their use is becoming highly 
reduced due to adverse side effects, drug resistance and a need for daily 
parenteral administration (Lawn et al., 2003). The gradual development and 
improvement of SbVs has decreased its side effects hence being a major 
component of the anti-leishmaniasis drugs. The most common organic 
compounds of SbVs used are pentostam or sodium antimony gluconate (SAG) and 
glucantime or meglumine antimoniate (MG) (Chakravarty and Sundar, 2010; 
Singh and Sivakumar, 2004). These drugs are available for intravenous or 
intramuscular use only. 100 mg of the active ingredient, pentavalent antimony, 
is present in 1 mL of sodium stibogluconate and 85 mg is found in meglumine 
antimoniate. The half-lives of the two variants differ hugely, the first having a 
half-life of just about 2 h and the second having a half-life of about 33 h 
(Vouldoukis et al., 2006). 
The mechanism of action of pentavalent antimonials is still highly debated. 
Some studies claim that the drug initially acts as a prodrug and the more active 
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as well as more toxic trivalent form acts as the active ingredient against 
leishmaniasis. Hence, there are several proposed models for the mechanism of 
action of pentavalent antimonials. The first model suggests that the pentavalent 
antimonials are converted into trivalent animonials by the action of various 
thiols like cysteine and cysteinyl-glycine that are predominant in lysosomes, 
glutathione in cytosol and trypanothione in parasites (Frézard and Demicheli, 
2010). The trivalent compounds are the active ingredient. The second model 
proposes that sodium stibogluconate inhibits the DNA unwinding enzyme DNA 
Topoisomerase I (TOPI). TOPI plays a crucial role in the maintenance aspect 
during the replication of DNA. Another model proposes that the drug acts by 
activating the host’s innate and adaptive immune system, which also protects 
the host from future infections (Walker and Saravia, 2004; Oliveira et al., 2012). 
Also, the distinct thiol metabolism of Leishmania is believed to be essential in 
the mechanism action of SbV drugs (Chakravarty and Sundar, 2010). 
Several side effects of the drug have been identified including headache, 
abdominal pain, anaemia, cardiotoxicity and reversible kidney failure. In the 
history of use of the drug, little of clinical resistance was observed. However, 
clinical resistance has been a threat during the past 15 years, yet it remains the 
primary choice of treatment in most parts of the world (Basu et al., 2005). L. 
donovani remains the only species identified as being drug resistant in several 
parts of India. Resistance of the drug in Indian state of Bihar was as a result of 
the high misuse of the drug and trivalent arsenic contamination of the drinking 
water, in addition to leishmaniasis having zoonotic transmission exception in 
East Africa and the Indian subcontinent where the transmission is highly 
anthroponotic (Chakravarty and Sundar, 2010; McConville and Ralph, 2013; Perry 
et al., 2013). Pentavalent antimonial resistance is accompanied by some of 
these common factors (i) aquaglyceroporin 1 (AQP1) (ii) an unknown efflux 
system (iii) thiols and (iv) Multidrug resistance protein A (MRPA) (Singh, 2006; 
Plourde et al., 2015). For instance, Plourde et al. (2015) reported that the 
susceptibility of an L. major promastigote AQP1 null mutant to antimonyl 
tartrate (SbIII) was very significantly reduced (60-fold). 
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 Amphotericin B 
Amphotericin B (AmB) is a polyene antibiotic and antifungal utilised since the 
1960s in the second line treatment for leishmaniasis. This compound performs 
selective actions against fungi in addition to Trypanosoma cruzi and Leishmania. 
The drug is used for various fungal infections like candidiasis, cryptococcosis, 
blastomyosis and most importantly pentavalent antimony-resistant cutaneous 
and visceral leishmaniasis (Kovacic and Cooksy, 2012; Croft et al., 2006). The 
mechanism of action of AmB is not fully understood but AmB has a high affinity 
for ergosterol, the prevalent sterol in many microbes including Leishmania, over 
cholesterol, the prevalent sterol for the mammalian host cells, hence the 
selective action. Amphotericin B causes an increase in membrane permeability 
of leishmanial parasites through interference of sterol metabolism and shifting 
construction of the cell membrane (Croft et al., 2006; Purkait et al., 2012; 
Balaña-Fouce et al., 1998). Excretion of the drug from the body may take up to 
several weeks to months (Kovacic and Cooksy, 2012). 
Many countries have adopted liposomal AmB (Ambisome) as the standard 
treatment however it is still expensive for single-course treatments and needs 
intravenous administration (Leprohon et al., 2015). Adverse side effects of the 
drug include fever, weight loss, hypotension, nausea, diarrhoea, anaemia and 
localised pain with or without phlebitis (Purkait et al., 2012). Clinical resistance 
to amphotericin B is not common; however shifting of the plasma membrane 
sterol profile may lead to substantial drug resistance for AmB, particularly in L. 
infantum/HIV co-infected individuals (Leprohon et al., 2015; Chakravarty and 
Sundar, 2010). Studies performed recently by Mwenechanya et al. (2017) explain 
how a single mutation, changing an  amino acid from asparagine to isoleucine 
(N176I) in Sterol 14α-demethylase, results in resistance to amphotericin B in L. 
mexicana promastigotes. 
 Miltefosine 
Hexadecyl phosphocholine, the chemical name of miltefosine (MLF), was 
originally intended to be used as an antitumor drug. The antileishmanial 
potential of the drug was discovered in the 1980s and it was the first oral 
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antileishmanial drug available for treatment (Vélez et al., 2010). With other 
drugs such as pentavalent antimonials and amphotericin B having various 
disadvantages such as reduced and variable efficacy, adverse side effects and 
parenteral administration, miltefosine is becoming the first choice of drug for 
effective treatment of leishmaniasis (Vélez et al., 2010). The actual 
antileishmanial mode of action of MLF has not been revealed yet. In 
Kinetoplastid parasites, miltefosine is shown to act via inhibition of lipid 
biosynthesis. Biosynthesis of Phospatidylcholine, one of the structural 
components of the plasma membrane is found to be inhibited in the parasites by 
the drug which is much higher potency than that of in mammalian cells; thus 
explaining the high level of specificity of the of miltefosine as an antiparasitic 
drug (Canuto et al., 2014). The major step of its action may be linked with its 
intracellular accumulation. The following steps are included in its intracellular 
accumulation; connection to plasma membrane, internalization in the parasite 
cell (two proteins, the beta subunit LdRos3 and the L. donovani miltefosine 
transporter ‘LdMT’), in addition to intracellular targeting and metabolism 
(Chakravarty and Sundar, 2010; Maltezou, 2009). 
Adverse effects associated with miltefosine includes vomiting, diarrhoea and 
ocular side-effects (Singh, 2006). Although the drug has showed a high cure rate 
in visceral leishmaniasis, some cases of resistance have been reported in various 
parts of the world, primarily in India. The main reason behind the drug 
resistance has been proposed to be the very long period of treatment and a long 
half-life of the drug in humans. Although the exact mechanism of resistance 
remains to be discovered, the role of integral membrane proteins that are 
responsible for the uptake of the drug have been indicated (Srivastava et al., 
2017). 
 Paromomycin 
Paromomycin (PRM) is an aminoglycoside aminocyclitol antibiotic that is 
synthesised by Streptomyces riomosus var Paromomycinusand PRM exhibits both 
anti-leishmanial and antibacterial activity (Sundar and Chakravarty, 2013). . This 
drug is used to treat visceral leishmaniasis parenterally, either as a single drug 
or combined with SbV, against cutaneous leishmaniasis it is used either as 
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topical or parenteral formulation (Sundar and Chakravarty, 2013). In India, Phase 
III of clinical trials with PRM proved to be 93-95% efficacy, whereas, in Africa, it 
proved to be 64-85% efficacy with the dose of 15 mg/kg for 21 days; hence this 
drug was considered in 2006 for the treatment of VL in India (Barrett and Croft, 
2012; Altamura et al., 2020). The drug is being marketed as paromomycin 
sulphate capsule with a brand name Humatin. With high efficacy rate, shorter 
duration of administration and limited side effects the drug has the potential to 
be used as the first line of treatment for leishmaniasis (Fernández et al., 2011). 
Studies indicate involvement of the drug in interfering with the translation 
mechanism of the cells. Ribosomal proteins are involved in such mode of action. 
The drug also interferes with membrane fluidity and mitochondrial membrane 
potential establishment, eventually leading to inhibition of respiration 
(Fernández et al., 2011). 
The most prominent adverse effects of the drug include diarrhoea, abdominal 
cramps, nausea, vomiting and heartburn. Prolonged use of the drug may lead to 
fungal or bacterial superinfection. Patients with renal diseases and ulcerative 
bowels are strictly recommended to avoid intake of the drug (Chawla et al., 
2011). The drug has not been widely used and therefore clinical resistance with 
visceral leishmaniasis is still unknown. As is the case for amphotericin B and 
miltefosine, there are geographical variations associated with variable efficacy 
of paromomycin against visceral leishmaniasis. For example, it is seen to be less 
effective in East Africa (such as Sudan), relative to India; the reasons for this 
remain currently unclear (Leprohon et al., 2015). Paromomycin-resistant strains 
of Leishmania show reduced accumulation of the drug within the organism due 
to a significant reduction in the initial binding of the drug (Chawla et al., 2011). 
A recent study by  Bhattacharya et al. (2019) reported a significant reduction in 
PRM sensitivity after the heterozygous knockout of protein kinase CDPK1 in L. 
infantum promastigotes to paromomycin compared to the wild type cells. 
 Pentamidine 
Pentamidine salts represent an antileishmanial drug that was first used for 
patients refractory to pentavalent antimonials (Chakravarty and Sundar, 2010). 
This drug is used for several parasitic and bacterial infections including 
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trypanosomiasis, leishmaniasis, pneumonia and babesiosis for patients with 
compromised immune systems. It is an aromatic diamidine, the active ingredient 
being its isethionate salt, used for prophylaxis. It can be given as injection via 
the veins or into the muscles (Lai A Fat et al., 2002). 99% of the patients were 
cured at first, however its efficacy dropped in the next two decades to curing 
70% of the patients. It stopped being used for visceral leishmaniasis after the 
decrease in its efficacy. It has however been utilised effectively in the 
treatment of new world and old world mucocutaneous leishmaniasis and 
cutaneous leishmaniasis. Fewer injections, based on short periods, leads to 
minimum toxicity and a high cure rate (Chakravarty and Sundar, 2010). 
There is still no clarity to the antileishmanial mechanism of action of 
pentamidine; however, it is thought to include effects on the mitochondrial 
inner membrane and to be a DNA minor groove binding. Also, it is believed to act 
by interfering with DNA replication, RNA transcription and metabolism of 
phospholipids and proteins in the target cell (Lai A Fat et al., 2002; Chakravarty 
and Sundar, 2010). Parenteral administration of the drug is associated with 
adverse side effects; however, they are less severe than pentavalent 
antimonials. Some of the adverse effects involve nephrotoxicity, damage to the 
pancreatic islet cells, anorexia, nausea, cardiac arrhythmias and localised 
necrosis (Hellier et al., 2000). Drug resistant strains of L. donovani and L. 
amazonensis show reduced uptake (18-fold and 75-fold, respectively) of the drug 
which is carrier-mediated and at the same time the efflux rate of the 
accumulated drug is much higher compared to wild type strains (Mukherjee et 
al., 2006; Chakravarty and Sundar, 2010). 
 Drug resistance mechanisms 
Drug resistance hinders the treatment of infections caused by microbes and 
creates a threatening situation for the patient’s health and safety. Several 
therapeutic strategies are facing failure due to the emergence of drug resistant 
microorganisms (Sereno et al., 2019). Drug therapy is unsuccessful and 
insufficient in such circumstances and the disease persists longer (Freitas-Junior 
et al., 2012). Some researches focused on how the most parasites have 
developed resistance to drugs (de Koning, 2008). Irregular and incomplete drug 
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intake often results in resistance to drugs in patients with leishmaniasis. Other 
than explicitly acquired resistance several parasite-associated factors play a 
major role in development of drug resistance. There is currently no vaccine for 
human use of leishmaniasis but there are prospective vaccines in development. 
There are alternative strategies to control drug resistance in leishmaniasis such 
as management of HIV/VL co-infection, monitoring drug resistance, combination 
therapy, free distribution of the drugs and monitoring therapy (Leprohon et al., 
2015; Chakravarty and Sundar, 2010; Croft et al., 2006). 
Drug combination has been used for the treatment of a number of infectious 
diseases (such as tuberculosis, HIV, Human African trypanosomiasis and malaria) 
and is now being considered for treatment of neglected diseases like 
leishmaniasis. There are two major reasons behind the establishment of 
combination therapies: reduction of the length of treatment for improvement of 
compliance (for instance, the miltefosine regimen includes drug intake two 
times a day for 4 weeks) and delaying the emergence of resistance for 
protection of the few available molecules (Leprohon et al., 2015; Chakravarty 
and Sundar, 2010; Croft et al., 2006). Therefore, a combination therapy is 
suggested in order to cope with this phenomenon, which improves the drug 
efficacy, shortens the course of treatment and reduces the resistance. 
Administration of sodium stibogluconate along with paromomycin is reported as 
effective and safe (Cobo, 2014; Croft and Coombs, 2003). 
In the case of pentavalent antimonials the more potent trivalent form is 
produced in the host macrophages and enters the parasite via membrane 
carriers. Gene deletion of such protein carriers is found in the resistant strains 
rendering reduced number of the carrier on the parasite. Over-expression of ATP 
binding cassette transporters, which have a prominent role in efflux of the drug, 
have also being linked to drug resistance (Chakravarty and Sundar, 2010). 
Parasite physiology also can influence resistance by changing macrophage 
biochemistry, leading to increased efflux of the pentavalent form of the drug 
(Croft et al., 2006). Miltefosine-resistant Leishmania promastigotes could be 
created by point mutations in the miltefosine transporter, LdMT, which is 
considered as a drug resistance mechanism that causes a decrease in drug 
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uptake and inhibits miltefosine uptake into the cell. It is indicative of the 
importance and involvement of this transporter in resistance of the Leishmania 
parasite to miltefosine. Another suggested mechanism could be the upregulation 
of ABC transporters and hence,  a rise in drug efflux (Ghorbani and Farhoudi, 
2018; Laffitte et al., 2016). 
 Trypanosomes and trypanosomiasis 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a 
vector-borne parasitic disease and is caused by protozoan parasites of the 
species Trypanosoma brucei (three subspecies: Trypanosoma brucei brucei, 
Trypanosoma brucei gambiense and T. b. rhodesiense). It is transmitted by the 
bite of an infected tsetse fly (Glossina species) that has acquired their infection 
from human beings or animals infected with pathogenic parasites. This disease is 
predominant in some regions of sub-Saharan Africa and only certain species of 
the fly transmits the disease (Aksoy et al., 2017; Mulenga et al., 2019; Wamwiri 
and Changasi, 2016; Hulpia et al., 2020a). According to WHO, about 10000 new 
cases are reported each year however many cases go undiagnosed and 
unreported. Sleeping sickness can be fatal if left untreated and is usually curable 
with medication, especially in the first stage of the disease (W.H.O., 2020d). 
The disease can take two forms depending on the parasite: East African 
trypanosomiasis caused by the parasite T. b. rhodesiense, and West African 
trypanosomiasis caused by T. b. gambiense. West African trypanosomiasis 
accounts for 98 percent of all reported cases and leads to a chronic infection 
whereas East African trypanosomiasis accounts for only 2 percent cases and 
causes an acute infection. The symptoms for the West African trypanosomiasis 
takes months or even years to appear whereas East African trypanosomiasis 
develops rapidly and the symptoms are observed within a few weeks or, at the 
most, months after infection (Maseleno and Hasan, 2012; Mulenga et al., 2019; 
Wamwiri and Changasi, 2016). Both forms of HAT can affect the central nervous 
system and eventually lead to coma and death if left untreated. The rural 
population, who are involved in agriculture, fishing and animal husbandry, are 
most exposed to the tsetse fly and thus to the disease of sleeping sickness 
(Thuita et al., 2008). 
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Another form of the disease, known as Animal African trypanosomiasis (AAT), is 
caused by other species and sub-species of Trypanosoma than those affecting 
human beings. T. b. brucei, T. congolense, T. equiperdum, T. evansi and T. 
vivax, as well as T. b. rhodesiense (which is a zoonosis), are some of the species 
that causes disease in wild and domestic animals (Morrison et al., 2016). This 
acts as a major hindrance to the development of agriculture in Africa. All the 
diseases have different local names such as Nagana, Dourine and Surra, names 
that are mostly associate with disease in cattle, horses and camels, respectively 
(Wamwiri and Changasi, 2016; Büscher et al., 2019). A different form of human 
trypanosomiasis is known as American trypanosomiasis or Chagas’ disease, and 
occurs mainly in rural areas of Latin America where there is widespread poverty. 
The disease was discovered by Brazilian physician Carlos Chagas in 1909 and 
hence the name (Rassi Jr et al., 2010; Pérez-Molina and Molina, 2018). It is 
transmitted by insect vectors called triatomine bugs that are infected with the 
parasite Trypanosoma cruzi. The triatomine bugs live in poor housing conditions 
such as houses made of mud, straw and palm thatch. They are active at night 
and during daytime hide themselves in crevices of walls and roofs. In people who 
have suppressed immune system (e.g. HIV-AIDS) if get infected with Chagas 
disease, the parasites can be reactivated in the circulating blood and this 
reactivation can potentially cause severe disease (Coura and De Castro, 2002; 
Pérez-Molina and Molina, 2018). 
 Morphology and life cycle 
Trypanosomes are polymorphic parasites showing morphological variation under 
different conditions. They are characterised by the presence of a single 
flagellum and the specialised DNA containing Kinetoplast. There are numerous 
circular DNAs, which makes up the mitochondrial genome (kDNA). Trypanosomes 
have thin, flat bodies, tapered at both ends, the pointed end being anterior and 
the blunt end being the posterior end (Figure 1.6). Length varies from 15 to 30 
μm and breadth at the middle is around 2.5 μm (Elias et al., 2007; Wheeler et 
al., 2019). It extends towards the anterior portion of the cell in a left-handed 
helical manner coiled around the cell body. The distal end of the flagellum is 
detached from the cell body, forming an overhang over the anterior portion of 
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the cell. It is involved in ingestion of nutrients from the surroundings (Ooi and 
Bastin, 2013; Kohl et al., 2003). 
 
Figure 1.6: Morphology of Trypanosoma brucei (Grunfelder et al., 2003). 
T. brucei has two hosts, an insect vector (tsetse fly) and a mammalian host 
(human or other mammal). When an uninfected tsetse fly bites an infected 
vertebrate host, it ingests trypomastigotes circulating in the bloodstream 
(Wheeler et al., 2019). The bloodstream trypomastigotes transform into 
procyclic trypomastigotes in the vector’s midgut and then multiply by 
longitudinal binary fission. In the next stage, the procyclic trypomastigotes leave 
the midgut and migrate to the salivary glands of the vector, transforming into 
epimastigotes. Here they multiply for several generations. In the salivary glands, 
epimastigotes transform back into metacyclic trypomastigotes that are the 
infective stage. When the infected tsetse fly bites a human or an animal; it 
injects the metacyclic trypomastigotes into their bloodstream. The metacyclic 
trypomastigotes transform into bloodstream trypomastigotes and are carried to 
various body fluids such as blood, lymph, and in some cases the cerebro-spinal 
fluid (Figure 1.7) (Kennedy, 2004; Tyler and Engman, 2001). Here the 
trypomastigotes continue to replicate by binary fission and continue to 
circulation (Mortara et al., 2008). 
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Figure 1.7: The life cycle of Africa trypanosomes in insect vector and mammalian host 
(Kennedy, 2004). 
 Geographical distribution 
There are two subspecies of T. brucei: T. b. rhodesiense and T. b. gambiense. 
These two subspecies are morphologically undistinguishable but cause distinct 
diseases in humans namely the acute East African trypanosomiasis (rHAT), which 
is caused by T. b. rhodesiense, and the chronic West African trypanosomiasis 
(gHAT) is caused by the parasite T. b. gambiense (Figure 1.8) (Brun et al., 2010; 
Burri and Blum, 2017). There is a third subspecies, T. b. brucei, which infects 
cattle and other animals and under normal conditions does not infect humans 
(Desquesnes et al., 2013). Sleeping sickness is a threat to millions of people in 
the countries of sub-Saharan Africa. During the last epidemic, which started in 
1970 and lasted until the late 1990s, the prevalence reached to Angola, the 
Democratic Republic of Congo, Central African Republic, Chad, northern Uganda, 
and South Sudan. According to WHO, the West African trypanosomiasis accounts 
for 98 percent of the reported cases and over the last 10 years, over 75 percent 
of the cases occurred in the Democratic Republic of Congo. Sleeping sickness 
was one of the major causes of mortality among the communities living here 
even of HIV-AIDS (W.H.O., 2020d; Franco et al., 2014). Though there has been a 
significant decline in the number of sleeping sickness cases as fewer than 1000 
cases were reported in 2018, the estimated population currently at risk is 65 
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million people. Since then, but the incidence has decreased by 95% between 
2000-2018. The world health organisation is working towards it elimination as a 
public health problem by the end of 2020, at least for T. b. gambiense HAT, and 
zero cases by 2030 (W.H.O., 2020d; Krishna et al., 2020). 
 
Figure 1.8: Epidemiology of Human African trypanosomiasis (Brun et al., 2010). 
The transmission of Chagas disease by the parasite T. cruzi through triatomine 
bugs mainly occurs in the Americas, in rural areas of Mexico, central America, 
and South America. Some rare cases are found in the southern regions of the 
United States. An estimated 6 to 7  million people are infected in America (Rassi 
Jr et al., 2010). Moreover, emigration of millions of people from endemic 
countries to non-endemic countries leads to spreading of the disease in the 
United States and Europe (W.H.O., 2020a; Rassi Jr et al., 2010). The countries 
where this disease burden is highest are Bolivia, Argentina, El Salvador, 
Honduras, Paraguay, Guatemala, Ecuador, French Guyana, Guyana and Surinam, 
Venezuela, Nicaragua, Brazil, and Mexico. In recent years, due to the 
implementation of screening of blood banks and vector-control programmes, the 
epidemiology of T. cruzi infection has improved remarkably in many endemic 
countries (Prata, 2001; López-Vélez et al., 2020). 
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 The genome 
Among the subspeciess of T. brucei, T. b. gambiense has the smallest genome 
with only 71-82% of the highest DNA content found in the species (Jackson et al., 
2010; Kennedy, 2013). The diploid genome of T. brucei is 35 megabase (Mb) in 
size. T. brucei has 11 Mb sized chromosome and an unspecified number of small 
and intermediate sized chromosomes of about 30-700 kb, which are responsible 
for the coding of subtelomeric regions of the chromosomes (Romero-Meza and 
Mugnier, 2019; Berriman et al., 2005). It has been reported that about 50% 
nuclear genome comprises of coding sequences (Donelson, 2002). 
The region between the telomere and the first housekeeping genes contains 
most of the assembled chromosome sequences. Long non-overlapping gene 
clusters are observed and are transcribed as polycistrons and undergo trans-
splicing and polyadenylation (Berriman et al., 2005). Gene families are expanded 
by means of tandem duplication which compensate for their lack of 
transcriptional control. The major families of proteins encoded by the genome 
include kinesins, kinesin-like proteins, protein kinases and adenylate cyclases 
(Berriman et al., 2005). The genes in the subtelomeric regions are responsible 
for the antigenic variation in the parasite which aid in escaping the host immune 
system. Variant surface glycoproteins (VSG) are encoded by the genes that 
express surface proteins; they are activated in a clonal manner during infection 
(Jackson et al., 2010; Berriman et al., 2005). Unexpressed telomere linked VSG 
genes are also found in about 100 linear mini-chromosomes of 50-150 kb 
(Donelson, 2002). 
 Pathology and clinical manifestation 
The two T. brucei subspecies causing sleeping sickness are morphologically 
undistinguishable. Sleeping sickness evolves through clinically distinct stages. 
The initial symptoms occur after a period of 5-6 days of the bite of the tsetse fly 
(Burri and Blum, 2017). There is reaction on the area of bite of the skin, which is 
called the trypanosomal chancre. This symptom is more common in East African 
trypanosomiasis. The disease then progresses from local symptom to the first 
(early) stage of infection (hemolymphatic stage) i.e. irregular pattern of fever, 
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headache, muscle, joint pain and enlarged lymph nodes (Krishna et al., 2020; 
Kennedy and Rodgers, 2019). In the second (late) stage the infection progresses 
to the central nervous system (meningoencephalitic stage) which is manifested 
by headache and mental changes. Patient may have problem in higher mental 
functions, with partial paralysis and hormonal imbalances, difficulty in 
concentration and adaptation to their surroundings and eventually a terminal 
somnolent state (Rodgers et al., 2019; Krishna et al., 2020). If left untreated, 
death ensues usually within 6 months (Burri and Blum, 2017). 
American trypanosomiasis or Chagas’ disease has an acute and a chronic phase. 
The acute phase occurs immediately after infection and can last up to a few 
weeks or months. In this phase the infection is mild with almost no symptoms. 
Following the acute phase, most infected people enter the chronic phase which 
is for a prolonged period, initially still with almost no symptoms. Most of the 
people who are infected are unaware of their infection as there are no severe or 
specific symptoms noticed. If left untreated, the infection remains lifelong and 
can also be fatal (Pérez-Molina and Molina, 2018; Rassi Jr et al., 2010). Chagas 
disease can have symptoms such as headache, painless swelling around the eye, 
palpitations, skin rash. If left untreated, it can cause congestive heart failure, 
megacolon and the weakening of other internal organs (Rassi Jr et al., 2000). 
 Diagnosis 
Early diagnosis of the disease is difficult because there are no specific signs or 
symptoms of the infection in the first stage (Büscher et al., 2017). Human 
African trypanosomiasis generally progresses in two stages and thus the diagnosis 
requires the confirmed presence of the parasite in any body fluid such as in the 
blood and lymph system or any other tissues which confirms the early stage of 
the infection. In the late stage known as the meningoencephalitic stage, the 
trypanosomes invade the central nervous system (CNS). For both the stages of 
the disease, an examination of the cerebrospinal fluid is done to confirm the 
second stage (Krishna et al., 2020; Mitashi et al., 2012). Serological tests can be 
done as a form of clinical diagnosis; this may include the card agglutination test 
for trypanosomiasis (CATT). This is a reliable way of testing a large population 
that is at risk. CATT recognises antibodies to T. b. gambiense but this is not the 
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recommended tool for screening T. b. rhodesiense because of the high level of 
parasitemia, which allows direct microscopical observation of the parasite in 
blood samples. The T. b. gambiense (gHAT) is not easy to detect with 
microscopy alone because of the low level of parasitemia except when the blood 
sample is highly concentrated. . (Büscher et al., 2013; Checkley et al., 2007; 
Kennedy, 2013). For the diagnosis of the second stage HAT, the criteria for CNS 
involvement include increased protein in the cerebrospinal fluid and a white 
blood cell (WBC) count of more than 5 cell/µL (Bonnet et al., 2015). However, 
sleeping sickness can be diagnosed through several laboratory methods, 
including enzyme-linked immunosorbent assay (ELISA), immunofluorescence (IF), 
indirect haemagglutination (IHA) (Burri and Blum, 2017). In addition, laboratory 
blood testing is also done to diagnose HAT with a polymerase chain reaction 
(PCR) test, which detects the DNA of the T. brucei in the blood sample 
(Migchelsen et al., 2011). 
 Treatment 
The largest impediment to treating African and American trypanosomiasis is the 
absence of any vaccine, this is because of the organism’s high antigenic variation 
which helps it to effectively evade the host immune system (Kennedy and 
Rodgers, 2019). Currently, the only viable method by which to treat the disease 
is chemotherapy. However, chemotherapy, especially when the disease is in its 
second stage, can result in the patient experiencing severe adverse side effects. 
Pentamidine, suramin, melarsoprol and eflornithine are the only drugs used to 
treat HAT, with nifurtimox and benznidazole being used to treat Chagas’ disease 
(Kennedy, 2013). A recent breakthrough in treating trypanosomiasis is by using 
the Nifurtimox-eflornithine combination treatment (NECT) (Kennedy and 
Rodgers, 2019; Franco et al., 2012; Priotto et al., 2009). The most advanced 
drug available against the disease is fexinidazole which is an orally-delivered 
nitroimidazole that has demonstrated highi safety and efficacy against T. b. 
gambiense HAT over a 10-day treatment (Büscher et al., 2017). Fexinidazole was 
authorized as a drug for treating sleeping sickness in November 2018 by the 
European Medicines Agency (EMA) (under Article 58). Fexinidazole is expected to 
improve the treatment management and the epidemiology of the gHAT 
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infections. Its main drawback is that resistance to it will result in cross-
resistance with nifurtimox (Lindner et al., 2020; P De Koning, 2020). 
The most viable preventive measure useful for African trypanosomiasis is to 
avoid being bitten by tsetse flies. This includes wearing long sleeved tops and 
pants of medium-weight material as tsetse flies cannot bite through them, 
avoiding going near bushes and use of insect repellent (Krishna et al., 2020). 
Vector control is the primary strategy to be used, and can be done with traps 
and screens in combination with pesticides and insecticides. To prevent Chagas’ 
disease, spraying of insecticides inside housing is effective to eliminate the 
triatomine bugs (Lidani et al., 2019; Legros et al., 2002). Blood donation 
screening can also be used to prevent the disease spreading through blood 
transfusions. The early detection and treatment of new cases will also be helpful 
in reducing the burden of the disease (Brun et al., 2001). 
 Pentamidine 
Pentamidine was registered in 1950 but has been used against trypanosomiasis 
since 1937 and as pentamidine mesylate against leishmaniasis since 1940. Later 
in 1987 it was revaluated and commercialised as pentamidine isethionate 
(Steverding, 2010; Bray et al., 2003). It is a positively charged aromatic 
diamidine compound that is soluble in water. The drug is administered 
parenterally since absorption from the gastrointestinal tract is usually 
ineffective. The drug can cross the blood-brain barrier and enter the 
cerebrospinal fluid (Sanderson et al., 2009; Sekhar et al., 2017), also trace 
amounts can be found in the liver and kidneys long after treatment because of 
selective binding on the respective organs (Bray et al., 2003). It is primarily used 
for the treatment of the early stage of T. b. gambiense African trypanosomiasis 
but almost never for T. b. rhodesiense sleeping sickness. The normal dose of the 
drug is 4 mg/kg body weight every day for a total period of 7 days (Dorlo and 
Kager, 2008; Barrett and Croft, 2012). The drug acts by selectively accumulating 
in the parasite’s cells; pentamidine is extremely effective with EC50 values of 1–
10 nM in drug sensitivity assays (Barrett and Croft, 2012). 
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Certain membrane transport proteins are utilised for this purpose and loss or 
mutation of the transporter proteins can render the parasite resistant to 
pentamidine. T. brucei parasites are reported to take up pentamidine by three 
different transporters: P2 aminopurine transporter (TbAT1), the high affinity 
pentamidine transporter (HAPT1) and the low affinity pentamidine transporter 
(LAPT1) (de Koning and Jarvis, 2001; Matovu et al., 2003; Bridges et al., 2007). 
HAPT1 activity has recently seemed to be primarily the result of loss or mutation 
of aquaglyceroporin 2 (TbAQP2) in T. brucei (Baker et al., 2012; Munday et al., 
2014; Alghamdi et al., 2020). Aquaglyceroporins (AQPs) are members of the 
major intrinsic protein family (MIP). AQP helps to move water, glycerol, urea, 
dihydroxyacetone and ammonia in T. brucei (Uzcategui et al., 2004; Zeuthen et 
al., 2006). Three genes encode the aquaglyceroporins (AQP1-3) in the T. brucei 
genome (Jeacock et al., 2017). An RNAi library screen shows that the loss of 
TbAQP2, but not of TbAQP3, leads to resistance to both pentamidine and 
melarsoprol (Alsford et al., 2012; Baker et al., 2012), and mutant alleles of 
TbAQP2 have been found in pentamidine- and melarsoprol-resistant strains 
(reviewed by P De Koning (2020)). 
Many other modes of action are also suggested by various studies which include 
binding and inhibition of nucleic acids and phospholipids of the cell membrane, 
disruption of kinetoplast DNA, inhibition of messenger RNA trans-splicing and 
interfering with correct protein production (Chakravarty and Sundar, 2010; Dorlo 
and Kager, 2008). Pentamidine treatment has several disadvantages, among 
which: it is ineffective against infection from T. b. rhodesiense and against stage 
II of T. b. gambiense. As the drug cannot sufficiently cross the blood brain 
barrier it is not very effective in cases where the parasite has infected the CNS. 
Some adverse effects of the drug are nephrotoxicity, which is reversible upon 
proper medical care. It may also cause hypoglycaemia due to increased secretion 
of insulin from the pancreas. Hypotension and cardiac arrhythmias are also 
observed in some patients (Krishna et al., 2020; Pohlig et al., 2016). 
 Melarsoprol 
Melarsoprol was introduced in 1949 and is a melaminophenyl-based organic 
arsenic compound (Nok, 2003). Until 2009 it was the most commonly used drug 
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for HAT, until the nifurtimox-eflornithine combination was introduced, which 
can treat the disease more effectively (Burri and Blum, 2017; Krishna et al., 
2020). This is still the only available drug for the treatment of stage II T. b. 
rhodesiense and the only generally affordable compound for the treatment of 
stage II T. b. gambiense. It is administered as a 3.6% solution dissolved in 
propylene glycol and distributed in 5 mL ampoules for intravenous injection 
(Nok, 2003; Baker et al., 2013). The major advantage of the drug is that it can 
be used in stage II of trypanosomiasis infection where the parasite has crossed 
the blood brain barrier of the host. It can also be used on both the T. b. 
gambiense and T. b. rhodesiense sub-species of the parasite (Gregus and 
Gyurasics, 2000). 
The exact mode of action of how arsenical compounds kill trypanosomes is still 
unknown. However, cell lysis occurs rapidly on application of the drug. The 
assumption is that the ATP supply of the cell is highly depleted by inhibition of 
glycolysis, ultimately leading to cell death. The drug interacts with low 
molecular weight thiols found in trypanosomes, yet this does not occur in 
mammalian cells. However, how this interaction reacts against the parasite 
remains unknown (Denise and Barrett, 2001; Nok, 2003). The mechanism of 
resistance has been intensively studied in recent years; the loss of both the P2 
and HAPT1 transporters are responsible for melarsoprol resistance. Moreover, 
drug resistance to melarsoprol and cross-resistance between pentamidine and 
melarsoprol has increased (Barrett et al., 2011; de Koning et al., 2000; Baker et 
al., 2013; Munday et al., 2014). The drug is highly toxic to the human body 
because of the presence of the arsenic group. In 5-10% of patients post 
treatment reactive encephalopathy has been observed, the symptoms of which 
include seizures, high fever, headaches and nausea. 50% of patients affected by 
encephalopathy die within 48 hours of treatment (Gehrig and Efferth, 2008; 
Checkley et al., 2007). 
 Suramin 
Suramin was discovered in 1920 and is a polysulfonated, symmetrical 
naphthalene derivative of urea first used for treating stage I T. b. rhodesiense 
infection in 1922. However, it does not significantly cross the blood-brain barrier 
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and therefore is administered only for the first stage of sleeping sickness. It 
derives from naphthalene-based dyes such as trypan red and trypan blue. 
Initially, trypan blue was described as having trypanocidal activities but was not 
permitted for human use since it is a coloured dye. Later the drug was 
synthesised as a naphthalene derivative which had colourless properties and was 
subsequently accepted for human use (Wiedemar et al., 2020; Docampo and 
Moreno, 2003; Sanderson et al., 2007). Treatment is usually by intravenous 
administration of 20 mg/kg, every 3-7 days for 4 weeks (Krishna et al., 2020). 
The drug has an extended half-life of approximately 41-78 days and binds 
effectively to serum proteins of human blood. It also binds with invariant surface 
glycoprotein 75 (ISG75) for which the parasites have a receptor, which is the 
main reason behind the drug accumulating within the parasitic cells via receptor 
mediated endocytosis (Barrett et al., 2011; Zoltner et al., 2016; Zoltner et al., 
2020). The RNAi library screen revealed that the suramin receptor is ISG75 
(Alsford et al., 2012). A recent study performed by (Wiedemar et al., 2018) 
proposed a link between antigenic variations and suramin resistance in T. brucei 
BSF. The connection between expression of a specific glycoprotein (VSG) and 
suramin resistance was identified by reverse genetics, which included the re-
introduction of the original VSG to suramin resistant parasites, which fully 
restored susceptibility to suramin in vitro (Wiedemar et al., 2018). 
In spite of a lot of speculation the exact mechanism of action of the drug 
remains to be discovered. Suramin bears six negative charges which participate 
in electrostatic interactions with several enzymes, causing inhibition of their 
activities. Glycolysis is thought to be a potent target of the drug since some of 
the enzymes suramin binds to participate in the glycolytic pathway (Nok, 2003; 
Wiedemar et al., 2020). However, it is unclear how suramin would enter the 
glycosomes (Zoltner et al., 2020). Drug resistance to suramin is rare because the 
drug simultaneously targets various enzymes. Observed side effects include 
stomal ulceration and fatigue. Less adverse symptoms include dermatitis, 
anaemia, peripheral neuropathy, and bone marrow toxicity (Wiedemar et al., 
2020; Nok, 2003; McCarthy et al., 2015). 
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 Nifurtimox-eflornithine combination therapy (NECT) 
Eflornithine, also known as α-difluoromethyl ornithine (DFMO), derives from the 
amino acid ornithine and acts by inhibiting the polyamine enzyme ornithine 
decarboxylase. It was first developed as an antineoplastic drug but as yet has 
not been used for cancer therapy, as it is not effective enough. The drug is, 
however, effective even during the later stages of T. b. gambiense infection but 
is ineffective against T. b. rhodesiense (Priotto et al., 2009; Barrett and Croft, 
2012; Kuemmerle et al., 2020). The drug deprives trypanosomes of polyamine 
synthesis for an extended period in comparison to mammalian cells (Priotto et 
al., 2009). In addition, it increases cellular levels of S-adenosyl methionine 
which causes unwanted methylation of proteins, lipids and nucleic acids within 
the cell (Willert and Phillips, 2012). The amino acid transporter (TbAAT6) 
mediates the uptake of eflornithine in T. brucei (Vincent et al., 2010), the loss 
of this transporter causes eflornithine resistance (Baker et al., 2011). 
Nifurtimox, a derivative of nitrofuran is used for melarsoprol failure, especially 
in combination with other therapies, particularly eflornithine. Its trypanocidal 
activity was empirically discovered and since 1967 it has been used for the 
treatment of Chagas’ disease caused by T. cruzi in Latin America. Nitrogen is the 
key active element during its action against the parasite trypanosome. The free 
nitrogen radical generated on single electron reduction of the drug interacts 
with cellular components and generates reactive oxygen species, resulting in cell 
death of the parasites (Steverding, 2010; Wilkinson et al., 2008). 
The combined efforts of the WHO and pharmaceutical corporations to shorten 
and simplify eflornithine-based therapy led to nifurtimox–eflornithine 
combination therapy (NECT) being developed in 2009 (Malvy and Chappuis, 
2011). Using nifurtimox and eflornithine combined is now the first line of 
treatment for patients in the second stage of T. b. gambiense infection (Lindner 
et al., 2019). In comparison with previous treatments, NECT is known to be 
cheaper and easier to administer than eflornithine, and less toxic than 
melarsoprol (Simarro et al., 2012). The NECT treatment is a 10-day regime with 
a 5 mg/kg oral administration of nifurtimox every 8 hours for 10 days and 200 
mg/kg of eflornithine in slow IV infusion every 12 hours for 7 days (Priotto et al., 
2007). In patients treated with eflornithine, mortality rates are much lower 
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compared to those treated with melarsoprol (Chappuis et al., 2005). NECT 
treatment has less serious adverse reactions, including nausea, headache, 
abdominal pain and anorexia (Priotto et al., 2009; Franco et al., 2012). 
 Benznidazole 
Benznidazole is a broad-spectrum antibiotic used for its antiprotozoal activities. 
Chemically, it is a nitroimidazole with a close similarity to metronidazole. The 
nitroheterocyclic compound is a prodrug which must be activated so that its 
potent cytotoxic effects are mediated (Trochine et al., 2014; Arrúa et al., 2019). 
Currently, the treatment of Chagas’ disease is based on two drugs: benznidazole 
and nifurtimox. Benznidazole is primarily used to treat American trypanosomiasis 
in the disease’s acute phase, however, it can also be effective in its chronic 
phase for cardiovascular disease patients (Arrúa et al., 2019; Bern et al., 2019). 
The mechanism of action of benznidazole is still being studied, indicates current 
hypothesis being that benznidazole reduction leads to the formation of glyoxal 
and a cytotoxic compound. Unfortunately, it has been reported over the past 
few years that some kind of resistance of T. cruzi to benznidazole has 
developed. The resistance mechanism to benznidazole includes the mutation of 
a nitroreductase that activates the drug by producing the nitro radical, and a P-
glycoprotein efflux pump (Arrúa et al., 2019; Müller Kratz et al., 2018). 
Benznidazole displays high toxicity; frequent side effects include 
hypersensitivity reactions, anorexia, vomiting, polyneuritis, and depression of 
cell production by the bone marrow (Caldas et al., 2019; Bern et al., 2019). 
 Drug resistance mechanisms 
Drug resistance was first discovered in trypanosomes by Paul Ehrlich and co-
workers (Ehrlich, 1907). Human African trypanosomiasis (HAT) is still considered 
a neglected tropical disease (Hulpia et al., 2020b). Despite there being a 
moderately long list of available drugs to treat the disease, over time many 
drugs have shown signs of resistance, limiting treatment options. Drug resistance 
is one of the factors that makes trypanosomiasis difficult to be treated 
effectively. T. brucei has been extensively used in scientific research for 
decades and is the model organism for researching cellular and molecular 
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mechanisms of the order of Kinetoplastida (P De Koning, 2020; Dickie et al., 
2020). Drug resistance in trypanosomes has been linked to changes in several 
transporters, including an amino acid transporter (TbAAT6) for eflornithine 
(Vincent et al., 2010), the P2 aminopurine transporter (TbAT1) for diamidines 
and melarsoprol (de Koning et al., 2004; Munday et al., 2015) and the high 
affinity pentamidine transporter (HAPT1/AQP2) for pentamidine and arsenic 
(Figure 1.9) (P De Koning, 2020; Munday et al., 2014). 
The failure rate of melarsoprol treatment began to increase in the 1990s. This 
has been attributed to the failure of drug uptake by the P2 and HAPT1 
transporters. The same transporters mentioned above also transport 
pentamidine and other diamidines. The AQPs are also known to have a major 
role in melarsoprol/pentamidine cross-resistance (MPXR) in T. brucei (Baker et 
al., 2012; Munday et al., 2014). Because of its resistance eflornithine has 
replaced melarsoprol as the first line of treatment in many areas of the world. 
However, it has been reported that there are some very rare cases of suramin 
and pentamidine resistance. Eflornithine monotherapy treatment failure has 
emerged in anecdotal accounts (Baker et al., 2013; Fairlamb, 2003; de Koning, 
2008). New drugs, to which the parasites will not yet have developed resistance, 
must be developed to overcome resistance to the current drugs. 
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Figure 1.9: Schematic representation showing some of the structures and the main 
transport proteins involve in the uptake of the commonly available anti-trypanosomal drugs 
for the T. brucei (P De Koning, 2020). 
 Pyrimidine biosynthesis and metabolism in 
Kinetoplastids 
 De novo biosynthesis of uridine monophosphate 
Pyrimidines and purines are the two types of nucleotides in the cell; they are 
aromatic compounds which are heterocyclic and nitrogenous in nature (De 
Koning et al., 2005; Peeters et al., 2005). These nucleotides are the major 
components of the nucleic acids (RNA and DNA), act as donors of nucleotide in 
second messenger molecules (cAMP and cGMP) and also act as modulators of 
enzyme activities. Most parasitic protozoa are able to synthesise pyrimidines de 
novo and also salvage the pyrimidine rings, except for Trichomonas vaginalis, 
Tritrichomonas foetus and Giardia lamblia, which acquire pyrimidines by use of 
their hosts. On the other hand, parasitic protozoa are all incapable of purine 
ring synthesis and they depend only on their host to salvage purine rings (Hulpia 
et al., 2020a; De Koning et al., 2005; Hulpia et al., 2020b). 
The enzymes glutamine-dependent carbamoylphosphate synthetase II (CPS II), 
aspartate carbamoyltransferase (ACT), dihydroorotase (DHO), dihydroorotate 
dehydrogenase (DHOD), orotate phosphorybosiltransferase (OPRT) and orotidine 
monophosphate decarboxylase (OMPDC) perform a sequence of reactions that 
results in uridine monophosphate (UMP) synthesis (Hammond and Gutteridge, 
1984; Carter et al., 2008). 
The pyrimidines de novo pathway biosynthesis process begins with the use of 
simple substrates (ATP, water, Glutamine and HCO3) to form carbamoyl 
phosphate. The enzyme CPS II catalyses this reaction. The next reaction is 
catalysed by enzyme ACT and occurs in the pathway between carbamoyl 
aspartate and carbamoyl phosphate. In the next step, the ring of the pyrimidine 
closes via the use of the enzyme DHO to remove a molecule of water from 
carbamoyl aspartate resulting in the formation of dihydroorotate. The enzyme 
DHOD is then used to produce orotate from dihydroorotate during the fourth 
step. The next step involves addition of the orotate to a 5-carbon ribose ring by 
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use of the OPRT enzyme, resulting in formation of orotidine-5-monophosphate 
(OMP). OMP is then decarboxylated by enzyme OMPDC during the final stage, to 
produce UMP (Figure 1.12: 1.10) (Berens et al., 1995; Hassan and Coombs, 1988; 
French et al., 2011). 
Pyrimidine de novo pathway for kinetoplastid parasites are different from the 
mammalian ones in different ways (Carter et al., 2008). For mammals, the 
pathways for the first three enzymes are encoded by a single gene while for 
kinetoplastid parasites the encoding is by use of different genes resulting in a 
multifunctional protein. Uridine diphosphate inhibits the enzyme CPS II in 
kinetoplastid parasites while uridine triphosphate inhibits the mammalian 
enzyme. In parasites the localization of the enzyme dihydroorate dehydrogenase 
is cytosolic while it is mitochondrial in mammals (Carter et al., 2008; Berens et 
al., 1995; Annoura et al., 2005). 
 
 
Ibrahim Abdullah Alfayez                               Chapter 1                                  60 
   
Figure 1.10: Pyrimidine biosynthesis pathways. Adapted from (Hammond and Gutteridge, 
1984; Carter et al., 2008); Abbreviations are described in the text. 
 Pyrimidine salvage and interconversion 
Generally, parasites are capable of synthesising pyrimidines de novo; in contrast, 
they are also able to salvage pyrimidines as nucleobases or nucleosides. It is for 
this reason that it becomes difficult to comprehend the separate importance of 
biosynthesis and salvage of pyrimidine, thus pyrimidine chemotherapy planning 
becomes complicated (Ali et al., 2013a). Pyrimidine nucleoside kinase or 
pyrimidine nucleoside phosphorylase are capable of converting pyrimidine 
nucleosides to their respective nucleotides and nucleobases forms (Hassan and 
Coombs, 1988). The beginning of pyrimidine pathway salvage takes place 
through pyrimidine nucleobases or nucleosides uptake into the cells of the 
parasites through transporters in the cell membrane. All pyrimidines with 
exemption of thymine and thymidine are transformed into uracil and later into 
UMP after being incorporated within the cell, this occurs through action uracil 
phosphoribosyl transferase enzyme (Figure 1.12: 1.11) (Gudin et al., 2006). 
Thus, UMP, the end product of salvage pathways and de novo biosynthesis, uses 
non-redundant pathways to act as an immediate precursor to every pyrimidine 
deoxyribonucleotide and ribonucleotide (Ali et al., 2013b). 
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Figure 1.11: Pyrimidine salvage pathways. Red arrows indicate that the reaction occurs in 
one direction, whereas blue arrows indicate that the reaction occurs in both directions. 
Abbreviations are described in the text. Adapted from (Hammond and Gutteridge, 1984; Ali 
et al., 2013a). 
Using ATP as the phosphate donor, the enzyme uridine nucleoside kinase is able 
to phosphorylate UMP into uridine triphosphate (UTP) through uridine 
diphosphate (UDP) in a two-step reaction (Carter et al., 2008). Three specific 
reactions are required for thymidine nucleotides, deoxycytidine and cytidine 
synthesis from UMP (Berens et al., 1995). After conversion of UMP to UTP 
through double phosphorylation, cytidine triphosphate synthase converts UTP to 
CTP (Carter et al., 2002; Fijolek et al., 2007; Hofer et al., 2001). In the second 
reaction, deoxyribonucleotides are synthesised from ribonucleoside diphosphates 
(GDP, UDP, CDP and ADP) through the enzyme ribonucleotide reductase (RR) 
(Berens et al., 1995). The third reaction involves production of deoxy-thymidine 
monophosphate (dTMP) from dUMP, a conversion process involving the enzyme 
thymidine synthase (TS), coupled to the folate cycle (Figure 1.12: 1.12) (Carter 
et al., 2002). 
In addition, UDP and CDP can also be transformed into dUDP and dCDP through 
ribonucleotide reductase, and the enzyme nucleotide diphosphokinase is then 
used to convert them into dUTP and dCTP, respectively. Furthermore, cytidine 
deaminase in kinetoplastid protozoa converts deoxycytidine and cytidine to 
deoxyuridine and uridine, respectively (Carter et al., 2008). 2’-deoxycytidine 
and uridine are also important in synthesis of dUMP and UMP respectively 
(Hassan and Coombs, 1988); first, uridine phosphatase is used to convert uridine 
to uracil. This is an important step in obtaining UMP since uridine kinase (UK) 
activity is absent in kinetoplastids (Gudin et al., 2006; Hammond and 
Gutteridge, 1982). Some studies disagree with the UK activity argument since 
they consider salvage of uridine in a more direct path. The Leishmania genome 
database has been used to identify a potential UK activity (Carter et al., 2008). 
According to (LaFon et al., 1982), salvage of thymidine is poor and thymidine 
kinase (TK) can be used to phosphorylate it to thymidine monophosphate (TMP), 
its genes are present in Leishmania and Trypanosoma spp. Thymine and 
thymidine can reversibly be converted via thymidine phosphorylase to give out 
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thymidine and thymine, respectively (Hammond and Gutteridge, 1984; Ali et al., 
2013b). 
 
Figure 1.12: Interconversions of pyrimidines. Green and red arrows indicate that the 
reaction occurs in one direction, whereas blue arrows indicate that the reaction occurs in 
both directions. Abbreviations are described in the text. Adapted from (Hammond and 
Gutteridge, 1984; Ali et al., 2013a). 
 Classification of membrane transporter proteins 
There are five mechanisms involved in molecule movements across the plasma 
membrane: exocytosis, facilitated diffusion, simple diffusion, endocytosis and 
active transport (Caspary, 1992). All biological membranes mediate compound 
movements across them via membrane protein transporters. Such integral 
membrane transport proteins are numerous in kinetoplastid protozoa where they 
help them in exportation and importation of drugs, uptake of nutrients, 
translocation of various molecules, regulate physiological concentrations and 
efflux of metabolites (Majumder, 2008; Kirk and Saliba, 2007; Rodriguez-
Contreras et al., 2007; de Koning and Diallinas, 2000). Since purine and 
pyrimidine nucleobases and/or nucleosides have a hydrophilic profile, their 
movement into the cell relies on the transportation through such transmembrane 
proteins (Molina-Arcas et al., 2009; Carter et al., 2008). 
There are two transport protein families in mammalian cells that aid in 
movement of nucleosides and nucleobases through the plasma membranes; these 
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include Equilibrative Nucleoside Transporters (ENT) and the Concentrative 
Nucleoside Transporters (CNT) (Baldwin et al., 1999; King et al., 2006; Young et 
al., 2013). Other gene families have also been described, however, including 
those in fungi, yeasts and bacteria (de Koning and Diallinas, 2000; Campagnaro 
and de Koning, 2020). However, only members of the ENT family have, to date, 
been found in protozoa (De Koning et al., 2005). In addition to the nucleoside 
salvage role played by the ENT transporters, they have also been shown to play 
an important function in protozoan pharmacology; this is particularly common in 
African trypanosomes as well as in Leishmania (Carter et al., 1999; Geiser et al., 
2005; Al-Salabi and de Koning, 2005; Rodenko et al., 2007; Kazibwe et al., 2009; 
Stewart et al., 2010; Ali et al., 2013a; Vodnala et al., 2013; Munday et al., 2015; 
Ranjbarian et al., 2017; Campagnaro and de Koning, 2020). Pyrimidine (5-
fluorouracil) nucleobases and purine nucleobases (allopurinol) as well as 
pyrimidine and purine nucleoside analogues are among the chemotherapeutic 
compounds. 
 Concentrative nucleoside transporters 
The family of CNTs, SLC28, encodes for the symporters that depend on an 
inward directed sodium gradient for its energy. For every import cycle, these 
electrogenic carriers import positive charge (Choudhuri and Chanderbhan, 2016; 
Baldwin et al., 2004). The CNT family in humans is made up of 3 members 
(CNT1, 2 and 3); each is made up of thirteen transmembrane domains (TMD) 
(Figure 1.12: 1.13). The selection of substrate depends on TMD7-9 (Baldwin et 
al., 2004; King et al., 2006). Eukaryotes and prokaryotes have been found to 
contain CNT family members, with mammalian members being sodium-
dependent and the prokaryotic being proton symporters. Protozoa have been 
found not to contain CNT family members (De Koning et al., 2005; Campagnaro 
and de Koning, 2020). Transportation of adenosine and pyrimidine nucleosides is 
through CNT1, transportation of uridine and purine nucleosides is through CNT2, 
while CNT3 moves both pyrimidine and purine nucleosides. Renal epithelial and 
intestinal cells contain localised CNT transporters (Gray et al., 2004; Choudhuri 
and Chanderbhan, 2016; Young et al., 2008). 
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 Equilibrative nucleoside transporters 
The ENT or SLC29 family are trans-membrane glycosylated proteins that are 
localised to the plasma membranes and mitochondria, and act as pyrimidine and 
purine nucleosides transportation modulators (it can also play a role in 
nucleobases uptake), as well as therapeutic analogues associated with them. 
There are eleven TMD in ENT transporters (Figure 1.12: 1.13). They are 
expressed in mammary glands, placenta, rain, liver, erythrocytes, spleen and 
heart and probably other cell types. Human beings have three best known ENTs; 
hENT1, hENT2 and hENT3. In mammalian cells, the ENT1 and ENT2 isoforms are 
widely distributed and well characterised (King et al., 2006; Pastor-Anglada and 
Pérez-Torras, 2018). ENTs makes it possible for molecules to move in and out of 
cells down concentration gradients (facilitated diffusion) (Landfear et al., 2004; 
King et al., 2006). Investigation of the ENT family in protozoans has also being 
carried out. Trypanosoma and Leishmania are examples of active ENT 
transporters that are driven by the protonmotive force (De Koning et al., 2005; 
Young et al., 2008). A good number of nucleobase and nucleoside drugs consider 
ENTs as their primary conduits. There is still scarce information concerning their 
mechanism of action and their molecular mechanisms. An older classification of 
the mammalian ENTs divides them into es transporters, which are nM 
concentrations sensitive to the nitrobenzyl mercaptopurine riboside (NBMPR) 
inhibitor, and the ei transporters, unaffected by NBMPR or needs higher 
concentrations for inhibition. The detailed structure of human Equilibrative 
Nucleoside Transporter (hENT1) has recently been reported (Young et al., 2013; 
Campagnaro and de Koning, 2020; Wright and Lee, 2019). 
ENT 1 and 2 are involved in the uptake of various pyrimidine and purine 
nucleosides. On the other hand, ENT3 transports adenine as well as pyrimidine 
and purine nucleosides (King et al., 2006). In addition, ENT4 plays an important 
role in regulating transportation of adenosine based on the pH level. ENT4 is also 
called the monoamine plasma membrane transporter (PMAT) since it is able to 
transport organic cations like neurotoxins, cationic drugs and biogenic amines 
(Barnes et al., 2006; King et al., 2006; Young et al., 2008). They control the 
efficacy of come drugs selectively through enhancing transportation across the 
cell membrane to their active sites and may also lead to transporter inhibition 
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when used as direct drug targets (Boswell-Casteel and Hays, 2017). The genome 
of T. brucei contains twelve ENT family members (Ortiz et al., 2009b), while the 
genome of Leishmania encodes five ENT transporters (Ortiz et al., 2009a). The 
large complement of ENT transporters in protozoa would make it highly 
challenging to target them by inhibitors with the aim of depriving the parasite of 
nucleosides. However, some of the protozoan ENT transporters are involved in 
the selective uptake of cytotoxic nucleosides and other therapeutics (Carter et 
al., 1999; Geiser et al., 2005; Al-Salabi and de Koning, 2005; Rodenko et al., 
2007; Kazibwe et al., 2009; Stewart et al., 2010; Ali et al., 2013a; Vodnala et 
al., 2013; Munday et al., 2015; Ranjbarian et al., 2017; Campagnaro and de 
Koning, 2020). 
 
Figure 1.13: Transmembrane topologies of mammalian members of the CNT and ENT 
families (King et al., 2006). 
 Nucleoside and nucleobase transporters in Kinetoplastids 
The uptake of pyrimidine/purine nucleobases or nucleosides plays a major role 
in the metabolism of parasitic protozoa like Trypanosoma and Leishmania. Due 
to their inability to synthesise de novo purine on their own, parasitic protozoa 
depend on their hosts for salvaged purines (De Koning et al., 2005; Campagnaro 
and de Koning, 2020). Protozoa however, show contrasting characteristics since 
they appear to carry out pyrimidine ring de novo synthesis on their own, and, 
therefore, do not have to depend entirely on uptake from the host (De Koning et 
al., 2005). 
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 Leishmania spp. 
Preformed purine nucleobases and nucleosides are initially translocated through 
the cell membrane of Leishmania. These nucleobases and nucleotides are unable 
to diffuse via the hydrophobic lipid bilayer since they are hydrophilic in nature. 
Thus, the selective transport process requires an advanced transport system 
(Carter et al., 2001; De Koning et al., 2005; Campagnaro and de Koning, 2020). 
The transportation of pyrimidines and purines in parasitic Leishmania spp. is 
dependent of a four-part mechanism. The parts are; NT1 (consisting of NT1.1 
and NT1.2), NT2, NT3 and NT4 (Aronow et al., 1987; Campagnaro and de Koning, 
2020; Carter et al., 2008). Studies of the genome of L. donovani have shown that 
it contains the genes for LdNT1, LdNT2, LdNT3 and LdNT4. Transporter proteins 
show considerable amino acid sequence homology to each other and also ENTs 
transporters in mammals (Carter et al., 2001). 
NT1 is selective for the pyrimidine nucleosides (cytidine, thymidine and uridine) 
and adenosine (Vasudevan et al., 1998), whereas NT2 transports the 6-oxopurine 
nucleosides xanthosine, guanosine and inosine (Carter et al., 2001; Boitz et al., 
2012). Specifically, the two similar genes NT1.1 and NT1.2 are used in encoding 
NT1. Alzahrani et al. (2017)  recently found out that NT1.1 obtained from L. 
mexicana and L. major has greater sensitivity to uracil inhibition, due to this, it 
is referred to as uridine-uracil transporter 1 (UUT1). NT1.2 would be named NT1. 
The transporters NT2 and NT1 are also used as the major transporters of the 
inosine analogue formycin B and adenosine analogue tubercidin, respectively 
(Landfear, 2013; Ortiz et al., 2007). In the recent past, it has been found that 
the various Leishmania species appear to contain conserved NT1 activity. The 
expression of NT2 from L. major and L. mexicana in T. brucei showed that it is a 
transporter of oxopurines that has no affinity for uridine or adenosine (Alzahrani 
et al., 2017). On the other hand, the transporters NT3 and NT4 are purine 
nucleobase carriers in nature (Landfear, 2011). At neutral pH, purine 
nucleobases are mainly carried by NT3, which demonstrates high rates of 
xanthine, adenine, hypoxanthine and guanine transport. In addition to being the 
main transporter for purine nucleobases in intracellular amastigotes, it is 
involved in low affinity adenine transportation (Ortiz et al., 2007; Ortiz et al., 
2009b). NT4 seems to have optimal functionality at acidic ranges of pH (Ortiz et 
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al., 2009a). Parasitic Leishmania survival seems to be essentially linked to NT3 
and NT4 uptake of nucleobases. This is because it was difficult to create NT3 
and NT4 simultaneous knockout (Ortiz et al., 2007). 
First pyrimidine nucleobase transporter in Leishmania was discovered in 2005 
and named as U1. It showed similar substrate binding and selectivity like U1 
transporter in T. brucei, which means that, like purine nucleobase transport, 
pyrimidine nucleobase transport activity and mechanism has similarity in 
Leishmania and Trypanosoma (Papageorgiou et al., 2005). Papageorgiou et al. 
(2005) showed that U1 had a high affinity for uracil with a Km value of 0.32 µM. 
The anti-metabolite 5-fluorouracil was found to be a good inhibitor for U1 with 
Ki value of 0.66 μM. Uracil and 5-fluorouracil are transported by the U1 
transporter in L. mexicana and L. major (Papageorgiou et al., 2005; Alzahrani et 
al., 2017). A summary of the purine and pyrimidine transport activities in 
Leishmania spp. is shown on Table 1.1. 












ADE >1000 288; 5.14+  4.6c;8.5d 39 NE2 
ADO 0.81 1.93+  5150c   
GUA    2.8c; 8.8d  NE3 
GUO   1.7 68c   
HYP >1000 >500  0.71c; 16.5d; 0.72d 420 NE2 
INO >500  0.3 125c   
XAN    23c; 8.5d; 115.2d   
CTS  >5000  NE1,c  NE2 
CTD 78.6     NE2 
TMN  560  NE1,c  237 
TMD 11.2   NE1,c  NE2 
URA >2500 29.7; 2.6+  NE1,c  0.32 
URD 13.3; 33.5+ 2; 3.12+    10.9 
HPP    54.3c   
5-FU  56.3    0.66 
Values in bold represent Km values; all others are Ki values. All Km and Ki values * from L. 
mexicana, except were stated otherwise; + from L. major; # at pH 5.5. ADE, adenine; ADO, 
adenosine; GUA, guanine; GUO, guanosine; HYP, hypoxanthine; INO, inosine; XAN, xanthine; 
CTS, cytosine; CTD, cytidine; TMN, thymine; TMD, thymidine; URA, uracil; 5-FU, 5-fluorouracil; 
URD, uridine; HPP, allopurinol. NE, no effect at 11 mM, 2500 μM, 3250 μM, 4100 μM, 525 μM. 
a(Alzahrani et al., 2017), from L. mexicana; b(Carter et al., 2000); c(Al-Salabi et al., 2003); 
d(Sanchez et al., 2004); e(Ortiz et al., 2007), at pH 5.5; f(Papageorgiou et al., 2005). Source: 
Table adapted from Campagnaro and de Koning (2020). 
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 Trypanosoma brucei 
The life cycle of T. brucei is complex and it involves many different hosts and 
environments. It also involved different tissues, the bloodstream and the 
cerebrospinal fluid in the case of vertebrates, and the gut, salivary glands, 
haemolymph, cardia in case of invertebrates. In order to adapt to dynamic and 
continually changing environments, it has developed a complex mechanism for 
the acquisition of nutrients such as purine uptake (Campagnaro and de Koning, 
2020). There are 12 ENT transporters expressed by T. brucei. The family are 
designated as TbAT1 and TbNT2-TbNT12 (Ortiz et al., 2009b). African BSF 
trypanosomes is express the P1, P2, H2, H3, HXT1, ADET1 purine transporters. 
Transporters in the T. brucei PCF, which are found in tsetse fly midgut, express 
P1, H1, H4 and ADET1 (Campagnaro and de Koning, 2020). 
The P1 type is known as a adenosine/inosine/guanosine high affinity transporter 
(Carter and Fairlamb, 1993). Its substrate interactions including bonds with the 
N3, N7, 3’OH, 5’OH functional groups of nucleosides (de Koning and Jarvis, 
1999). BSF of T. brucei expresses multiple P1 transporters. T. brucei genome 
contains eight P1 genes these are NT2, NT3, NT4, NT5, NT6, NT7, NT9 and NT10 
(Sanchez et al., 2002; Al-Salabi et al., 2007; Sanchez et al., 2004). Chromosome 
2 contains a cluster of related six genes encoding type P1 transporters. These 
are NT2-NT7 (Landfear et al., 2004). These six transporters are involved in the 
uptake of adenosine and inosine, sometimes they also take up hypoxanthine 
(Sanchez et al., 2002). In BSF and PCF of T. brucei, NT9 and NT10 were 
expressed (Al-Salabi et al., 2007; Sanchez et al., 2004), NT9 and NT10 are also in 
mitochondrial membrane hence indicating the role it plays in transportation of 
nucleoside into this organelle from the cytosol (Acestor et al., 2009; van 
Hellemond et al., 2005). The TbAT1 or P2 transporter is known as a transporter 
of adenine and adenosine. It is encoded by TbAT1 which is just one gene as 
expressed by BSF (de Koning and Jarvis, 1999; Matovu et al., 2003). 
Antitrypanosomal drugs such as arsenical melarsoprol and the diamidine 
pentamidine are also carried by P2 in BSF T. brucei (Munday et al., 2013; Carter 
et al., 1999; Baker et al., 2013). Although T. brucei AQP2 is the major 
transporter of melarsoprol and pentamidine, P2 is also involved the transport of 
these drugs (Munday et al., 2014). The activity of NT11 and NT12, which are the 
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two last members of the ENT family in T. brucei, is not clearly known. There are 
suggestions that they encode adenine and pentamidine transporters (Ortiz et al., 
2009b). TbNT11.1 and TbNT11.2 are two similar genes that composes TbNT11 
region, meanwhile TbNT12 locus is composed by TbNT12.1 and TbNT12.2 (De 
Koning et al., 2005). The report of them transporting adenine and pentamidine 
could not be reproduced in the De Koning lab. 
The H1 and H4 transporters mediate the transportation of nucleobases in the 
procyclic form of T. brucei. H1 has no affinity to pyrimidine nucleobase or to 
purine or pyrimidine nucleosides, and specifically mediates the uptake of purine 
nucleobases (De Koning and Jarvis, 1997a; De Koning et al., 2005). H4, also 
known as NT8.1, shows a high affinity for purine nucleobases and a low uracil 
affinity. H4 is encoded by one of three nucleobase transporter genes on 
chromosome 11 on a tandem repeat (Burchmore et al., 2003a). H2 and H3 are 
the two purine nucleobase transporters identified in the BSF of T. brucei for 
transporting nucleobases (De Koning and Jarvis, 1997a). The uptake of some 
pyrimidine nucleobase and purine nucleobases is mediated by H2, meanwhile H3 
is specific for the uptake of nucleobases and has no affinity for pyrimidines, or 
for purine nucleosides (De Koning and Jarvis, 1997a). 
Nucleoside and pyrimidine nucleobases require a transport protein to facilitate 
its entry in the plasma membrane; this is because they do not diffuse at an 
efficient rate through the plasma membrane. The genes encoding these 
transporters have not been identified fully in protozoans (Bellofatto, 2007; De 
Koning, 2007). The U1 carrier in procyclic forms was the first pyrimidine activity 
in T. brucei to be identified. U1 has a high uracil affinity and is selectively 
permeable to uracil with a Km value of 0.46 µM, and is inhibited by uridine and 
the cytotoxic analogue 5-fluorouracil with Ki values of 48 µM for uridine and 3.2 
µM for 5-fluorouracil. U1 has no affinity for pyrimidine nucleosides other than 
low affinity for uridine, nor for any purines (de Koning and Jarvis, 1998). Gudin 
et al. (2006) identified cytosine (C1) and uridine (U2) transport activities in PCF 
of T. brucei. C1 is inhibited by cytidine and uracil and has a high affinity with 
low capacity for cytosine. U2 has high affinity for uridine with a Km of 4.1 μM, 
and U2 also shows high and moderate affinity towards thymidine and cytidine, 
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respectively (Gudin et al., 2006). (Ali et al., 2013a) reports indicate that BSF of 
T. brucei has 2 transport mechanisms that are used to transport pyrimidines. 
These two transporters are for thymidine (T1) and uracil (U3). The U3 
transporter has a high uracil affinity with a Km of 0.54 µM and extremely low 
uridine affinity with Ki value of >1000 μM. None of the genes encoding 
pyrimidine-specific transporters have been identified. A summary of the purine 
and pyrimidine transport activities in T. b. brucei is presented in Table 1.2. 
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Table 1.2: Kinetic parameters of T. brucei purine and pyrimidine transporters. 
Transporter  Substrate 
ADE ADO GUA GUO HYP INO XAN CTS CTD TMN TMD URA URD 5-FU HPP 
P1/NT2 NE3,c 0.15a; 
0.26b; 
0.38c 





 NE3,c >500c NE4,c 110c  NE3,c NE2,c NE2,c NE2,c NE2,c  260c 
NT5d  2 2.2  49.4           
NT6d  1.4 4.3             
NT7d  0.3 1.8             
NT9e 148 0.068  6.2 320 2.75     510  235   
NT10e  0.41    0.53          
NT11f 2.7; 8 266 651  141  7.2 NE1    NE2   67 
H1g 3.6 348 1.8 >1000 9.3 >1000 7.2 NE1 NE1 1300 NE1 NE1 NE1  5 
H2h 3.2 590 0.36 10.9 0.123 167 8.8 >500 NE1 82 >1000 60 >500  4 
H3h 8.8 NE1 5.6 NE1 4.7 NE1 28.8 NE1 NE3 NE1 NE3 NE1 NE3  194 
NT8/H4i 2.6 860 2.6 4.7 0.55 20 5      95  2.5 
U1 NE1,j NE1,j NE5,j NE1,j NE1,j NE1,j  NE1,j NE1,j NE1,j NE1,j 0.46j 48j; 
33k 
3.0m  
U2k         0.04
1 
 0.38  4.1   
U3i  NE1   NE1  NE1 >2500  >2500 >10000 0.54 9500 2.6e  
C1k        0.048 0.42   0.36    
ADET1n 0.57 NE1 NE5  NE1 NE1 NE1  NE1 NE1 NE1 NE1 NE1   
HXT1n NE1 NE1 NE5  22 NE1 NE1  NE1 NE1 NE1 NE1 NE1   
Values in bold represent Km values; all others are Ki values. ADE, adenine; ADO, adenosine; GUA, guanine; GUO, guanosine; HYP, hypoxanthine; INO, inosine; XAN, 
xanthine; CTS, cytosine; CTD, cytidine; TMN, thymine; TMD, thymidine; URA, uracil; 5-FU, 5-fluorouracil; URD, uridine; HPP, allopurinol. NE, no effect at 11 mM, 2500 
μM, 3250 μM, 4100 μM, 525 μM. a(Carter and Fairlamb, 1993); b(de Koning and Jarvis, 1998); c(de Koning and Jarvis, 1999); d(Sanchez et al., 2002); e(Al-Salabi et al., 
2007); f(Ortiz et al., 2007); g(De Koning and Jarvis, 1997a); h(de Koning and Jarvis, 1997b); i(Burchmore et al., 2003b); j(de Koning and Jarvis, 1998); k(Gudin et al., 
2006); i(Ali et al., 2013a); m(Papageorgiou et al., 2005); n(Campagnaro et al., 2018a). Source: Table adapted from Campagnaro and de Koning (2020). 
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 Trypanosoma cruzi 
The first information about the ability of T. cruzi to transport purines was 
available from the 1970s (Marr et al., 1978). The existence of at least 3 
nucleoside transport mechanisms in a T. cruzi was reported in these initial 
studies. In one study the transport mechanism of T. cruzi was investigated in a 
tubercidin-resistant strain and reported one carrier for pyrimidines and 
tubercidin, one for thymidine with no affinity for tubercidin, and one for 
adenosine and inosine. The resistance was selected after exposure to ionized 
radiation; however, this ionization may have caused mutations in other 
transporter genes, creating some uncertainty about the report (Finley et al., 
1988; Nozaki and Dvorak, 1993). Four genes encode ENT transporters in T. cruzi, 
of which at least 3 encode different purine and pyrimidine transport systems 
(Campagnaro et al., 2018b). This was found through their expression and cloning 
in PCF of T. brucei. TcrNB1 has high affinity for hypoxanthine and guanine, with 
a Km value of 0.093 μM for hypoxanthine and Ki value of 0.122 μM for guanine. 
Secondly, TcrNT1 has affinity for inosine and guanosine, with Km value of 1.0 μM 
for inosine and Ki value of 0.97 μM for guanosine. The third is TcrNT2 which has 
affinity for thymidine (Km value of 0.223 μM). TcrNB2 is the fourth one it is an 
ENT with unknown function (Campagnaro et al., 2018b). These 4 ENT genes that 
are found in a T. cruzi do not appear to transport adenine or adenosine 
(Campagnaro and de Koning, 2020). A summary of the purine and pyrimidine 
transport activities in T. cruzi is shown in Table.1.3. 
Table 1.3: Kinetic parameters of T. cruzi purine and pyrimidine transporters. 
Substrate Transporter 
TcrNB1 TcrNT1 TcrNT2 
ADE 3.73 >1 mM NE 
ADO NE 38.9 1556 
GUA 0.122 NE  
GUO 17.1 0.97 NE 
HYP 0.093 23.9 NE 
INO 314.8 1.0 NE 
XAN 18.36 410.3 NE 
CTS >1 mM NE NE 
CTD >500 μM NE 728 
TMN >1 mM >1 mM >1 mM 
TMD >1 mM >1 mM 0.223 
URA >1 mM NE NE 
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URD >1 mM >1 mM 65.5 
2’-deoxyURD   1.11 
Tubercidin   695.7 
Values in bold represent Km values; all others are Ki values. NE, no effect at a, 1 mM; b, 250 μM; c, 
25 μM. Abbreviations: ADE, adenine; ADO, adenosine; CTD, cytidine; CTS, cytosine; GUA, 
guanine; GUO, guanosine; HPP, allopurinol; HYP, hypoxanthine; INO, inosine; TMD, thymidine; 
TMN, thymine; URA, uracil; URD, uridine; XAN, xanthine. The substrate affinity of TcrNB2, the 
fourth ENT identified in T. cruzi genome has not been identified yet. Source: Table taken from 
Campagnaro and de Koning (2020). 
 The current understanding of mode of action of 5-FU 
in Kinetoplastid parasites 
Most nucleobase and nucleoside analogues are hydrophilic molecules and thus 
need specific membrane transporter proteins to enter cells. When they arrive in 
the cell, they are activated by intracellular metabolic steps to triphosphate 
derivatives (Galmarini et al., 2002; P De Koning, 2020). Cytotoxic fluoro-
pyrimidine nucleobase and nucleoside analogues, for example, 5-FU and 5F-
2'dUrd are antimetabolites that interfere with the synthesis of nucleic acids. 
These agents could exert cytotoxic action by being integrated into and changing 
the RNA and DNA macromolecules or by interfering with numerous enzymes 
involved in the production of nucleic acids such as thymidylate synthase (TS), or 
by altering the metabolism of physiological nucleobases or nucleosides. These 
activities result in the disruption of RNA or DNA synthesis and/or structure, and 
apoptotic cell death (Galmarini et al., 2002; Longley et al., 2003). 
Pyrimidine nucleotide metabolism instead is more varied in kinetoplastid 
parasites. The metabolism and mode of action of the pyrimidine analogue 5-FU 
was studied using metabolomic evaluation of T. brucei and Leishmania 5-FU 
resistant cell lines and the sensitive parental strains (Ali et al., 2013a; Alzahrani 
et al., 2017). In T. brucei, 5-FU was a substrate for uracil phosphoribosyl 
transferase (UPRT) and assimilated into a large number of metabolites for 
example precursors for the biosynthesis of lipids (e.g. CDP-ethanolamine and 
CDP-choline) and sugar metabolism (e.g. UDP-N-acetylglucosamine, UDP-
galactose and UDP-glucose), hypothetically affecting variant surface 
glycoprotein (VSG) glycosylation or GPI anchors, both of which are essential 
functions to trypanosomes (Ali et al., 2013a; Donelson, 2003), 5-FU may exert its 
toxicity via integration into RNA (Figure 1.14A). Ali et al. (2013a) mentioned that 
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sugar nucleotide metabolism contributes significantly to 5-FU mode of action in 
T. brucei, and that changes in this pathway could make major contributions to 5-
FU resistance. 
In contrast, the pyrimidine analogue 5-FU in L. major and L. mexicana is not a 
substrate for UPRT as no fluorinated ribonucleotides  or 5F-UMP can be detected 
by metabolomic evaluations of the sensitive parental strain and Leishmania 5-FU 
resistant cells. The mechanism of action of 5-fluoro-pyrimidines such as 5-FU in 
Leishmania species have largely the same mechanism of action (Alzahrani et al., 
2017). In general, promastigotes of Leishmania converted 5-FU to 5-F2'dUrd, 
which was phosphorylated by thymidine kinase (TK) to produce 5F-dUMP. 5F-
2'dUrd could be transformed into 5-FU, the reaction, mediated by uridine 
phosphorylase (UP), the reaction evidently being reversible. Consequently, 5-FU 
has a general mechanism of anti-leishmanial activity via inhibiting TS by 
accumulation of 5F-dUMP, and secondly  TK by 5F-2'dUrd and the consequent 
disruption of deoxynucleotide metabolism (Figure 1.14B) (Alzahrani et al., 
2017). 
The potent bactericidal impacts of 5-FU against numerous bacterial pathogens 
were described in the last thirty years. 5-FU was established to inhibit the 
growth of Staphylococcus epidermidis and Staphylococcus aureus with an MIC50 
below 0.8 mg/L. The MIC50 represents the minimum inhibitory concentration 
(MIC) needed to prevent the growth of the organism by fifty percent. 5-FU was 
established to perform synergistically with β-lactams against gram-negative 
bacteria and hindering the formation of biofilm. 5-FU correspondingly applies its 
bactericidal impact through the inhibition of biosynthesis of the cell wall (Yssel 
et al., 2017). Another study, by Singh et al. (2015), has shown that 5-FU is 
incorportated into sugar nucleotides (for example, UDP-MurNAc-pentapeptide, 
UDP-GlcNAc and UDP-Gal) and results in the interruption of cell wall and nucleic 
acid biosynthesis. 
While the pyrimidine analogue 5-FU is widely used to treat a wide array of 
cancers, which include colorectal cancer and breast cancer (Longley et al., 
2003). There is now a clear understanding of how 5-FU induces cell death and 
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cytotoxicity; not merely in bacteria and cancer cells but also in protozoa, for 
example in Leishmania species and likewise in T. b brucei (Figure 1.14). 
 
Figure 1.14: Possible biochemical linkages between 5-FU toxicity and damage to RNA and 
DNA in A) T. brucei and B) Leishmania spp. The curved green bar schematically represents 
the plasma membrane of the parasites. Abbreviations: FUMP, FUDP, FUTP: fluorouridine -5'-
mono-, di-, and triphosphate, respectively; FdUMP, FdUDP, FdUTP: fluorodeoxyuridine-5'-
mono-, di-, and triphosphate, respectively; dUMP: deoxyuridine-5'-monophosphate; dTMP, 
dTDP, dTTP: deoxythymidine-5'-mono-, di-, and triphosphate, respectively; 5-FU: 5-
fluorouracil; 5F-2’dUrd: 5-fluoro-2’deoxyuridine; UPRT: uracil phosphoribosyl transferase; 
ND: nucleoside diphosphatase; NDK: nucleoside diphosphate kinase.; RNR: 
ribonucleoside-diphosphate reductase; RNAP: RNA Polymerase; UP: uridine 
phosphorylase; TdlK: thymidylate kinase; TS: thymidylate synthase; TK: thymidine kinase. 
Source: Adapted from (Ali et al., 2013a; Alzahrani et al., 2017). 
 The applications of RNA sequencing (RNA-seq) and 
RNA interference target-sequencing (RIT-seq) 
In an effort to identify the gene(s) coding for kinetoplastid uracil transporters, a 
number of investigative avenues have been explored. Owing to the fact that the 
BLAST search for pyrimidine transporter genes using yeast, prokaryote, as well 
as fungal uracil transporter sequences has never yielded any candidate gene 
from any the available protozoan genomes, we have come to a conclusion that 
the genes cannot be identified by homology to known pyrimidine transporter 
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genes. For this reason, in an attempt to identify pyrimidine transporter genes of 
L. mexicana and T. b. brucei, RNA-seq and RIT-seq were undertaken in previous 
work in the De Koning laboratory (Ali, 2013; Alzahrani, 2017). In order to gain 
more details about pyrimidine salvage pathways in Trypanosoma and Leishmania 
species, 5-FU-resistant cell lines of T. b. brucei BSF and L. mexicana 
promastigotes were generated by subjecting cultures to an increasing 
concentration of 5-FU in vitro (Ali et al., 2013a; Alzahrani et al., 2017). 
 RNA-seq of WT and 5-FU resistant T. brucei BSF and L. 
mexicana promastigotes 
According to (Wang et al., 2009; Kukurba and Montgomery, 2015), in order to 
determine the differential gene expression under varying environmental or 
physiological conditions, RNA-sequencing is taken as a prevailing method where 
deep-sequencing technologies are employed. The findings showed that first [3H]-
5-FU rates in Tbb-5FURes reduced greatly, and 5-FU and uracil transport in 
Lmex-5FURes were completely eliminated (Ali et al., 2013a; Alzahrani et al., 
2017). To find out changes in transcription between wild-type cells and 5-FU 
resistant cell lines of L. mexicana and T. brucei, analysis of RNA-seq was 
conducted. The RNA-seq, and parts of the analysis of the dataset, was carried 
out in the Glasgow Polyomics Facility, including the preparation of cDNA and 
Illumina sequencing. All the resistant strain genomes (Tbb-5FURes and Lmex-
5FURes) were sequenced in parallel with their respective parental wild-type 
strains. The main reason for the screening was to find genes encoding 
pyrimidine-specific transporters in L. mexicana and/or T. brucei. A statistical 
analysis was conducted in order to find a group of genes that were expressed 
differentially between the resistant and sensitive strains. 
For L. mexicana promastigotes, RNA-sequencing of the parental and 5-FU 
adapted strains of L. mexicana showed numerous changes in gene expression. 
There were 3967 differentially expressed genes in L. mexicana (P < 0.05), while 
the total number of down-regulated genes with a minimum of 3-TM domains in 
Lmex-5FURes was 100. When compared with L. mexicana M379 wild-type 
promastigotes, fatty acid desaturase gene (LmxM.10.1320; log2 fold-change = -
0.32; P ≤ 0.01) was one of the most highly annotated differentially down-
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regulated genes in Lmex-5FURes with 6 TMs, and the next was a glucose 
transporter gene (LmxM.32.0290; log2 fold-change = -0.52; P ≤ 0.01) (Alzahrani, 
2017). 
Similarly, a large number of changes in gene expression were observed from 
comparative RNA-sequencing of the parental and 5-FU adapted T. brucei strains. 
There were 2828 differentially expressed genes in T. brucei (P < 0.05), while the 
total number of down-regulated genes with a minimum of 3-TM domains in Tbb-
5FURes was 248. Compared to the reference T. b. brucei TREU 927 genome, 3 
cation transporter genes (Tb11.v5.0514, Tb927.11.9000 and Tb927.11.9010; log2 
fold-change = -1.2, -1.2 and -1.04; respectively; P < 0.001) were among the most 
down-regulated genes in Tbb-5FURes, with 6-14 TMs, followed by 2 glucose 
transporter genes (Tb927.10.8520 and Tb927.10.8530; log2 fold-change = -0.78 
and -1.09; respectively; P ≤ 0.01) and a fatty acid desaturase gene 
(Tb927.2.3080; log2 fold-change = -0.68; P ≤ 0.01) (Alzahrani, 2017). 
Thus, The RNAseq highlighted fatty acid desaturases and glucose transporters in 
both kinetoplastid species, and a cluster of cation transporters specifically in T. 
b. brucei. 
 RIT-seq of 2T1 PYR6-5-/- selected with 5-FU and 6-AU 
The genome-wide RNA interference (RNAi) library screen is a superior method 
for genetic screens for genes to be connected to function and accurate 
phenotypes, where knockdown confers resistant populations. The T. b. brucei 
PCF is the first organism used in the application of this method (Alsford et al., 
2012; Chou et al., 2015; Mohr and Perrimon, 2012; Morris et al., 2002). The basic 
idea behind RIT-seq method is that every RNAi target fragment serves as barcode 
that can reveal the associated number of cells conveying the fragment in a 
mixed population (Glover et al., 2015). Over the past few years, identification of 
transporters of novel trypanosomal drug, including TbAQP2 as a determining 
factor for sensitivity of pentamidine (Baker et al., 2012; Munday et al., 2014); 
the aminopurine carrier TbAT1 as the melarsoprol transporter (Burkard et al., 
2011); and amino acid carrier TbAAT6 as the eflornithine transporter (Baker et 
al., 2011; Burkard et al., 2011); all have been made possible by the use of RNAi-
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libraries, sequencing the RNAi fragments in the cells growing out after challenge 
(RNAi Target sequencing; RITseq). Consequently, in order to identify the genes 
contributing to pyrimidine transport in T. brucei BSF, the genome-scale 
tetracycline-inducible RNAi library screens in T. brucei were implemented. 
The RNAi library screen was carried out in London School of Hygiene and Tropical 
Medicine (LSHTM) at Dr Sam Alsford’s laboratory and the library was set as per 
the established procedure (Glover et al., 2015). A pyrimidine-auxotrophic 2T1 
PYR6-5-/- cell line was generated by deleting both alleles of the PYR6-5 gene that 
is required for pyrimidine biosynthesis from the 2T1 cell line (Ali et al., 2013b). 
The NotI restriction enzyme was used to digest pZJM RNAi plasmid library so as 
to produce the 2T1 PYR6-5-/- RNAi library. Tetracycline was then used to induce 
the 2T1 PYR6-5-/- cell lines (Alsford et al., 2011; Glover et al., 2015). 
To generate Tet-inducible dsRNA expression, the pZJM-RNAi plasmid library was 
created from randomly sheared 600-bp genomic DNA fragments with 
approximately 11× genome-coverage (complexity of 500,000 fragments) (Alsford 
et al., 2011; Glover et al., 2015), which permits dsRNA expression for RNA 
interference knockdown (Glover et al., 2015). At the 14th day of incubation with 
5-FU or at the 24th day of incubation with 6-AU, genomic DNA was extracted 
from the pyrimidine auxotrophic 2T1 PYR6-5-/- cells. The resistant population 
was isolated from the rest of the samples and the remaining samples were sent 
to Beijing Genomics Institute (BGI; Hong Kong). In order to reveal the candidate 
pyrimidine transporter genes in T. brucei, RNAi target fragments were 
sequenced using an Illumina HiSeq platform. The RIT-seq data was analysed 
before applying a stringency cut off as >99 reads per kilobase per transcript. The 
results from sequencing runs with varying read depths were compared using 
barcoded reads expressed as kilobase of transcript per million mapped reads 
(RPKM) (Alzahrani, 2017; Alsford et al., 2011; Glover et al., 2015). 
Genomic DNA from the 2T1 pyrimidine auxotrophic-PYR6-5-/- cell lines 
challenged with 5-FU and 6-AU was isolated and sequenced at days 14 and 24, 
respectively. At the 14th day, the number of hits implicated from RIT-seq of 2T1 
PYR6-5-/- screened with 5-FU was 521, while the number of hits found in RIT-seq 
of 2T1 PYR6-5-/- screened with 6-AU at 24th day was 290. Based on 5-FU selection 
Ibrahim Abdullah Alfayez                               Chapter 1                                  79 
   
of 2T1 the PYR6-5-/- RNAi library, genes Tb927.10.8530 (glucose transporter 2A) 
and Tb927.2.3080 (fatty acid desaturase) with a RPKM value of 6317 and 58392, 
respectively, were the most conspicuous hits. Glucose transporter 2A and fatty 
acid desaturase were also found in the RIT-seq data for 2T1 PYR6-5-/- screened 
with 6-AU at the 24th day, with RPKM values of 4058 for glucose transporter 2A 
and 439 for fatty acid desaturase, respectively (Alzahrani, 2017). 
 Metal ion transporters 
Metal ions participate in many different important metabolic functions in the 
body, gene regulation and in free radical homeostasis. Any anomalies in metal 
ion homeostasis are likely to lead to a severe illness or even death (Nelson, 
1999; Rolfs and Hediger, 1999). Membrane proteins that are found in all living 
cells function as conduits for the regulated transport of solutes, metal ions, and 
other small molecules across the cell membranes (Neverisky and Abbott, 2016). 
The channels and ion transporters are proteins embedded with in a membrane 
and participate in many vital cell processes. These processes include the 
regulation of the electrochemical gradient across membranes, substrate 
transport, regulation of intracellular pH and energy generation. Even though 
both channels and ion transporters are membrane-bound proteins, there exists a 
few differences (Demirbilek et al., 2019; Akpunarlieva and Burchmore, 2017). 
Ion transport can either be active or passive transport. Active transport is aided 
by primary and secondary active transporters, while passive transport is 
facilitated by ion channels. The primary active transporters comprise ion pumps 
and secondary active transporters comprise ion co-transporters and exchangers 
(Neverisky and Abbott, 2016; Demirbilek et al., 2019). The key difference 
between channels and ion transporters is that some ion transporters act as ion 
pumps, facilitating the movement of ions (against the electrochemical gradient) 
across the membrane (Demirbilek et al., 2019). 
The ZIP family of metal ion transporters are broad and can be found in all 
phylogenetic levels of living organisms. The solute carrier 39 (SLC39) proteins 
belong to this family of proteins (Eide, 2004). All ZIP/SLC39A proteins are 
thought to have the same topology, consisting of eight transmembrane (TM) 
domains, C-terminal and N-terminal extracellular on the cell surface or in the 
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lumen of cell organelles (see figure 1.15A) (Bowers and Srai, 2018). The human 
genome has 14 encoded ZIP/SLC39A transporters, with their genes designated 
SLC39A1-SLC39A14. The genes encode the proteins ZIP1–ZIP14. In the human 
genome, ZIP transporters are found within distinct sub-cellular compartments 
(see figure 1.15B) (Jeong and Eide, 2013; Takagishi et al., 2017; Bowers and 
Srai, 2018). It is still not clear how proteins in the ZIP family and other 
transporters or trafficking systems coordinate in an effort to regulate zinc 
homeostasis (Jeong and Eide, 2013). Transporters and channels for inorganic ions 
have been studied less extensively as potential targets for drugs in T. brucei. 
Conversely, transporters of organic nutrients such as sugars, amino acids, 
metabolites, nucleobases, and nucleosides have been widely studied (Steinmann 
et al., 2015). 
According to Nyarko et al. (2002), heavy metals such as mercury and cadmium in 
drug sensitivity assays are extremely toxic to T. b. brucei parasites. Toxicity is 
also a key disadvantage of using heavy metals in drugs against kinetoplastid 
parasites for human use (Jeong and Eide, 2013; De Carvalho and de Melo, 2017). 
Many studies have shown that ion transporters are essential in the survival of 
Leishmania and Trypanosoma parasites. Steinmann et al. (2015) reported that 
calcium-activated potassium channels TbK1 and TbK2 are vital for T. brucei BSF 
to survive in culture. The reason for this is that RNAi-mediated downregulation 
of either of the proteins found in T. brucei BSF parasites causes growth defects 
followed by cell death. Although Leishmania iron transporter, LIT1, can 
transport divalent cations of zinc, manganese and cadmium, it is exhibits 
increased affinity for ferrous iron. When the LIT1 gene was deleted in L. 
amazonensis amastigotes, it made the parasites unable to proliferate within 
macrophages that would otherwise result in the development of lesions in mice 
(Richard et al., 2002; Flannery et al., 2011). Null mutants of the mitochondrial 
iron transporter, MIT1, in Leishmania were unsuccessfully generated. This 
further supports the crucial role played by this ion transporter in ensuring the 
survival of L. amazonensis promastigotes (Huynh et al., 2012). 
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Figure 1.15: Predicted topology and subcellular localisation of the metal ion transporter 
proteins of the ZIP family. A) Predicted structures and transport mechanisms of ZIP family 
metal ion transporters. B) Subcellular localization of human ZIP transporters. Zinc transport 
directions are displayed as arrows, and the inset shaded in yellow depicts a ZIP transporter 
's predicted topology. Figures taken from (Bowers and Srai, 2018; Jeong and Eide, 2013). 
 Glucose transporters 
During the metabolic activity of kinetoplastid parasites, glycosomes play a very 
important role. In kinetoplastid species such as Trypanosoma and Leishmania, 
the glycolytic pathway is different in the way that the enzymes of that 
metabolic pathway are present in a glycosome, a specialised organelle found in 
the cytoplasm  (Opperdoes, 1987; Gualdrón‐López et al., 2013; Bayele et al., 
2000). Within this organelle in kinetoplastids, the compartmenting for glycolysis 
is different from other organisms whose glycolytic pathway occurs free in the 
cytosol, producing pyruvate, before proceeding to further oxidation within the 
mitochondria (Hannaert, 2011; Hart and Opperdoes, 1984). Glucose is a basic 
and important source of energy for different organisms, including Trypanosoma 
and Leishmania spp. However, hydrophilic glucose cannot pass through the cell 
membrane into the inside of a cell, and instead depends on glucose transporters 
embedded in cell membranes, which enable the passive transportation of 
hydrophilic glucose molecules intracellularly (Delrot et al., 2000; Akpunarlieva 
and Burchmore, 2017; Manolescu et al., 2007; Pereira and Silber, 2012). Once 
inside the cell, the glucose is broken down by glycolysis and the pentose 
phosphate pathway (Barrett, 1997; Landfear, 2011). In glycolysis, a molecule of 
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glucose is metabolised into two molecules of pyruvate, and yields two molecules 
of ATP (Saunders et al., 2011; Drew et al., 2003). 
 Leishmania glucose transporters 
Glucose is an important source of energy for L. mexicana promastigote form. It 
is also an important nutrient for building blocks used in synthesising different 
biomolecules (Akpunarlieva and Burchmore, 2017; Rodriguez-Contreras et al., 
2007). To this end, glucose transporters play a crucial role in the viability of a 
variety of pathogenic protozoa, where they have a great influence in both 
nutrition and metabolism. Considering Leishmania spp, the parasite experiences 
different stages of life cycle, which exposes the organism to different types of 
sugars in varying concentrations in their environments. The procyclic 
promastigotes depend on the catalysis of glucose and amino acids, and at the 
later stages of promastigote development, more amino acid is used, and less 
glucose (Inbar et al., 2017; Landfear, 2010; Rodriguez-Contreras et al., 2007). 
The glucose transporters in L. mexicana promastigote and amastigote forms have 
a high glucose affinity, with Km values of 24 μM and 29 μM for promastigote and 
amastigote, respectively. The Km values for the two transporters are closely 
comparable, suggesting that the same transporter is expressed in both stages of 
development (Burchmore and Hart, 1995). 
There exists a cluster of three glucose transporters in the genome of L. 
mexicana, LmexGT1, LmexGT2 and LmexGT3 (Burchmore et al., 2003a). This 
cluster is part of the sugar transporter sub-family of the Major Facilitator 
Superfamily (MFS) (Deng et al., 2014; Dean et al., 2014). Although the three 
LmexGTs differ in terms of their hydrophilic domains at the carboxyl and amino 
terminal ends, their amino acid sequence is 90% similar (Burchmore and 
Landfear, 1998). Each of the three glucose transporters has twelve 
transmembrane domains, enabling them to transport glucose molecules through 
the plasma membrane via a passive transport mechanism (Burchmore et al., 
2003a; Silber et al., 2009; Pereira and Silber, 2012). The cluster consisting of 
these three transporters in L. mexicana promastigotes was deleted by a targeted 
gene replacement. Following this technique, it was discovered that the transport 
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of radiolabelled 2-deoxy-D-glucose in Lmex-GT1-3 KO cells ‘Δlmexgt’ was 
completely abolished (Burchmore et al., 2003a). 
With the individual re-expression of the three transporters LmexGT1, LmexGT2 
and LmexGT3 into complete knockout of LmexGT1-3 in L. mexicana 
promastigotes, the uptake of glucose, galactose, fructose and mannose is 
observed. LmexGT2 and LmexGT3 have Km values of 109 μM and 208 μM 
respectively, which means that these two transporters are high affinity glucose 
transporters. On the other hand, LmexGT1 has a high Km value of 1.22 mM, 
suggesting a relatively low glucose affinity. From fluorescent microscopy, 
LmexGT1 is mainly localised in the flagellum, while LmexGT2 and LmexGT3 are 
concentrated on the plasma membrane (Burchmore et al., 2003a; Rodriguez-
Contreras et al., 2007). These observations are consistent with the lower glucose 
levels in the environments in which promastigotes are exposed to. LmexGT2 has 
mRNA levels in promastigotes approximately fifteen times higher compared to 
the amastigote form, while mRNA levels in both LmexGT1 and LmexGT3 are 
expressed at the same levels in both stages of life cycle (Burchmore and 
Landfear, 1998). In addition, there was a low growth rate of Lmex-GT1-3 KO 
cells, suggesting a lower rate of infection to macrophages. This affirms that the 
survival of amastigotes is at least partly dependent on the expression of isoforms 
of LmexGT1-3 (Burchmore et al., 2003a). 
 Trypanosomes glucose transporters 
The African trypanosomes that reside in the bloodstream depend entirely on the 
uptake of glucose to generate energy by glycolysis. The BSF that live in the 
mammalian blood express a broad specificity, high capacity hexose transporter. 
The absolute requirement for glucose uptake for the survival of these organisms 
makes the transporter and the glycolytic enzymes potential drug targets (Lamour 
et al., 2005; Landfear, 2010). Conversely, trypanosomes of procyclic form use 
amino acids (mainly proline) as their main source of energy using the Krebs cycle 
and the respiratory chain (Pereira and Silber, 2012; Tetaud et al., 1997). 
Glucose uptake by T. brucei BSF was studied by using an inhibitor for its 
transporter and it was found that the glucose transport mechanisms are very 
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distinct from that found in human erythrocytes and had 10 fold increased 
affinity for glucose (Seyfang and Duszenko, 1993). 
The genome of T. brucei contains a cluster of the hexose transporter genes with 
6 copies of the THT1 genes, and 5 copies of THT2 (Landfear, 2010). THT1 mRNA 
is mainly expressed in the parasite of the bloodstream form, while THT2 is 
entirely expressed in the procyclic form (Haanstra et al., 2011). Considering the 
amino acid sequence, THT1 and THT2 are about 80% identical (Borst and 
Fairlamb, 1998). The six genes encoding THT1 are >99.5% identical by amino acid 
sequence. The same is true for the THT2 isoforms and their amino acid 
sequence, which are also >99.5% identical. The functions of three glucose 
transporters 1B, 1E and 2A have been experimentally verified (Barrett et al., 
1995; Feistel et al., 2008; Bringaud and Baltz, 1993). On the other hand, the 
functions of the other eight glucose transporter genes have been deduced from 
their amino acid sequences. In the previous studies, glucose transporter 1B was 
confirmed as a functional glucose transporter, heterologously expressed in L. 
mexicana for the uptake of glucose (Feistel et al., 2008). The glucose 
transporter 1E was expressed in Xenopus oocytes, and showed a significant 
increase in the uptake of radiolabelled 2-deoxy-D-glucose (Bringaud and Baltz, 
1993). Also Barrett et al. (1995), cloned glucose transporter 2A from T. brucei 
PCF, which is expressed in Xenopus oocytes, a confirmation that the 2A is 
responsible for glucose transport in PCF of trypanosomes. 
 Uracil transporter families in other species 
Uracil transport is a physiological activity of a cell present in the most organisms 
whether unicellular or multicellular. The molecular basis of uracil transport 
comes from microbiological studies, about half a century ago (de Koning and 
Diallinas, 2000) Further, previous studies on bacteria and fungi have shown the 
existence of uracil transport in those cells (Amillis et al., 2007). The uracil 
transporter from Aspergillus nidulans (FurD) belongs to the NAT/NCS2 family 
(nucleobase ascorbate transporters or nucleobase cation symporter family 2), 
whose function is to transport uracil and protons (Hamari et al., 2009). NAT 
transporters also participate in mediating the uptake of toxic pyrimidine 
analogues, for example, the 5‐fluorouracil which is an anticancer analogue 
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(Kourkoulou et al., 2018; Byrne et al., 2016). It has been found that most of the 
uracil transport mutants are resistant to 5-fluorouracil. The uracil transport 
mutants were used as a guide in identifying and cloning the gene coding for 
uracil permeases in both bacteria and yeast (Andersen et al., 1995). The 
knockout of the FurD gene in A. nidulans contributed to a full phenotype of 
resistance to 5-fluorouracil and completely reduced uptake of radiolabelled 
uracil (Amillis et al., 2007). The Km value of FurD is 0.45 μM, implying a high 
affinity of this transporter to uracil and its position 5-substituted analogues: 5-
fluorouracil (Ki of 0.46 μM), 5-chlorouracil (Ki of 0.46 μM) and 5-aminouracil (Ki 
of 0.86 μM). However, FurD has no affinity for adenine, cytosine, guanine, 
hypoxanthine, thymidine or uridine (Ki >1500 μM). FurD mediated radiolabelled 
uracil  and was inhibited by xanthine (Ki value of 94 μM) and uric acid (Ki value 
of 99 μM) (Amillis et al., 2007). These findings suggest that FurD transporter has 
the capability to transport xanthine and uric acid (Hamari et al., 2009). 
Given that BLAST analysis does not identify any FurD homologues in either 
metazoan or protozoan genome databases, the uptake of uracil must be 
mediated by a transporter from another family of genes (De Koning, 2007; 
Amillis et al., 2007). The closest homologues of FurD include the Fur4p gene, 
which encodes the Saccharomyces cerevisiae uracil transporter (Jund et al., 
1977; JUND et al., 1988), the PIUP gene which encodes the Paenibacillus larvae 
uracil permease, and UraA gene which encodes the Escherichia coli uracil 
transporter. These genes have amino acid similarities 46.2% for Fur4p , 54.6% for 
PlUP and 37.1% for UraA with FurD (Jund et al., 1977; JUND et al., 1988; 
Andersen et al., 1995; Stoffer-Bittner et al., 2018). Fur4p, UraA and PIUP 
mutants in S. cerevisiae, E. coli and P. larvae respectively were found to be 
resistant to 5-flurouracil and lacked radiolabelled uracil transport. Fur4p belongs 
to the NCS1 family, while UraA and P1UP are proton symporter and prototypical 
members of NAT, also known as the NCS2 family of proteins (Jund et al., 1977; 
Andersen et al., 1995; JUND et al., 1988; Stoffer-Bittner et al., 2018; Krypotou 
et al., 2015). 
The UraA/H+ symporters found in S. cerevisiae, E. coli, and A .nidulans belong to 
the NAT family of transporters. This symporter participates in the proton driven 
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uptake of uracil into the cells (Hamari et al., 2009; Kalli et al., 2015). UraA 
possesses a novel structural fold which consists of 14 transmembrane segments. 
These segments have their N terminal and C terminal domains located on the 
cytosolic side of the cells. An unwound fragment precedes two short, 
antiparallel β strands in UraA, followed by a short α helix. It is the unwound 
segment that differentiates UraA from other transmembrane proteins. The 
protein has 14 domains, which can further be divided into two main domains: 
core and gate domains. The core domain consists of TM1, TM2, TM3, TM4, TM5, 
TM8, TM9, TM10, TM11 and TM12, whereas the gate domain consists of TM5, 
TM6, TM7, TM12, TM13 and TM14. Between these two domains is an interface 
which accommodates residues that can either be protonated or deprotonated, 
meeting the requirement for symporters coupled with protons (see figure 1.16) 
(Kalli et al., 2015; Lu et al., 2011; Yu et al., 2017). The TM3 and TM10 
transmembrane regions in uracil transporter is characterised by a pair of anti-
parallel β-strands structure, which is crucial in the binding and transportation of 
substrate uracil. During the transport process, the core domain is responsible for 
substrate binding, while the gating domain becomes responsible for changing the 
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Figure 1.16: The structure of the E. coli uracil transporter UraA. A) The amino acid sequence 
of UraA; Grey colour indicates the core domain while cyan colour indicates the gate 
domain; h1 to h14 refer to the number of transmembrane helices. B) The crystal structure of 
UraA showing the gate (grey colour) and the core (cyan colour) domains. Figure modified 
from Kalli et al. (2015). 
 Aims of the study 
The main aim of this research is to identify the gene family encoding the 
protozoan pyrimidine transporters and assess candidate genes potentially 
involved in the transport of, or sensitivity to, 5-fluorouracil. For this, we will use 
functional expression and reverse genetic approaches such as overexpression and 
knockout constructs of the target genes. The research described in this thesis 
had the following five specific aims: 
1. To characterise the cation transporters of T. b. brucei BSF. 
The purpose of this chapter is to continue working on the characterization of the 
CATs, which were among the few differentially expressed transporters in the 
5FURes strain, and therefore must be considered as potential candidates for 
uracil transporter, or at least change something in the cellular biochemistry that 
changes susceptibility to 5-FU. Moreover, none of these potential transport 
genes have been previously characterised in protozoa and as such they are of 
interest in their own right as well. Here, we overexpress of CATs in the Tbb-
5FURes cell lines and continue work on the characterization of CATs to attempt 
to acquire a double knockout for these genes in T. b. brucei s427 WT, aiming to 
determine their involvement, direct or indirect, in pyrimidine uptake and 
resistance to the pyrimidine analogues. As part of the characterisation efforts, 
we also assess the susceptibility of the overexpressing cell lines Tbb-CAT1-4 to 
heavy metal ions, as the analysis of Tbb-CAT1-4 protein sequences with Pfam 
(http://pfam.xfam.org) revealed that they belong to a family of Zip zinc 
transporter (PF02535). 
2. To investigate the role of fatty acid desaturase in 5-FU resistant cells of L. 
mexicana and T. brucei that was clearly associated with 5-FU resistance for 
as yet unknown reasons. 
The aim is to understand the role of the Tbb-FAD and Lmex-FAD genes in 5-FU 
resistance. We will investigate whether overexpression of these genes restores 
the sensitivity to 5-FU, or the transport of 5-FU/uracil in vitro. 
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3. To clone and functionally express the A. nidulans uracil transporter FurD in 
order to examine whether 5-FU resistant strains could restore the sensitivity 
to 5-FU, or the transport of 5-FU/uracil. 
This would allow a functional screening of potential transporter genes. 
Moreover, it would expand knowledge of the mechanisms used by T. brucei and 
L. mexicana to transport pyrimidines. 
4. To determine whether glucose transporters are associated with resistance to 
5-FU in kinetoplastid parasites, as this possibility was prominently indicated 
in recent RITseq and RNAseq analyses. 
The primary aim of this work is to determine the sensitivity to and transport of 
5-FU after the full knockout of genes responsible for transportation of glucose in 
L. mexicana promastigotes. The chapter also focuses on examining the 
sensitivity/transport of Lmex-GT1-3 KO cells that re-express individual glucose 
transporters to 5-FU/uracil. In addition, an investigation is conducted to 
ascertain whether, when the FurD uracil transporter is introduced, this is able to 
restore the sensitivity/transport to 5-FU in Lmex-GT1-3 KO cells. Moreover, an 
assessment is carried out to find out the effects of the absence of glucose in the 
extracellular medium T. b. brucei s427 WT PCF in the sensitivity to 5-FU and the 
growth rate. 
5. To characterise the TcrNT2 and TcrNB2 transporters and assess its 
transporter activity using the L. mexicana-Cas9ΔNT1 strain as a surrogate 
system. 
This work is linked with the previous study by (Campagnaro et al., 2018b), who 
cloned TcrNT2 and TcrNB2 into the L. mexicana-Cas9 nucleoside transporter 1 
knockout cell line (L. mexicana-Cas9ΔNT1). thereby enabling their transport 
activity to be assessed. Another objective of this study is to continue working on 
the characterisation of TcrNT2 and TcrNB2 transporters to establish if they can 
be used as drug delivery system. 
 
Ibrahim Abdullah Alfayez                               Chapter 2                                 89 
 
2 Material and Methods 
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 Materials 
 Media and media components  
HMI-9 and SDM-79 medium powder for culturing T. b. brucei bloodstream form 
and T. b. brucei procyclic forms were bought from Gibco™ (Life Technologies, 
Paisley, UK). Heat-inactivated Fetal Bovine Serum (FBS) was from PAA 
Laboratories (Linz, Austria). Sodium bicarbonate (NaHCO3) and β-
mercaptoethanol were purchased from Sigma (Dorset, UK). HOMEM medium for 
culturing L. mexicana promastigote form was obtained from Gibco™ (Life 
Technologies, Paisley, UK). L-Proline was purchased from Sigma (Dorset, UK), 
whereas Penicillin-Streptomycin antibiotic was obtained from Gibco™ (Life 
Technologies, Paisley, UK). 
 Chemicals including nucleoside and nucleobase 
analogues 
Promega (Madison, USA) supplied dNTPs, GoTaq DNA Polymerase and T4 DNA 
Ligase. Both the restriction enzymes and Phusion High-Fidelity DNA Polymerase 
were obtained from New England BioLabs (Hitchin, UK). The NucleoSpin® PCR 
and Gel extraction kit, and the NucleoSpin Plasmid purification kit were 
purchased from Macherey-Nagel® GmbH & Co. KG (Düren, Germany). Dimethyl 
Sulfoxide (DMSO) and glycerol were obtained from Merck (Sigma-Aldrich 
Company Ltd, Dorset, UK). 
The Pentamidine, 6-Azauracil, 5-Fluorouracil, Amphotericin B, Miltefosine, 
Tubercidin, 5-Fluoro-2’-deoxyuridine, Deferoxamine, Salicylhydroxamate 
(SHAM), Diminazene aceturate, Cadmium(II) acetate, Mercury(II) chloride, 
Barium chloride, Lead(II) chloride,  Copper(II) chloride, Zinc chloride and Iron(III) 
chloride hexahydrate compounds, and resazurin sodium salt were bought from 
Sigma-Aldrich® (Poole, UK). Novel adenosine analogues were designed and 
synthesised by Dr. Fabian Hulpia in the laboratory of Professor Serge van 
Calenbergh (University of Ghent, Belgium). 
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 Radiolabelled compounds 
The following radiolabelled compounds were used during the project: [3H]-Uracil 
(24.8 Ci/mmol), [3H]-Thymidine (56.6 Ci/mmol) and [3H]-Adenine (40.3 
Ci/mmol) were obtained from Perkin-Elmer (Waltham, MA, USA). [3H]-5-
Fluorouracil (20 Ci/mmol) and [3H]-2-deoxy-D-glucose (18.7 Ci/mmol) were from 
Moravek Inc (California, USA). [3H]-Adenosine (40 Ci/mmol) was purchased from 
American Radiolabelled Chemicals Incorporated (St Louis, MO, USA), while 
custom-made [3H]-Pentamidine (38.4 Ci/mmol) was purchased from Amersham 
Plc (Buckinghamshire,UK). 
  Culturing of kinetoplastid cells 
 Culturing of T. b. brucei BSF and PCF 
In this project, six strains of bloodstream form (BSF) of T. b. brucei were used. 
1) Tbb-5FURes was adapted to a high level of resistance to 5-Fluorouracil (Ali et 
al., 2013a), 2) from another strain, T. b. brucei Lister 427-WT. 3) B48, a multi-
drug resistant strain that was generated by double knockout of the TbAT1 gene 
(Matovu et al., 2003) and adaptation to growth in high levels of pentamidine in 
vitro (Bridges et al., 2007). 4) T. b. brucei MITat1.2, clone 221a (2T1) strain 
(Alsford et al., 2005). was generously donated by Prof. David Horn (University of 
Dundee). 5) The pentamidine-resistant Aquaporin 2/3 double null strain 
(aqp2/aqp3 null) and 6) Aquaporin 1-3 triple null strain (aqp1/aqp2/aqp3 null); 
aqp1/aqp2/aqp3 null were obtained by the knockout of the aquaporin genes 
specifically implicated in resistance to pentamidine in field isolates (Alsford et 
al., 2012; Jeacock et al., 2017). 
The standard HMI-9 medium (Barrett and Croft, 2012; Hirumi and Hirumi, 1989) 
was used for culturing the six strains, complemented with 10% FBS, 3.0 g/L 
sodium hydrogen carbonate and 14 μl of β-mercaptoethanol per one litre of 
medium, with pH of 7.4 (T. brucei BSF cultures were not supplemented with 
Penicillin-Streptomycin antibiotic). A Millipore Express®PES Membrane Filter was 
used to filter-sterilise the medium inside the biosafety cabinet. The parasite 
cells in the vented flasks were cultured and incubated at 37 ºC under 5% CO2 and 
Ibrahim Abdullah Alfayez                               Chapter 2                                 92 
 
the parasite cells were passaged three times for every week. One strain of 
procyclic forms (PCF) of T. b. brucei-s427 WT was used in this study. PCF of T. 
b. brucei Lister s427 were maintained in non-vented plastic flasks with SDM-79 
culture medium at 27 ºC with pH of 7.4 and supplemented with 10% FBS and 7.5 
μg/mL haemin. 
 Culturing of L. mexicana promastigote form 
In this project, four strains of L. mexicana promastigote form were used: 1) L. 
mexicana wild type (MNY/BZ/62/M379 strain), 2) L. mexicana 5-FU resistant 
cells (Lmex-5FURes), a strain that was adapted to high levels of resistance to 5-
Fluorouracil in vitro (Alzahrani et al., 2017). 3) Glucose transporter null mutant 
(Lmex-GTs KO) in L. mexicana promastigotes wild type from which all three 
glucose transporters LmexGT1-3 have been deleted, and re-expression of each 
glucose transporter genes separately (Lmex-GT1, Lmex-GT2 and Lmex-GT3) in 
the Lmex-GTs KO strain (Burchmore et al., 2003a) kindly gifted by Dr Richard 
Burchmore (University of Glasgow). 4) L. mexicana-Cas9 T7 strain (derived from 
L. mexicana WT promastigotes by expression of the Streptococcus pyogenes Cas9 
nuclease gene ‘Cas9’ and maintained on 32 μg/mL hygromycin  (Beneke et al., 
2017). As described by (Al-Salabi et al., 2003), HOMEM medium was used to 
culturing of L. mexicana cell lines in the unvented flask, supplemented with 10% 
of FBS and 1% Penicillin-Streptomycin antibiotic at 25 °C. 
  Growth curves 
The standard HMI-9 medium added with 10% FBS was used to determine the 
growth rates of the T. b. brucei BSF strains, while the growth rates of the T. b. 
brucei PCF were determined in the SDM-79 medium supplemented with 10% FBS 
and either 1 g/L of glucose, 0.2 g/L of glucose or no glucose. The growth rates 
of the L. mexicana promastigotes were determined in the standard HOMEM 
medium supplemented with 10% FBS in the presence and absence of 5 mM of L-
proline. After every 24 hours, cells were counted in a sample of the culture, 
using either a Neubauer haemocytometer chamber (Hawksley, UK) or by a 
coulter particle counter and size analyzer (Beckman, US) to count the cells in 
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triplicate. An average of the triplicate readings was taken and plotted using 
GraphPad PRISM 8 software to obtain the growth curves. 
 Preparation of stabilates 
In order to prepare stabilates of L. mexicana promastigotes and T. b. brucei 
BSF/PCF, cell cultures were added to an equivalent volume of the corresponding 
culture medium (HMI-9, SDM-79 or HOMEM) containing 30% sterilized glycerol, in 
long-term storage cryogenic tubes. Before the cryogenic tubes were transferred 
to liquid nitrogen store, they were first frozen at a temperature of -80 °C for 72 
h. For the recovery of stabilates, the cryogenic tubes were brought out from the 
liquid nitrogen store, and thawed at 25 °C and then cultivated to the suitable 
medium. In this project, the cells were renewed after 20 passages by bringing 
out fresh cells from the liquid nitrogen store. 
 Molecular techniques 
The sequences of the nucleotide and amino acid for a gene of interest were 
obtained from GeneDB (genedb.org) and TritrypDB (tritrypdb.org/tritrypdb) 
websites. The sequence alignments and the primers that were used in this 
project were created and designed by using the CLC Genomics Workbench 
version 7.0 software package (CLC bio, Qiagen). 
 Polymerase chain reactions PCR 
All the primers used in this project were all synthesized by Eurofins MWG Operon 
(Ebersberg, Germany) and Sigma-Aldrich (Dorset, UK). PCR with specific primers 
was used to amplify the genomic DNA of T. b. brucei, T. cruzi and L. mexicana. 
In order to determine the best annealing temperature, a gradient PCR was 
performed. A gene of interest (GOI) from the genomic DNA in Table 2.1 and 
Table 2.2 was amplified by the Phusion High-Fidelity DNA Polymerase, whereas 
GoTaq DNA Polymerase was used for the PCR screening in Table 2.3 and Table 
2.4. Upon completion of the PCR reaction, a 1% or 2% of agarose gel (1 g or 2 g 
of agarose in 100 mL of 1% TAE buffer) was run to visualise the PCR products 
with 5 μL of SYBR Safe DNA gel stain (Invitrogen) under UV light. 
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Table 2.1: The PCR master mix for Phusion High-Fidelity DNA Polymerase. 
No. Component Volume 
1 dd H2O 34 µl 
2 5x Phusion GC buffer 10 µl 
3 10mM dNTP 1 µl 
4 10 µM Forward primer 2 µl 
5 10 µM Reverse primer 2 µl 
6 Genomic DNA 0.5 µl 
7 Phusion polymerase 0.5 µl 
Total of reaction 50 µl 
Table 2.2: The PCR condition for Phusion High-Fidelity DNA Polymerase. 
Hot lid on 110°C  
Temperature step: 98°C for 30 seconds 
Start cycle (x35) 
Temperature step: 98°C for 10 seconds 
Temperature step: *°C for 40 seconds (*: Best melting temperature based on a 
gradient PCR) 
Temperature step: 72°C for * seconds (*:30 sec/kb of DNA of interest) 
End cycle 
Temperature step: 72°C for 10 min 
Store at 10°C - ∞ 
Table 2.3: The PCR master mix for GoTaq DNA Polymerase. 
No. Component Volume 
1 dd H2O 34 µl 
2 5x GoTaq reaction buffer 10 µl 
3 10mM dNTP 1 µl 
4 10 µM Forward primer 2 µl 
5 10 µM Reverse primer 2 µl 
6 Genomic DNA 0.5 µl 
7 Go Taq polymerase 0.5 µl 
Total of reaction 50 µl 
Table 2.4: The PCR condition for GoTaq DNA Polymerase. 
Hot lid on 110°C  
Temperature step: 95°C for 3 min 
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Start cycle (x35) 
Temperature step: 95°C for 30 seconds 
Temperature step: *°C for 30 seconds (*: Best melting temperature based a 
gradient PCR) 
Temperature step: 72°C for * seconds (*:1 min/kb of DNA of interest) 
End cycle 
Temperature step: 72°C for 10 min 
Store at 10°C - ∞ 
 List of primers for PCR 
Table 2.5 displays the primers used in the genetic modification of L. mexicana 
and T. b. brucei. Suitable restriction sites were added onto particular primers so 
as to permit the cloned DNA fragment to be digested and then ligated into a 
suitable plasmid. 






Sequence (5'UTR – 3'UTR) 
Amplicon 
name 




HDK1339 Reverse BamHI 
GGTTGGATCCTTAACTGCGATAAAT
GC 




HDK1345 Reverse BglII 
AATCAGATCTTTACGCGCCCTTCCCG
G 




HDK1428 Reverse XhoI 
GGTTCTCGAGTCAGTAAACAGCAAA
AC 





HDK1538 Reverse XhoI 
CCGGCTCGAGCTATATGGCAAGCAC
AATA 
HDK1551 Forward BglII 
AGATCTATGGGACTGGGCTTCGAAT
TCT TcrNT2 
HDK1552 Reverse XhoI 
AAATTTCTCGAGCTACCCGCGCAAG
GTCTG 
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1-4 










HDK802 Forward ApaI GGGCCCATGCCTTTTTTCAGTTCC TcrNB2 in 
Tryp HDK803 Reverse MluI 
ACGCGTCTATATGGCAAGCACAATA
GCC 
HDK535 Forward - CGGACAGGTATCCGGTAAGC - 
HDK335 Reverse - TGGCCACACAACCCGGTGT - 
HDK340 Reverse - CGTGGAGCAGCTGAAGGACA - 
HDK531 Forward - ATGCGTTTCGGTCGCTTTCA - 
HDK532 Reverse - TCAGTAAACAGCAAAACCCT - 
HDK429 Forward - TTCGAGTTTTTTTTCCTTTT - 
HDK1052 Forward - GCTGCTGTCCAAGTGGCACTAG Tbb-CAT 1-
4 KO HDK1053 Reverse - CTGACGGTGGCGCTTAGGCAT 
HDK1523 Forward  TCCGCTGCAAACAAACTTCTGG 
NT1 KO 
HDK1524 Reverse  TACGCCGCTACGATGATCCAGC 
MB39 Forward - ATGAAAAAGCCTGAACTCAC 
Hygromycin 
MB40 Reverse - ACTCTATTCCTTTGCCCTCG 
MB37 Forward - ATGATTGAACAAGATGGATTGC 
Neomycin 
MB38 Reverse - TCAGAAGAACTCGTCAAGAAG 
HDK282 Forward - CGAATTCATGGCCAAGCCTTTGTCT 
Blasticidin 
HDK283 Reverse - CGAATTCTTAGCCCTCCCACACATA 
 Isolation of genomic DNA 
The NucleoSpin Tissue kit (MACHEREY-NAGEL, Germany) was used to extract 
genomic DNA for the T. b. brucei and L. mexicana, according to the instructions 
given by the manufacturer. Firstly, the cells were centrifuged at 1000 × g for 10 
min. Thereafter, the cells were resuspended in 200 μL Buffer T1, 200 μL Buffer 
B3 and 25 μL Proteinase K (provided with the kit). The mixture was vortexed 
vigorously and incubated at a temperature of 70 °C for a period of 10 to 15 min. 
Next, 210 μL of pure ethanol was added and vortexed vigorously. The specimen 
was thereafter put into a NucleoSpin tissue column and centrifuged for 1 minute 
at 11,000 × g. The specimen was washed by using 500 μL Buffer BW and 
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thereafter centrifuged for 1 minute at 11,000 × g. Then, the specimen was 
washed again by using 600 μL Buffer B5 and centrifuged for 1 min at 11,000 × g. 
Subsequently, the specimen was centrifuged for 1 min at 11,000 x g.  Lastly, 
buffer BE (50 μL) was added to elute DNA from the membrane. The 
concentration of DNA was measured by using the NanoDrop-1000 
spectrophotometer (Thermo Scientific, UK), and the specimens of the DNA were 
kept at a temperature of -20 °C. 
 Plasmid construction and transfection 
 Expression plasmids in T. b. brucei and L. mexicana 
 Generation of plasmids for expression and transfection into T. 
b. brucei BSF 
The fatty acid desaturase gene Tb427.02.3080 (Tbb-FAD), four cation 
transporter genes Tb427tmp.01.0725 (Tbb-Cation1), Tb427tmp.01.0730 (Tbb-
Cation2), Tb427tmp.01.0760 (Tbb-Cation3) and Tb427tmp.01.0770 (Tbb-
Cation4), and Aspergillus nidulans uracil transporter gene A6N844 (FurD) and T. 
cruzi NB2 TcCLB.506445.110 (TcrNB2) were expressed in the Tbb-5FURes, Tbb-
s427 WT and B48 strains by using the pHD1336 plasmid that contains the 
Blasticidin resistance gene. The pHD1336 vector is constitutively expressed and 
integrates into the non-transcribed ribosomal RNA (rRNA) spacer (Figure 2.1) 
(Biebinger et al., 1997) and has been found to be very effective for the 
overexpression of genes in T. b. brucei BSF and PCF (Munday et al., 2013; 
Alzahrani et al., 2017; Campagnaro et al., 2018b). The suitable restriction 
enzymes were used to digest the pHD1336 plasmid and the gene of interest 
(GOI). Then, as explained by the manufacturer’s protocol, the ligation of 
digested GOIs into the digested pHD1336 plasmid was performed, using the T4 
DNA Ligase kit. After that, the pHD1336 plasmid including the GOIs was 
transformed into the XL1-blue cells (E. coli) using a heat shock approach 
according to the manufacturer’s protocol (Appendix 3). PCR screening of 
bacterial colonies on the plate was used to detect the colonies containing the 
desired target gene by using HDK429 forward and HDK335 reverse primers of the 
plasmid. Briefly, after overnight incubation, pick bacterial colonies from the LB 
agar plate with a sterile 200 µl pipette tip (green), and streak them onto a new 
Ibrahim Abdullah Alfayez                               Chapter 2                                 98 
 
LB agar plate and then use the residual bacteria for a PCR reaction, dipping the 
tip into the PCR reaction mix. The new LB agar plate was then incubated at 37 
ºC overnight. For each plasmid, five colonies containing the GOI were grown 
overnight in 10 mL of 100 µg/mL of ampicillin at 37 °C. Cultures were 
centrifuged at 4,500 x g for 10 min, the supernatant discarded and the pellet 
used for the plasmid purification (miniprep) using the NucleoSpin Plasmid 
purification kit following the manufacturer’s instructions. After PCR screening, 
the pHD1336 plasmids having the GOIs were sent to Source Bioscience for Sanger 
sequencing (Livingston, United Kingdom). After the sequences of the target gene 
were verified, the produced plasmids were named as pHDK219 (Tbb-FAD), 
pHDK069 (FurD), pHDK199 (Tbb-Cation1), pHDK200 (Tbb-Cation2), pHDK201 
(Tbb-Cation3), pHDK202 (Tbb-Cation4) and pHDK223 (TcrNB2). 
For transfection, the linearization was set up by NotI restriction enzyme; 1×107 
T. b. brucei BSF were washed with 100 µL of transfection buffer and mixed with 
10 µg of ethanol-precipitated DNA of the expression construct. The cells were 
electroporated using Program X-001 of the Amaxa Nucleofector (Amaxa AG, 
Germany). Cells were then transferred to 20 mL of HMI-9 medium containing 10% 
FBS and allowed to recover overnight at 37 °C and 5% CO2. After recovery, 5 
μg/mL Blasticidin was added to the culture as a selective marker for the 
expression construct; using limiting dilution (1:10, 1:25 and 1:100) the cells were 
plated out in a 96-well plate to produce individual clones. PCR was used to 
screen the antibiotic resistant clones: 1) the forward primer of pHD1336 plasmid 
HDK535 and the reverse primers of the GOI were used to confirm the linearity of 
the transfected vector, whereas, 2) the forward primers of the GOI and the 
reverse primer of the pHD1336 plasmid ‘HDK335’ were used to confirm the 
presence of the GOIs into Tbb-5FURes, Tbb-s427 WT and B48 strains after 
transfection has occurred. 
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Figure 2.1: Linear map of pHD1336 plasmid. 
This plasmid was used to over-express Tbb-FAD, Tbb-Cation1, Tbb-Cation2, Tbb-Cation3 
and Tbb-Cation4 genes into Tbb-5FURes and Tbb-s427 WT strains, and heterologous 
expression of FurD gene in Tbb-5FURes strain and TcrNB2 gene in B48 strain. 
 Generation of plasmids for expression and transfection into L. 
mexicana promastigote form 
The fatty acid desaturase gene LmxM.10.1320 (Lmex-FAD) and the Aspergillus 
nidulans uracil transporter gene A6N844 (FurD) were expressed in the Lmex-
5FURes, L. mexicana WT and Lmex-GTs KO strains by using the pNUS-HcN 
plasmid which contains a G418 resistance gene (Figure 2.2) (Tetaud et al., 
2002). In addition, the pNUS-HcN plasmid was used to express the T. cruzi high-
affinity thymidine transporter TcCLB.506773.50 (TcrNT2) and T. cruzi NB2 
TcCLB.506445.110 (TcrNB2) in the L. mexicana-Cas9-NT1 KO strain. The pNUS-
HcN vector was used to heterologously express TbAQP2 in L. mexicana 
promastigote form, causing a very large sensitisation to pentamidine (40-fold) 
and cymelarsan (~1000-fold) (Munday et al., 2014). 
The appropriate restriction enzymes were used to digest the pNUS-HcN plasmid 
and the gene of interest (GOI). Thereafter, the T4 DNA Ligase kit was used to 
perform the ligation of the digested GOI into the digested pNUS-HcN plasmid. 
After ligation, the pNUS-HcN plasmid containing the GOI was transformed into 
the XL1-blue cells (E. coli) by heat shock as described in the manufacturer’s 
protocol. The bacterial colonies that were on the plate were subjected to PCR 
screening using the forward primer of the GOI and the reverse primer of pNUS-
HcN plasmid (HDK340), which was used to detect colonies having the desired 
target gene. After PCR screening, the pNUS-HcN plasmid containing the desired 
target gene was sent to Source Bioscience (Livingston, United Kingdom) for 
Sanger sequencing. Once the correct sequences were verified, 25 µg of the 
generated plasmids (pHDK220 ‘Lmex-FAD’, pHDK245 ‘FurD’, pHDK270 ‘TcrNT2’ 
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and pHDK271 ‘TcrNB2’) were precipitated by ethanol and resuspended in 15 µL 
sterile water. 
The plasmid DNA was not digested before transfection since it was designed for 
episomal expression. L. mexicana promastigotes (5 × 107 cells) were washed with 
100 µL transfection buffer and mixed with 10 µg DNA of the expression 
construct. The cells were electroporated with the Amaxa Nucleofector Device 
(Amaxa AG, Germany), using Program U-033. Cells were then transferred to 20 
mL HOMEM medium containing 10% FBS and allowed to recover overnight at 25 
°C. After recovery, 50 μg/mL of G418 was added to the culture as a selection 
agent for the expression construct. After that, the cells were plated out in a 96-
well plate to produce individual clones by limiting dilution (1:10, 1:25 and 
1:100). PCR was used to screen the positive clones, the forward primer of the 
GOI and the reverse primer of pNUS-HcN plasmid (HDK340) were used to confirm 
the presence of the target gene into Lmex-5FURes, Lmex-WT, Lmex-GTs KO and 
L. mex-Cas9-NT1 KO strains after transfection. 
 
Figure 2.2: Linear plasmid map of pNUS-HcN. 
This plasmid was used to express Lmex-FAD and FurD in Lmex-5FURes, Lmex-WT and 
Lmex-GTs KO strains, and heterologous expression of TcrNT2 and TcrNB2 in L. mex-Cas9-
NT1 KO and Lmex-5FURes strains. 
 Gene knockout plasmids in T. b. brucei and L. mexicana 
 Targeted gene replacement plasmids 
Dr. Khalid Alzahrani (Prof Harry de Koning Lab, University of Glasgow) has 
generated the plasmid constructs that are used for deleting the chromosomal 
locus containing the four cation transporter genes (CATs) in the T. b. brucei 
s427-WT. In this study, pHDK149 (with Blasticidin resistance cassette), pHDK150 
(with Neomycin resistance cassette), and pHDK207 (with Hygromycin B 
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resistance cassette) are the three knockout constructs used to remove CATs from 
the genome of T. b. brucei s427 WT (Figure 2.3). The four CAT genes are located 
in tandem array on chromosome 11 and are annotated as cation transporters 
(Tb427tmp.01.0725, Tb427tmp.01.0730, Tb427tmp.01.0760 and 
Tb427tmp.01.0770) in the TritrypDB (tritrypdb.org/tritrypdb) website. Before 
transfection, NotI and XhoI restriction enzymes digested the knockout constructs 
so as to release the antibiotic resistance cassette between the 3’UTR and 5’UTR 
flanking regions of the four-CAT tandem array (Figure 2.3). These constructs 
were then transfected into T. b. brucei s427-WT as explained in section 
2.3.4.1.1. 
 
Figure 2.3: The plasmid construct for the knockout of four cation transporter genes (CATs) 
in T. b. brucei s427-WT. 
 Targeted CRISPR gene knockout plasmids 
The Knockout strategy of nucleoside transporter 1 (NT1) containing the two 
nucleoside transporter genes (NT1.1 and NT1.2) in L. mexicana-Cas9 was 
performed exactly as described previously (Beneke et al., 2017). L. mexicana-
Cas9 T7 strain (Beneke et al., 2017) was generously donated by Professor Eva 
Gluenz (University of Oxford). Briefly, primers number 1 to 5 (Listed in Table 
2.6) were used to produce NT1 KO in L. mexicana-Cas9 and these primers were 
designed using an online platform named LeishGEdit (Beneke et al., 2017). The 
deletion of NT1 locus requires the amplification of two single guide RNA (sgRNA) 
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by using primers 1 - 3 to direct Cas9 (nuclease and typically derived from 
Streptococcus pyogenes) to cut immediately upstream (5′) or downstream (3′) of 
the target locus of NT1 (Table 2.7 and 2.8). To create CRISPR plasmids specific 
to the target locus of NT1, pTBlast and pTPuro plasmids (with blasticidin and 
puromycin cassettes respectively (Figure 2.4)) were amplified using primers 4 
and 5 (Table 2.9 and 2.10). These constructs were to integrate into the NT1 
locus after cutting with the two sgRNAs. 
Table 2.6: The list of primers that are designed and used to generate NT1 KO in L. mexicana-
Cas9. 
1 5’ and 3’ sgRNA primers: Low case indicates the T7 RNAP promoter (left), Upper case 
indicates the 20 nucleotides of the sgRNA target sequences (middle) and Low case 
indicates Cas9-backbone-start (right). 2 Upstream forward and downstream primers (NT1 
KO): Upper case indicates the 30 nucleotides homology flanks for target-gene specific (left) 
and Lower case indicates primer binding sites for pTBlast and pTPuro (right). 
No. Primer name Sequence (5’ → 3’) 




HDK15081 5' sgRNA primer (NT1 KO) 
gaaattaatacgactcactataggTGCGACTTTGG
ATGCACTGAgttttagagctagaaatagc 













Table 2.7: The PCR reaction that was prepared for the amplification of 5’ and 3’ sgRNA. 
No. Component Volume 
1 dd H2O 23.5 µl 
2 Phusion HF buffer 5 µl 
3 10mM dNTPs 1 µl 
4 10 µM G00 primer 10 µl 
5 10 µM of 5’ or 3’ sgRNA primers 10 µl 
6 Phusion polymerase 0.5 µl 
Total of reaction 50 µl 
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Table 2.8: The programme that was used for the amplification of 5’ and 3’ sgRNA by using 
PCR. 
Temperature step: 98°C for 30 seconds  
Start cycle (x35) 
Temperature step: 98°C for 10 seconds 
Temperature step: 60°C for 40 seconds 
Temperature step: 72°C for 15 seconds 
End cycle 
Temperature step: 72°C for 10 min 
Store at 10°C - ∞ 
Table 2.9: The PCR reaction that was prepared for the amplification of pTBlast and pTPuro 
plasmids. 
No. Component Volume 
1 dd H2O 34 µl 
2 Phusion HF buffer 8 µl 
3 10mM dNTPs 1 µl 
4 50% MgCl2  3 µl 
5 3% DMSO 2.4 µl 
6 10 µM Upstream forward primer 16 µl 
7 10 µM Downstream reverse primer 16 µl 
8 30 ng of pTBlast or pTPuro plasmids 0.5 µl 
9 Phusion polymerase 0.5 µl 
Total of reaction 80 µl 
Table 2.10: The programme that was used for the amplification pTBlast and pTPuro 
plasmids by using PCR. 
Hot lid on 110°C  
Temperature step: 94°C for 5 min  
Start cycle (x40) 
Temperature step: 94°C for 30 seconds 
Temperature step: 65°C for 30 seconds 
Temperature step: 72°C for 2.15 min  
End cycle 
Temperature step: 72°C for 7.30 min 
Store at 10°C - ∞ 
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After that, the two sgRNA templates and two resistance cassettes (pTBlast and 
pTPuro) were transfected into L. mexicana cas9 as described by (Beneke et al., 
2017) into L. mexicana-Cas9 and that cell line was maintained in the presence of 
32 μg/mL of hygromycin. For the transfection, the two sgRNA templates and two 
KO resistance cassettes were heat-sterilised at 94 °C for 5 minutes. Then, 1 × 
107 cells of L. mex-Cas9 promastigotes was washed with 150 µL of transfection 
buffer and mixed with 100 µL of the heat-sterilised mixture of the two sgRNA 
templates and the two KO resistance cassettes. The mix was electroplated with 
the Amaxa Nucleofector Device, using Program X-001 (Amaxa AG, Germany). 
Cells were then transferred to 20 mL HOMEM medium containing 10% FBS and 
allowed to recover overnight at 25 °C. After recovery, 5 μg/mL of blasticidin and 
20 μg/mL of puromycin were added to the culture as a selective marker for the 
knockout constructs. After that, the cells were plated out in the 96-well plate to 
produce individual clones by limiting dilution (1:10, 1:25 and 1:100). Thus, to 
yield the NT1 KO, L. mexicana-Cas9 was transfected once, with two sgRNA 
templates and two antibiotic resistance markers (pTBlast and pTPuro). The 
combination of two antibiotic resistance markers was used to eliminate any 
heterozygous cells that retain a copy of NT1. 
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Figure 2.4: The plasmid maps of (A) pTBlast and (B) pTPuro constructs for the knockout of 
the target locus of NT1 in L. mexicana-Cas9 promastigotes by using CRISPR technique. 
pT plasmids serve as template DNA for PCR amplification of blastcidine and puromycin 
cassettes (Beneke et al., 2017). 
 Quantitative real-time PCR (qRT-PCR) 
qRT-PCR enables the quantification of specific RNAs to be studied after the 
generation of the complementary DNA (cDNA) by using reverse transcriptase 
(Stephenson, 2016). An experiment was carried out as previously described (Ali 
et al., 2013b; Alzahrani et al., 2017), the expression levels of target genes that 
expressing in T. b. brucei and L. mexicana were measured and then comparison 
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with the control cell lines by the use of qRT-PCR. However, the quantification of 
the heterologous expression of a gene (such as FurD and TcrNB2 genes) relative 
to the house keeping gene (GPI8) is difficult as the gene was simply not present 
in the control cells (L. mexicana and T. b. brucei). However, the relative level 
of expression in multiple clonal cell lines expressing the gene of interest is 
possible and of value as a basis to select one of the clones for further 
experimentation. RNA was extracted for the T. b. brucei and L. mexicana using 
the NucleoSpin RNA kit (Macherey-Nagel, Germany) in accordance with the 
manufacturer’s instructions. The NanoDrop ND-1000 spectrophotometer was 
used to quantify the RNA concentration and RNA samples were stored at a 
temperature of -80 °C until further use. The designing of the qRT-PCR primers 
was designed by use of Primer Express 3.0 software (Table 2.11). For each 
sample, 20 μL total volume was obtained by diluting 4 μg of RNA in RNase-free 
water, after which complementary DNA (cDNA) was synthesised using the 
Precision nanoScriptTM 2 Reverse Transcription kit (PrimerDesign Ltd, UK) in 
accordance with the manufacturer’s protocol. The cDNA was produced under the 
following conditions: 1) For annealing step: heat to 65 °C for 5 min and directly 
cool the tubes in ice. 2) For extension step: incubate at 42 °C for 20 min, 
followed by heat inactivation of the reaction by incubation at 75 C for 10 min. 
Then, the cDNA samples were kept at -20 °C until further use. For each primer 
pair and the house keeping (GPI8) primers, the primer efficiency was measured 
by the previously described method of Pfaffl to ensure proper and efficient 
binding of primers (Pfaffl, 2001). The cDNA was amplified using the 
PrecisionPLUS OneStep RT-qPCR Master Mix kit (PrimerDesign Ltd, UK) in a 7500 
Real-Time PCR System coupled to a desktop computer (Thermo Fisher Scientific, 
UK). To ensure that only one product at a time is being amplified, a dissociation 
curve was used. Samples without reverse transcriptase (RT) or cDNA were used 
in the experiment as negative controls, whereas the GPI8 of T. b. brucei and L. 
mexicana of which are constitutive genes expression were used as a house 
keeping control. In each case, the gene expression was normalised to GPI8 
expression which is a standard reference gene in T. b. brucei and L. mexicana 
(Kang et al., 2002). Relative quantification was calculated using the delta delta 
ct method. Applied Biosystems 7500 Fast Real-Time PCR System Software 
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(Thermo Fisher Scientific, UK) was used for analysis of data. Each experiment 
was carried out with three independent determinations. 
Table 2.11: The list of primers that designed and used in qRT-PCR. 
Primer 
name 
Position Sequence (5'UTR to 3'UTR) Gene 
HDK1488 Forward GCACTCACCATAAACACACCAATC 
Tbb-FAD  
HDK1487 Reverse GCGCTGCACAGGTACGAA 
HDK1494 Forward ACCAAATCCCCGCCAAGTA 
Lmex-FAD 
HDK1498 Reverse TGTCGCGGAAGACGTAGTACA 
HDK1438 Forward GTGGGCATTCACCCTTATCA 
FurD 
HDK1439 Reverse CCTTACTGGGAAGCCATAACTC 
HDK1289 Forward CACGGCGGGTGTGAAAGT 
Tbb-CAT 1-4 KO 
HDK1283 Reverse AAAGATCGCCACAACATGCA 
HDK568 Forward GCTTCTCGCCGTCGTTGA 
Lmex-NT1 
HDK569 Reverse ATGATCCAGCGCTGCTTGT 
HDK1565 Forward ACTTGCCCGCCCACTACTA 
TcrNB2 
HDK1566 Reverse CGTCAGGGCACCAGAAACA 
GPI8FT Forward TCTGAACCCGCGCACTTC 
T. b. brucei GPI8 
GPI8RT Reverse CCACTCACGGACTGCGTTT 
GPI8FL Forward GGCTGTCATTGTCTCCTCCT 
L. mexicana GPI8 
GPI8RL Reverse GTACATGGTAAGCGCATTGG 
 Drug sensitivity assays using Alamar blue dye 
In this project, the Alamar blue assay (resazurin sodium salt) was used to 
determine the drug sensitivity of the L. mexicana promastigotes and T. b. brucei 
BSF/PCF strains in vitro. Alamar blue dye was used as a metabolic cell function 
indicator and based on the reduction of resazurin sodium salt (blue colour and 
non-fluorescent) to resorufin (pink colour and fluorescent) by live cells (Räz et 
al., 1997; Gould et al., 2008). 
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 Drug sensitivity assay for T. b. brucei BSF 
HMI-9 medium with 10% FBS (100 μL) was added to all wells of a white 96-well 
plate apart from the first well. 200 μL of a known concentration of test 
compounds were diluted in HMI-9 medium and placed in the first well. 
Compounds were tested in one plate and every compound was diluted over two 
rows (23 concentrations), leaving the last well of every dilution as a negative 
control having 100 μL of HMI-9 medium. After that, 100 μL of T. b. brucei 
culture at a density of 2×105 cells/mL was added into every well in the plate and 
incubated for 48 h at a temperature of 37 ºC under 5% CO2. After 48 h, Alamar 
blue dye (20 μL of a solution of 12.5 mg resazurin sodium salt in 100 mL 
phosphate buffered saline PBS) was added and the plate was incubated under 
the same conditions for 24 h. 
With the metal ion compounds, Alamar blue assay was performed as explained 
above with the exception that (8x105 cell per mL) were added in each well of 
HMI-9 culture medium containing the serially diluted tested drugs, and the 
incubation time before the addition of Alamar blue dye was 18 h at 37 °C and 
incubated with 20 μL of Alamar blue dye for additional time of 24 h (Nyarko et 
al., 2002).  
The FLUOstar OPTIMA plate reader (BMG Labtech, Germany) was used to read 
the fluorescence intensity at 544 nm wavelength for excitation and 620 nm 
wavelength for emission. The EC50 values and fluorescence data were 
determined and plotted by the GraphPad Prism 8.0 Software. Pentamidine and 
Diminazene were used as positive control and every experiment was done on 3-4 
independent times in this project. 
 Drug sensitivity assay for T. b. brucei PCF 
In T. b. brucei procyclic forms, the drug sensitivity assay was done as described 
in section 2.4.1, with the exception that (4x105 cell per mL) were added in each 
well of SDM-79 culture medium containing the serially diluted tested drugs, and 
the incubation time before the addition of Alamar blue dye (20 μL) was 72 h at 
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27 °C and incubation with resazurin sodium salt was for an additional period of 
24 h. 
 Drug sensitivity assay for L. mexicana promastigote form 
In L. mexicana promastigote form, Alamar blue was done as explained for T. b. 
brucei BSF (section 2.4.1), with the exception that 2x106 cells/mL of HOMEM 
culture medium complemented with 10% FBS were added in each well, the 
incubation time before the addition of Alamar blue dye (20 μL) was 72 h at 25 
°C, and the plates were incubated with Alamar blue dye for an additional period 
of 48 h. 
 Transport assays 
For the study and characterization of the transporters of L. mexicana 
promastigotes and T. brucei BSF to be possible, the two species were subjected 
to transport assays. This can be achieved either by using dose-dependent assays 
or time course assays, using radiolabeled pyrimidines, purines, diamidines, and 
2-deoxy-D-glucose as required. 
The uptake assay protocol for T. b. brucei BSF and L. mexicana promastigotes 
has been described previously in detail (Al-Salabi et al., 2003; Al-Salabi and de 
Koning, 2005; Gudin et al., 2006; Wallace et al., 2002). The kinetoplastid 
parasite cultures were incubated for approximately 40-48 h to reach the mid to 
late logarithmic stage of growth. Cell pellets were then produced after 
centrifuging the culture medium at 1000 × g, 25 °C for 10 min. The assay buffer 
(AB; 33 mM HEPES, 98 mM NaCl, 4.6 mM KCl, 0.5 mM CaCl2, 0.07 mM MgSO4, 5.8 
mM NaH3PO4, 0.03 mM MgCl2, 23 mM NaHCO3, 14 mM D-glucose, pH 7.3, stored at 
4 °C) was used to wash the pellets twice. The cells were resuspended in AB to a 
cell density of 1×108 cells/mL. The suspended cells were allowed to recover 
from centrifugation stress at room temperature for 30 min. A radiolabeled test 
compound, at a predetermined concentration in 100 µL, is then incubated 
together with 100 μL of the suspended cells for a time that is predefined but 
variable depending on the assay. The transport assay was stopped by the 
addition of 750 μL ice-cold stop solution. The stop solution is usually comprised 
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of 2 mM unlabeled analogue of the radiochemical. The step is followed by 
prompt centrifugation through an oil layer (1:7 mixture of mineral oil and di-n-
butyl phthalate) at 14800 × g for 60 s. Liquid nitrogen was used to freeze the 
microfuge tubes quickly, and the cell pellets at the bottom of the tube were 
collected into scintillation vials after cutting off the tip of the Eppendorf tube. 
500 μL of 2% of sodium dodecyl sulfate (SDS; 10 g SDS in 500 mL H2O) was used to 
lyse the pellets with shaking for 60 to 90 min at 40 rpm using a gyro rocker 
(GENEO BioTechProducts GmbH, Germany). To each vial 3 mL of scintillation 
solution (Optiphase Hisafe-2) was added, and the vials were incubated overnight 
at room temperature in the dark, followed by vigorous shaking. Scintillation was 
measured using a Hidex 300 SL liquid scintillation counter (LabLogic Systems Ltd, 
Sheffield, UK). The assays were carried out in triplicate and three repeated 
independent experiments. 
With transport of radiolabeled 2-deoxy-D-glucose in L. mexicana promastigotes, 
the experiment was performed as described above apart from the fact that cells 
were washed twice with phosphate buffered saline (PBS, pH 7.4) and 
resuspended at a density of 1×108 cells/mL in PBS instead of AB. The stop 
solution of D-glucose, the solution of radiolabeled of 2-deoxy-D-glucose and 
saturation label of D-glucose were all prepared in PBS instead of AB (Seyfang and 
Landfear, 2000). 
 Time-course assay 
T. brucei and L. mexicana cells were incubated with a radiolabeled substrate in 
a concentration below the Km for every transporter to facilitate the evaluation 
of the transport of purine, pyrimidine, pentamidine, and 2-deoxy-D-glucose as a 
function of time. The experiment was conducted in triplicate for each time 
period. The cells were incubated with the same volume of radiolabeled test 
compounds to measure the radiolabel association with cells at the point of 
transporter saturation. To determine this, usually 2 mM of the corresponding 
unlabeled solution is used. The process mentioned above was followed after 
which the calculation of linear regression was conducted using Prism 8 GraphPad 
Software. The rate of uptake of the transport assay is considered to be linear if 
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r2>0.95 and an F-test shows insignificant deviation from linearity (P>0.05). All 
the procedures were performed triplicate in three independent successions. 
  Dose-dependent assay 
The addition of increasing concentrations of unlabeled substrates in the 
presence of a radiolabeled substrate at a constant level was used to determine 
biochemical parameters such as Km, Ki and Vmax. This was performed for a preset 
time and well within the linear transport phase, as first determined by the time 
course assay. The experiment was conducted in triplicate for every 
concentration. Similar steps were followed as described above to obtain 
scintillation measurements. The lowered scintillation intensity caused by the 
increasing level of unlabeled substrate allowed for the determination of Km and 
Vmax through the application of the Michaelis-Menten equation 
V0=Vmax([substrate]/([substrate]+Km)), using Prism 8 GraphPad Software. The 
inhibition constant (Ki) of  unlabeled substrates was determined by calculating 
the 50% Inhibitory Concentration (IC50) through the fitting of an inhibition curve 
by a non-linear regression with variable slope using the Prism 8 GraphPad 
Software, and applying the Cheng-Prusoff equation: Ki=IC50/(1+(L/Km)), where 
the Km is that determined for the labeled permeant and L represents the 
radiolabel concentration (Cheng and Prusoff, 1973). Based on the obtained Ki, 
the Gibbs free energy of binding (ΔG0) is calculated by: ΔG0= –RTln(Ki) in which R 
is the gas constant and T the absolute temperature (de Koning and Jarvis, 1999). 
 Statistics 
In drug sensitivity assays, transport assays and quantitative RT-PCR statistical 
significance was determined using unpaired t-test significance indicated by * 
P<0.05; ** P<0.01; *** P<0.001. 
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3 Assessment of the role of the T. b. brucei cation 
transporters in toxicity of 5-FU and heavy metals 
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 Introduction 
Kinetoplastid protozoa express many membrane transport proteins that enable 
them to take up nutrients, efflux metabolites, regulate physiological 
concentrations, translocate various molecules, and import or export drugs. 
Kinetoplastid parasites are capable of salvage as well as synthesis of pyrimidine 
nucleotides (Majumder, 2008; Kirk and Saliba, 2007; Rodriguez-Contreras et al., 
2007; De Koning et al., 2005; Hammond and Gutteridge, 1984). The gene family 
encoding pyrimidine nucleobase transporters in kinetoplastid parasites has not 
yet been identified (De Koning, 2007; Ali et al., 2013a). In this study, the 
pyrimidine analogue 5-fluorouracil is used as a tool to try to identify the gene(s) 
encoding uracil transport functions in trypanosomes. Resistance to 5-fluorouracil 
was generated in T. b. brucei s427 BSF, yielding the clonal line Tbb-5FURes (Ali 
et al., 2013a). The rate of 5-FU transport is substantially reduced (> 65%) in this 
cell line. Likewise, the transport rate of [3H]-uracil in the Tbb-5FURes cells was 
also only partly reduced from the wild-type levels. 
There are three cation transporter genes (CATs) in T. b. brucei BSF, that all 
could be considered as potential candidates for pyrimidine transporters, 
following an evaluation of the wild-type and the 5-FU resistant the T. b. brucei 
cell line (Ali et al., 2013a). That analysis, performed by former PhD student 
Khalid Alzahrani in the De Koning group, was done through RNA sequencing, 
which allows transcriptome analyses of genomes using deep-sequencing 
technologies, with the goal of studying the difference in gene expression 
between cell lines or conditions (Nagalakshmi et al., 2010). The results of this 
analysis found significant differences between the expression level of the genes 
Tb11.v5.0514, Tb927.11.9000 and Tb927.11.9010 in the Tbb-5FURes and the 
control strain (T. b. brucei Lister s427WT), as the three CATs were significantly 
down-regulated in the Tbb-5FURes strain (Alzahrani, 2017). The mRNA 
abundance of Tb11.v5.0514, Tb927.11.9000 and Tb927.11.9010 in the Tbb-
5FURes was down-regulated with a log2 fold-change of -1.2, -1.2 and -1.04, 
respectively (P < 0.001) compared to the parental wild-type strain. In T. b. 
brucei Lister 427 strain BSF, the corresponding cation transporter genes IDs are 
Tb427tmp.01.0725, Tb427tmp.01.0730, Tb427tmp.01.0760 and 
Tb427tmp.01.0770, named here as Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-
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CAT4 respectively (Table 3.1). These four CATs are almost identical and located 
in tandem array on chromosome 11 and annotated as cation transporters in 
TriTrypDB website. The four cation transporter genes share an amino acid 
sequence identity ranging from 86.43% to 98.73% when compared with each 
(Table 3.2). The multiple sequence alignment result of the four CATs is 
presented in Appendix 5. 
Table 3.1: Annotation of cation transporter genes in the genome of T. b. brucei s427 wild 
type. 
Gene code Chromosome Transcript Name 
Tb427tmp.01.0725 11 1185 bp Tbb-CAT1 
Tb427tmp.01.0730 11 1185 bp Tbb-CAT2 
Tb427tmp.01.0760 11 1152 bp Tbb-CAT3 
Tb427tmp.01.0770 11 1164 bp Tbb-CAT4 
Table 3.2: Amino acid sequence identity calculated between Tbb-CAT1, Tbb-CAT2, Tbb-
CAT3, Tbb-CAT4, hZIP2 and zntA. 
Gene name GeneDB ID Tbb-CAT1 Tbb-CAT2 Tbb-CAT3 Tbb-CAT4 
Tbb-CAT1 Tb427tmp.01.0725 - 98.73% 90.36% 86.43% 
Tbb-CAT2 Tb427tmp.01.0730 98.73% - 91.62% 86.93% 
Tbb-CAT3 Tb427tmp.01.0760 90.36% 91.62% - 93.28% 
Tbb-CAT4 Tb427tmp.01.0770 86.43% 86.93% 93.28% - 
hZIP2 a AAF35832.1 26.94% 26.46% 25.26% 30.72% 
zntA b A0A256LFN4 35.14% 35.14% 32.43% 32.43% 
a Zinc transporter hZIP2 in Human; b Zinc/cadmium/lead-transporting P-type ATPase in 
Escherichia coli (strain K12). 
The purpose of this chapter is to continue working on the characterization of the 
CATs, which were among the few differentially expressed transporters in the 
5FURes strain, and therefore must be considered as potential candidates for 
uracil transporter, or at least change something in the cellular biochemistry that 
changes susceptibility to 5-FU. Moreover, none of these potential transport 
genes have been previously characterised in protozoa and as such they are of 
interest in their own right as well. Here, we overexpress of CATs in the Tbb-
5FURes cell line (Ali et al., 2013a), and continue work on the characterization of 
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CATs to attempt to acquire a double knockout for these genes in T. b. brucei 
s427 WT, aiming to determine their involvement, direct or indirect, in 
pyrimidine uptake and resistance to the pyrimidine analogues. As part of the 
characterisation efforts, we also assess the susceptibility of the overexpressing 
cell lines Tbb-CAT1-4 to heavy metal ions, as the analysis of Tbb-CAT1-4 protein 
sequences with Pfam (http://pfam.xfam.org) revealed that they belong to a 
family of zinc and iron transporters. 
 Results 
 Knockout of Tbb-CAT1-4 by homologous recombination 
into T. b. brucei s427-BSF 
Previous work in our laboratories showed that the overexpression of the cation 
transporter genes (Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-CAT4) resulted in 
increased sensitivity to 6-Azauracil in the 5FU resistant cell lines (Alzahrani, 
2017). Thus, we decided to try to delete the 4 cation transporter genes, which 
would lead to the complete deletion of CATs and thus give a stronger phenotype. 
Dr. Khalid Alzahrani (Prof Harry de Koning Lab, University of Glasgow) previously 
constructed the plasmids that can be used for deleting the chromosomal locus 
containing the four CATs, and named them as pHDK149 (with blasticidin 
resistance cassette), pHDK150 (with neomycin resistance cassette), and pHDK207 
(with hygromycin B resistance cassette) (Figure 3.1). 
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Tbb-CAT2 Unique 3’Unique 5’ Tbb-CAT1 Tbb-CAT4Tbb-CAT3
Length: 10.572 bp







Figure 3.1: Knockout strategy used for the replacement of the genomic locus on 
chromosome 11 containing a tandem array of four cation transporter genes (Tbb-CAT1-4). 
 PCR confirmation for single knockout of CAT1-4 in T. b. brucei 
Following transfection, PCR screening was used to evaluate the integration of 
each antibiotic resistance cassette into T. b. brucei s427 WT. Since the genome 
of T. b. brucei is diploid, the complete deletion of CATs requires two rounds of 
deletion. For that reason, we used three antibiotic resistance cassettes 
(Neomycin, Blasticidin and Hygromycin B) to achieve double knockout for CATs 
from the genome of T. b. brucei s427 WT. After the transfection of three 
different selective markers into T. b. brucei s427 WT, a specific pair of primers 
for every antibiotic selective marker were used to amplify the 3’UTR and 5’UTR 
regions and ran on 1% of agarose gel to be observed visually. The correct 
integration of the constructs was confirmed with PCR, first pair with unique 
forward primer binding pre-5′ UTR (HDK1052) with reverse primers to the 
antibiotic cassette (HDK283 for blasticidin, MB39 for hygromycin and MB37 for 
neomycin); and second pair with unique reverse primer binding post-3′ UTR 
(HDK1053) and forward to the antibiotic cassette (HDK282 for blasticidin, HDK40 
for hygromycin and MB38 for neomycin). The bands in Figure 3.2 corresponded to 
the expected sizes of ~1.8 kb for blasticidin, ~2.5 kb for hygromycin and ~2.4 kb 
for neomycin integrations into T. b. brucei s427 WT after transfection.This 
shows that all three constructs were able to delete the TbCAT1-4 locus. 
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Figure 3.2: Confirmation for single KO of CATs integration by PCR after transfection into T. 
b. brucei WT s427 cell line by amplification of the antibiotic resistance genes. 
A) with Blasticidin; B) with Hygromycin; C) with Neomycin. The bands at ~1.8 kb, ~2.5kb and 
~2.4 kb represent the antibiotic resistance markers of Blasticidin, Hygromycin B and 
Neomycin respectively. L: 1kb DNA Ladder (Promega); 2,4,6,8,10,12: non-transfected control 
(gDNA from Tbb-s427 WT); 1 and 3: Tbb-sKO-CAT1-4+/- blasticidin; 5 and 7: Tbb-sKO-CAT1-
4+/- hygromycin; 9 and 11: Tbb-sKO-CAT1-4 +/- neomycin. 
 qRT-PCR confirmation and growth curve of single knockout of Tbb-
CAT1-4 in T. b. brucei 
An analysis of the expression levels of single knockout of the CATs was 
performed and compared to the control of Tbb-s427 WT through the use of qRT-
PCR (Figure 3.3). The gene expression was normalised to GPI-8 expression which 
is a standard reference gene for qRT-PCR in T. brucei (Kang et al., 2002). The 
Tbb-sKO-CAT1-4+/- blasticidin recorded the lowest level of mRNA expression 
(0.52-fold; P < 0.001) among the three antibiotic resistance cassettes, while 
Tbb-sKO-CAT1-4 +/- neomycin was also significantly decreased with 0.59-fold (P < 
0.01). In contrast, there was no significant difference between the expression 
levels for Tbb-sKO-CAT1-4+/- hygromycin and the control Tbb-s427WT (P > 0.05). 










































































Figure 3.3: The expression levels of sKO of Tbb-CAT1-4 genes with three antibiotic 
cassettes (blasticidin, hygromycin and neomycin) in Tbb-s427 WT determined by qRT-PCR 
and compared to the control. 
Levels were corrected against expression of the housekeeping gene (T. b. brucei GPI8). The 
presented results are the average and ± SEM of 4 independent repeats. ** P < 0.05; *** P < 
0.001. 
The growth of single knockout of Tbb-CAT1-4 genes and the control Tbb-s427 WT 
was analysed in HMI-9 medium supplemented with 10% FBS, at 37 ºC under 5% 
CO2. The density of the cell culture was evaluated every 24 h and cells were 
passaged every 48 h once the growth has reached between 1.5 and 2 x 106 
cells/ml (Figure 3.4). The result of the study showed that there was no effect on 
growth following the deletion of the first allele of the Tbb-CAT1-4 genes in Tbb-
s427 WT when compared to the control Tbb-s427 WT. 




































Figure 3.4: The growth curve of Tbb-s427 WT and Tbb-WT + TbbCAT1-4 sKO with three 
antibiotic cassettes (blasticidin at 5 μg/ml, hygromycin at 2 μg/mL and neomycin at 1 µg/ml) 
on HMI-9 medium supplemented with 10% FBS. 
The cells were seeded at the density of 1×104 cells/mL, and cell densities were determined 
every 24h. Samples were and counted taken from three separate cultures of the same cell 
line and the average of these three determinations is shown. The error bars are too small to 
be visible in the graph. Cultures were grown in the respective antibiotics. 
 Drug sensitivity assay of heterozygote (CAT 1-4 +/-) in Tbb-s427 WT 
The alamar blue assay is a convenient technique that relies on the metabolic 
activity of living cells, as dead cells fail to convert the blue resazurin to the 
pink, fluorescent resorufin (Gould et al., 2008). Therefore, the alamar blue dye 
(resazurin sodium salt) was used to evaluate drug sensitivity of a single knockout 
of the CAT transport locus to 5-flourouracil and 6-azauracil compounds. 
Pentamidine was used as a positive control against T. b. brucei s427 WT and 
hemizygous knockout cells (Figure 3.5). The results show that the drug 
sensitivity of T. b. brucei s427-WT to these compounds was the same as the 
generated cell lines (P > 0.05), presumably because the CATs were still 
expressed, albeit at a lower level. Several attempts were made to produce a null 
mutant for Tbb-Cation1-4 by replacing the second allele of Tbb-CAT1-4 genes 
with all three antibiotics-resistance constructs (Neomycin, Blasticidin and 
Hygromycin) but were unable to remove both Tbb-CAT1-4 alleles. However, we 
were not able to conduct a complete double knockout for the Tbb-CAT1-4 genes 
as it resulted in the death of the cells and, as a result, showed the essentiality 
of their function for continued growth of the T. b. brucei BSF. Furthermore, 
Alzahrani (2017) showed that the genes encoding cation transporters are 
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essential for the cell viability of T. brucei BSF: RNAi-mediated downregulation of 
Tbb-Cation1-4 confirmed that these genes are essential, as a growth defect was 































































































































































































































































Figure 3.5: The averages of EC50 values of Tbb-s427 WT and Tbb-s427WT + Tbb-CAT1-4 sKO 
with three antibiotic cassettes (blasticidin, hygromycin and neomycin) to A) 5-fluorouracil, 
B) 6-Azauracil and C) Pentamidine determined by using the alamar blue assay. 
Each bar represents the average of three independent repeats is shown ± SEM in µM. 
 Uptake of uracil by Tbb-s427WT+sKO-CAT1-4+/- strain 
The uptake of 0.1 μM of [3H]-uracil in the Tbb-s427 WT and Tbb-s427WT+sKO-
CAT1-4+/- was investigated in order to check whether the single knockout of the 
CAT transport locus causes changes to the rate of uracil transport (Figure 3.6). 
[3H]-Uracil uptake was linear for 10 minutes in Tbb-s427 WT (Linear regression; 
r2 = 0.96) with a rate of 0.317 ± 0.034 pmol. (107 cells)-1.s-1 (n=1), and was 
completely inhibited by 1 mM unlabelled uracil. The uptake of [3H]-uracil in Tbb-
s427WT + sKO-CAT1-4+/- was almost the same as the wild type cells, with a rate 
of 0.345 ± 0.045 pmol. (107 cells)-1.s-1 (Linear regression; r2 = 0.95; n=1). The 
addition of 1 mM unlabelled uracil completely inhibited the uptake of [3H]-uracil 
in Tbb-s427WT+sKO-CAT1-4+/-. This result confirmed that the sKO of the CAT 
transport locus does not change the rate of uracil uptake in comparison to the 
parental cell line Tbb-s427 WT. 
Ibrahim Abdullah Alfayez                               Chapter 3                                 121 
 




































+ 1 mM Uracil
 
Figure 3.6: [3H]-Uracil transport by Tbb-s427 WT and Tbb-s427WT + Tbb-CAT1-4+/-. 
Transport of 0.1 μM [3H]-uracil by Tbb-s427WT and Tbb-s427WT + Tbb-CAT1-4+/- was 
measured over 10 minutes in the presence (open symbols) or absent (closed symbols) of 1 
mM unlabelled uracil. The graph shows one representative experiment in triplicate, and 
error bars represent ± SEM. 
 Over-expression of Tbb-CAT1, Tbb-CAT2, Tbb-CAT3, and 
Tbb-CAT4 in the Tbb-5FURes strain BSF 
Dr. Khalid Alzahrani (Prof Harry de Koning Lab, University of Glasgow) has 
generated the plasmid constructs that are used for the individual overexpression 
of each of the four cation transporter genes in the Tbb-5FURes strain, based on 
the vector pHD1336 and named as pHDK199 (Tbb-CAT1), pHDK200 (Tbb-CAT2), 
pHDK201 (Tbb-CAT3) and pHDK202 (Tbb-CAT4) (Figure 3.7). The pHD1336 
plasmid is constitutively expressed and integrates into the non-transcribed 
ribosomal RNA (RRNA) spacer. 
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Figure 3.7: Schematic representations of pHDK199, pHDK200, pHDK201 and pHDK202 
plasmids. 
 PCR confirmation of plasmid integration of Tbb-CAT1-4 into Tbb-
5FURes 
The Tbb-5FURes + Tbb-CAT1o.e, Tbb-5FURes + Tbb-CAT2o.e, Tbb-5FURes + Tbb-
CAT3o.e and Tbb-5FURes + Tbb-CAT4o.e cells were retrieved from liquid nitrogen 
storage and PCR was used to confirm the presence of an extra copy of each 
cation transporters in the Tbb-5FURes strain. These cell lines were generated by 
Dr Khalid Alzahrani and Ibrahim Alfayez at the De Koning laboratory. After 
genomic DNA extraction, PCR technique was performed to confirm the presence 
of Tbb-CAT1 (1185 bp), Tbb-CAT2 (1185 bp), Tbb-CAT3 (1152 bp), and Tbb-CAT4 
(1164 bp) genes in the Tbb-5FURes strain by using HDK1039 as forward primer for 
Tbb-CAT1-4 and HDK335 as reverse primer for the pHD1336 plasmid (Figure 
3.8A). Also, PCR was used to confirm the linearization of the circular pHDK199, 
pHDK200, pHDK201 and pHDK202 plasmids into Tbb-5FURes strain by using 
HDK535 as forward primer for pHD1336 plasmid and the reverse primer for each 
gene (HDK1040 for Tbb-CAT1; HDK1041 for Tbb-CAT2 and Tbb-CAT3; HDK1042 
for Tbb-CAT4). It is expected that the four cell lines do not give bands (~2.6 Kb) 
as it is linearized by NotI before transfection (Figure 3.8B). 
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Figure 3.8: PCR confirmation for the linearity of pHDK199, pHDK200, pHDK201 and 
pHDK202 plasmids and the present of Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-CAT4 
genes into Tbb-5FURes strain after transfection. 
A) Confirmation of the presence of Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-CAT4 genes 
into Tbb-5FURes strain after transfection. L: 1kb DNA Ladder (Promega); 1: Tbb-CAT1, Tbb-
CAT2, Tbb-CAT3 and Tbb-CAT4 (~1200 bp) respectively; 2: Non-transfected control (gDNA 
of Tbb-5FURes strain); 3: negative control. B) Confirmation of the linearization of pHDK199, 
pHDK200, pHDK201 and pHDK202 plasmids after transfection into Tbb-5FURes strain. L: 
1kb DNA Ladder (Promega); 1: pHDK199, pHDK200, pHDK201 and pHDK202 plasmids 
respectively; 2: Undigested plasmids of pHDK199, pHDK200, pHDK201 and pHDK202 (~2.6 
kb); 3: negative control. 
 qRT-PCR confirmation and growth curve of overexpression of Tbb-
CAT1-4 in Tbb-5FURes 
The level of mRNA expression for Tbb-5FURes + Tbb-CAT1o.e, Tbb-CAT2o.e, Tbb-
CAT3o.e and Tbb-CAT4o.e was analysed and compared to the control cell line by 
qRT-PCR (Figure 3.9). The Tbb-5FURes + Tbb-CAT4o.e recorded the highest 
transcription level, amounting to a 2.80-fold increase (P < 0.01) compared to the 
control Tbb-5FURes. When compared to the control cell lines (Tbb-5FURes), the 
expression level of Tbb-CAT1o.e and Tbb-CAT2o.e in the Tbb-5FURes was recorded 
as 1.32 and 2.33-fold, respectively (P < 0.01), while, the expression of Tbb-
5FURe s+ Tbb-CAT3o.e increased approximately (2.53 -fold; P < 0.05). 


















































































Figure 3.9: The expression levels of Tbb-CAT1, Tbb-CAT2, Tbb-CAT3, and Tbb-CAT4 in Tbb-
5FURes strain (BSF) and compared to the Tbb-5FURes determined by qRT-PCR. 
Levels were corrected against expression of the housekeeping gene (GPI8). The presented 
results are the average and ± SEM of 3 independent replicates. * P < 0.05; ** P < 0.01. 
Figure 3.10 shows the analysis of the growth of the Tbb-5FURes, Tbb-5FURes + 
Tbb-CAT1o.e, Tbb-5FURes + Tbb-CAT2o.e, Tbb-5FURes + Tbb-CAT3o.e and Tbb- 
5FURes + Tbb-CAT4o.e was assessed in HMI-9 medium complemented with 10% 
FBS; cell densities were determined every 24 h. Cells were passaged every 48 h 
once the growth had reached between 1.5 and 2 x 106 cells/mL. The result show 
that there was no effect on the growth of Tbb-5FURes + Tbb-CAT1o.e, Tbb-
CAT2o.e, Tbb-CAT3o.e and Tbb-CAT4o.e when Tbb-CAT1, Tbb-CAT2,  Tbb-CAT3, 
and Tbb-CAT4 genes were overexpressed in comparison with the control Tbb-
5FURes. 





































Figure 3.10: The growth assay of Tbb-5FURes, Tbb-5FURes + Tbb-CAT1o.e, Tbb-5FURes + 
Tbb-CAT2o.e, Tbb-5FURes + Tbb-CAT3o.e and Tbb-5FURes + Tbb-CAT4o.e on HMI-9 medium 
supplemented with 10% FBS. 
 The cells were seeded at the density of 1×104 cells/mL, and cell densities were 
determined every 24h. This result represents data from two similar independent 
determinations.Drug sensitivity test of overexpression (Tbb-CAT1-4) in 
Tbb-5FURes 
The Alamar blue assay was used to determine the EC50 of the Tbb-5FURes over-
expressing Tbb-CAT1, Tbb-CAT2, Tbb-CAT3, and Tbb-CAT4 in order to verify 
these clones are resistant to 5-FU and sensitisation to 6-Azauracil before 
performing any transport assays; the Alamar blue assay was performed in 
parallel with the wild-type strains. Pentamidine was used as  control drug 
throughout the assessment (Figure 3.11). The sensitivity of Tbb-5FURes to 5-FU 
was strongly decreased (Resistance Factor (RF) = 92; P < 0.0001) in comparison 
with the Tbb-s427 wild type. The Resistance Factor (RF), defined as the ratio of 
de EC50 values of the transgene parasite to that of the wild-type s427 strain, is 
calculated by [RF; EC50(Tbb-5FURes)/EC50(427WT)]. None of the 5-FU resistant 
cell lines that overexpressed Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-CAT4 
exhibited significant differences in the sensitivity to 5-FU when compared to the 
control cells (P > 0.05), although the overexpressing clones for each CAT trended 
towards higher sensitivity, consistent with the initial observation from RNAseq 
that CAT downregulation was associated with 5FU resistance. Interestingly, the 
Tbb5-FURes displayed increased sensitivity to 6-AU (5.8-fold more sensitive to 6-
AU; P < 0.001) when compared to the wild type strain, probably indicating a 
reduced uracil salvage pathway and increasing reliance on de novo synthesis. 6-
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AU is considered to be an inhibitor of pyrimidine de novo biosynthesis pathway; 
specifically, it is a known inhibitor of orotidylate decarboxylase in trypanosomes 
(Jaffe, 1961). However, Tbb-5FURes + Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-
CAT4 cells exhibited significantly reduced sensitivity to 6-AU (RF = 0.6, 0.55, 
0.52 and 0.56, respectively) compared to the parental 5FURes line. Also, the 
sensitivity of Tbb-s427 wild type and Tbb-5FURes overexpressing Tbb-CAT1, Tbb-


















































































































































































































































































































































Figure 3.11: Effect of overexpression of Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-CAT4 on 
sensitivity of Tbb-5FURes strain to A) 5-fluorouracil, B) 6-Azauracil and C) Pentamidine 
determined by using the alamar blue assay. 
Each bar represents the average of three independent repeats is shown ± SEM in µM. * P < 
0.05; ** P < 0.01; *** P < 0.001. 
 Transport of uracil by overexpression of CAT 1-4 in Tbb-5FURes 
The transport of 0.1 μM of [3H]-uracil in the Tbb-5FURes expressing Tbb-CAT1, 
Tbb-CAT2, Tbb-CAT3 and Tbb-CAT4 was determined in order to check whether 
the overexpression of each cation transporter could cause changes in the rate of 
uracil transport (Figure 3.12). [3H]-Uracil transport was linear for 10 min in Tbb-
s427 WT cells (r2 = 0.99) with a rate of 0.237 ± 0.016 pmol.(107 cells)-1.s-1. 
Although the uptake of [3H]-uracil was reduced by 26.4% in Tbb-5FURes cells, 
with a rate of 0.174 ± 0.021 pmol.(107 cells)-1.s-1 (not significantly different from 
wild type P > 0.05 by F-test; n=1), the uptake of [3H]-uracil in all Tbb-5FURes 
over-expressing Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-CAT4 was very similar 
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to that of the wild-type, with a rate of 0.247 ± 0.022,  0.225 ± 0.04, 0.264 ± 0.05 
and 0.218 ± 0.027 pmol.(107 cells)-1.s-1, respectively (n=1). This result confirmed 
that Tbb-CAT1-4 does not transport uracil, but may (up) regulate uracil 
transport in some way. There was partial decline in transport rate of [3H]-uracil 
in the Tbb-5FURes cells relative to the wild type. This is attributed to the high 























































Figure 3.12: [3H]-Uracil uptake in T. brucei strains. The uptake of 0.1 μM of [3H]-uracil over 10 
minutes by Tbb-s427WT , Tbb-5FURes and Tbb-5FURes + Tbb-CAT1o.e, Tbb-5FURes + Tbb-
CAT2o.e, Tbb-5FURes + Tbb-CAT3o.e and Tbb-5FURes + Tbb-CAT4o.e. Linear regression 
correlation coefficients (r2) for each line are given in the inset table. 
Figure shows one representative experiment in triplicate, and error bars represent ± SEM. F-
test was determined by GraphPad Prism 8. 
 Effect of heavy metal ions, ion chelators and a TAO 
inhibitor on T. b. brucei BSF 
According to a Pfam analysis (https://pfam.xfam.org) Tbb-CAT1-4 protein 
sequences identified that the sequences can be part of the Zip Zinc transporter 
family (PF02535). For that reason, we conducted a test of single knockout of the 
cation transporters in Tbb-s427 wild type and of the overexpressing clones for 
each of four cation transporter genes (Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-
CAT4) in Tbb-5FURes to establish their susceptibility to heavy metal ions ( Cd2+, 
Hg2+, Ba2+, Pb2+, Cu2+, Zn2+ and Fe2+),  Salicylhydroxamic acid (SHAM) and 
Deferoxamine (DFOA). The experiments were carried out at least three times for 
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each compound tested, and pentamidine and diminazene aceturate were used as 
positive control in this assay (Table 3.3). 
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Table 3.3: Effect of Heavy metal ions, Salicylhydroxamic acid (SHAM) and Deferoxamine (DFOA) on Trypansoma brucei brucei (BSF). 
All EC50 Values were obtained using Alamar blue assay and are given as means in µM (±SEM), of 3 independent repeats. * P < 0.05; ** P < 0.01; *** P < 0.001 by 
unpaired Student's T-test. Pentamidine and Diminazene is a standard drug used as control in this assay. 
Tbb-s427 WT = wildtype strai,  2T1 = T. b. brucei 2T1 cell. (Alsford et al., 2005), aqp2/aqp3 null = Aquaporin2/3 double knockout and aqp1/aqp2/aqp3 null = 
aquaporin1-3 triple knockout BSF T. brucei 2T1. SHAM = Salicylhydroxamic acid and DFOA = Deferoxamine. ND = not determined. P values were calculated statistically 
by unpaired t-test, using Microsoft Excel function (comparing two arrays with three readings each, 2-tailed and type-2: comparing one value with only one other 'its 
control' and not with every other in the table). Student’s unpaired t-test, comparing aTbb-WT vs Tbb-sKO-CAT1-4+/-, bTbb-5FURes vs Tbb-5FURes+overexpressing of 
each individual CATs and c2T1 vs aqp1/aqp2/aqp3 null. 
                                    
Compounds   


























11.9 ± 0.46 1077 ± 43 215 ± 50 14.6 ± 2.7 54.1 ± 6.4 0.0041 ± 
0.0007 
N.D 






12.7 ± 0.44 1275 ± 57 204 ± 29 14.6 ± 2.6 50.6 ± 5.6 0.0053 ± 
0.0002 
N.D 






13 ± 1.2 1032 ± 38 234 ± 62 10.3 ± 0.90 70.1 ± 2.72 0.0039 ± 
0.0008 
N.D 






13.4 ± 0.39 1069 ± 7 214 ± 38 11.1 ± 0.72 69.5 ± 3.87 0.0037 ± 
0.0005 
N.D 






14.1 ± 0.36 1015 ± 8 250 ± 60 9.2 ± 1.32 56.1 ± 5.90 0.0032 ± 
0.0007 
N.D  






13.9 ± 0.08 973 ± 18 175 ± 19 9.9 ± 2.58 58.7 ± 7.35 0.0038 ± 
0.0011 
N.D 






13.1 ± 0.49 978 ± 52 226 ± 17 10.8 ± 0.46 62.1 ± 5.99 0.0029 ± 
0.0006 
N.D  


























10.2 ± 1.86 1035 ± 
144 
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The analysis did not identify any significant differences in the sensitivity to 
Mercury, Barium, Lead, Copper, Zinc, Iron, SHAM and Deferoxamine for the Tbb-
sKO-CAT1-4+/- compared to the wild type control (P > 0.05). However, the 
outcome of the test showed a significant reduction in the sensitivity of Tbbs427-
sKO-CAT1-4+/- to Cadmium with 21.6 ± 1.5 µM when compared to the control 
Tbb-s427 wild-type, which displayed an EC50 of 7.2 ± 1.2 µM (3-fold resistant to 
Cadmium; P < 0.01). Moreover, the EC50 of the overexpression of Tbb-CAT1, Tbb-
CAT2, Tbb-CAT3, and Tbb-CAT4 in Tbb-5FURes to Mercury, Lead, Copper, Zinc, 
Iron, SHAM and Deferoxamine did not exhibit any significant difference when 
compared to the parental cell line Tbb-5FURes (P > 0.05). Interestingly, the 
increased gene expression of either Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 or Tbb-CAT4 
in the Tbb-5FURes cell line significantly increased sensitivity to Cadmium 
compared to Tbb-5FURes (8.2 ± 0.4 µM), with an average 2.8 ± 0.5 µM, 3.3 ± 0.9 
µM, 1.9 ± 0.4 µM and 0.03 ± 0.004 µM respectively. Cell lines Tbb-CAT1o.e, Tbb-
CAT2o.e, Tbb-CAT3o.e and Tbb-CAT4o.e were also more sensitive to Barium, with 
EC50 values of 3500 ± 98 µM, 3545 ± 31 µM, 3183 ± 164 µM and 3361 ± 36 µM 
respectively, compared to 4216 ± 140 µM recorded for the Tbb-5FURes. 
The activity of the above listed compounds against 2T1, aqp2/aqp3 null and 
aqp1/aqp2/aqp3 null was also determined. The result showed that there was no 
significant difference between 2T1, aqp2/aqp3 null and aqp1/aqp2/aqp3 null 
cell lines; only the aqp1/aqp2/aqp3 null showed approximately 4-fold increased 
sensitivity to Cadmium (P < 0.05), which may indicate that AQP1 can mediate 
the efflux of cadmium ions taken up by one or more of the CAT transporters. 
There were no significant differences in heavy metal ion sensitivity between CAT 
single knockout and AQP double knockout cell lines. 
 Discussion 
Transport proteins are important for the movement of drugs in and out of the 
cell, making them special intermediaries in both therapy and drug resistance. 
Thus, the generation and characterization of drug resistant lines provides 
valuable information on resistance mechanisms, and can potentially be used to 
identify new drug transporters. For instance, multi-drug resistant T. b. brucei 
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line B48 was generated in vitro by stepwise increasing the concentration of 
pentamidine until these cells lost the transport activity know as the High Affinity 
Pentamidine Transporter (HAPT1) (Matovu et al., 2003; Bridges et al., 2007). 
Recently, the HAPT1 activity was found to be encoded by T. brucei 
aquaglyceroporin 2 (TbAQP2) (Baker et al., 2012; Munday et al., 2014). An 
essential role is played by purine and pyrimidine nucleotides in nucleic acid 
synthesis (DNA and RNA), as well as in prokaryotic and eukaryotic cell 
metabolism (de Koning and Diallinas, 2000; Rodriguez-Contreras et al., 2007; 
Campagnaro and de Koning, 2020). Pyrimidine analogue 5-fluorouracil was found 
to be a good inhibitor of high-affinity uracil transporters in L. major (LmajU1) 
and T. b. brucei (TbU1) (Campagnaro and de Koning, 2020). Apart from the 
chemotherapeutic potential of pyrimidine analogues, 5-FU can be used a s a tool 
to identify a novel family of transporters in protozoa (Domin et al., 1993; de 
Koning and Diallinas, 2000; De Koning, 2007; Bellofatto, 2007). 
Multiple lines of investigation have been followed to date to try to identify the 
gene(s) coding for kinetoplastid uracil transporters. The BLAST searches for 
pyrimidine transporter genes using fungal, yeast and prokaryote sequences have, 
until this day, not produced a single candidate gene from any of the available 
protozoan genomes, leading us to conclude that no genes can be identified by 
homology to known pyrimidine transporter genes. Therefore, previous work in 
our laboratory undertook whole genome sequencing, RNA-seq and RIT-seq and as 
a way of finding the pyrimidine transporter genes of T. b. brucei (Ali, 2013; 
Alzahrani, 2017). The generation of the 5-FU-resistant cell lines of T. b. brucei 
s427 WT was undertaken through exposure to increasing concentrations of 5-FU 
in vitro as a way of gaining additional insights into pyrimidine salvage pathways 
in Trypanosoma species (Ali et al., 2013a). RNA sequencing (RNA-Seq) is seen as 
a powerful technique where deep-sequencing technologies are utilised in 
sequencing RNA as a way of determining the differential gene expression under 
different physiological or environmental conditions (Wang et al., 2009; Kukurba 
and Montgomery, 2015). An attempt was made to identify the pyrimidine 
transporter genes by following up Tbb-CAT1-4 genes. Overexpression and 
knockout strategies were utilised as investigative tools. Overexpression of a 
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candidate gene can be a powerful tool when the effect of a drug is reversed by 
overexpression and compensates for a reduced gene expression in the resistant 
line (Prelich, 2012). The knockout technique was utilised in deleting one allele 
of the Tbb-CAT1-4 tandem-array locus in T. b. brucei wild-type BSF. It is 
possible to utilise these methods in studying either function gain or function 
phenotypes loss.  
Subcellular localisation using an N-terminal tag showed that the putative cation 
transporter Tb927.11.9000 appeared to be localised in the cytoplasm; however 
with a C-terminal fusion the protein localised to the nuclear envelope and 
endoplasmic reticulum in PCF trypanosomes. As this transporter is an integral 
membrane protein, it cannot be localised free in the cytoplasm. The putative 
cation transporter Tb927.11.9010 was localised to the endocytic organelles of T. 
b. brucei PCF (TrypTag, 2020).  
The hypothesis was that, if the TbCAT transporters had the capacity to transport 
uracil and 5-FU, their overexpression in Tbb-5FURes would lead to a significant 
rise in the sensitivity to 5-FU and a significant decline in the sensitivity to 6-AU 
which is an indication of a restored uracil salvage pathway and thereby reduced 
reliance on de novo synthesis, of which 6-AU is an inhibitor of pyrimidine de 
novo biosynthesis pathway in trypanosomes (Jaffe, 1961). In contrast, a 
significant reduction in the sensitivity to 5-FU and a significant rise in sensitivity 
to 6-AU would result from the knockout of TbCAT transporter genes and the thus 
abolished uracil salvage pathway, leading to an increasing reliance on de novo 
synthesis. We succeeded in utilising the expression plasmid pHD1336 to 
overexpress the Tbb-CAT1-4 genes in Tbb-5FURes. This plasmid has been found 
to be very effective for overexpression of genes in T. b. brucei (Munday et al., 
2013; Alzahrani et al., 2017; Biebinger et al., 1997; Campagnaro et al., 2018b). 
Munday et al. (2013) utilised the pHD1336 plasmid for the heterologous 
expression of T. congolense aminopurine transporter (TcoAT1) in multi-drug 
resistant T. b. brucei lines B48, which allowed its characterisation as a P1-type 
nucleoside transporter. Moreover, Alzahrani et al. (2017) identified that NT1.1 in 
L. major and L. mexicana is sensitive to inhibition by uracil and named as 
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uridine-uracil transporter 1 (UUT1), using this vector that expressed NT1.1 gene 
in T. b. brucei B48 strain. Also, this vector was used to express and characterise 
the TcrNBT1, TcrNT1 and TcrNT2 ENT-family transporter genes in T. brucei 
procyclic TbNBT-KO cells showing that TcrNB1 is a high-affinity hypoxanthine 
transporter, TcrNT1 is a high-affinity inosine/guanosine transporter and TcrNT2 
is a high-affinity thymidine transporter (Campagnaro et al., 2018b). PCR and 
qRT-PCR confirmed the overexpression of candidate pyrimidine transporter 
genes and the presence of knockout constructs, and their correct integration. 
We determined the sensitivity of the 5-Fluorouracil and 6-Azauracil pyrimidine 
analogues in a single knockout of Tbb-CAT1-4 genes in T. b. brucei s427 WT with 
the use of alamar blue method and found no significant difference; pentamidine 
was used as a control against the T. brucei s427 WT and heterozygous knockout 
cells. Further results showed that the uptake of [3H]-uracil in Tbb-s427WT + Tbb-
CAT1-4+/- was almost the same as the wild type cells. Similarly, the introduction 
of any cation transporters into Tbb-5FURes did not significantly increase the rate 
of transport of [3H]-uracil of the 5-FU resistant cell lines, which was in any case 
only partly reduced from wild-type levels (F-test was determined by GraphPad 
Prism 8). However, this outcome does not mean that Tbb-CAT1-4 genes are not 
involved in the 5-FU sensitivity or transport, for the reason that the first allele 
of these genes was deleted while the second allele still exists in the genome of 
hemizygous knockout cells. Unfortunately, we were unable to make a full double 
knockout for the Tbb-CAT1-4 genes, as this led to the death of the cells, showing 
that their function is essential for the growth of the T. b. brucei. It has 
previously been shown that the deletion of both alleles of two other cation 
transporters, forming a heteromeric potassium channel, led to cell death 
through the elimination of ion conductance (Steinmann et al., 2015; Clayton, 
1999).  
Thus, it is possible for us to speculate that the double knockout of the Tbb-
CAT1-4 genes affected the viability of Tbb BSF by disrupting the intracellular ion 
distribution in T. brucei s427 WT. Consequently, it is possible that these CATs 
are iron transporters; iron ions are very important in mitochondrial metabolism, 
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as they are essential to the function of cytochromes and of Trypanosome 
Alternative Oxidase (TAO) (Saimoto et al., 2013; Shiba et al., 2013). However, 
this appears to rule out the possible involvement of CAT transporters in uracil 
uptake as we have reason to believe that the pyrimidine transporter genes are 
not essential in T. b. brucei BSF for two reasons. 1) The ability of pyrimidine 
prototrophic T. b. brucei cells to grow in pyrimidine-free HMI-9 media (Ali et al., 
2013b). 2) There was a reduction of [3H]-5-FU uptake rate by greater than 65% 
when T. b. brucei WT adapted to high levels of 5-FU (Tbb-5FURes). Whereas 
transport of [3H]-uracil was only partly reduced in the Tbb-5FURes cells 
compared to s427-WT cells (Ali et al., 2013a). Moreover, an identical experiment 
using L. mexicana promastigotes totally eliminated (94.5%) [3H]-5-FU transport in 
the 5-FU resistant cell lines (Lmex-5FURes), thereby revealing that the uracil/5-
FU transporters are not essential when it comes to these organisms although 
they are important when it comes to the anti-protozoal activity of 5-FU 
(Alzahrani et al., 2017). 
On the other hand, the Tbb-CAT1-4 protein sequences analysis with Pfam 
showed that they belong to the family of zinc and iron transport. That reason 
makes it of interest to conduct a test of single knockout of the Tbb-CAT1-4 
genes in Tbb-s427WT and also test the overexpressing of each of the four CAT 
transporter genes (Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-CAT4) in Tbb-
5FURes by making a comparison of them with respect to sensitivity to heavy 
metal ions, ion chelators and a TAO inhibitor. We found that the effect of 
increased gene expression of Tbb-CAT1, Tbb-CAT2, Tbb-CAT3 and Tbb-CAT4 in 
Tbb-5FURes significantly increased the sensitivity to Cadmium and Barium. In 
addition, we observed a significant decrease in the sensitivity of single knockout 
clones of Tbb-CAT1-4 in Tbb-s427 wild-type to Cadmium. The ZIP/SLC39A family 
of metal ion transporters have been identified at all phylogenetic levels and 
consist of fourteen transporters encoded in the human genome. These genes are 
designated SLC39A1-SLC39A14 and encoded 'protein ZIP1-ZIP14', respectively 
(Jeong and Eide, 2013; Eide, 2004). The ZIP proteins transport essential (e.g. 
zinc) as well as non-essential, toxic heavy metals (e.g. cadmium and mercury) 
(De Carvalho and de Melo, 2017; Jeong and Eide, 2013). It is still not clear how 
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proteins in the ZIP family, together with other transporters or trafficking 
systems coordinate in to regulate zinc homeostasis (Jeong and Eide, 2013). In 
the case of non-essential heavy metal ions such as cadmium, the main 
mechanism of entry into trypanosomes is through divalent metal ion 
transporters, mainly for calcium, due to its similar ionic radius (De Carvalho and 
de Melo, 2017). Although Cd2+ is obviously not the intended substrate for the 
TbbCAT transporters, we show here that they provide a potential point of entry 
for the heavy metal if there is a sufficient concentration of the ions in the 
parasite’s immediate environment. Sensitivity to the metal ion, correlated to 
the level of TbbCAT expression is one method to assess the capacity of the 
carrier to take up that ion, especially if excess of that ion is deleterious to cell 
growth or survival. Alternatively, uptake of a radioactive isotope of the metal 
can be measured in an appropriate scintillation counter or gamma radiation 
counter, depending on the isotope. A further method would be to measure 
cellular content of the metal ion spectroscopically. Further, fluorescent probes 
(chelators) can serve as specifc reporters for some of the dications including Ca2+ 
and Zn2+ (Eren and Argüello, 2004; Gee et al., 2002). 
Studies by Nyarko et al. (2002) first reported that heavy metals such as cadmium 
and mercury in drug sensitivity assays are extremely toxic to T. b. brucei 
parasites. Toxicity is also a key disadvantage of using heavy metals in drugs 
against kinetoplastid parasites for human use (Jeong and Eide, 2013; De Carvalho 
and de Melo, 2017). To gain an insight into the possible resistance mechanism, 
cross-resistance between the Tbb-s427WT + Tbb-CAT1-4+/- and aqp1/aqp2/aqp3 
null cell lines for some heavy metal ions, ion chelators and a TAO inhibitor was 
assessed. The result showed that there was no cross-resistance pattern between 
the Tbb-CAT1-4+/- and aqp1/aqp2/aqp3 null cell lines. 
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4 Assessment of the role of fatty acid desaturase 
in T. brucei BSF and L. mexicana promastigotes 
in 5-FU sensitivity 
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 Introduction 
Fatty acid desaturases are enzymes that convert saturated fatty acid to 
unsaturated fatty acid through the removal of two hydrogen atoms from fatty 
acids, introducing a double bond. The main function of fatty acid desaturases in 
the mammalian cell is to maintain the function and structure of biological 
membranes through balancing of the proportion of saturated and unsaturated 
fatty acids of phospholipids bilayer (Alloatti and Uttaro, 2011; Los and Murata, 
1998). There are three classes of desaturases have been observed in 
Kinetoplastid parasites. Class one is Delta ‘Δ’ desaturases usually introduces a 
double-bond x-carbons from the carboxyl end. Class two Omega ‘ω’ comprises 
enzymes that introduce a double-bond x-carbons from the methyl end. Finally, 
class three groups Chi and nu ‘v + x’ desaturases that add a double-bond x-
carbons from an existing double bond (Alloatti and Uttaro, 2011; Petrini et al., 
2004). T. brucei and L. mexicana cells can take up lipids from host environments 
by transportation of protein-bound fatty acids or receptor-mediated endocytosis 
of lipoprotein. Additionally, they can synthesise their own fatty acids de novo 
via a mitochondrial type II prokaryotic-type pathway (Smith and Bütikofer, 2010; 
Zhang and Beverley, 2010). In a screen for determinants for 5-FU resistance, 
fatty acid desaturases featured prominently, prompting speculation that they 
may have a role in uracil salvage or usage. 
The gene family encoding pyrimidine nucleobase transporters in kinetoplastid 
parasites has not yet been identified (De Koning, 2007; Ali et al., 2013a). In this 
chapter, the pyrimidine analogue 5-fluorouracil is used as a tool to try to 
identify the uracil transporter in T. b. brucei BSF and L. mexicana 
promastigotes, or any other mechanism that may play a role in determining 
uracil salvage. Previous work in our laboratories (Alzahrani (2017); Ali (2013)) 
showed a fatty acid desaturase as one of the most promising candidate gene for 
a pyrimidine uptake determinant, following an evaluation of the wild-type and 
the 5-FU resistant cell lines of the T. b. brucei BSF (Tb427.02.3080) and L. 
mexicana promastigotes (LmxM.10.1320) by use of RNA Sequencing (RNA-seq) 
analyses of 5-FU resistant cell lines in T. b. brucei BSF and L. mexicana 
promastigotes, and by RNA Interference Target Sequencing (RIT-seq) analyses in 
T. b. brucei BSF. Analysis of this fatty acid desaturase in T. b. brucei s427 wild-
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type BSF (Tbb-FAD) and the homologous fatty acid desaturase in L. mexicana 
M379 promastigotes (Lmex-FAD) showed a high level of identity (69.43%) (Table 
4.1). The sequence alignment result of the Tbb-FAD in T. b. brucei s427 wild-
type BSF and Lmex-FAD in L. mexicana M379 promastigotes is presented in 
Appendix 6. 
The aim of this study is the role of Tbb-FAD and Lmex-FAD genes in 5-FU 
resistance. We will investigate whether overexpression of these genes is able to 
restore the sensitivity to 5-FU, or the transport of 5-FU/uracil in vitro. 
Table 4.1: Annotation of fatty acid desaturase genes in the genome of T. b. brucei s427 WT 
BSF and L. mexicana M379 promastigote form. 
Gene ID Annotation Chromosome 
TM 
domains 











10 6 1185 bp Lmex-FAD 
 Results 
 Over-expression of Tbb-FAD in Tbb-5FURes and Tbb-s427 
WT BSF 
The fatty acid desaturase Tb927.2.3080 (Tbb-FAD) is a candidate gene that is 
potentially responsible for uracil transport following an analysis of the WT and 5-
FU resistant lines for T. b. brucei by use of RNA sequencing. The expression level 
of Tb927.2.3080 was significantly decreased in Tbb-5FURes with a log2 fold-
change of -0.68 compared to the reference T. b. brucei TREU 927 genome (P  ≤ 
0.01) (Alzahrani, 2017). Moreover, this gene Tb927.2.3080 (fatty acid 
desaturase) has been identified to be a top hit in the RNAi library screening 
results whereby it leads to 58392 and 439 RPKM after analysis of the pyrimidine-
auxotrophic 2T1 PYR6-5-/- cell lines after selection with 5-FU at day 14 or 6-AU at 
day 24, respectively. (Alzahrani, 2017). The RIT-seq experiment was performed 
at the lab of Dr Sam Alsford at London School of Hygiene and Tropical Medicine. 
For T. b. brucei strain Lister 427, the correspondent fatty acid desaturase is 
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Tb427.02.3080 and will be referred to as Tbb-FAD throughout this study. Tbb-
FAD is located in chromosome 2 and comprises six transmembrane domains and 
is annotated as fatty acid desaturase (TriTrypDB). 
 PCR confirmation for over-expression of Tbb-FAD in Tbb-5FURes 
and Tbb-s427 WT 
The Tbb-FAD gene was amplified by PCR from the genome of T. b. brucei Lister 
427 strain by using HDK1338 as forward and HDK1339 as reverse primers. The 
Tbb-FAD gene was expressed in the Tbb-5FURes and Tbb-s427 WT strains by 
using the pHD1336 plasmid. The pHD1336 plasmid and the Tbb-FAD gene were 
digested by the MluI and BamHI restriction enzymes respectively. The Tbb-FAD 
gene was then ligated into pHD1336 in order to generate plasmid pHDK219 
(Figure 4.1). By inserting the gene into the pHDK219 vector, the MluI and BamHI 
restriction enzymes digested the vector, which helped in the identification of 
the relative sizes of the resulting DNA fragments. As shown in Figure 4.2, the 
Tbb-FAD gene is identified as the band at ~1.2 kb whereas the vector is 
represented by the band at ~6.5 kb. After the transfection of the linearized 
pHDK219 into the Tbb-5FURes and Tbb-s427 WT strains, PCR was used to confirm 
the linearity of the pHDK219 plasmid and integration of the Tbb-FAD gene in 
positive clones. The presence of the expected products (~1.2 kb for the 
integration while no band for the linearity of the circular of pHDK219 plasmid) 
was verified by running the PCR products on 1% agarose gel to be visualised 
under UV light (Figure 4.3 and Figure 4.4). 
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Figure 4.1: Plasmid map of pHDK219 vector for the homologous expression of Tbb-FAD 
gene in Tbb-5FURes and Tbb-s427WT strain. 
 
Figure 4.2: Digestion of pHDK219 plasmid by MluI and BamHI restriction enzymes to drop 
out Tbb-FAD gene (1227 bp) from the pHDK219 plasmid (6.5 kb). 
L: 1 kb DNA ladder (Promega); 1: Digested plasmid (MluI and BamHI); 2: Undigested 
plasmid for pHDK219. 
 
Figure 4.3: PCR confirmation for the linearity of pHDK219 vector and the integration of Tbb-
FAD gene into Tbb-5FURes strain after transfection. 
A) Confirmation of the linearization of pHDK219 vector into Tbb-5FURes strain after 
transfection by using HDK535 as forward primer for pHD1336 plasmid and HDK1339 as 
reverse primer for Tbb-FAD gene. L: 1kb DNA Ladder (Promega); 1: Clone1; 2: Clone2; 3: 
Clone3; 4: Undigested PHDK219 (~2.6 kb). B) Confirmation of the integration of Tbb-FAD 
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gene into Tbb-5FURes strain after transfection by using HDK1338 as forward primer for Tbb-
FAD gene and HDK335 as reverse primer for pHD1336 plasmid. L: 1 kb DNA Ladder 
(Promega); 1: Clone1; 2: Clone2; 3: Clone3; 4: Non-transfected control (gDNA from Tbb-
5FURes strain). 
 
Figure 4.4: PCR confirmation for the linearity of pHDK219 vector and the integration of Tbb-
FAD gene into Tbb-s427WT strain after transfection. 
A) Confirmation of the linearization of pHDK219 vector into Tbb-s427WT strain after 
transfection by using HDK535 as forward primer for pHD1336 plasmid and HDK1339 as 
reverse primer for Tbb-FAD gene. L: 1kb DNA Ladder (Promega); 1: Clone1; 2: Clone2; 3: 
Clone3; 4: Undigested PHDK219 (~2.6 kb). B) Confirmation of the integration of Tbb-FAD 
gene into Tbb-s427WT strain after transfection by using HDK1338 as forward primer for 
Tbb-FAD gene and HDK335 as reverse primer for pHD1336 plasmid. L: 1kb DNA Ladder 
(Promega); 1: Clone1; 2: Clone2; 3: Clone3; 4: Non-transfected control (gDNA from Tbb-
s427WT strain). 
 qRT-PCR confirmation and growth rate of Tbb-FAD in Tbb-5FURes 
and Tbb-s427 WT strains 
The assessment of the transcription level for the Tbb-FAD gene in Tbb-5FURes 
clones 1-3 and Tbb-s427WT clones 1-3 was conducted first and compared with 
the parental cell lines by the use of qRT-PCR. The Tbb-5FURes + Tbb-FADo.e 
clone 3 recorded the highest level of messenger RNA expression (3.7-fold; P < 
0.001) compared with the control Tbb-5FURes. On the other hand, the 
expression level of the Tbb-5FURes + Tbb-FADo.e clone 2 amounted to 2.2-fold (P 
< 0.01), whereas the expression level in Tbb-5FURes + Tbb-FADo.e clone 1 
increased 1.5-fold (P < 0.001) relative to the control cell line (Figure 4.5A). The 
further results showed that the Tbb-s427WT + Tbb-FADo.e clone 2 recorded the 
highest transcription level, amounting to a 2.9-fold increase (P < 0.001) 
compared to the control Tbb-s427WT. When compared to the control cell lines 
(Tbb-s427WT), the expression level of Tbb-s427WT + Tbb-FADo.e clone 1 and 3 
were recorded as 2.7 and 2.5-fold, respectively (P < 0.001) (Figure 4.5B). 










































































































































































Figure 4.5: Quantitative RT-PCR of Tbb-FAD gene expression in the Tbb-5FURes and Tbb-
s427WT strains. 
A) The expression levels of Tbb-FAD gene in Tbb-5FURes and compared to the control 
(Tbb-5FURes) determined by qRT-PCR. B) The expression levels of Tbb-FAD gene in Tbb-
s427WT and compared to the control (Tbb-s427WT) determined by qRT-PCR.  Levels were 
corrected against the expression level of the housekeeping gene (T. b. brucei GPI8). The 
presented results are the average of 3 replicates ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001. 
For all the three clones of the Tbb-5FURes + Tbb-FADo.e and the Tbb-s427WT + 
Tbb-FADo.e, and its parental cell lines, the assessment was done on their growth 
in HMI-9 medium supplemented with 10% FBS and incubated at 37 ºC under 5% 
CO2, and the cell densities were determined every 24h (Figure 4.6A and B). The 
outcomes of the study demonstrated that there was no effect on the growth 
when the Tbb-FAD gene was overexpressed in the Tbb-5FURes and Tbb-s427WT 
for all three clones compared with the control cell lines. 
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Figure 4.6: The growth rates of Tbb-5FURes and Tbb-s427WT strains expressing Tbb-FAD. 
A) The growth curve of Tbb-5FURes expressing Tbb-FAD clones 1-3 on HMI-9 medium 
supplemented with 10% FBS. B) The growth curve of Tbb-s427WT expressing Tbb-FAD 
clones 1-3 on HMI-9 medium supplemented with 10% FBS. The cells were seeded at the 
density of 1×104 cells/mL, and cell densities were determined every 24h. Cells were 
passaged every 48 hours, when the growth had reached between 1.5 and 2 x 106 cells/mL. 
Each data point in this result represents the mean of three similar independent repeats. 
 Drug sensitivity assay of overexpression of Tbb-FAD in Tbb-5FURes 
and Tbb-s427 WT with pyrimidine analogues 
The effects of increased gene expression of the Tbb-FAD gene for the three 
clones in the Tbb-5FURes and Tbb-s427WT strains on susceptibility to 5-FU and 
6-AU were assessed through the use of the Alamar blue assay as shown in Figure 
4.7 and Figure 4.8. The results of the study did not show any significant 
difference among the EC50 values of 5-FU and 6-AU when making a comparison 
between the over-expressing cell lines and the control cell lines (Tbb-5FURes 
and Tbb-s427 WT) (n=3; P > 0.05). Pentamidine was applied as control compound 
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for the over-expressing cell lines and the control cell lines, and no significant 

























































































































































































































































































Figure 4.7: Alamar blue drug sensitivity assay of overexpression of Tbb-FAD gene in Tbb-
5FURes clones 1-3 and Tbb-5FURes by using 5-fluorouracil (A), 6-azauracil (B) and 
pentamidine (C). 














































































































































































































































































Figure 4.8: Alamar blue drug sensitivity assay of overexpression of Tbb-FAD gene in Tbb-
s427WT clones 1-3 and Tbb-s427WT by using 5-fluorouracil (A), 6-azauracil (B) and 
pentamidine (C). 
The mean of three independent repeats is shown ± SEM in µM. ns = not significant. 
 Uracil uptake for overexpression of Tbb-FAD in Tbb-5FURes and 
Tbb-s427 WT 
Figure 4.9 shows that uptake of 0.1 µM of [3H]-uracil in Tbb-s427 WT, Tbb-
5FURes, Tbb-s427WT + Tbb-FADo.e and Tbb-5FURes + Tbb-FADo.e was linear over 
3 minutes (r2 = 0.99, 0.98, 0.99 and 0.99 respectively). The rates were 0.51 ± 
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0.03, 0.44 ± 0.030, 0.47 ± 0.041 and 0.43 ± 0.006 pmol.(107 cells)-1.s-1 for Tbb-
s427WT, Tbb-5FURes, Tbb-s427WT + Tbb-FADo.e and Tbb-5FURes + Tbb-FADo.e 
trypanosomes, respectively (n=1). However, the overexpression of Tbb-FAD in 
Tbb-s427WT and Tbb-5FURes did not change the rate of uracil uptake in 
comparison to the parental cell lines (Tbb-s427 WT and Tbb-5FURes). The 
addition of 1 mM unlabelled uracil completely inhibited the uptake of [3H]-uracil 
in all four cell lines. The transport rate of [3H]-uracil in the Tbb-5FURes cells 
was only partly reduced from the wild-type levels, as the measurement has the 
problem of high background of uracil generated by transport via TbU3. 
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Figure 4.9: Transport of 0.1 μM of [3H]-uracil by Tbb-s427 WT, Tbb-5FURes, Tbb-s427WT + 
Tbb-FADo.e and Tbb-5FURes + Tbb-FADo.e was measured over 3 minutes in the presence 
(open symbols) or absent (closed symbols) of 1 mM unlabelled uracil. 
Symbols represent the average of triplicate determinations in a single representative 
experiment, and error bars represent ± SEM. 
 Over-expression of Lmex-FAD in Lmex-5FURes and L. 
mexicana-WT promastigotes 
Another gene that acts as a candidate for a determining influence on pyrimidine 
transport, following an analysis of the differences in the gene expression for the 
WT and 5-FU resistant line for L. mexicana promastigote form by using RNA-seq, 
is the fatty acid desaturase LmxM.10.1320 (Lmex-FAD). The gene exhibited a 
significant reduction in the transcription level by recording a change of Log2 fold 
by -0.32 when comparing the Lmex-5FURes strain with L. mexicana wild-type (P 
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≤ 0.01) (Alzahrani, 2017). LmxM.10.1320 is located on chromosome 10 where it is 
known to comprise six transmembrane domains and it is also annotated as a 
fatty acid desaturase (TritrypDB). 
 PCR conformation of plasmid presence of Lmex-FAD in Lmex-
5FURes and L. mexicana-WT 
The Lmex-FAD gene was amplified by PCR from genomic DNA of L. mexicana 
M379 strain by using HDK1344 as forward and HDK1345 reverse primers. The 
pNUS-HcN plasmid was used to express the Lmex-FAD gene in Lmex-5FURes and 
L. mexicana-WT. The pNUS-HcN plasmid and the Lmex-FAD gene were digested 
by the NdeI and BglII restriction enzymes and T4 DNA Ligase was used to perform 
the ligation, generating plasmid pHDK220 (Figure 4.10). The integration of Lmex-
FAD gene into the pHDK220 was verified by a diagnostic restriction digest with 
restriction enzymes BglII and NdeI. As shown in Figure 4.11, the Lmex-FAD gene 
is represented by the band at ~1.2 kb, while the empty pHDK220 vector 
represented a band at ~6.4 kb. Following the transfection of the episomal 
plasmid pHDK220 into Lmex-5FURes and L. mexicana WT, PCR was used to verify 
the presence of pHDK220 in positive clones, using HDK1344 as forward primer for 
the Lmex-FAD gene and HDK340 as reverse primer for the pNUS-HcN plasmid 
(Figure 4.12). 
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Figure 4.10: Plasmid map of pHDK220 vector for the homologous expression of Tbb-FAD 
gene in Lmex-5FURes and L. mexicana WT strains. 
 
Figure 4.11: Digestion of pHDK220 plasmid by NdeI and BglII restriction enzymes to drop 
out Lmex-FAD gene (1185 bp) from the pHDK220 plasmid. 
L: 1 kb DNA ladder (Promega); 1: Digested plasmid (NdeI and BglII); 2: Undigested plasmid. 
 
Figure 4. 12: PCR Confirmation of the presence of Lmex-FAD gene into Lmex-5FURes and L. 
mexicana WT after transfection. 
A) Confirmation of the presence of Lmex-FAD gene in the Lmex-5FURes strain after 
transfection by using HDK1344 as forward primer for Lmex-FAD gene and HDK340 as 
reverse primer for pNUS-HcN plasmid. L: 1kb DNA Ladder (Promega); 1: Clone1; 2: Clone2; 
3: Clone3; 4: Non-transfected control (gDNA of Lmex-5FURes strain). B) Confirmation of the 
presence of Lmex-FAD gene in the L. mexicana-WT strain after transfection by using 
HDK1344 as forward primer for Lmex-FAD and HDK340 as reverse primer for pNUS-HcN 
plasmid. L: 1kb DNA Ladder (Promega); 1: Clone1; 2: Clone2; 3: Clone3; 4: Non-transfected 
control (gDNA of L. mexicana-WT strain). 
 Quantitative RT-PCR confirmation of Lmex-FAD overexpression in 
Lmex-5FURes and L. mexicana-WT 
Following the PCR confirmation of overexpressing of Lmex-FAD in Lmex-5FURes 
and L. mexicana-WT, the gene expression level was determined using qRT-PCR. 
All three clones (1, 2 and 3) of overexpressing of Lmex-FAD gene in Lmex-5FURes 
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significantly increased the mRNA levels compared to the control Lmex-5FURes 
(5.5-fold, 5.5-fold and 3.9-fold; P < 0.001, respectively) (Figure 4.13A). Also, the 
expression levels in Lmex-WT + Lmex-FADo.e clone 1, 2 and 3 significantly 
increased 2.9-fold, 4-fold and 2.9-fold, respectively (P < 0.001) compared with 











































































































































































Figure 4.13: The expression levels of Lmex-FAD gene in Lmex-5FURes and L. mexicana-WT. 
A) The expression levels of Lmex-FAD gene in Lmex-5FURes and compared to the control 
(Lmex-5FURes) determined by qRT-PCR.B) The expression levels of Lmex-FAD gene in 
Lmex-WT and compared to the control (L. mexicana-WT) determined by qRT-PCR.  Levels 
were corrected against the expression level of the housekeeping gene (L. mexicana GPI8). 
The presented results are the average of 4 replicates ± SEM. *** P < 0.001. 
 Drug sensitivity assay with 5-Fluorouracil 
As shown in Figure 4.14, the Alamar blue assay was used to help in the 
assessment of the susceptibility of the Lmex-FAD overexpressing Lmex-5FU 
resistant cell line. The results show that the sensitivities of Lmex-5FURes and 
the three Lmex-FADo.e clones in the Lmex-5FURes to 5-FU were almost identical 
to the Lmex-5FU resistant cell lines (n=3; P > 0.05). Additionally, there was no 
significant difference in the pentamidine EC50 values between the overexpressing 
cell lines and the control cell line (P > 0.05). 






























































































































































Figure 4.14: Alamar blue drug sensitivity assay for overexpression of Lmex-FAD gene in 
Lmex-5FURes clones 1-3 using 5-fluorouracil (A) and pentamidine was used as a positive 
control (B). 
The mean of three independent determinations in µM is shown ± SEM. ns = not significant. 
In addition, the Alamar blue assay was used also to determine the EC50 values for 
the overexpressing cell lines (L. mexicana WT + Lmex-FADo.e clones 1-3) and the 
parental cell line (L. mexicana WT) (Figure 4.15). The result showed that there 
were no significant differences in the EC50 values for 5-fluorouracil and 
pentamidine between the overexpressing cell lines and the parental control 
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Figure 4.15: Alamar blue drug sensitivity assay of L. mexicana wild type and overexpression 
of Lmex-FAD gene in L. mexicana WT clones 1-3 using 5-fluorouracil (A) and pentamidine 
was used as a positive control (B). 
The mean of three independent repeats is shown ± SEM in µM. ns = not significant. 
 Drug sensitivity assay with amphotericin B and miltefosine 
Amphotericin B increases membrane permeability of leishmanial parasites, and 
miltefosine is has been shown to act by inhibiting lipid biosynthesis of 
Leishmania species (Kovacic and Cooksy, 2012; Canuto et al., 2014), making 
them excellent control drugs with modes of action that are unrelated to 
nucleoside transport or nucleoside metabolism. Thus, it is crucial to screen 
whether over-expression of the FAD gene in L. mexicana may cause any 
alteration in the sensitivity rates of amphotericin B and miltefosine, which 
would be indicative of a general effect on cellular fitness. Figure 4.16 presents a 
visual illustration of an evaluation of the sensitivity of the Lmex-5FURes and the 
three Lmex-FADo.e clones in the Lmex-5FURes to amphotericin B and miltefosine. 
The EC50 values of the 5-FU resistant cell lines (Lmex-5FURes) to miltefosine 
significantly increased compared to the wild-type control (L. mexicana WT), 
with an average of 7.1 ± 0.03 µM and 3.2 ± 0.06 µM respectively. The Lmex-
5FURes strain was found to have a 2.2-fold resistance to miltefosine when 
compared with the wild-type control (n=3; P < 0.0001). The results of the study 
identified a significant increase in the sensitivity of Lmex-5FURes + Lmex-FADo.e 
clone 3 to miltefosine (3.3 ± 0.15 µM) in comparison with the Lmex-5FURes (7.1 
± 0.03 µM; P < 0.0001). Also, the study identified that the sensitivity of Lmex-
5FURes + Lmex-FADo.e clone 1 and clone 2 to miltefosine record significant 
difference from the outcomes of the Lmex-5FURes (6.7 ± 0.04 µM and 6.2 ± 0.26 
µM, respectively (P > 0.05).  The study further identified that the sensitivity of 
L. mexicana WT, Lmex-5FURes and Lmex-5FURes + Lmex-FADo.e clones 1-3 to 
amphotericin B did not record any significant differences (n=3; P > 0.05). 

















































































































































































Figure 4.16: The drug sensitivity assay of Lmex-5FURes and Lmex-5FURes + Lmex-FAD 
clones 1-3 to Amphotericin B (A) and Miltefosine (B). 
The mean of three independent determinations in µM is shown ± SEM. * P < 0.05; ** P < 0.01; 
*** P < 0.001. 
In addition, a comparison was made between the effects of amphotericin B and 
miltefosine on the L. mexicana WT + Lmex-FADo.e clones 1-3 with the L. 
mexicana WT. The comparison is demonstrated in Figure 4.17 where it was 
identified that there was no significant difference between the EC50 values for 
the clonal lines when compared with the L. mexicana WT (n=3; P > 0.05), with 
the exception that the EC50 of the Lmex-WT + Lmex-FADo.e clone 1 to 
amphotericin B significantly increased compared to the wild-type control (L. 
mexicana WT), with an average 0.75 ± 0.08 µM and 1.1 ± 0.04 µM (n=3; P < 0.05) 
respectively. 











































































































































Figure 4.17: The drug sensitivity assay of the L. mexicana wild type and L. mexicana WT + 
Lmex-FADo.e clones 1-3 to mphotericin B (A) and Miltefosine (B). 
The mean of three independent determinations in µM is shown ± SEM. * P < 0.05. 
 Uracil transport for overexpression of Lmex-FAD in Lmex-5FURes 
and L. mexicana-WT 
The transport of 0.1 μM of [3H]-uracil in the Lmex-5FURes and L. mexicana-WT 
expressing Lmex-FAD was determined in order to check whether the 
overexpression of Lmex-FAD could cause changes the uracil transport (Figure 
4.18). The L. mexicana-WT and Lmex-WT + Lmex-FADo.e cell lines showed very 
similar high levels of uptake when incubated with 0.1 μM of [3H]-uracil, with a 
linear phase of at least eight minutes, (with a rate of 0.051 ± 0.0022 and 0.050 ± 
0.0017 pmol.(107 cells)-1.s-1, respectively; n=1). Moreover, the overexpression of 
Lmex-FAD gene in Lmex-5FURes did not change the rate of uracil uptake in 
comparison to the parental cell line Lmex-5FURes. The addition of 1 mM of 
unlabelled uracil completely abolished the transport of 0.1 μM of [3H]-uracil in 
all four cell lines, showing it is saturable. 
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Lmex-5FURes + 1mM Uracil
Lmex-WT + 1mM Uracil
Lmex-WT + Lmex-FADo.e + 1mM Uracil
Lmex-5FURes + Lmex-FADo.e + 1mM Uracil
 
Figure 4.18: Transport of 0.1 μM of [3H]-uracil by L. mexicana-WT, Lmex-5FURes, Lmex-WT + 
Lmex-FADo.e and Lmex-5FURes + Lmex-FADo.e was measured over 8 minutes in the 
presence (open symbols) or absent (closed symbols) of 1 mM unlabelled uracil. 
Figure shows a representative experiment in triplicate, and error bars represent ± SEM. 
 Discussion 
Up to this moment, only ENT genes are identified as encoding purine and 
pyrimidine transporters in protozoans (De Koning et al., 2005; Campagnaro and 
de Koning, 2020), however, the involvement of other gene families has been 
proposed (Bellofatto, 2007; De Koning, 2007; Campagnaro et al., 2018a; Balcazar 
et al., 2017). A very strong technique for genetic screens for genes to be linked 
to function and precise phenotypes, where knockdown confers resistant 
populations, is the genome-wide RNA interference (RNAi) library screen. The 
first organism utilised in the application of this technique is T. b. brucei PCF 
(Alsford et al., 2012; Chou et al., 2015; Mohr and Perrimon, 2012; Morris et al., 
2002). The utilisation of RNAi library screening helped to identify novel 
trypanosomal drug transporters in the last few years, including TbAQP2 as a 
determinant of pentamidine sensitivity (Baker et al., 2012; Munday et al., 2014), 
the aminopurine transporter TbAT1 as the carrier for melarsoprol (Burkard et 
al., 2011) and amino acid transporter TbAAT6 as the carrier for eflornithine 
(Baker et al., 2011; Burkard et al., 2011). Consequently, in order to identify the 
genes contributing to pyrimidine transport in T. b. brucei BSF, RNAi library 
screens in T. b. brucei lines exposed to 5-FU and 6-AU were implemented. 
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Both RNA-seq in (Trypanosoma brucei and Leishmania) and RIT-seq data 
revealed fatty acid desaturase (Tbb-FAD) as one of the most prominent hits to 
be linked to 5-FU resistance in T. b. brucei BSF (Ali, 2013; Alzahrani, 2017). We 
expected that RNAi knockdown of the candidate pyrimidine transporters in T. b. 
brucei cell lines would cause resistance for 5-FU as this could indicate the loss of 
an influx transporter for 5-FU/uracil in the T. b. brucei cells. From RNAi library 
screening results, it is seen that the downregulation of Tbb-FAD genes bestows a 
level of resistance to 5-FU/6-AU in 2T1 PYR6-5-/- cells. Moreover, RNA-seq shows 
that fatty acid desaturase is an interesting hit also connected to 5-FU resistance 
in L. mexicana promastigotes (Alzahrani, 2017). The T. b. brucei and L. 
mexicana cells can take up lipids from host environments, and have their own 
lipid synthesising abilities de novo (Smith and Bütikofer, 2010; Zhang and 
Beverley, 2010).  
The results in this chapter show that overexpression of Tbb-FAD gene in Tbb-
5FURes and T. b. brucei s427 wild-type does not cause an increase in the 
sensitivity to 5-FU. Similarly, overexpression of the Lmex-FAD gene in Lmex-
5FURes and L. mexicana wild-type had no effect on 5-FU sensitivity via using the 
Alamar blue assay.  Additionally, the uptake rate of [3H]-uracil in Tbb-5FURes + 
Tbb-FADo.e and Tbb-s427WT + Tbb-FADo.e was almost identical to the parental 
cell lines (Tbb-5FURes and Tbb-s427WT). Likewise, overexpression of Lmex-FAD 
gene into Lmex-5FURes and L. mexicana wild-type did not increase the transport 
rate of [3H]-uracil. Therefore, it is still not clear how fatty acid desaturase (Tbb-
FAD and Lmex-FAD) determines sensitivity to pyrimidine nucleobases or 
transport in L. mexicana and T. b. brucei. However, while it is clear that the 
regular expression of the FD gene is not limiting the sensitivity to 5-FU, it 
appears that a strong reduction in expression may cause resistance. We also 
recommend tagging FAD gene with GFP or Myc and transfecting the tagged genes 
in T. brucei and L. mexicana. Then, perform a conventional and fluorescent 
western blot to assess whether the proteins are expressed and quantify their 
expression. Fluorescence microscopy showed that putative fatty acid desaturase 
Tb927.2.3080 is localised in the endoplasmic reticulum of T. b. brucei PCF 
(TrypTag, 2020). Recent research has shown that the gene encoding cytochrome 
B5-dependent oleate desaturase Tb927.2.3080 is essential for the cell viability of 
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T. brucei procyclic form. This is because RNAi-mediated downregulation of fatty 
acid desaturase shows that this gene is essential for T. brucei PCF to survive, 
since the growth defect was noted after induction with tetracycline (Alloatti et 
al., 2010). In other research, Ali et al. (2013b) and Alzahrani et al. (2017) 
showed that uracil/5-FU transporters are not essential when it comes to these 
organisms (T. b. brucei and L. mexicana) although they are important when it 
comes to the anti-protozoal activity of 5-FU. A report from Ali et al. (2013a) 
showed that 5-FU, a substrate for uracil phosphoribosyltransferase (UPRT), is 
incorporated into precursors for lipid biosynthesis such as UDP-ethanolamine. 
Thus, it is possible to speculate on the possibility of downregulating fatty acid 
desaturase by T. b. brucei as a way of avoiding 5-FU’s deleterious effects. 
The overexpression of the Tbb-FAD gene in Tbb-5FURes and Lmex-FAD gene in 
Lmex-5FURes does not re-sensitise the parasites to 5-FU in vitro. Although, the 
over-expression of Lmex-FAD gene in Lmex-5FURes cells caused significant 
sensitisation to miltefosine compared to the parental cell line (Tbb-5FURes). 
Therefore, it is still not clear how FAD determines sensitivity to pyrimidine 
nucleobases or transport in L. mexicana and T. b. brucei. However, while it is 
clear that the regular expression of the FAD gene is not limiting the sensitivity to 
5-FU, it appears that a strong reduction in expression may cause resistance, 
hence the observation that overexpression did not change susceptibility to 5-FU, 
but RNAi-mediated downregulation (RITseq) did. A further study of FAD 
knockdown phenotypes is thus recommended to understand the functional 
characterization of Tbb-FAD gene in T. brucei BSF using the RNAi technique. 
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5 Heterologous expression of the Aspergillus 
nidulans uracil transporter (FurD) in T. b. brucei 
BSF and L. mexicana promastigotes  
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 Introduction 
One of the defining characteristics of a cell is its ability to be selectively 
permeable. As such, very few molecules can cross the phospholipid bilayer that 
is the cell membrane. Transportation of most ions, nutrients and metabolites 
across the cell membrane is facilitated by transporters. Transporters are 
specialised membrane proteins that move molecules across the cell membrane, 
often regulated by various signalling pathways. Numerous membrane 
transporters have been identified in Kinetoplastid protozoa, and their functions 
include absorption of nutrients, regulation of ion gradients, excretion of 
metabolites, and transportation of drugs (Majumder, 2008; Kirk and Saliba, 
2007; Rodriguez-Contreras et al., 2007; Akpunarlieva and Burchmore, 2017). 
Uracil transport is known to be an almost ubiquitous cellular activity that is 
found in cell types from free-living prokaryotes to eukaryote cells (de Koning and 
Diallinas, 2000). Highly specific uracil transporters are described in mammalian 
cells (Baldwin et al., 1999; King et al., 2006). In protozoa, the L. major LmajU1 
as well as T. b. brucei TbU1 and TbU3 transporters have been characterised by 
their kinetic characterisations, but the genes coding for these transporters have 
not been parameters (Amillis et al., 2007;; De Koning, 2007; Campagnaro and de 
Koning, 2020; Bellofatto, 2007), whereas in bacteria, yeasts and fungi multiple 
uracil transporter genes have been identified (de Koning and Diallinas, 2000; 
Andersen et al., 1995; Jund et al., 1977; Stoffer-Bittner et al., 2018; Amillis et 
al., 2007). Uracil transporter mutants have been identified to be resistant to the 
toxic uracil analogue 5-fluorouracil in several instances, and have been shown to 
be deficient in the uptake of radiolabelled uracil (Palmer et al., 1975; Jund et 
al., 1977; Andersen et al., 1995; Amillis et al., 2007; Stoffer-Bittner et al., 
2018). For example, the deletion of the FurD gene from Aspergillus nidulans has 
contributed to the phenotype of full resistance to 5-fluorouracil, and completely 
abolished the uptake of radiolabelled uracil (Amillis et al., 2007). 
The A. nidulans FurD uracil transporter is classified as Nucleobase-Ascorbate 
Transporter or Nucleobase Cation Symporter family 2 (NAT/NCS2 family). This 
group of transporters are active, proton driven transporters specialised in 
transporting protons and nucleobase. Structurally, FurD consists of twelve 
transmembrane protein segments (Gournas et al., 2008; de Koning and Diallinas, 
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2000; Krypotou et al., 2015). However, BLAST analysis does not identify any FurD 
homologues in any protozoan or metazoan genome databases and the uracil 
uptake must be mediated by a transporter from a different gene family (De 
Koning, 2007; Amillis et al., 2007). Although uracil transporters have been 
identified in other organisms as highlighted in Table 5.1, the degree of FurD 
homology observed for S. cerevisiae Fur4p (46.2%), P. larvae PIUP (54.6%) and E. 
coli UraA (37.1%) is relatively moderate (Amillis et al., 2007; JUND et al., 1988; 
Andersen et al., 1995; Stoffer-Bittner et al., 2018). Furthermore, Appendix 7 
provides the results for the alignment of FurD amino acid sequences in A. 
nidulans, the UraA in E. coli, the Fur4p in S. cerevisiae and PIUP in P. Larvae. 
Resistance to 5-fluorouracil was generated in L. mexicana promastigotes and T. 
b. brucei s427 BSF, which produced the Lmex-5FURes and Tbb-5FURes clonal 
lines, respectively. Uracil and 5-FU transport rates in these cell lines are strongly 
reduced, particularly in the L. mexicana cell lines (Ali et al., 2013a; Alzahrani et 
al., 2017). For that reason, it is of interest to clone and functionally express 
FurD into the 5-FU resistant cell lines (Tbb-5FURes and Lmex-5FURes) and L. 
mexicana wild-type in order to investigate whether the sensitivity to 5-FU, or 
the transport of 5-FU/uracil in vitro resistant strains could be restored by the 
introduction of a confirmed uracil/5-FU transporter. This would allow a 
functional screening of potential transporter genes. Moreover, it would expand 
knowledge into the mechanisms used by T. brucei and L. mexicana to transport 
pyrimidines. The importance of choosing FurD from A. nidulans is that the 
transporters of FurD have previously been characterized in detail (Prof George 
Diallinas Lab, National and Kapodistrian University of Athens, Greece). A study 
performed by Amillis et al. (2007) showed that the knockout of the FurD gene in 
A. nidulans contributed to a full phenotype of resistance to 5-FU and completely 
reduced uptake of radiolabelled uracil. The A. nidulans uracil transporter FurD is 
a confirmed uracil/5-FU transporter. 
Table 5.1: The amino acid sequence identity of the FurD uracil transporter of A. nidulans 




Chromosome Length (aa) TMs 
% Identity with 
FurD 
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FurDa AN11247.3 3 544 12 - 
Fur4pb NP_009577.1 2 633 12 46.2% 
UraAc  X73586.1 - 429 14 37.1% 
PIUPd PL1_0655 - 421 12 54.6% 
a Aspergillus nidulans uracil transporter; b Saccharomyces cerevisiae uracil transporter; c 
Escherichia coli uracil permease; d Paenibacillus larvae uracil transporter; aa: amino acids; TMs: 
transmembrane domains. 
 Results 
 Heterologous expression of FurD in Tbb-5FURes BSF 
The aim of this section is to functionally express FurD in Tbb-5FURes in order to 
investigate whether the sensitivity/transport to 5-FU in vitro could be restored 
by the introduction of a confirmed uracil/5-FU transporter. 
 PCR confirmation of integration of FurD in Tbb-5FURes 
A plasmid construct used to express FurD genes in Tbb-5FURes, pHDK069 (Figure 
5.1) had previously been generated by Dr. Jane Munday (Prof Harry de Koning 
Lab, University of Glasgow). Following transfection of NotI-linearized pHDK069 
plasmid, based on pHD1336 plasmid (Biebinger et al., 1997), into the Tbb-
5FURes strain, PCR was applied to verify the linearisation of the circular 
pHDK069 vector and the integration of the FurD gene in positive clones. The 
presence of the expected products (~1.6 kb for the integration, while no band 
for the linearity of the circular of pHDK69 plasmid) were verified by running the 
PCR products on 1% of agarose gel to be seen visually under UV light (Figure 5.2). 
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Figure 5.1: Plasmid map of pHDK069 vector for the heterologous expression of Aspergillus 
nidulans uracil transporter gene (FurD) in Tbb-5FURes. 
 
Figure 5.2: PCR confirmation for the linearity of pHDK069 plasmid and the integration of 
FurD gene into Tbb-5FURes strain after transfection. 
A) Confirmation of the linearisation of pHDK069 vector into Tbb-5FURes strain after 
transfection by using HDK535 as forward primer for the pHD1336 plasmid and HDK532 as 
reverse primer FurD gene. L: 1kb DNA Ladder (Promega); 1: Clone 1; 2: Clone 2; 3: Clone 3; 
4: Undigested pHDK069; 5: Negative control (no DNA). B) Confirmation of the integration of 
FurD gene (~1.6 kb) into Tbb-5FURes strain after transfection by using HDK531 as forward 
primer for FurD and HDK335 as reverse primer for the pHD1336 plasmid. L: 1kb DNA Ladder 
(Promega); 1: Clone 1; 2: Clone 2; 3: Clone 3; 4: Non-transfected control (gDNA of Tbb-
5FURes). 
 Growth rates and qRT-PCR confirmation of expression of FurD in 
Tbb-5FURes 
The evaluation of the expression levels for A. nidulans uracil transporter in Tbb-
5FURes + FurD clones 1-3 was compared with the control Tbb-5FURes by the use 
of qRT-PCR (Figure 5.3). The FurD gene in Tbb-5FURes + FurD clone 1 recorded 
the highest level of transcript expression (102-fold; P < 0.001) compared with 
the control, although the other two clones also appear to express the gene 
robustly: 94-fold for clone 2 (P < 0.001) and 101-fold for clone3 (P < 0.001). 
However, the quantification of fold-overexpression relative to the control is 
difficult as the gene was simply not present in the control cell line; either way, 
the experiment clearly showed the expression of FurD in all three clones. 





































































Figure 5.3: The expression levels of FurD gene in Tbb-5FURes and compared to the control 
(Tbb-5FURes) determined by qRT-PCR. 
Levels were corrected against the expression level of the housekeeping gene (T. b. brucei 
GPI8). The presented results are the average of 4 replicates ± SEM. *** P < 0.001 by Unpaired 
Student’s T-test. 
An assessment of the growth of Tbb-5FURes + FurDo.e clones 1-3 and the control 
Tbb-5FURes was done in HMI-9 medium complemented by 10% FBS and incubated 
at 37 ºC under 5% CO2. The cell density was determined after every 24 h and 
cells were passaged every 48 hours once the growth has reached between 1.5 
and 2 x 106 cells/mL. (Figure 5.4). The result of the analysis identified that 
there was no effect on the growth of the Tbb-5FURes + FurD clone 1-3 when 































Tbb-5FURes + FurD clone1
Tbb-5FURes + FurD clone3
Tbb-5FURes + FurD clone2
 
Figure 5.4: The growth curve of Tbb-5FURes and Tbb-5FURes expressing FurD clones 1, 2 
and 3 on HMI-9 medium supplemented with 10% FBS. 
The cells were seeded at the density of 1×104 cells/mL, and cell densities were determined 
every 24h. Cells were passaged every 48 hours once the growth had reached between 1.5 
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and 2 x 106 cells/mL. Each data point in this result represents the mean of two similar 
independent repeats. 
 Drug sensitivity assay with 5-FU and 6-AU 
An investigation into the sensitivity of Tbb-5FURes expressing FurD gene to 5-FU 
and 6-AU was conducted and a comparison made with the Tbb-5FURes as shown 
in Figure 5.5. The results showed that 5-FU had an average EC50 value of 4130 ± 
200 µM against Tbb-5FURes, compared to 70 + 6 µM for Tbb-s427 WT, a 59-fold 
resistance (n=3; P < 0.001). The sensitivities of Tbb-5FURes + FurD clones 1, 2, 
and 3 to 5-FU were highly similar to the 5-FU resistant cell line (P > 0.05). 
Interestingly, the Tbb-5FURes demonstrated increased sensitivity to 6-AU, an 
inhibitor of pyrimidine biosynthesis, with an average EC50 value of 305 ± 20 µM, 
while Tbb-s427 WT displayed EC50 value of 1849 + 86 µM (6.1-fold sensitisation to 
6-AU; n=3; P < 0.001). However, there was no significant difference in the 6-AU 
EC50 values between three clones of the Tbb-5FURes + FurD and the Tbb-5FURes 
control (P > 0.05). The increased 6-AU sensitivity in the 5-FURes-based clones 
appears to indicate the much higher reliance on pyrimidine biosynthesis over 
salvage pathways. As expected, the analysis did not identify any significant 
difference in the susceptibility to pentamidine, included as internal control, for 
any of the strains (P > 0.05). The Alamar blue assay result indicated that 
expressing of FurD in Tbb-5FURes did not lead to an increase in the sensitivity to 
5-FU in Tbb-5FURes. It therefore appears that the reduced uptake of 5-FU in 5-
FU is likely to be just one of the adaptations to the drug, and reversing it does 
not significantly restore sensitivity. This hypothesis will need substantial follow-
on for verification by using Western immunoblotting and immunofluorescence 
microscopy to confirm the expression and quantification of FurD in T. b. brucei. 







































































































































































































































































Figure 5.5: Alamar blue drug sensitivity assay of expression of FurD gene in Tbb-5FURes 
using 5-fluorouracil (A), 6-azauracil (B) and pentamidine (C). 
The mean of three independent repeats is shown ± SEM. *** P < 0.001. 
 Uracil transport by Tbb-5FURes expressing FurD 
The rate of transport of 0.1 μM of [3H]-uracil in Tbb-5FURes expressing FurD was 
investigated in order to check whether the expression of FurD could cause 
increases in uracil transport (Figure 5.6). [3H]-Uracil uptake was linear for 4 
minutes in Tbb-s427 wild-type (n=4), with a rate of 0.22 ± 0.082 pmol.(107 cells)-
1.s-1. When Tbb-5FURes + FurD cells were incubated with 0.1 μM of [3H]-uracil, 
we similarly observed a rate of transport of 0.24 ± 0.11 pmol.(107 cells)-1.s-1 that 
was linear for at least four minutes (n=4), and was not significantly different 
from the parental cell lines Tbb-5FURes, with a rate of 0.17 ± 0.075 pmol. (107 
cells)-1.s-1 (n=4; P > 0.05), although the rate of uptake trended higher in cells 
expressing FurD. The addition of 1 mM of unlabelled uracil completely abolished 
the transport in all cell lines, showing the uptake is saturable. Thus, the 
expression of FurD in Tbb-5FURes caused no significant changes in the rate of 
uracil uptake compared with parental cell lines Tbb-5FURes, which was in any 
case only partly reduced from wild-type levels. When adapting T. b. brucei BSF 
to high levels of 5-FU, the rates of uptake of [3H]-5-FU is decreased by > 22%. A 
similar experiment using L. mexicana promastigotes strongly reduced 5-FU 
transport (> 98%) in the resistant cell line. It is thus clear that 5-FU resistance in 
this T. brucei cell line is not the (sole) result of reduced uptake of the drug. 
However, it was previously shown that uracil uptake was much more profoundly 
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impacted in 5-FU resistant L. mexicana (Alzahrani, 2017) and we next 




































Tbb-s427WT + 1mM Uracil
Tbb-5FURes
Tbb-5FURes + 1mM Uracil
Tbb-5FURes + FurD + 1mM Uracil
Tbb-5FURes + FurD
 
Figure 5.6: [3H]-Uracil transport by Tbb-s427WT, Tbb-5FURes and Tbb-5FURes expressing 
FurD. 
Transport of 0.1 μM of [3H]-uracil by Tbb-s427WT, Tbb-5FURes and Tbb-5FURes + FurD was 
measured over 4 minutes in the presence (open symbols) or absent (closed symbols) of 1 
mM unlabelled uracil. Figure shows a representative out of four independent experiments. 
Symbols represent the average of triplicate determinations and error bars represent ± SEM. 
P > 0.05 was determined by unpaired Student’s T-test. 
 The heterologous expression of FurD in Lmex-5FURes 
promastigotes 
The investigations described above have shown that heterologous expression of 
FurD in the Tbb-5FURes had no effect on the sensitivity of the cells to 5-FU. In 
the same way cloning of the FurD gene into the Tbb-5FURes could not increase 
the rate of transporting 0.1 μM of [3H]-uracil significantly, yet it was only a slight 
reduction of the levels observed in wild types (see section 5.2.1). Hence, the 
objective of this section is to examine the effects that Lmex-5FURes could 
display towards the sensitivity of 5-FU following a heterologous expression of the 
FurD gene, and the transport of uracil/5-FU after a functional uracil/5-FU 
transporter is introduced. 
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 PCR and qRT-PCR confirmation of the presence of FurD in Lmex-
5FURes 
PCR was used to amplify the FurD gene from plasmid pHDK069, using primers 
HDK1427 as forward and HDK1428 as reverse. The pNUS-HcN plasmid was used to 
express the FurD gene in the Lmex-5FURes (Tetaud et al., 2002). The XhoI and 
BglII restriction enzymes were used to digest the pNUS-HcN plasmid and FurD 
gene; the T4 DNA Ligase was used to ligate the digested FurD gene into the 
digested pNUS-HcN plasmid to generated plasmid pHDK254 (Figure 5.7). The 
FurD integration into pHDK254 was verified by diagnostic digest with XhoI and 
BglII restriction enzymes, which resulted in a band of ~6.5 kb for the plasmid, 
and a band at ~1.6 kb for FurD gene (Figure 5.8). After transfection of the 
pHDK254 plasmid into Lmex-5FURes, PCR was used to verify the existence of 
pHDK254 plasmid in positive clones using forward primer HDK531 for FurD gene 
and HDK340 as reverse primer for pNUS-HcN plasmid sequence (Figure 5.9). 
 
Figure 5.7: Plasmid map of pHDK254 vector for the heterologous expression of Aspergillus 
nidulans uracil transporter FurD in Lmex-5FURes and L. mexicana wild-type. 
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Figure 5.8: Restriction digest products for pHDK254 plasmid with XhoI and BglII to release 
FurD. 
L: 1 kb DNA ladder (Promega); 1: Digested plasmid by XhoI and BglII to release FurD gene 
(1635 bp) from pHDK254 (~6.5kb); 2: Undigested plasmid for pHDK254. 
 
Figure 5.9: Confirmation of the presence of FurD gene into Lmex-5FURes strain after 
transfection by using HDK531 as forward primer for FurD gene and HDK340 as a reverse 
primer for pNUS-HcN plasmid. 
L: 1kb DNA Ladder (Promega); 1: Clone1; 2: Clone2; 3: Clone3; 4: Non-transfected control 
(genomic DNA of Lmex-5FURes). 
qRT-PCR was used to examine the level of expression for the FurD gene in Lmex-
5FURes after cloning and the results were compared with those of the control 
lines of Lmex-5FURes as highlighted in Figure 5.10.  Notably the results 
confirmed that the Tbb-5FURes + FurD clone 1 was at 30-fold (P < 0.001), while 
the results in Tbb-5FURes + FurD clone 3 increased to 69-fold (P < 0.001) in 
relation to the control cell lines, but Tbb-5FURes + FurD clone 2 recorded the 
highest expression level, amounting to a 232-fold increase (P < 0.001) compared 
to the control cell lines. Besides, there is a possibility of speculating the 
differences in expression levels of the cell lines reflected by the numbers of 
episomal plasmid pHDK254 that located in the genome of Tbb-5FURes parasites.  








































































Figure 5.10: The expression levels of FurD gene in Lmex-5FURes and compared to the 
control (Lmex-5FURes) determined by qRT-PCR. 
Levels were corrected against the expression level of the housekeeping gene (L. mexicana 
GPI8). The presented results are the average of 4 replicates ± SEM. *** P < 0.001 by unpaired 
Student’s T-test. 
 Drug sensitivity assay with 5-FU and 6-AU 
We investigated whether the expression of FurD in the Lmex-5FURes changed 
the sensitivity to 5-FU and 6-AU in vitro. This was assessed and compared with 
the Lmex-5FURes as shown in Figure 5.11, but no significant differences in the 
EC50 values against 5-FU were observed for the three Lmex-5FURes + FurD clones 
(P > 0.05). The results showed that 5-FU had an average EC50 value of 14 ± 0.45 
mM against Lmex-5FURes, while L. mexicana WT displayed EC50 value amounting 
to 50 + 9 µM, a 284-fold resistance to 5-FU (n=3; P < 0.001). The sensitivities of 
Lmex-5FURes + FurD clones 1, 2, and 3 to 6-AU were highly similar to those of 
the 5-FU resistant cell line (P > 0.05). In addition, there were no significant 
differences in the EC50 values of pentamidine between the expressing cell lines 
and the control (P > 0.05). The EC50 values indicated that expressing of FurD in 
Lmex-5FURes did not lead to decreasing the EC50 value of 5-FU. 


































































































































































































































































































Figure 5.11: Alamar blue drug sensitivity assay of expression of FurD gene in Lmex-5FURes 
by using 5-fluorouracil (A), 6-azauracil (B) and pentamidine (C). 
The mean of three independent determinations is shown ± SEM. *** P < 0.001. 
 Transport assay with uracil and 5-FU, and kinetic characterisation of 
FurD transporter 
The results for Lmex-5FURes were significantly different from those observed in 
the Tbb-5FURes (Figure 5-6). As such, there appeared to be a completely loss of 
function of the LmexU1 as the rate of transportation of radiolabeled uracil was 
reduced by approximately 95% (Figure 5.12). The transport rate decreased from 
0.068 ± 0.004 pmol.(107 cells)-1.s-1 to 0.009 ± 0.0002 pmol.(107 cells)-1.s-1, which 
made the Lmex-5FURes a more suitable expression system for the heterologous 
expression of the FurD transporter than Tbb-5FURes. A previous report indicated 
the rate of uptake of [3H]-5FU L. mexicana promastigotes almost completely 
abolished 5-FU transport in the resistant cell lines (Alzahrani et al., 2017). 
Besides, the presence of TbU3 in Tbb-5FURes cells made it difficult to use Tbb-
5FURes cells as expression system due to the high background of uracil transport 
(Ali et al., 2013a); there is no known equivalent of TbU3 in L. mexicana. 
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Figure 5.12: Radiolabelled uracil transport by L. mexicana-WT and Lmex-5FURes. 
Transport of 0.1 μM of [3H]-uracil by L. mexicana-WT and Lmex-5FURes was measured over 
4 minutes in the presence (open symbols) or absent (closed symbols) of 1 mM unlabelled 
uracil. Figure shows one representative experiment and error bars are ± SEM of triplicate 
determinations. 
Subsequent experiments were performed using 0.1 μM of [3H]-uracil and [3H]-5-
fluorouracil to assess the transport rate of uracil and 5-FU in Lmex-5FURes 
expressing FurD in parallel with their 5-FU resistant cell line counterparts 
(Figure 5.13A and B). Indeed, the heterologous expression of FurD in Lmex-
5FURes revealed a very high level of [3H]-uracil transport, with a rate of uptake 
of 0.21 ± 0.027 pmol.(107 cells)-1.s-1 and a linear phase over 45 seconds (r2=0.97; 
Figure 5.13A). The addition of 1 mM of unlabelled uracil completely abolished 
the transport, showing that the uptake via FurD is saturable. The uptake rate of 
0.1 μM [3H]-5-fluorouracil over 20 seconds, in the presence or absence of 1 mM 
unlabelled 5-fluorouracil. However, under these conditions, the uptake of 0.1 μM 
of [3H]-5-fluorouracil was much more quickly equilibrated than [3H]-uracil, 
resulting in a non-linear rate of uptake after 10 seconds (Figure 5.13, blue 
dashed line), presumably because uracil is metabolised at a much higher rate 
than its fluorinated analogue. The heterologous expression of FurD in Lmex-
5FURes revealed a very high level of [3H]-5-fluorouracil uptake, with a rate of 
uptake of 0.14 ± 0.008 pmol.(107 cells)-1.s-1 and a linear phase over 10 seconds 
(solid blue line; r2=0.99; Figure 3.13B); in both strains [3H]-5-fluorouracil 
transport was completely inhibited in the presence of 1 mM unlabelled 
fluorouracil. This result very much confirmed that uracil and 5-FU share the 
same transporter FurD, as transport of both substrates was very strongly 
increased upon expression of this carrier. 
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Figure 5.13: [3H]-Uracil and [3H]-5-Fluorouracil transport by Lmex-5FURes and Lmex-5FURes 
expressing FurD. 
A) Transport of 0.1 μM of [3H]-uracil by Lmex-5FURes (●) and Lmex-5FURes + FurD (■) was 
measured over 45 seconds in the presence or absent of 1 mM unlabelled uracil (○) and (□) 
respectively. B) Transport of 0.1 μM of [3H]-5-fluorouracil by Lmex-5FURes (●) and Lmex-
5FURes + FurD (■) was measured over 20 seconds in the presence or absent of 1 mM 
unlabelled 5-fluorouracil (○) and (□) respectively. The blue dashed line is showing the rate of 
uptake using a non-linear regression analysis (saturation plot). Symbols represent the 
average of triplicate determinations in a single representative experiment and error bars 
represent ± SEM. 
The transport of 0.1 μM of [3H]-uracil was also investigated in Lmex-5FURes 
expressing FurD using longer incubations (Figure 5.14A). The result showed that 
the rate of 0.1 μM of [3H]-uracil uptake in Lmex-5FURes + FurD became non-
linear after 5 minutes (dashed green line). The linear phase of uptake (blue 
line), showed a rate of 2.1 ± 0.17 pmol.(107 cells)-1.s-1 (r2=0.97). The addition of 
1 mM unlabelled uracil was completely inhibited the FurD transporter. The 
uptake assay with 0.1 μM of [3H]- 5-fluorouracil was also performed using longer 
incubations, which presented a non-linear uptake after 10 seconds (dashed green 
line), with a rate of 0.39 ± 0.04 pmol.(107 cells)-1.s-1 (r2=0.98) over the 9 seconds 
of the linear phase of uptake (blue line); the FurD transporter was completely 
inhibited by 1 mM unlabelled 5-fluorouracil (Figure 5.14B), showing that uracil 
and 5-fluorouracil uptake are mediated by a saturable transporter rather than by 
simple diffusion. These findings show very clearly that uracil and 5-fluorouracil 
is highly concentrated in Lmex-5FURes cells expressing FurD, but this saturates 
in less than 5 minutes and 9 seconds, respectively. 
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Figure 5.14: [3H]-Uracil and [3H]-5-Fluorouracil transport by Lmex-5FURes expressing FurD 
over 10 minutes and 60 seconds, respectively. 
A) Transport of 0.1μM of [3H]-Uracil by Lmex-5FURes + FurD (●) was measured over minutes 
in the presence (open symbols) or absent (closed symbols) of 1 mM unlabelled uracil (○). B) 
Transport of 0.1μM of [3H]- 5-fluorouracil by Lmex-5FURes + FurD (●) was measured over 60 
seconds in the presence (open symbols) or absent (closed symbols) of 1 mM unlabelled 5-
fluorouracil (○). Symbols represent the average of triplicate determinations in a single 
representative experiment and error bars represent ± SEM. 
Subsequent transport assays were performed using 0.1 μM of [3H]-uracil and 
incubations for 10 seconds as our time point – within the linear phase – in order 
to characterise uracil uptake in Lmex-5FURes expressing FurD. Figure 5.15A 
shows representative inhibition curves for the inhibition of 0.1 μM of [3H]-uracil 
transport by unlabelled uracil and 5-fluorouracil. Uracil and 5-fluorouracil were 
stronger inhibitors and, calculated from the Michaelis-Menten saturation plots 
(in competition with 0.1 μM of [3H]-uracil) (Figure 5.15B), an average Km value of 
0.97 ± 0.16 μM and Vmax of 3.89 ± 0.25 pmol.(107 cells)-1.s-1 for uracil (n=3) was 
calculated. This compared to a Ki value of 0.75 ± 0.24 (n=3) for 5-fluorouracil. 
Thus, FurD is a highly selective and high-affinity transporter for uracil and 5-
fluorouracil when expressed in Lmex-5FURes. 











































































Figure 5.15: Inhibition of 0.1 μM of [3H]-uracil over 10 seconds. 
A) Inhibition of 0.1 μM of [3H]-uracil over 10 seconds by various concentrations of 
unlabelled uracil (●) and unlabelled 5-fluorouracil (■). B) The latter inhibition curve was also 
converted to a Michaelis-Menten saturation curve. Figure shows a representative out of 
three independent experiments in triplicates. Symbols represent the average of triplicate 
determinations in a single representative experiment and error bars represent ± SEM. 
The data from the FurD inhibition profiles is listed in Table 5.2, which highlights 
that the average Ki value for 5-fluorouracil inhibition of uracil transport was 
almost identical to the average of Km value for uracil uptake (n=3). Interestingly, 
the interaction of uracil and 5-fluorouracil with FurD led to a very similar Gibbs 
free energy (ΔG0) of association: -34.3 and -35.1 kJ/mol, respectively. Thus, the 
anticancer drug 5-fluorouracil was as good a substrate as uracil for FurD 
transporter. These results are consistent with the previous characterisations of 
this transporter in A. nidulans, showing that FurD has very high-affinity for uracil 
(Km of 0.45 μM) and 5-fluorouracil (Ki of 0.46 μM) (Amillis et al., 2007). 
Table 5.2: Transport of uracil in Lmex-5FURes expressing Aspergillus nidulans FurD. 
VmaxKm and Ki values represent the mean of three independent determination in triplicates ± 
SEM. Gibbs free energy of substrate-transporter interactions were calculated from the Km 
and Ki. 
Lmex-5FURes expressing Aspergillus nidulans FurD 
Radiolabel [3H]-Uracil ΔG0 δ(ΔG0) n 
Km (µM) 0.971 ± 0.166 -34.3 -- 3 
Vmax pmol. (10
7 cells)-1.s-1 3.897 ± 0.251 -- -- 3 
Inhibitors (Ki µM) 
   
5-Fluorouracil 0.758 ± 0.249 -35.1 -0.8 3 
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 The heterologous expression of FurD in L. mexicana WT 
promastigotes 
Above, it was confirmed that the heterologous expression of FurD gene in Lmex-
5FURes could not increase the sensitivity of the cells to 5-FU; although, it led to 
increased transportation of radiolabeled uracil and 5-FU to levels exceeding the 
wild-type activity (see section 5.2.2). Thus, the purpose of this section was to 
provide further detailed information on the sensitivity/transport to 5-FU in wild-
type L. mexicana promastigotes expressing FurD. 
 PCR and qRT-PCR confirmation of the existence of FurD in L. 
mexicana WT 
A plasmid construct used to express FurD gene in L. mexicana WT, pHDK254 
(Figure 5.7) had been used previously for the heterologous expression of FurD in 
Lmex-5FURes. Following transfection of this episomal plasmid pHDK254, which 
was based on the pNUS-HcN plasmid, into the L. mexicana WT strain, PCR was 
applied to verify the existence of pHDK254 in positive clones, using HDK531 as 
forward primer for the FurD gene and HDK340 as reverse primer for the pNUS-
HcN plasmid (Figure 5.16). Quantitative real time PCR was performed to quantify 
the levels of FurD gene expression in L. mexicana WT cells compared to that in 
the control. All three clones 1, 2 and 3 of expressing of FurD gene in L. mexicana 
wild-type significantly increased the mRNA levels compared to the control L. 
mexicana WT (27-fold, 50-fold and 25-fold; P < 0.001, respectively) (Figure 
5.17). 
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Figure 5.16: Confirmation of the presence of FurD gene into L mexicana-WT strain after 
transfection by using HDK531 as forward primer for FurD gene and HDK340 as a reverse 
primer for pNUS-HcN plasmid.  
L: 1kb DNA Ladder (Promega); 1: Clone1; 2: Clone2; 3: Clone3; 4: Non-transfected control 



































































Figure 5.17: The expression levels of FurD gene in L mexicana-WT and compared to the 
control (L mexicana-WT) determined by qRT-PCR. 
Levels were corrected against the expression level of the housekeeping gene (L. mexicana 
GPI8). The presented results are the average of 4 replicates ± SEM. *** P < 0.001 by Unpaired 
Student’s T-test. 
 Drug sensitivity assay with 5-FU and 6-AU 
The sensitivity of the L. mexicana wild-type and the three FurD clones in the L. 
mexicana-WT parasites to 5-FU and 6-AU was investigated using the usual Alamar 
blue assay (Figure 5.18). Expression of FurD gene did not lead to increasing or 
decreasing the sensitivity to 5-FU or 6-AU in L. mexicana wild-type expressing 
FurD, as the EC50 values of Lmex-5FURes and three clones for Lmex-5FURes + 
FurD were almost the same (n=3; P > 0.05). In addition, there were no 
significant differences in the EC50 values of pentamidine between the expressing 
cell lines and the control (P > 0.05). 








































































































































































































Figure 5.18: Alamar blue drug sensitivity assay of expression of FurD gene in L mexicana-
WT by using 5-fluorouracil (A), 6-azauracil (B) and pentamidine (C). 
The mean of three independent determinations is shown ± SEM. 
 Transport assay with 5-Fluorouracil 
The uptake rate of 0.1 μM of [3H]-5-fluorouracil in L. mexicana wild-type 
expressing FurD was investigated in order to check whether the introduction of 
FurD could cause increases in the 5-fluorouracil transport (Figure 5.19). This 
study assessed the uptake of 0.1 μM of [3H]-5-fluorouracil by promastigotes of L. 
mexicana wild-type and found that the transport was linear for at least 120 
seconds with a rate of 0.0024 ± 0.0007 pmol.(107 cells)-1.s-1 (n=2). However, 
under these conditions, the [3H]-5-fluorouracil in L. mexicana-WT + FurD was 
quickly saturated, resulting in a non-linear rate of uptake after 30 seconds (blue 
dashed line). The linear phase of 30 s displayed a rate of uptake of 0.022 ± 0.004 
pmol.(107 cells)-1.s-1 (solid blue line; r2=0.99; n=2). In both strains, [3H]-5-
fluorouracil transport was completely inhibited in the presence of 1 mM 
unlabelled 5-fluorouracil indicating that the uptake was saturable. 
Ibrahim Abdullah Alfayez                               Chapter 5                                 176 
 






































Lmex-WT + FurD (over 120s)
Lmex-WT + FurD (over 30s)
L. mexicana-WT
Lmex-WT + FurD + 1mM 5-FU







Figure 5.19: [3H]-5-Fluorouracil transport by L mexicana-WT and L mexicana-WT expressing 
FurD. 
Transport of 0.1 μM of [3H]- 5-fluorouracil by Lmex-WT (●) and Lmex-WT + FurD (■) was 
measured over 120 seconds in the presence or absent of 1 mM unlabelled 5-fluorouracil (○) 
and (□) respectively. The blue dashed line is showing the rate of uptake using non-linear 
regression analysis (equation for a saturation curve). Figure shows a representative out of 
two independent experiments. Symbols represent the average of triplicate determinations in 
a single representative experiment, and error bars represent ± SEM. 
 Discussion 
Uracil transport is recognised as an ubiquitous cellular activity that usually exists 
in free-living prokaryotes as well as eukaryote cells (de Koning and Diallinas, 
2000). Uracil transporter mutants are known for their resistance to 5-fluorouracil 
(Palmer et al., 1975; Jund et al., 1977; Andersen et al., 1995; Amillis et al., 
2007; Stoffer-Bittner et al., 2018). It was also confirmed earlier that when the 
FurD gene is deleted from A. nidulans, the cells gain resistance against 5-
fluorouracil and they exhibit a significantly reduced ability to transport 
radiolabeled uracil (Amillis et al., 2007). A. nidulans FurD belongs to the NAT 
family that works as an active proton-driven transporter with the ability to 
transport uracil and protons (Gournas et al., 2008; de Koning and Diallinas, 
2000). However, protozoan genomes do not contain any FurD homologues and 
the uracil uptake must be mediated by a transporter from a different gene 
family  (Amillis et al., 2007; De Koning, 2007). Up to this moment, the only 
known genes involved in encoding transporters for pyrimidines and purines in 
protozoans are the ENT genes (De Koning et al., 2005; Campagnaro and de 
Koning, 2020). However, proposals for other families of genes have been 
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suggested (Bellofatto, 2007; De Koning, 2007; Campagnaro et al., 2018a; 
Balcazar et al., 2017). 
Several close homologues of FurD gene have been identified. They include the 
Fur4p gene encoding the S. cerevisiae uracil transporter (Jund et al., 1977; 
JUND et al., 1988), and UraA gene encoding E. coli uracil permease and PlUP 
gene encoding the P. larvae uracil transporter, which show a similarity in amino 
acids of 46.2%, 37.1% and 54.6% with FurD, respectively (Jund et al., 1977; JUND 
et al., 1988; Andersen et al., 1995; Stoffer-Bittner et al., 2018), see Appendix 7 
for a multiple alignment. Known mutants of these transporters include a Fur4p 
mutant in S. cerevisiae, a PlUP mutant in P. Larvae, and a UraA mutant in E. 
coli. Notably, these mutants cannot transport radiolabeled uracil and they are 
resistant to the 5-fluorouracil. Furthermore, their protein families resemble 
those of other prokaryotic and eukaryotic uracil transporters since Fur4p belongs 
to the NCS1 family, while P1UP and UraA are proton symporters and prototypical 
members of the NCS2/NAT family (Jund et al., 1977; Andersen et al., 1995; 
JUND et al., 1988; Stoffer-Bittner et al., 2018; Krypotou et al., 2015). 
Resistance to 5-fluorouracil was generated in both T. b. brucei s427-wild type 
BSF and L. mexicana promastigotes, which led to the production of clonal lines 
Tbb-5FURes and Lmex-5FURes, respectively (Ali et al., 2013a; Alzahrani et al., 
2017). These cell lines exhibit a notably reduced ability to transport uracil and 
5-FU, which is virtually abolished in the cell lines of L. mexicana. The possibility 
of restoring sensitivity to 5-FU through the expression of FurD in the resistant 
strains was assessed using the Alamar blue assay. According to the results, there 
was no significant difference in the EC50 values of 5-FU and 6-AU between the 
parental cells and those expressing FurD in Tbb-5FURes and Lmex-5FURes cell 
lines. In addition, the expression of FurD did not affect the sensitivity of the L. 
mexicana wild type to 5-FU, and it seems likely that the rate of transport is not 
limiting 5-FU toxicity, but the rate of incorporation into the nucleotide pool in L. 
mexicana wild-type. 
We investigated whether heterologous expression of FurD gene in 5-FU resistant 
cell lines of T. b. brucei and L. mexicana is indeed able to restore the uptake of 
uracil/5-fluorouracil. The findings confirmed that the cells expressing FurD in 
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Lmex-5FURes and L. mexicana-WT had a much higher uptake of [3H]-uracil/5FU 
than the wild type activity. As the resistance was induced, stepwise, to a very 
high concentration of 5-FU in Lmex-5FURes, it is possible that the cells 
developed defects in both the uptake and the metabolism of the 5-FU, making 
them fully resistant to 5-FU, whether it enters the cells or not. Therefore, a 
metabolic adaptation appears to have rendered the Lmex-5FURes cells 
insensitive to intracellular 5-FU. It was additionally noted that the transport rate 
of [3H]-uracil and [3H]-5-fluorouracil is highly concentrated in Lmex-5FURes cells 
expressing FurD, but this saturates in less than 5 minutes and 9 seconds, 
respectively. Radiolabelled of 5-fluorouracil and uracil are taken up for 9 
seconds and 5 minutes linearly and then completely flat. The introduction of 
FurD into Tbb-5FURes cells did not significantly increase the rate of transport of 
[3H]-uracil, although the rate did trend higher. There are two possible reasons 
for this outcome. First, the transport rate of [3H]-uracil in the Tbb-5FURes cells 
was only partly reduced from the wild-type levels, as it entails the problem of 
high background generated by transport via TbU3. Second, it could be because 
FurD was not correctly produced or routed to the Tbb-5FURes cells plasma 
membrane. The latter is however unlikely since the expression of FurD in Lmex-
5FURes and L. mexicana-WT highlighted significantly higher levels of [3H]-
uracil/5FU transport. 
We further kinetically characterised the transport activity of the A. nidulans 
uracil transporter FurD in Lmex-5FURes promastigotes. The findings confirm that 
FurD has a very high affinity for uracil with (Km of 0.97 ± 0.17 μM) and 5-
fluorouracil (Ki of 0.76 ± 0.25 μM). This result is almost identical to the previous 
characterisations of this uracil transporter in A. nidulans, which also showed 
that FurD has very high-affinity for uracil (Km of 0.45 μM) and 5-fluorouracil (Ki 
of 0.46 μM) (Amillis et al., 2007). Another report by Amillis et al. (2007) found 
that FurD exhibited high affinity for several 5 substituted analogues of uracil and 
6-azauracil (Ki 0.46 μM for 5-chlorouracil, Ki 0.86 μM for 5-aminouracil, 3.3 µM 
for thymine (5-Methyluracil) and Ki 1.9 μM for 6-azauracil), showing remarkable 
tolerance for 5-position substitutions. However, no affinity was observed in 
other pyrimidines and purines including thymidine, uridine, hypoxanthine, 
adenine, cytosine, or guanine (Ki >1500 μM). Thus, FurD is a highly selective and 
Ibrahim Abdullah Alfayez                               Chapter 5                                 179 
 
high-affinity transporter for uracil when expressed in Lmex-5FURes  
promastigotes. The anticancer drug 5-fluorouracil was as good substrate as uracil 
for FurD transporter in Lmex-5FURes. Regarding to the uracil transporter in 
Leishmania and Trypanosoma spp, L. major promastigotes the LmajU1 (Km of 
0.32 µM) was the only transporter identified with high affinity for uracil 
(Papageorgiou et al., 2005). The LmajU1 closely resembles the TbU1 transporter 
found in T. brucei procyclic forms (Km of 0.46 µM) and TbU3 transporter in T. 
brucei BSF (Km of 0.54 µM). The anti-metabolite 5-fluorouracil was found to be a 
good inhibitor for LmajU1, TbU1 and TbU3 transporters (de Koning and Jarvis, 
1998; Ali et al., 2013a). 
The observations described in this chapter clearly show that the 5-FURes cell 
lines are not solely resistant because of deficiencies in 5-FU uptake and that the 
resistance phenotype cannot be rescued by restoring 5-FU uptake to wild-type 
levels and even beyond, by the introduction of a known uracil/5-FU transporter. 
As the resistance was induced, stepwise in vitro, to a very high concentration of 
5-FU in the 5FU-Res cells, it is possible that the cells developed defects in both 
the uptake and the metabolism of the 5-FU. Thus, it is possible to speculated 
that the metabolic adaptation appears to have rendered the 5FURes cells 
insensitive to intracellular 5-FU. Therefore, we highly recommended to assess 
the metabolism of 5-FU, using metabolomic assessments of L. mexicana clonal 
lines adapted to high concentrations of 5-FU, the sensitive L. mexicana-WT and 
5-FU resistant cell lines expressing FurD. 
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6 Investigation of glucose transporters in L. 
mexicana promastigotes in the sensitivity to 5-
FU 
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 Introduction 
There is no doubt that glucose is one of the most basic and significant sources of 
energy for different organisms. Due to the hydrophilic profile of glucose, 
however, it cannot enter the cells by itself through the cell membranes, and 
thus relies on transporters (Pereira and Silber, 2012; Delrot et al., 2000). 
Considering Leishmania spp, the parasite goes through a complex life cycle; this 
makes the organism pass through different kinds of environments, with varying 
concentrations and types of sugar available to them. The procyclic 
promastigotes rely on the catalysis of glucose and amino acids, and at 
subsequent stages of promastigote development, an increased level of amino 
acid is used and glucose usage is reduced, likely because the availability of 
glucose in highly limited after the sandfly has digested its bloodmeal (Inbar et 
al., 2017; Landfear, 2010; Rodriguez-Contreras et al., 2007). The African 
trypanosomes that reside in the bloodstream depend entirely on the uptake of 
glucose to generate energy by glycolysis (Lamour et al., 2005; Landfear, 2010). 
Conversely, trypanosomes of procyclic form (PCF) use amino acids (mainly 
proline) as their main source of energy using the Krebs cycle and the respiratory 
chain (Pereira and Silber, 2012; Tetaud et al., 1997). It is in the cell membranes 
that the glucose transporters are embedded and exercise the ability to conduct 
the passive transportation of glucose to the intracellular space (Delrot et al., 
2000; Akpunarlieva and Burchmore, 2017; Manolescu et al., 2007; Landfear, 
2010). Glucose transporters were proposed as candidate genes with the 
responsibility for facilitating uracil uptake by following the analyses of the wild-
type and 5-FU resistant lines for T. b. brucei BSF and L. mexicana promastigotes 
after RNA sequencing of 5-FU resistant cell lines, as well as RIT sequencing 
analyses of the 2T1 PYR6-5-/- cell line challenged with 5-FU and 6-AU (Alzahrani, 
2017).  
Tbb-5FURes were found to down-regulated glucose transporters THT2 
(Tb927.10.8520) and 2A (Tb927.10.8530) levels of expression with a log2 fold-
change of -0.78 and -1.09 relative to the reference T. b. brucei TREU 927 
genome (P ≤ 0.01).  In contrast, Tbb-5FURes up-regulated glucose transporter 1B 
(Tb927.10.8440) with a log2 change of 0.29 (P < 0.05). Similarly, Tb927.10.8460 
is another glucose transporter gene that was also up-regulated in Tbb-5FURes 
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with log2 of 0.29 (P < 0.05). The transcription of a glucose transporter D2 
(recently named as LmexGT4; LmxM.32.0290) was significantly elevated in 
Lmex-5FURes (Log2 = 0.52) in comparison with L. mexicana wild-type (P ≤ 0.01). 
Moreover, glucose transporter 2A (Tb927.10.8530) was the top hit in RIT 
sequencing results, contributing to 4058 and 6317 RPKM (Reads Per Kilobase of 
transcript per Million mapped reads) after analysis was conducted on the 
pyrimidine-auxotrophic 2T1 cell lines selection with 6-AU and 5-FU respectively 
(Alzahrani, 2017). The link between uracil transport and glucose transport 
emerges from the transcriptomic analysis of 5-FU resistant cell lines and RIT-seq 
analysis of the selected RNAi library (Alzahrani, 2017). There is a possibility that 
the knockdown or down-regulation of either one or several of these glucose 
transporter genes such as glucose transporter 2A in 5-FU resistant cell lines can 
be responsible for causing increased levels of resistance to 5-FU. 
A cluster of three glucose transporter genes named as LmexGT1, LmexGT2 and 
LmexGT3, which belong to the encoding permeases of the SLC2 or GLUT 
transporter family, is contained in the genome of L. mexicana (Pereira and 
Silber, 2012; Augustin, 2010). These three LmexGTs exhibit 90% identity in 
amino acid sequences and are arranged as a tandem repeat on chromosome 20 
(GeneDB). L. mexicana’s glucose transporters LmexGT1, LmexGT2 and LmexGT3 
are characterised by 12 transmembrane domains as the proteins promoting the 
passive transportation of glucose (Burchmore et al., 2003a; Silber et al., 2009). 
In order to investigate an link between glucose transporters and 5-FU sensitivity, 
Glucose Transporter null mutants in L. mexicana wild-type promastigotes (Lmex-
GT1-3 KO), from which all three glucose transporter genes had been deleted by 
targeted gene replacement, and the re-expression of each of these three glucose 
transporter genes individually into Lmex-GT1-3 KO cells (Burchmore et al., 
2003a), were kindly gifted by Dr Richard Burchmore (University of Glasgow) 
(Figure 6.1). The Lmex-GT1-3 KO cells are not able to transport glucose 
(Burchmore et al., 2003a), but re-expression of the LmexGT1, LmexGT2 and 
LmexGT3 individually into Lmex-GT1-3 KO cells enables the uptake of glucose 
(Rodriguez-Contreras et al., 2007). 
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Figure 6.1: Knockout strategy used for the replacement of the genomic locus on 
chromosome 20 containing a tandem array of three glucose transporter genes (LmexGT1-3). 
sKO: single knockout; dKO: double knockout. Adapted from (Burchmore et al., 2003a). 
The primary aim of this chapter is to determine the sensitivity to and transport 
of 5-FU after the full knockout of genes responsible for transportation of glucose 
in L. mexicana promastigotes. The chapter also focuses on examining the 
sensitivity/transport of Lmex-GT1-3 KO cells that re-express individual glucose 
transporters to 5-FU/uracil. In addition, an investigation is conducted to 
ascertain whether, when the FurD uracil transporter is introduced, this is able to 
restore the sensitivity/transport to 5-FU in Lmex-GT1-3 KO cells. Moreover, an 
assessment is carried out to find out the effects of the absence of glucose in the 
extracellular medium T. b. brucei s427 WT procyclic form in the sensitivity to 5-
FU and the growth rate. 
 Results 
 The assessment of growth rate of Lmex-GT1-3 KO in the 
presence and absence of 5 mM L-proline 
To examine the effect of the deletion of glucose transporters locus in L. 
mexicana on the growth rate, the growth of the L. mexicana wild-type, Lmex-
5FURes and Lmex-GT1-3 KO cell lines was assessed in HOMEM medium 
supplemented with 10% FBS and incubated at 25 °C (HOMEM media contains 3 
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g/L glucose); the cell densities were determined every 24 h. The Lmex-GT1-3 KO 
cultures had almost the same density as L. mexicana-WT and Lmex-5FURes 
(Figure 6.2A). However, to understand the potential impact of an energy source 
on the glucose transporter knockout cell lines, we prepared a new medium 
supplemented with 5 mM L-proline. As T. brucei and T. cruzi will consume much 
more proline from the medium when in a glucose-limited environment (Lamour 
et al., 2005; Silber et al., 2009; Tonelli et al., 2004; Drew et al., 2003), it is 
possible that Lmex-GT1-3 KO also need proline as energy sources. It was 
anticipated that adding 5 mM proline to HOMEM medium would cause an increase 
in the growth rates of the Lmex-GT1-3 KO cell lines. However, the density of the 
Lmex-GT1-3 KO culture (8.6 × 108 cell/mL) was very slightly below that of the L. 
mexicana-WT (1.05 x 109 cell/mL) and Lmex-5FURes strains (8.8 x 108 cell/ml) 
(Figure 6.2B). Although reproducible, this does not constitute a major growth 


























































1×10 9 L. mexicana-WT
Lmex-5FURes
Lmex-GT1-3 KO
B) + 5mM L-proline
 
Figure 6.2: The growth curves of L. mexicana WT, Lmex-5FURes and L.mex-1-3 KO on 
HOMEM medium supplemented with 10% FBS and incubated at 25 °C. 
A) Standard condition and B) with 5 mM of L-proline. Cells were seeded at a density of 1×105 
cells/mL, and cell densities were determined every 24 h. Cells were passaged every 48 h 
once growth had reached between 5 and 8 × 106 cells/mL. Each data point in this result 
represents the average of three independent repeats. 
 Drug sensitivity assay with 5-FU in the presence and 
absence of 5 mM L-proline 
By using the Alamar blue assay as a proxy for cell numbers, a close look at the 
growth inhibition curve of L. mexicana promastigotes in the presence of 5-FU 
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revealed a noticeably biphasic inhibition curve, which is attributed to a 
leishmanistatic effect at low concentrations and a leishmanicidal effect at 
higher concentrations (Figure 6.3). As mentioned in the introduction, glucose 
transporters have been identified as a potential candidate carrier for uracil, or 
at least a modulator of uracil uptake. Therefore, the viability assay using Alamar 
blue dye was performed to determine the effect of the deletion of glucose 
transporter locus in L. mexicana on sensitivity to 5-fluorouracil, while 
pentamidine was used as a positive control (Figure 6.4). 
Interestingly, the EC50 values of the double knockout of glucose transporter 
genes in L. mexicana to 5-FU significantly increased compared to the L. 
mexicana WT at low concentrations (EC50 (1)), with an average 3430 ± 440 µM 
and 36.6 ± 3.6 µM respectively (n = 3; figure 6.4A). The Lmex-GT1-3 KO cells was 
found to be 93-fold resistant when comparison was made with the L. mexicana 
WT (n=3; P < 0.001). The Lmex-GT1-3 KO cells also exhibited a small but highly 
significantly increased sensitivity to pentamidine with an EC50 value of 0.36 ± 
0.03 µM (0.6-fold more sensitive to pentamidine; n=3; P < 0.001) compared to 
0.61 ± 0.02 µM in L. mexicana wild-type cells (Figure 6.4B). 
In order to determine whether the choice of energy source can influence the 
sensitivity of the L. mexicana glucose transporters KO cell lines to 5-FU, HOMEM 
media with 5 mM of L-proline were prepared. The results showed that there was 
no significant difference in the EC50 values of 5-FU against L. mexicana WT, 
Lmex-5FURes and Lmex-GT1-3 KO in the presence or absence of 5 mM of L-
proline in the extracellular media (P > 0.05). 
In conclusion, the loss of glucose transporter genes is associated with resistance 
to 5-FU as the Lmex-GT1-3 KO leads to decreasing the sensitivity to 5-FU in 
kinetoplastid parasites. Sensitivity to 5-FU is not different in the presence of 
high levels of proline. 
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Figure 6.3: The biphasic inhibition curve of L. mexicana WT promastigotes against 5-
fluorouracil by using the Alamar blue fluorescent dye as a proxy for the cell number. 
The leishmanistatic effect at low concentrations EC50 (1) was 36.6 ± 3.6 µM whereas the 
leishmanicidal effect at higher concentrations (EC50)2 was 12221 ± 1940 µM. The curve 





































































































































































































































Figure 6.4: The Alamar blue drug sensitivity assay of L. mexicana WT, Lmex-5FURes, L.mex-
GT1-3 KO using 5-fluorouracil (A) and pentamidine (B). 
The mean of three independent determinations is shown ± SEM. Con: Normal condition; 
Pro: +5 mM L-proline; Cidal: leishmanicidal effect; Static: leishmanistatic effect. * P < 0.05; 
** P < 0.01; *** P < 0.001. P value was determined by unpaired two-tailed Student’s T-test. 
 Transport assays with 5-fluorouracil, uracil, 2-deoxy-D-
glucose and pentamidine 
The rate of uptake of [3H]-uracil and [3H]-5-fluorouracil in L. mexicana-WT and 
Lmex-GT1-3 KO was investigated in order to check whether the deletion of 
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glucose transporter locus in L. mexicana could cause reduced uracil and 5-
fluorouracil transport. The uptake of radiolabelled uracil and 5-fluorouracil by L. 
mexicana-WT and Lmex-GT1-3 KO was performed in parallel on the same day, 
using the same solutions (Figure 6.5A and B). The uptake of 0.1 μM [3H]-uracil 
(Figure 6.5A) and [3H]-5-fluorouracil (Figure 6.5B) was linear over the 8 minutes 
(for uracil and 5-fluorouracil) duration of the experiment in L. mexicana-WT 
with a rate of 0.062 ± 0.012 pmol.(107 cells)-1.s-1 and 0.11 ± 0.03 pmol.(107 cells)-
1.s-1, respectively (n=3). In contrast, the transport of 0.1 μM of [3H]-uracil by 
Lmex-GT1-3 KO cells was reduced by 81% compared with wild-type cells (n=3; 
Figure 6.5C). The transport of 0.1 μM of [3H]-5-fluorouracil by Lmex-GT1-3 KO 
was almost completely absent (98%) and became not significantly different from 
the uptake in the presence of 1 mM unlabelled 5-fluorouracil, with a calculated 
rate of 0.0013 ± 0.0005 pmol. (107 cells)-1.s-1 (n=3, linear regression; Figure 
6.5D), so that it is believed that the Lmex-GT1-3 KO cells have lost the uracil 
transport activity (Lmex-U1)(Alzahrani et al., 2017). In conclusion, the full 
knockout of glucose transporters in L. mexicana promastigotes lead to significant 
decrease in the transport rate of [3H]-Uracil/5-FU, as the uptake of radiolabelled 
uracil and 5-fluorouracil in the Lmex-GT1-3 KO cells was 81% and 98% lower than 
in wild-type cells, respectively. 
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Figure 6.5: [3H]-Uracil and [3H]-5-Fluorouracil transport were performed in parallel on the 
same day by L. mexicana-WT and Lmex-GT1-3 KO. 
A) Transport of 0.1 μM of [3H]-uracil by L. mexicana-WT (●) and Lmex-GT1-3 KO (■) was 
measured over 8 minutes in the presence or absent of 1mM unlabelled uracil (○) and (□) 
respectively. B) Transport of 0.1 μM of [3H]-5-fluorouracil by L. mexicana-WT (●) and Lmex-
GT1-3 KO (■) was measured over 8 minutes in the presence or absent of 1mM unlabelled 5-
fluorouracil (○) and (□) respectively. Symbols in A and B panels represent the average of 
triplicate determinations in a single representative experiment and error bars represent ± 
SEM. C) and D) Comparison between L. mexicana-WT and Lmex-GT1-3 KO cell lines for the 
transport rate of [3H]-uracil and [3H]-5-fluorouracil. Data in C and D panels represent the 
average rate of transport of 0.1 μM of [3H]-uracil and [3H] 5-fluorouracil as obtained in three 
independent experiments each performed in triplicate and error bars are ± SEM. ** P < 0.001 
and *** P < 0.001, Statistical relevance was found by unpaired Student's T-test (n=3). 
In section 6.2.2, it was observed that the double knockout of glucose 
transporters in L. mexicana promastigotes significantly increased the sensitivity 
to pentamidine compared with wild-type cells (n=3; P < 0.001). Thus, the uptake 
of 25 nM of [3H]-pentamidine in Lmex-GT1-3 KO was investigated in order to 
check whether the deletion of glucose transporters leads to an increase in the 
rate of pentamidine transport. The results show that there was no significant 
difference in the transport of 25 nM of [3H]-pentamidine between the Lmex-GT1-
3 KO and wild-type strain (P > 0.05; n=3; figure 6.6A). The transport of 25 nM of 
[3H]-pentamidine was statistically identical in L. mexicana-WT and Lmex-GT1-3 
KO cells, with a rate of 0.083 ± 0.01 pmol. (107 cells)-1.s-1 and 0.057 ± 0.007 
pmol. (107 cells)-1.s-1, respectively (P > 0.05; n=3; Figure 6.6B). Therefore, the 
results indicate that the Lmex-GT1-3 KO parasites can up-regulate the other 
































































































Figure 6.6: [3H]-Pentamidine transport by L. mexicana-WT and Lmex-GT1-3 KO. 
A) Transport of 25 nM of [3H]-pentamidine by L. mexicana-WT (●) and Lmex-GT1-3 KO (■) 
was measured over 4 minutes in the presence or absent of 1 mM unlabelled pentamidine (○) 
and (□) respectively. Symbols represent the average of triplicate determinations in a single 
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representative experiment and error bars represent ± SEM. B) Comparison between L. 
mexicana-WT and Lmex-GT1-3 KO cell lines for the transport rate of 25 nM of [3H]-
pentamidine. Data represent the average rate of transport of 25 nM of [3H]-pentamidine as 
obtained in three independent experiments each performed in triplicate and error bars are ± 
SEM. No statistical relevance was found by unpaired Student's T-test (n=3). 
Next, the rate of uptake of [3H]-2-deoxy-D-glucose in L. mexicana-WT, Lmex-
5FURes and Lmex-GT1-3 KO investigated in order to check whether Lmex-5FURes 
cells resistance to 5-fluorouracil was linked to changes in the transport of 
radiolabelled 2-deoxy-D-glucose transport (Figure 6.7). The results showed that 
the rate of 0.1 μM of [3H]-2-deoxy-D-glucose uptake in Lmex-5FURes cells was 
completely identical to the rate in L. mexicana-WT, with an average of 0.0079 ± 
0.0003 pmol. (107 cells)-1.s-1 and 0.0072 ± 0.00005 pmol. (107 cells)-1.s-1 and a 
linear phase over 60 seconds, respectively (P > 0.05 by F-test; n=1). The uptake 
of 0.1 μM of [3H]-2-deoxy-D-glucose in both strains was completely inhibited in 
the presence of 1 mM unlabelled 2-deoxy-D-glucose. As expected, the transport 
of 0.1 μM of [3H]-2-deoxy-D-glucose by Lmex-GT1-3 KO was completely abolished 
and became identical to the uptake in the presence of 1 mM unlabelled 2-deoxy-
D-glucose, so that it is believed that the Lmex-GT1-3 KO cells have lost the 
glucose transport activity (Lmex-GT). It is clear that Lmex-5FURes cells are still 
maintaining the glucose transport activity, but lost uracil/5-fluorouracil 
transporter. Notwithstanding the observation that Lmex-5FURes and Lmex-GT1-3 
KO cells had somewhat similar resistance profiles (see section 6.2.2), these data 
clarify that glucose and uracil/5-fluorouracil are taken up by different transport 
proteins. 
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Figure 6.7: [3H]-2-deoxy-D-glucose transport by L mexicana-WT, Lmex-5FURes and Lmex-
GT1-3 KO. 
Transport of 0.1 μM of [3H]- 2-deoxy-D-glucose by L. mexicana-WT, Lmex-5FURes and Lmex-
GT1-3 KO was measured over 60 seconds in the presence or absent of 1 mM unlabelled 2-
deoxy-D-glucose. Figure shows a representative experiment in triplicate and error bars 
represent ± SEM. P > 0.05; F-test was determined by GraphPad Prism 8. 
 The evaluation of 5-FU EC50 of L. mexicana in normal and 
glucose free medium 
The Alamar blue assay was used to determine the EC50 values for the L. 
mexicana-WT in the standard condition, L. mexicana-WT in glucose-free medium 
and Lmex-GT1-3 KO, to test whether the absence of glucose in the extracellular 
medium could potentially decrease the susceptibility of L. mexicana-WT to 5-
fluorouracil, as the absence of glucose transporters does. The result showed that 
there was no significant difference against 5-FU between the L. mexicana-WT 
cells in glucose free medium and L. mexicana-WT cells in standard condition 
(n=4; P > 0.05; Figure 6.8A). The presence or absence of glucose in the medium 
therefore does not affect the sensitivity of L. mexicana-WT parasites to 5-FU. It 
is clear that the presence  of glucose in the medium is not necessary for 
uracil/5FU transport but the presence of the glucose transporters is necessary 
for uracil/5FU transport. 
Throughout the assessment, pentamidine was used as an unrelated control drug. 
Surprisingly, the Lmex-GT1-3 KO cells exhibited a small but highly significantly 
increased sensitivity to pentamidine in standard medium, with an EC50 value of 
0.36 ± 0.02 µM (P < 0.0001) compared to 1.01 ± 0.03 µM in L. mexicana wild-type 
cells (Figure 6.8B). Moreover, the sensitivity of the Lmex-GT1-3 KO cell lines in 
glucose free medium to pentamidine was significantly decreased (RF=2; n=4; P < 
0.001) compared to the Lmex-GT1-3 KO cells in the standard medium. The 
nature of the association of low glucose levels and glucose transporter knockout 
with pentamidine efficacy remains unclear at this moment. However, it could be 
speculated that, since pentamidine accumulates in the parasite’s mitochondrion 
(Baker et al., 2013), a shift in mitochondrial energy pathways, related to the 
usage of either glucose or amino acids as primary energy source, could 
contribute to this, with the different pathways being more or less sensitive to 
inhibition by the drug. 
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Figure 6.8: The Alamar blue drug sensitivity assay of L. mexicana-WT, Lmex-5FURes and L 
mexicana-WT in glucose free medium using 5-fluorouracil (A) and pentamidine (B). 
The mean of four independent determinations is shown ± SEM. *** P < 0.001 by unpaired 
two-tailed Student’s T-test. 
 Re-expression of LmexGT1, LmexGT2 and LmexGT3 into 
Lmex-GT1-3 KO promastigotes 
The genome of L. mexicana contains three genes that encode glucose 
transporters, named as LmexGT1, LmexGT2, and LmexGT3. These genes have 12 
transmembrane domains and are located on chromosome 20 in a tandem array 
(geneDB). The proteins are similar isoforms but reflect some differences that 
distinguish them at the C and N terminal domains (Burchmore and Landfear, 
1998). The alignment of the amino acid sequences for L. mexicana glucose 
transporters LmexGT1, LmexGT2, and LmexGT3 is presented in Appendix 8. The 
LmexGT1, LmexGT2 and LmexGT3 genes were expressed episomally in the Lmex-
GT1-3 Knockout cell lines through the use of the pX63NEO plasmid containing the 
neomycin resistance gene (LeBowitz et al., 1991; Burchmore et al., 2003a). This 
section aims to conduct an investigation as to whether the sensitivity to 5-FU, or 
the transport of 5-FU/uracil in vitro can be restored through the add-back of 
LmexGT1, LmexGT2, and LmexGT3 individually into Lmex-GT1-3 KO cells. 
 Drug sensitivity assay with 5-fluorouracil 
As previously reported in section 6.2.2, the deletion of the glucose transporter 
locus in L. mexicana promastigotes was found to confer resistance to 5-FU. It 
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was therefore decided to test the sensitivity of the Lmex-GT1-3 KO cells re-
expressing the individual glucose transporter genes (LmexGT1, LmexGT2 and 
LmexGT3) to 5-FU (Figure 6.9). The re-expression of LmexGT1, LmexGT2 and 
LmexGT3 in Lmex-GT1-3 KO cells caused significant sensitisation to 5-FU, with 
average EC50 values of 98.1 ± 12.3 µM, 393 ± 96 µM and 304 ± 59 µM, respectively 
(n=3; P < 0.001), while Lmex-GT1-3 KO cells displayed EC50 value amounting to 
1597 ± 116 µM. Surprisingly, Lmex-GT1-3 KO + LmexGT1, Lmex-GT1-3 KO + 
LmexGT2 and Lmex-GT1-3 KO + LmexGT3 displayed a significant decrease in 
pentamidine sensitivity relative to the parental cell line (n=3; P < 0.01; 2-fold, 
3.2-fold and 3.3-fold, respectively). It should be noted that LmexGT1, LmexGT2 
and LmexGT3 transporters encoded by the episomal expression vector are 
somewhat under-expressed compared to wild-type parasites as shown by 
(Rodriguez-Contreras et al., 2007). It is clear that the expression of individual 
LmexGT in Lmex-GT1-3 KO cells significantly increased the sensitivity to 5-FU 






















































































































































Figure 6.9: Alamar blue drug sensitivity assay of re-expression of glucose transporter genes 
(LmexGT1, LmexGT2 and LmexGT3) in Lmex-GT1-3 KO by using 5-fluorouracil (A) and 
pentamidine (B). 
The mean of three independent determinations is shown ± SEM. ** P < 0.01 and *** P < 0.001 
by unpaired two-tailed Student’s T-test. 
 Transport assay with 5-fluorouracil and uracil 
The transport rate of [3H]-uracil and [3H]-5-fluorouracil in L. mexicana-WT, 
Lmex-GT1-3 KO, Lmex-GT1-3 KO + LmexGT1, Lmex-GT1-3 KO + LmexGT2 and 
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Lmex-GT1-3 KO + LmexGT3 was investigated in order to check whether the re-
expression of individual glucose transporter genes in Lmex-GT1-3 KO cells could 
cause changes in the uracil and 5-fluorouracil transport (Figure 6.10). The 
uptake of 0.1 μM of [3H]-uracil (Figure 6.10A) and [3H]-5-fluorouracil (Figure 
6.10B) was linear over the 8 minutes (for uracil and 5-fluorouracil) duration of 
the experiment in L. mexicana-WT with a rate of 0.044 ± 0.008 pmol. (107 cells)-
1.s-1 and 0.051 ± 0.006 pmol.(107 cells)-1.s-1, respectively. The uptake of 0.1 μM 
of [3H]-uracil in both Lmex-GT1-3 KO + LmexGT1, Lmex-GT1-3 KO + LmexGT2 
and Lmex-GT1-3 KO + LmexGT3 was significantly increased, with a rate of 0.013 
± 0.0002, 0.011 ± 0.002 and 0.012 ± 0.001, respectively compared with the 
parental Lmex-GT1-3 KO cells (n=2; P < 0.01 by Paired Student’s T-test). 
Moreover, the re-introduction of LmexGT1, LmexGT2 and LmexGT3 into Lmex-
GT1-3 KO cells greatly increased the rate of 0.1 μM of [3H]-5-fluorouracil uptake 
to 0.03 ± 0.002, 0.03 ± 0.001 and 0.023 ± 0.0001, respectively compared with 
the control Lmex-GT1-3 KO cells. The expression of individual glucose 
transporters correlates with increased uptake of radiolabelled uracil and 5-FU 
(30% and 50%, respectively). All of them appear to be responsible to uracil and 
5-FU transport, but indirect effects are likely. 
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Figure 6.10: [3H]-Uracil and [3H]-5-Fluorouracil transport by L mexicana-WT, Lmex-GT1-3 KO 
and re-expression of each glucose transporter genes (LmexGT1, LmexGT2 and LmexGT3) in 
Lmex-GT1-3 KO. 
A) Transport of 0.1 μM of [3H]-uracil by L. mexicana-WT,  Lmex-GT1-3 KO, Lmex-GT1-3 KO + 
LmexGT1, Lmex-GT1-3 KO + LmexGT2 and Lmex-GT1-3 KO + LmexGT3 was measured over 
8 minutes in the presence or absent of 1 mM unlabelled uracil. B) Transport of 0.1 μM of 
[3H]-5-fluorouracil by L. mexicana-WT,  Lmex-GT1-3 KO, Lmex-GT1-3 KO + LmexGT1, Lmex-
GT1-3 KO + LmexGT2 and Lmex-GT1-3 KO + LmexGT3 was measured over 8 minutes in the 
presence or absent of 1 mM unlabelled 5-Fluorouracil. Symbols in A and B figures represent 
the average of triplicate determinations in a single representative experiment and error bars 
represent ± SEM. 
 Affinity of LmexGT1, LmexGT2 and LmexGT3 in the Lmex-GT1-3 KO 
cells for glucose, uracil and 5-fluorouracil 
In order to investigate whether the glucose, uracil and 5-fluorouracil shared the 
same transporter, the inhibition of 0.1 μM of [3H]-2-deoxy-D-glucose uptake in 
Lmex-GT1-3 KO cells re-expressing LmexGT1, LmexGT2 and LmexGT3 by various 
concentrations of unlabelled glucose, uracil and 5-fluorouracil - over 30 seconds 
as our time point - was assessed (Figure 6.11). The affinity of LmexGT1, 
LmexGT2 and LmexGT3 for glucose was evaluated by competition with 0.1 μM of 
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[3H]-2-deoxy-D-glucose, LmexGT1 had a lower affinity for glucose (Ki of 577 ± 78 
μM; n=3), while LmexGT2 and LmexGT3 showed relatively high affinity for 
glucose (Ki of 59 ± 8 and 123 ± 9 μM, respectively; n=3; table 6.1). These results 
are consistent with the previous characterisations of LmexGT1, LmexGT2 and 
LmexGT3 for glucose in L. mexicana promastigotes, showing that LmexGT1 has a 
higher Km for glucose (1.22 ± 0.22 mM) compared to LmexGT2 or LmexGT3 (109 ± 
22 μM and 208 ± 40 μM, respectively) (Rodriguez-Contreras et al., 2007). These 
values were approximately double the Ki values determined by us for the three 
glucose transporter isoforms. 
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Figure 6.11: Inhibitory effect of various concentrations of unlabelled glucose (●), unlabelled 
uracil (●) and unlabelled 5-fluorouracil (●) on the uptake of 0.1 μM of [3H]-2-deoxy-D-glucose 
over 30 seconds by Lmex-GT1-3 KO + LmexGT1 (A), Lmex-GT1-3 KO + LmexGT2 (B) and 
Lmex-GT1-3 KO + LmexGT3 (C). 
Figures show a representative out of three independent experiments in triplicates. Symbols 
represent the average of triplicate determinations in a single representative experiment and 
error bars represent ± SEM. 
Moreover, uracil and 5-fluorouracil had no considerable effect on transport 
mediated by LmexGT1, LmexGT2 and LmexGT3 as none of them inhibited the 
transport of 0.1 μM of [3H]-2-deoxy-D-glucose up to 2.5 mM (n=2; Table 6.1). 
These results clearly confirmed that the effect of D-glucose on 2-deoxy-D-
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glucose transport is very different from the effect of uracil and 5-fluorouracil in 
L. mexicana promastigote form (LmexGT1, LmexGT2 and LmexGT3 as a 
straightforward glucose transporter). 
Table 6.1: Ki for various concentrations of glucose, uracil and 5-fluorouracil on the uptake of 
0.1 μM of [3H]-2-deoxy-D-glucose over 30 seconds by Lmex-GT1-3 KO + LmexGT1, Lmex-
GT1-3 KO + LmexGT2 and Lmex-GT1-3 KO + LmexGT3. Ki values represent the mean of at 




LmexGT1 LmexGT2 LmexGT3 
D-glucose 577 ± 78 58.9 ± 7.8 123 ± 9 3 
Uracil N.E (> 2.5 mM) N.E (> 2.5 mM) N.E (> 2.5 mM) 2 
5-Fluorouracil N.E (> 2.5 mM) N.E (> 2.5 mM) N.E (> 2.5 mM) 2 
 The heterologous expression of the FurD in Lmex-GT1-3 KO 
promastigotes 
It has been determined that the introduction of the FurD transporter in the 
Lmex-5FURes and L. mexicana-WT does not result in increased sensitivity to 5-FU 
(Chapter 5). However, high levels of [3H]-uracil and 5-FU uptake do occur in 
those cells, and these levels are much higher than those of wild type activity 
(see sections 5.2.2 and 5.2.3). Thus, the purpose of this section is to examine 
the effects of expression of FurD in the Lmex-GT1-3 KO cell lines on the 
sensitivity/transport to 5-FU when a confirmed uracil/5-FU transporter is 
introduced. 
 PCR and qRT-PCR confirmation of the existence of FurD in Lmex-
GT1-3 KO cells 
A plasmid construct used in the expression of FurD gene in Lmex-GT1-3 KO 
strain, pHDK254 (Figure 5.7) had been used previously to express of FurD 
transporter in Lmex-5FURes and L. mexicana-WT. Following the transfection of 
episomal pHDK254 plasmid into the Lmex-GT1-3 KO strain, PCR was used to 
verify the presence of pHDK254 vector in several positive clones. The 
verification process is conducted using HDK340 as reverse primer for the pNUS-
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HcN plasmid and HDK531 as forward primer for the FurD gene (Figure 6.12). 
Quantitative real time PCR is performed for the purpose of quantifying the levels 
of FurD gene expression in Lmex-GT1-3 KO cells in comparison to the control cell 
lines. All three clones expressing (1, 2 and 3) of FurD gene in the Lmex-GT1-3 KO 
cells recorded a significant increase in the gene expression signal in comparison 
to the control Lmex-GT1-3 KO cells (9.1-fold, 7.6-fold and 6.3-fold; P < 0.001, 
respectively; Figure 6.13). 
 
Figure 6.12: Confirmation of the presence of FurD gene into Lmex-GT1-3 KO strain after 
transfection by using HDK531 as forward primer for FurD gene and HDK340 as a reverse 
primer for pNUS-HcN plasmid. 
L: 1kb DNA Ladder (Promega); 1: Clone 1; 2: Clone 2; 3: Clone 3; 4: Non-transfected control 
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Figure 6.13: The expression levels of FurD gene in Lmex-GT1-3 KO and compared to the 
control (Lmex-GT1-3 KO) determined by qRT-PCR. 
Levels were corrected against the expression level of the housekeeping gene (L. mexicana 
GPI8). The presented results are the average of 2 cDNA each performed in duplicates, and 
error bars are ± SEM. *** P < 0.001 by unpaired student’s T-test. 
 Drug sensitivity assay with 5-fluorouracil 
The sensitivity of the Lmex-GT1-3 KO cells and the three FurD clones in the 
Lmex-GT1-3 KO parasites to 5-FU and pentamidine was investigated using the 
usual Alamar blue assay (Figure 6.14). Results showed a significant increase in 
the sensitivity of Lmex-GT1-3 KO + FurD clone 1, 2 and 3 to 5-FU (213 ± 48, 247 
± 54 and 90 ± 9 µM, respectively) compared with the parental cell lines Lmex-
GT1-3 KO (1460 ± 256 µM; n=4; P < 0.01 by unpaired Student’s T-test). The 
susceptibility of clones 1, 2 and 3 to 5-FU was increased 7-fold, 6-fold and 16-
fold, respectively. The expression of FurD gene did not change the sensitivity to 
pentamidine in Lmex-GT1-3 KO cell lines, as the EC50 values of Lmex-GT1-3 KO 
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Figure 6.14: Alamar blue drug sensitivity assay of expression of FurD gene in Lmex-GT1-3 
KO and L. mexicana by using 5-fluorouracil (A) and pentamidine (B). 
The mean of four independent determinations is shown ± SEM. * P < 0.05, ** P < 0.01 and *** 
P < 0.001 by unpaired Student’s T-test. 
 Transport assay with 5-fluorouracil 
The transport rate of 0.1 μM of [3H]-5-fluorouracil in Lmex-GT1-3 KO expressing 
FurD was investigated in order to check whether the introduction of FurD 
transporter could cause increases in the 5-fluorouracil transport as well (Figure 
6.15). This study evaluated the uptake of 0.1 μM of [3H]-5-fluorouracil by 
promastigotes of L. mexicana wild-type and found that the transport was linear 
for at least 120 seconds with a rate of 0.0025 ± 0.0002 pmol. (107 cells)-1.s-1. 
Indeed, the introduction of FurD in Lmex-GT1-3 KO cells revealed a very high 
level of [3H]-5-fluorouracil uptake, with a rate of uptake of 0.0056 ± 0.0004 
pmol. (107 cells)-1.s-1 and a linear phase over 120 seconds (P < 0.0001 by F-test; 
n=1). The uptake of 0.1 μM of [3H]-5-fluorouracil by Lmex-GT1-3 KO parasites 
was not significantly different from zero (P > 0.05, F-test). In both strains, [3H]-
5-fluorouracil transport was completely inhibited in the presence of 1 mM 
unlabelled 5-fluorouracil indicating that the uptake was saturable. In conclusion, 
the effect of expression of FurD in Lmex-GT1-3 KO increased the rate of 
transport of [3H]-5-FU, even much above the wild type activity, as well as 
increasing the sensitivity to 5-FU. 











































L. mexicana-WT + 1 mM 5-FU
Lmex-GT1-3 KO
Lmex-GT1-3 KO + 1 mM 5-FU
Lmex-GT1-3 KO + FurD
Lmex-GT1-3 KO + FurD + 1 mM 5-FU
 
Ibrahim Abdullah Alfayez                               Chapter 6                                201 
    
Figure 6.15: [3H]-5-Fluorouracil transport by L. mexicana-WT, Lmex-GT1-3 KO and Lmex-
GT1-3 KO + FurD. 
Transport of 0.1 μM of [3H]-5-fluorouracil by L. mexicana-WT, Lmex-GT1-3 KO and Lmex-
GT1-3 KO + FurD was measured over 120 seconds in the presence or absent of 1 mM 
unlabelled 5-fluorouracil. F-test was calculated using Prism 8 GraphPad Software. 
 Trypanosoma brucei brucei s427-WT procyclic form 
The bloodstream forms of T. b. brucei is entirely dependent on blood glucose to 
gain energy by glycolysis (Bayele et al., 2000). For this reason, the procyclic 
form of T. b. brucei is used to determine the growth rate and sensitivity of 5-FU 
and 6-AU pyrimidine analogues. This section chiefly aims at specifying and 
characterising the relationship that exists between mechanism of action of 5-FU 
and glucose metabolism in T. b. brucei s427-WT PCF. 
 The assessment of growth rate of T. b. brucei s427-WT PCF with and 
without glucose 
In examining how the absence of glucose within the extracellular medium in T. 
brucei Lister s427 PCF affects the growth rate, the growth of T. b. brucei 
procyclic cell lines are assessed in SDM-79 medium supplemented with 10% FBS 
and 0.6 g/L proline. There was the testing of three different D-glucose 
concentrations in SDM-79 medium: 1 g/L D-glucose (standard condition), 0.2 g/L 
of D-glucose and D-glucose-free incubated at 27 °C. After every 24 h, the cell 
densities were determined, and the cells were passaged every 24 h into fresh 
medium. Despite the reduction or absence of D-glucose in T. b. brucei-s427 WT 
PCF, there was no difference in the growth rate of the three conditions (Figure 
6.16). The conclusion arrived at was that the decreased concentration of D-
glucose did not cause any changes in the rate of growth for T. b. brucei-s427 
wild type PCF in vitro. 
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 SDM-79 with 1 g/L D-glucose (Standard)
SDM-79 with 0.2 g/L D-glucose
SDM-79 in D-glucose-free medium
 
Figure 6.16: The growth rate of T. b. brucei-s427 wild type PCF on SDM-79 medium 
supplemented with 10% FBS, 0.6 g/L proline, and 1 g/L glucose 'standard condition' (●), 0.2 
g/L D-glucose (●) and D-glucose free (●), and incubated at 27ºC, and cell densities were 
determined every 24h. 
Cells were passaged every 24 hours into a fresh medium. Each data point in this result 
represents the average of three similar independent determinations. 
 The evaluation of 5-FU and 6-AU EC50 of T. b. brucei s427 PCF in 
normal medium, low glucose and glucose-free medium 
6-AU is considered to be an inhibitor of pyrimidine de novo biosynthesis 
pathway, specifically an inhibitor of orotidylate decarboxylase in trypanosomes 
(Jaffe, 1961). For this reason, we test the sensitivity of 6-AU against the T. b. 
brucei s427 PCF cell lines in normal medium, low glucose and glucose-free 
medium. In Figure 6.17, a biphasic inhibition curve of 6-azauracil shows a 
depiction that is not typical of a drug sensitivity curve. The situation thus 
depicts the potential presence of two EC50 values for 6-AU. According to the 
property of 6-AU, the presentation of the first EC50 value shows how the cell 
growth is inhibited by the drug (trypanostatic effect) and the second EC50 shows 
how the cells are killed by drug (trypanocidal effect). In the sensitive test of 6-
AU, the three different conditions of growth provide the same results and 
biphasic inhibition curves. The viability assay with using Alamar blue dye was 
performed to determine the effects of the presence or absence of D-glucose in 
SDM-79 medium on sensitivity of the T. b. brucei s427 PCF cells to 5-FU and 6-
AU, while pentamidine was used as an unrelated control drug (Figure 6.18). The 
results of the study showed that, in all the three different conditions of growth, 
no significant difference existed on the sensitivity (normal conditions, 0.2 g/L D-
glucose and D-glucose-free) in T. b. brucei s427 PCF cells to 5-FU, with an EC50 
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values of 13 ± 2.8 µM, 11 ± 1.5 µM and 6 ± 0.8 µM, respectively (n=4; P > 0.05 by 
unpaired Student’s T-test). There is no significant different in the sensitivity of 
three different growth conditions of D-glucose to 6-AU (n=4; P > 0.05 by 
unpaired Student’s T-test). There was no significant difference in the sensitivity 
to pentamidine for all the three different growth conditions of the T. b. brucei 
s427 PCF cells. It was concluded that, in the extracellular media, neither the 
absence nor presence of glucose has any effect on the sensitivity of procyclic 
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Figure 6.17: The biphasic inhibition curve of T. b. brucei-s427 wild type PCF against 6-
azauracil by using the Alamar blue fluorescent dye as a representative for the cell number. 
The trypanostatic effect at low concentrations EC50 (1) was 1218 ± 83.8 µM and the 
trypanocidal effect at higher concentrations EC50 (2) was 3.50 ± 1.04 µM. 
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Figure 6.18: The Alamar blue drug sensitivity assay of T. b. brucei-s427 wild type PCF on 
SDM-79 medium supplemented with 10% FBS, 0.6 g/L of proline and three different growth 
conditions for glucose (1 g/L glucose 'standard condition', 0.2 g/L glucose and glucose free 
medium) using 5-fluorouracil (A), 6-azauracil (B) and pentamidine (C). 
The mean of four independent determinations is shown ± SEM. P value was determined by 
unpaired two-tailed Student’s T-test. 
 Discussion 
Promastigotes and amastigotes of L. mexicana are supplied with energy by 
glucose as a primary nutrient and building blocks enhancing the synthesis process 
of different biomolecules. Glucose and amino acid catabolism are relied upon by 
the procyclic promastigotes, while the utilisation of amino acids is increased in 
the later stages of promastigote development (Inbar et al., 2017; Landfear, 
2010). It is through the pentose phosphate pathway and glycolysis that glucose is 
metabolised (Barrett, 1997; Landfear, 2011). Glycolysis is a pathway responsible 
for converting one glucose molecule to two pyruvate molecules following the 
generation of two ATP molecules (Saunders et al., 2011; Drew et al., 2003). It is 
both through the three high-affinity glucose transporters, LmexGT1-3, and the 
low-affinity glucose transporter LmexGT4 that L. mexicana promastigotes take 
up exogenous glucose. However, the major sources of glucose are LmexGT1-3, 
but the situation is not exclusive for the L. mexicana promastigotes since Lmex-
GT1-3 Knockout cell lines are still grown in culture (Burchmore et al., 2003a; 
Feng et al., 2013; Feng et al., 2009). The situation indicates that Lmex-GT1-3 
KO cells have the potential to up-regulate the alternative lower affinity glucose 
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transporter LmexGT4 as an alternative source of carbon and energy, as well as 
use amino acids for their energy needs (Feng et al., 2013; Landfear, 2011). 
There is a close relationship between the three glucose transporters LmexGT1-3, 
but they each display distinct biological and functional properties, including 
differential localisation, substrate specificity, and developmental stage 
expression (Burchmore and Landfear, 1998; Akpunarlieva and Burchmore, 2017).  
It was confirmed through multiple alignments that the three LmexGT 
transporters represented up to 90% identity in the sequence of amino acids due 
to their differences at the C and N terminal domains (Burchmore et al., 2003a). 
The separate and independent re-expression of the LmexGT1, LmexGT2, and 
LmexGT3 into Lmex-GT1-3 KO cells enables the uptake of glucose, fructose, 
galactose and mannose. LmexGT1 is a low-affinity glucose transporter while 
LmexGT2 and LmexGT3 are high-affinity glucose transporters. Fluorescent 
microscopy showed that LmexGT1 is localised mainly in the flagellum whereas 
LmexGT2 and LmexGT3 are predominantly localized on the plasma membranes 
(Burchmore et al., 2003a; Rodriguez-Contreras et al., 2007). 
Previous work in our laboratory’s RNA-seq and RIT-seq analyses of the 5-FU 
resistant cell lines have identified candidate genes for uracil transporter 
including glucose transporter 2A and glucose transporter THT2 in T. b. brucei 
BSF. The most striking results that emerged from the RIT-seq and RNA-seq data 
is the presence of glucose transporter 2A in both the RNA-sequencing data and 
the genome-wide RNA-interference screen. Therefore, there is the possibility 
that the knockdown or down-regulation of either one or some of these glucose 
transporter genes in 5-FU resistant cell lines can be responsible for causing 
increased levels of resistance to 5-FU. Several genes encoding for glucose 
transporters were identified up-regulated in Tbb-5FURes and Lmex-5FURes using 
RNA-sequencing. The conclusion made was that there is a high probability that 
Lmex-5FURes and Tbb-5FURes up-regulated some glucose transporter genes to 
help in compensating for the glucose transporter genes that had been down-
regulated. The purpose of this compensation is to create a balance in the 
provision of sufficient amounts of glucose to the cells. A glucose transporter null 
mutant line, Lmex-GT1-3 KO cells, was created by Burchmore et al. (2003a) 
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through the deletion of the glucose transporters locus which including LmexGT1, 
LmexGT2, and LmexGT3 genes in L. mexicana promastigotes. 
Thus, we decided to determine the sensitivity of the full knockout of glucose 
transporter genes in L. mexicana against 5-fluorouracil. The result revealed a 
significant reduction in the sensitivity of the double knockout of LmexGT1-3 
genes in L. mexicana to 5-FU when compared to the wild type cell lines. Using 
radiolabelled 5-FU and uracil, transport assays were performed in L. mexicana-
WT and Lmex-GT1-3 KO strain. The results showed that the Lmex-GT1-3 KO cells 
no longer accumulate uracil and 5-FU. The situation is evidence showing that the 
uptake of pyrimidine in L. mexicana promastigotes is either mediated or 
regulated by the glucose transporters. The Alamar blue assay results from the L. 
mexicana-WT in glucose free medium have demonstrated that the presence or 
absence of glucose in the medium does not influence the sensitivity to 5-FU. 
Similarly, the presence or absence of glucose in the extracellular medium does 
not affect the sensitivity of T. b. brucei procyclic form to 5-FU and 6-AU. The 
results of our study show that the Lmex-5FURes cell lines are still maintaining 
the glucose transport activity, but lost uracil/5-FU transporter. Thus, it is not 
the uptake of glucose that is important for the uptake of uracil, but the 
presence of the transporters, occupied or not. 
There was a significant increase of the sensitivity to 5-FU in the re-expression of 
individual LmexGT in Lmex-GT1-3 KO cells but not quite back to wild-type cells. 
After the introduction of the glucose transporter genes, all the three genes did 
appear to have a very similar ability of functioning with regards to the 
(regulation of) uptake of 5-fluorouracil and uracil (restoring uptake to ~50% of 5-
FU and ~30% of uracil uptake of wild type, respectively). There were no 
measurable effects of 5-fluorouracil and uracil on glucose transport by LmexGT1, 
LmexGT2 and LmexGT3, showing that none of them caused any inhibition to the 
transport of 0.1 μM of [3H]-2-deoxy-D-glucose up to 2.5 mM. Therefore, these 
results clearly confirmed that the effect of D-glucose on 2-deoxy-D-glucose 
transport is very different from the effect of uracil and 5-FU on the same 
process in L. mexicana promastigotes and that LmexGT1, LmexGT2 and LmexGT3 
are straightforward glucose transporters.  
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An evaluation of the affinity of LmexGT1, LmexGT2 and LmexGT3 for glucose 
was conducted by competition with 0.1 μM of [3H]-2-deoxy-D-glucose. The result 
showed that LmexGT1 has a lower affinity for glucose (Ki of 577 ± 78 μM), while 
LmexGT2 and LmexGT3 showed higher affinity for glucose (Ki of 59 ± 8 and 123 ± 
9 μM, respectively). These results are consistent with the previous 
characterisations of LmexGT1, LmexGT2 and LmexGT3 for glucose in Lmex-GT1-
3 KO parasites, showing that LmexGT1 has a higher Km for glucose compared to 
LmexGT2 or LmexGT3 (Rodriguez-Contreras et al., 2007), These Km values were 
within 2-fold of the Ki values determined by us. The sequence of the L. donovani 
LdGT4 is orthologous to L. mexicana LmexGT4, and shares 66.5% of the 
nucleotide identity. LdGT4 expressed in Xenopus oocytes was estimated to have 
a Km of ~150 mM, which was an indication that LmexGT4 is a very lower-affinity 
substrate for D-glucose (Feng et al., 2009; Langford et al., 1995) and that its 
primary function may in fact not be the uptake of glucose, especially considering 
that the promastigotes of GT1-3-KO strain appear to be truly null for glucose 
uptake, at least at the assay conditions and label concentration used. In L. 
mexicana wild type, the amastigote and promastigote glucose transporter have a 
high affinity for glucose, with a Km value of 24 ± 8 μM and 29 ± 3 μM 
respectively. However, the Vmax of amastigote for glucose uptake was 0.132 
pmol.(107 cells)-1s-1 and ~20-fold lower than the Vmax of promastigote (2.21 
pmol.(107 cells)-1s-1). In amastigote and promastigote forms, the similar values of 
Km for glucose transport is a likely suggestion of the expression of the same 
transporter in both of these developmental stages (Burchmore and Hart, 1995). 
The findings show that the uptake of uracil and glucose by separate transporters 
in L. mexicana promastigotes is an indication that LmexGT1, LmexGT2 and 
LmexGT3 are straightforward glucose transporting genes and not the 5-FU 
transporter. Considering that both 5-FU and uracil are pyrimidines, it could be 
speculated that the metabolism of glucose regulates the uptake of uracil and 5-
FU, as the pathways overlap in the process of glycosylation (e.g. UDP-glucose, 
UDP-galactose, UDP-N-acetylglucosamine) and lipid biosynthesis (CDP-
ethanolamine, CDP-choline). The effect of introduction of FurD transporter in 
Lmex-GT1-3 KO cells increased the rate of transport of [3H]-5FU and reversed 5-
FU resistance in the Lmex-GT1-3 KO cells. It therefore appears that the effect of 
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the LmexGT knockout is to severly restrict 5-FU uptake, because they are still 
sensitive to the drug when FurD transporter is introduced. Also, the activity of 
the FurD transporter, unlike the Leishmania uracil transporter, is not regulated 
by the presence or absence of the glucose transporters. The study by Ortiz et al. 
(2010) indicated that the deletion of the purine nucleobase transporter 3 (NT3) 
or both NT3 and the nucleoside transporter 2 (NT2) in L. major parasites 
resulted in strong up-regulation of uridine and adenosine uptake mediated by 
the nucleoside transporter 1 (NT1) and also induced up to a 200-fold increase in 
the level of the NT1 protein but not mRNA. Another study by Seyfang and 
Landfear (1999) showed that a strong up-regulation of glucose (5-fold), 
adenosine (11-fold) or myo-inositol (25-fold) uptake was found when Leishmania 
species were depleted of the respective substrates during culture.When T. 
brucei PCF for tubercidin resistance were subjected to RNAi library screening, it 
was reported that silencing of glucose transporters conferred resistance to the 
toxic levels of tubercidin (Drew et al., 2003).  The study from Drew et al. (2003) 
with functionally expressed THT1 and THT2 in Xenopus oocytes showed that the 
uptake of [3H]-tubercidin and [3H]-adenosine was not significantly increased, 
while there was a significant increase of [3H]-glucose.  Tubercidin (7-
deazaadenosine), as a substrate for adenosine kinase in mammalian cells, is 
reported to be incorporated into DNA and RNA. However, the inhibition of 
tubercidin to phosphoglycerate kinase specifically targets the glycolysis pathway 
and kills procyclic trypanosomes (Drew et al., 2003; Hulpia et al., 2019). 
However, RNAi silencing of the glucose transporters occurs over several days. 
The lengthy duration consequently gives time to tubercidin resistant cell lines to 
increase their reliance on such amino acids as proline, which serves both as 
energy source and carbon (Drew et al., 2003), and thus reduces the need for 
glycolysis. Ali et al. (2013a) found that the level of 5F-UDP-glucose and of 5F-
UDP-N-acetylglucosamine in Tbb-5FURes cells treated with 5-FU was 6.5-fold 
reduced relative to T. b. brucei s427-WT cells treated with 5-FU. The situation is 
an indicated that changes in the glycosylation pathway could make substantial 
contributions to 5-FU resistance. The most important conclusion from this 
investigation is that glucose transporters are required for the expression of 
functioning of uracil/5-FU transporters in L. mexicana promastigotes. 
Ibrahim Abdullah Alfayez                             Chapter 7                                  209 
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Chagas’ disease, also known as American trypanosomiasis, is an illness that 
threatens the life of many people in the endemic regions. Chagas’ disease is 
caused by the protozoan Trypanosoma cruzi. The condition is named after a 
Brazilian physician, Carlos Chagas, who discovered the disease in 1909. Chagas’ 
disease is transmitted to animals as well as human beings by an arthropod vector 
(triatomine bugs) (Rassi Jr et al., 2010; Pérez-Molina and Molina, 2018). The 
disease is named as one of the 13 most neglected tropical diseases (NTD) by the 
World Health Organisation (WHO). Approximately 9 million individuals are 
affected by American trypanosomiasis. Regarding this, people from Mexico, 
Central America, and South America are most affected, but the infection is also 
increasingly prevalent in the southern United States. However, most of the 
people remain unaware of the infection. If Chagas’ disease is left untreated, it 
may result in disabilities and conditions that are life-long, resulting in the poor 
quality of life and, in complicated cases, death (Souto et al., 2019). Currently, 
there are no vaccines for the treatment of Chagas’ disease. However, nifurtimox 
and benznidazole are the only drugs possessing a proven efficacy against the 
infections of T. cruzi (Bern, 2015; Pérez-Molina and Molina, 2018). Concerning 
this, nifurtimox and benznidazole are not effective in infections that are 
recognised as chronic. Therefore, they are only useful for the acute phases of 
the infection. Some strains of T. cruzi have natural resistance to these drugs, 
thus, novel drugs with better efficacy for the protozoa with minimal side effects 
for the host are needed (Filardi and Brener, 1987). 
.In kinetoplastid parasites such as T. cruzi, Lesihmania spp and African 
trypanosomes , only members of the ENT family have been found to be involved 
in nucleoside and nucleobase uptake (Campagnaro and de Koning, 2020; De 
Koning et al., 2005). Apart from their role in nucleoside salvage, the ENT 
transporters have been shown to play a vital role in the pharmacology of 
protozoan chemotherapy, particularly of African trypanosomes, but also of 
Leishmania (Carter et al., 1999; Geiser et al., 2005; Al-Salabi and de Koning, 
2005; Rodenko et al., 2007; Kazibwe et al., 2009; Stewart et al., 2010; Vodnala 
Ibrahim Abdullah Alfayez                             Chapter 7                                  211 
 
 
et al., 2013; Munday et al., 2015; Ranjbarian et al., 2017). These 
chemotherapeutic compounds include purine and pyrimidine nucleoside 
analogues (5-fluoro-2’-deoxyuridine, idoxuridine, cordycepin, aristeromycin and 
neplanocin), as well as purine (allopurinol) and pyrimidine (5-fluorouracil) 
nucleobases. 
Through the comparison of genomic of T. cruzi ENT gene sequences with 
sequences of other trypanosomatids, Campagnaro et al. (2018b) indicated the 
presence of four ENT genes in T. cruzi; for instance, TcrNB1, TcrNB2, TcrNT1, 
and TcrNT2 genes. Three of the four genes, TcrNB1, TcrNT1 and TcrNT2 were 
cloned and characterised in T. brucei procyclic TbNBT-KO cells. However, 
TcrNB2 did not show any detectable activity with all substrates that were 
tested. Campagnaro et al. (2018b) reported that TcrNB1 has a high affinity for 
hypoxanthine and guanine. TcrNT1 is a high affinity inosine and guanosine 
transporter, whereas TcrNT2 has an affinity for 2′‐deoxypyrimidines with Km of 
0.223 μM for thymidine. Notably, the 4 ENT genes in T. cruzi do not transport 
adenosine or adenine (Campagnaro and de Koning, 2020). Thus, two issues 
remain outstanding: the identity of the T. cruzi adenosine transporter and the 
substrate of TcrNB2. It should be noted that adenosine uptake would be hard to 
detect in the T. brucei expression system, due to the very active P1 transport 
system. 
In L. mexicana promastigotes, nucleoside transporter 1 (LmexNT1) mediates the 
uptake of adenosine as well as pyrimidine nucleosides (Alzahrani et al., 2017). 
More importantly, the locus of the NT1 comprises two similar genes. These genes 
are NT1.1 and NT1.2 (Table 7.1). According to Alzahrani et al. (2017) posits the 
sensitivity of NT1.1 from L. major and L. mexicana to inhibition by uracil, which 
was then named uridine‐uracil transporter 1 (UUT1). In these species, NT1.2 will 
carry the NT1’s title. 
Thus, the research that is linked with the previous study by (Campagnaro et al., 
2018b), cloned TcrNT2 and TcrNB2 in L. mexicana-Cas9 nucleoside transporter 1 
knockout cell lines (L. mexicana-Cas9ΔNT1) hence, assessing its transport activity. 
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Another objective of this study is to continue working on the characterisation of 
TcrNT2 and TcrNB2 transporters to establish if they can be used in the drug 
delivery system. The T. cruzi being a very pathogenic parasite poses a great 
challenge in working with its cellular culture. Additionally, it was not possible to 
culture the T. cruzi parasites in the research laboratory at University of 
Glasgow. Given that almost the entirety of nucleoside transport studies in 
trypanosomatids has been performed on Leishmania and T. brucei spp., we 
decided to rationally characterise the TcrNT2 and TcrNB2 from T. cruzi.  
Table 7.1: Annotation of the nucleoside transporter 1 (LmexNT1) in the genome of L. 
mexicana M379 promastigote form. 

















1476 bp NT1.2 
 Results 
 PCR and qRT-PCR confirmation of knockout of NT1 in L. 
mexicana-Cas9 by using CRISPR technique 
In order to eliminate the transport of adenosine and pyrimidine nucleoside 
mediated by LmexNT1, we knocked out the cluster of two tandem arrayed NT1.1 
and NT1.2 genes encoding for LmexNT1 transporter on chromosome 15 in L. 
mexicana-Cas9ΔNT1 cells by using the CRISPR-Cas9 system (Beneke et al., 2017; 
Beneke and Gluenz, 2019) (Figure 7.1). The nucleotide sequence alignment 
results of the NT1.1 and NT1.2 genes in L. mexicana promastigotes, showed a 
high level of identity, 98.98%, as presented in Appendix 9. In this study, we used 
the genome editing CRISPR-Cas9 system in L. mexicana promastigotes following 
the protocols designed by (Beneke et al., 2017). Briefly, the deletion of the NT1 
locus requires the amplification of 5’ sgRNA-NT1 and 3’ sgRNA-NT1 by using 
HDK1508 and HDK1510 as forward primers, respectively; and HDK1502 as reverse 
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primer that serves as template. 5’ sgRNA-NT1 and 3’ sgRNA-NT1 were amplified 
to direct Cas9 to cut immediately upstream (5’) or downstream (3’) of the target 
locus of NT1. The presence of the expected product (~120 bp for both 5’ sgRNA-
NT1 and 3’ sgRNA-NT1) was verified by running on 2% of agarose gel to be 
observed visually (Figure 7.2A). To create CRISPR plasmids specific to the target 
locus of NT1, pTBlast-NT1 and pTPuro-NT1 were amplified using HDK1507 as 
forward primer and HDK1509 as reverse primer; and pTBlast and pTPuro plasmids 
served as template to amplify the blasticidin and puromycin resistance markers 
for the NT1 region. The presence of the expected product (~1.7 kb for pTBlast-
NT1 and ~1.8 kb for pTPuro-NT1) was verified by running The PCR products on 1% 
of agarose gel to be seen visually under UV light (Figure 7.2B). 
NT1.1 and NT1.2 




5’ sgRNA-NT1 3’ sgRNA-NT1
HDK1509 
(DRP) 




Figure 7.1: Workflow of CRISPR-Cas9 rapid gene knockout used for the replacement of the 
NT1 locus on chromosome 15 containing a tandem array of two nucleoside transporter 1 
genes (NT1.1 and NT1.2) in L. mexicana-Cas9. 
Abbreviations are described in the text. Adapted from Beneke et al. (2017). 
 




Figure 7.2: PCR amplification of 5’ sgRNA-NT1 and 3’ sgRNA-NT1 templates for knockout of 
NT1 locus in L. mexicana-Cas9; and PCR amplification of blasticidin and puromycin 
resistance markers. 
A) PCR amplification of 5’ sgRNA-NT1 and 3’ sgRNA-NT1 templates for knockout of NT1 
region (NT1.1 and NT1.2 genes) in L. mexicana-Cas9.  L: 100 bp DNA ladder (Promega); 1 
and 2: 5’ sgRNA-NT1 (~120 bp); 3 and 4: 3’ sgRNA-NT1 (~120 bp); Negative control (No 
sgRNA scaffold). B) PCR amplification of blasticidin and puromycin resistance markers. L: 1 
kb DNA ladder (Promega); 1 and 2: Blasticidine-NT1 (~1.7 kb); 3 and 4: Puromycin-NT1 (~1.8 
kb); Negative control (No genomic DNA). 
To verify the loss of NT1 locus in drug-resistant transfectants diagnostic PCR was 
performed to amplify PCR products within the open reading frame of 
the NT1 locus, using primers that are unique to the NT1 locus. A region of the 
NT1 amplicon was amplified with genomic DNA-specific primers, using HDK1523 
as forward primer and HDK1524 as reverse primer, and PCR products were run on 
1% of agarose gel to be observed visually. PCR diagnostics of the L. mexicana-
cas9 and L. mexicana-Cas9ΔNT1 cells showing the approximate expected presence 
and absence of the NT1-specific bands (~1 kb) (Figure 7.3). 
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Figure 7.3: PCR validation of knockout of NT1 region in L. mexicana-Cas9 by using CRISPR-
Cas9 system. 
L: 1kb DNA Ladder (Promega); 1: L. mexicana-Cas9; 2: L. mexicana-Cas9ΔNT1 3: Negative 
control (No genomic DNA). 
Confirmation of fold decreases of gene mRNA level due to the deletion of a 
double NT1 region was assessed using qRT-PCR and gene expression was 
normalised to GPI-8 expression in L. mexicana. From the below Figure 7.4, we 
can see the mRNA levels of the L. mexicana-Cas9 cell lines are 1 as the 
endogenous double alleles are still existence. However, in L. mexicana-Cas9ΔNT1, 
the gene expression of the NT1 locus could not be detected by qRT-PCR 
confirming the complete loss of the NT1 region in L. mexicana-Cas9ΔNT1 and thus 














































Figure 7.4: The expression levels of NT1 in L. mexicana-Cas9ΔNT1 compared to the control (L. 
mexicana-Cas9) determined by qRT-PCR. Levels were corrected against the expression 
level of the housekeeping gene (L. mexicana GPI8). 
The presented results are the average of 2 cDNA preparations, each performed in duplicate, 
and error bars are ± SEM. ***, P < 0.001 by unpaired student’s T-test. 
 Confirmation of tubercidin resistance phenotype in L. 
mexicana-Cas9ΔNT1 
As a cytotoxic adenosine analogue for Leishmania, tubercidin is transported by 
the NT1 transporter (Scott, 2008). In the determination of EC50 of the tubercidin 
resistant cells (L. mexicana-Cas9ΔNT1), the Alamar blue assay was applied to 
verify if the clone is resistant to tubercidin before performing the transport 
assays; the assay was performed in parallel with the L. mexicana-Cas9 cells. 
Throughout the assessment, pentamidine was used as the specific control. 
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Tubercidin showed anti-leishmanial activity against L. mexicana-Cas9 
promastigotes, with an average EC50 value of 0.43 ± 0.15 µM (n=4) (Figure 7.5). 
On the other hand, L. mexicana-Cas9ΔNT1 cells were becoming highly resistant to 
tubercidin and displayed an average EC50 value of 25.9 ± 1.9 µM (n=4). When 
comparing L. mexicana-Cas9ΔNT1 to the parental cell lines, L. mexicana-Cas9ΔNT1 
was thus 60-fold more resistant to tubercidin (P < 0.0001). In contrast, the 
sensitivity of L. mexicana-Cas9 and L. mexicana-Cas9ΔNT1 to pentamidine was not 
significant different (P > 0.05). These results clearly confirmed that L. mexicana-
Cas9ΔNT1 had lost NT1 transport activity, with NT1 null mutants becoming 
















































































Figure 7.5: Alamar blue drug sensitivity assay of the deletion of LmexNT1 in L. mexicana-
cas9 by using tubercidin (A) and pentamidine (B) as positive control. 
The mean of four independent determinations is shown ± SEM. *** P < 0.001 by unpaired 
Student’s T-test. 
 Confirmation of the abolition of adenosine and thymidine 
uptake in L. mexicana-Cas9ΔNT1 
We assessed adenosine and thymidine transport in the L. mexicana-Cas9 and L. 
mexicana-Cas9ΔNT1 cell lines. Figure 7.6A shows that the uptake of 0.1 µM of 
[3H]-adenosine by L. mexicana-Cas9 cells had a high rate of adenosine uptake 
and thus became non-linear within a second, with metabolism apparently 
limiting the rate of uptake. In contrast, the transport of 0.1 µM of [3H]-
adenosine by L. mexicana-Cas9ΔNT1 promastigotes was virtually abolished (~98%) 
and became statistically identical to the uptake in the presence of 1 mM 
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unlabelled adenosine (P > 0.05), so it is clear that the L. mexicana-Cas9ΔNT cells 
have lost at least the high affinity adenosine transport activity (LmexNT1) (if 
Leishmania expresses any low affinity adenosine transporter it has not been 
reported and we found no evidence for it). We similarly found that the transport 
of 0.05 µM of [3H]-thymidine was greatly reduced in L. mexicana-Cas9ΔNT1 cells 
compared with L. mexicana-Cas9, with a rate of uptake 0.00004 ± 0.000006 
pmol. (107 cells)-1.s-1 (Figure 7.6B). Thymidine transport by L. mexicana-Cas9ΔNT1 
cells were reduced by ~85% but still significantly different from zero (F-test, P = 
0.026), meaning the little transport seen by the L. mexicana-Cas9ΔNT1 strain is 
not negligible, and it was higher than the saturation control with 1 mM 
unlabelled thymidine. This could be taken as preliminary evidence of a low 
affinity secondary transporter for thymidine, but this would need further 
investigation. Knockout of LmexNT1 in L. mexicana-Cas9 promastigote form 
completely abolished the uptake of adenosine and greatly reduced thymidine 
uptake. These findings agree with the Alamar Blue data (Figure 7.5, above) 
which showed that L. mexicana-Cas9ΔNT1 cell lines became highly resistant to 
tubercidin. 
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Figure 7.6: [3H]-Adenosine and [3H]-Thymidine transport by L. mexicana-cas9 and L. 
mexicana-Cas9ΔNT1. 
A) Transport of 0.1 µM of [3H]-adenosine by L. mexicana-cas9 (●) and L. mexicana-Cas9ΔNT1 
(●) was measured over 20 s in the presence or absence of 1 mM unlabelled adenosine (○) 
and (○) respectively. B) Transport of 0.05 μM of [3H]-thymidine by L. mexicana-cas9 (●) and 
L. mexicana-Cas9ΔNT1 (●) was measured over 180 seconds in the presence or absence of 1 
mM unlabelled thymidine (○) and (○) respectively. Symbols represent the average of 
triplicate determinations in a single representative experiment and error bars represent ± 
SEM. F-test was determined by GraphPad Prism 8. 
 The heterologous expression of TcrNT2 in L. mexicana-
Cas9ΔNT1 
In a phylogenetic analysis of T. cruzi ENT transporters with other 
trypanosomatids (Leishmania spp., T. brucei and T. congolense), TcrNT2 is 
grouped close to the Leishmania NT1 transporter, which transports pyrimidine 
nucleosides and adenosine. Furthermore, it possesses a structural similarity to 
the Leishmania NT1 transporters which supports that the TcrNT2 transporter 
would take part in the transportation of pyrimidine nucleosides and adenosine 
(Campagnaro et al., 2018b). Using this information, TcrNT2 transporter was 
expressed in a model cell line, L. mexicana-Cas9ΔNT1, to continue the 
characterisation of its transporter activity, and in testing the susceptibility of 
the TcrNT2 expressing cells to adenosine and pyrimidine analogues. We also test 
the possibility of using L. mexicana-Cas9ΔNT1 promastigotes as a surrogate system 
for the expression of TcrNT2 transporters of T. cruzi, particularly transportation 
of thymidine through L. mexicana-Cas9ΔNT1 cells indicated a strong reduction of 
approximately ~85%.  
 PCR confirmation of the presence and growth rate of TcrNT2 in L. 
mexicana-Cas9ΔNT1 
Using HDK1551 as forward primer while HDK1552 as reverse primer, the TcrNT2 
gene was amplified from plasmid pHDK222 using PCR. The pNUS-HcN plasmid was 
used to express the TcrNT2 gene in the L. mexicana-Cas9ΔNT1 (Tetaud et al., 
2002). The pNUS-HcN plasmid as well as TcrNT2 gene were digested using BglII 
and XhoI restriction enzymes; the digested TcrNT2 gene was ligated, using T4 
DNA ligase, into the digested pNUS-HcN plasmid to generated plasmid pHDK270 
(Figure 7.7). The integration of TcrNT2 gene into pHDK270 vector was verified by 
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diagnostic digest with BglII and XhoI, which resulted in a band of ~6.2 kb for the 
plasmid and TcrNT2 gene band at ~1.4 kb (Figure 7.8A). After transfection of the 
pHDK270 plasmid into L. mexicana-Cas9ΔNT1, PCR was applied to verify the 
existence of the pHDK270 plasmid in positive clones, using forward primer 
HDK1551 for TcrNT2 gene and HDK340 as reverse primer for the pNUS-HcN 
plasmid sequence (Figure 7.8B). 
 
Figure 7.7: Plasmid map of pHDK270 vector for the heterologous expression of T. cruzi 
high-affinity thymidine transporter (TcrNT2) in L. mexicana-Cas9ΔNT1 cells. 
 
Figure 7.8: Restriction digest products for pHDK270 plasmid and confirmation of the 
presence of TcrNT2 gene into L. mexicana-Cas9ΔNT1 cells after transfection. 
A) Restriction digest products for plasmid pHDK270 with BglII and XhoI to release the 
TcrNT2 gene. L: 1 kb DNA ladder (Promega); 1: Digested plasmid by BglII and XhoI to 
release TcrNT2 (1323 bp) from pHDK270 (~6.2 kb); 2: Undigested plasmid for pHDK270. B) 
Confirmation of the presence of TcrNT2 gene into L. mexicana-Cas9ΔNT1 strain after 
transfection by using HDK1551 as forward primer for TcrNT2 and HDK340 as a reverse 
primer for pNUS-HcN. L: 1kb DNA Ladder (Promega); 1: Clone 1; 2: Clone 2; 3: Clone 3; 4: 
Non-transfected control (gDNA from L. mexicana-Cas9ΔNT1). 
The growth rate of L. mexicana-Cas9, L. mexicana-Cas9ΔNT1 and L. mexicana-
Cas9ΔNT+TcrNT2 strains were plotted after measuring the growth of the cell cultures 
Ibrahim Abdullah Alfayez                             Chapter 7                                  220 
 
 
for 6 days at 24 h intervals (Figure 7.9). The growth rates of these cell lines, 
although the rate of difference is small (L. mexicana-Cas9ΔNT1+TcrNT2: 1.53 × 107 
cell/mL, L. mexicana-Cas9: 1.42 × 107 cell/mL and L. mexicana-Cas9ΔNT1: 1.14 × 
107 cell/mL). All the three cell lines displayed very good growth, almost at the 
same rate over 6 days, just reaching the stationary phase after day 3. Similar to 
what was observed earlier, the doubling time of all the cell lines was ~6.5 hours 































Figure 7.9: The growth rate of L. mexicana-Cas9 and L. mexicana-Cas9ΔNT1 and L. mexicana-
Cas9ΔNT1 expressing TcrNT2 on HOMEM medium supplemented with 10% FBS at 25°C. 
The cells were seeded at the density of 1×105 cells/mL, and cell densities were determined 
every 24 h. Each data point in this result represents the mean of two similar independent 
repeats.  
The Alamar blue assay was used to assess the effects of deleting LmexNT1 from 
the L. mexicana-Cas9 cell line and of the expression of TcrNT2 in L. mexicana-
Cas9ΔNT1 cells with respect to sensitivity to analogues of 5-fluoro-2’-
deoxyuridine, tubercidin, and other adenosine analogues (Table 7.2). The main 
interest is checking whether the drugs are effective only when it is taken up by 
the TcrNT2 transporter. Thus, L. mexicana-Cas9ΔNT1+TcrNT2 acts as the main cell 
line while the remaining two cell types are used as controls, although the 
experiment also gives information about the ability of LmexNT1 to transport 
these analogues. 
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 Drug sensitivity assay with adenosine and pyrimidine analogues 
Table 7.2: The EC50 of different adenosine analogues and 5-fluoro-2’-deoxyuridine (pyrimidine analogue) on L. mexicana-Cas9, L. mexicana-Cas9ΔNT1 and L. 
mexicana-Cas9ΔNT1+TcrNT2 promastigotes, obtained from drug sensitivity assay.  
Adenosine analogues/ 
5-F-2’dU 
L. mexicana-Cas9 L. mexicana-Cas9ΔNT1 L. mexicana-Cas9ΔNT1+TcrNT2 
EC50± SEM (µM) EC50± SEM (µM) RF vs Cas9 P value vs Cas9 EC50 ± SEM (µM) RF vs ΔNT1 P value vs ΔNT1 
FH3141 1.08 ± 0.202 14.5 ± 1.77 13.4 P < 0.01 1.86 ± 0.21 7.83 P < 0.01 
FH3143 0.12 ± 0.021 0.93 ± 0.18 7.74 P < 0.05 0.30 ± 0.01 3.11 P < 0.05 
FH3147 8.41 ± 1.613 > 100 ± 0.00 > 11.8 P < 0.001 13.7 ± 1.25 7.28 P < 0.01 
FH3167 0.22 ± 0.091 8.95 ± 1.59 40.7 P < 0.01 0.21 ± 0.02 41.9 P < 0.01 
FH3169 0.24 ± 0.055 2.00 ± 0.19 8.43 P < 0.01 0.32 ± 0.05 6.26 P < 0.01 
FH8517 3.18 ± 0.775 12.5 ± 1.47 3.93 P < 0.01 9.77 ± 0.67 1.28 P > 0.05 
JB588 0.51 ± 0.093 8.82 ± 1.12 17.3 P < 0.01 4.10 ± 0.19 2.15 P < 0.05 
TH1003 0.16 ± 0.018 2.90 ± 0.57 18.4 P < 0.01 0.38 ± 0.02 7.68 P < 0.05 
FH8505 47.2 ± 1.47 53.27 ± 5.29 1.13 P > 0.05 36.2 ± 1.34 1.47 P < 0.05 
FH6367 1.42 ± 0.177 2.05 ± 0.42 1.44 P > 0.05 1.07 ± 0.09 1.91 P > 0.05 
FH7429-UP 8.0 ± 0.825 9.37 ± 1.15 1.17 P > 0.05 4.12 ± 0.88 2.27 P < 0.05 
Tubercidin 1.02 ± 0.160 25.7 ± 0.94 25.2 P < 0.001 0.82 ± 0.13 31.2 P < 0.001 
5-F-2’dU 2.19 ± 0.111 58.4 ± 8.66 26.6 P < 0.01 3.94 ± 0.36 14.8 P < 0.01 
Pentamidine 0.87 ± 0.104 1.25 ± 0.22 1.43 P > 0.05 1.12 ± 0.17 1.11 P > 0.05 
The EC50 are shown as averages in µM (± SEM) of at least 3 independent determinations. Pentamidine is a standard drug used as control in this assay. The P values show 
the level of significance of the sensitivity of the analogues have on the cell lines. The drugs in bold have a significantly different level of sensitivity on the cells. P 
values were determined by unpaired Student’s T-test: Not significant P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001. RF: resistance factor in comparison to Cas9 (L. 
mexicana-cas9) and ΔNT1 (L. mexicana-Cas9ΔNT1); SEM: standard error of mean. 5-F-2’dU: 5-fluoro-2’-deoxyuridine. 
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Generally, most of the tested tubercidin analogues indicated EC50 values in the 
low micro molar or sub micromolar range and with comparable or superior 
activity compared to pentamidine. L. mexicana-Cas9ΔNT1+TcrNT2 displayed 
increased sensitivity to 5-fluoro-2’-deoxyuridine (14.8-fold more sensitive to 5-
fluoro-2’-deoxyuridine; P < 0.01) as compared to the strain of L. mexicana-
Cas9ΔNT1. However, its inhibition to 5-fluoro-2’-deoxyuridine, a pyrimidine 
analogue, was as expected. The sensitivity of L. mexicana-Cas9ΔNT1 cells to 5-
fluoro-2’-deoxyuridine was decreased (RF = 26.6; P < 0.001) compared to the L. 
mexicana-Cas9 cells. 5-Fluoro-2’-deoxyuridine was used as control for the proper 
knockout of the LmexNT1 in L. mexicana-Cas9ΔNT1 cell line. 
Interestingly, the sensitivity to tubercidin was increased due to addition of 
TcrNT2 in L. mexicana-Cas9ΔNT1 cells compared to L. mexicana-Cas9ΔNT1 (25.7 ± 
0.94 µM), with an average EC50 of 0.82 ± 0.13 µM (P < 0.001). It was found that 
the L. mexicana-Cas9ΔNT1+TcrNT2 strain has a 7.8, 41.9, 6.3 and 7.7-fold higher 
sensitivity to FH3141, FH3167, FH3169 and TH1003, respectively, relative to L. 
mexicana-Cas9ΔNT1. These analogues are all analogues of tubercidin, following a 
halogen addition at the C7 position (Hulpia et al., 2020a). For all the three cell 
lines, TH1003 showed the best performance, thus, the bromo group at C7 
presence increased the sensitivity of these cell lines to this analogue. Notably, 
the L. mexicana-Cas9ΔNT1+TcrNT2 cell line restored the sensitivity to tubercidin and 
most of tubercidin analogues with substitutions on C7. Therefore, transport 
assays were conducted next to check the rate of uptake of the interesting 
adenosine and thymidine analogues. 
 Transport studies and kinetic characterisation 
As it was noted that the cells containing the T. cruzi NT2 transporter are more 
sensitive to some of the tubercidin and adenosine analogues, it was decided to 
check the transport rate of 50 nM of [3H]-adenosine by the same transporter 
(Figure 7.10). The L. mexicana-Cas9 cell lines showed very high levels of uptake 
when incubated with 50 nM of [3H]-adenosine, with a linear phase of at least 15 
seconds and a rate of 0.104 ± 0.012 pmol. (107 cells)-1.s-1. However, the 
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expression of TcrNT2 in L. mexicana-Cas9ΔNT1 did not change the rate of 
adenosine uptake in comparison to the parental cell lines L. mexicana-Cas9ΔNT1 
(P > 0.05 by F-test). The addition of 1 mM unlabelled adenosine completely 
inhibited the uptake of [3H]-adenosine in all three cell lines, showing it is 
saturable. From Figure 7.10, it is clear that the TcrNT2 did not recognise 
adenosine as a substrate, at least not at the low adenosine concentration used. 
As a result, other sets of experiments were conducted, applying 50 nM of [3H]-
thymidine as a substrate and its uptake rate was measured, as observed from 
the figure 7.11. 







































L. mexicana-Cas9 + 1mM ADO
L. mexicana-Cas9ΔNT1 + 1mM ADO




Figure 7.10: [3H]-Adenosine transport was by L. mexicana-Cas9, L. mexicana-Cas9ΔNT1 and 
L. mexicana-Cas9ΔNT1+TcrNT2. 
Transport of 50 nM of [3H]-adenosine by L. mexicana-cas9 (●), L. mexicana-Cas9ΔNT1(●) and 
L. mexicana-Cas9ΔNT1+TcrNT2 (●) was measured over 180 seconds in the presence or absent of 
1 mM unlabelled adenosine (○), (○) and (○) respectively. Figure shows a representative 
experiment in triplicate, and error bars represent ± SEM. F-test was determined by 
GraphPad Prism 8. 
First, uptake was measured applying 50 nM of [3H]-thymidine over 3 minutes, but 
this incubation time was not sufficient (Figure 7.11A), as a result of the low 
amount of radiolabel accumulated. Thus, we conducted the thymidine time 
course using an incubation time of 10 minutes. This showed that [3H]-thymidine 
at 50 nM was transported by L. mexicana-Cas9ΔNT1+TcrNT2 in a linear manner over a 
period of 10 minutes with an uptake rate of 0.0048 ± 0.0002 pmol. (107 cells) -1.s-
1 (Figure 7.11B), indicating that the transporter has not yet saturated at 50 nM 
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for 10 minutes. When compared to the parental cell lines L. mexicana-Cas9ΔNT1, 
the rate of transport of the L. mexicana-Cas9ΔNT1 expressing TcrNT2 over 3 min 
and 10 min were significantly increased (~ 6.5- and 6.2-fold; P < 0.001 by F-test, 
respectively). The uptake of 50 nM of [3H]-thymidine by promastigotes of L. 
mexicana-Cas9 was linear for at least 30 seconds, but with with a rate of only 
0.00042 ± 0.000003 pmol.(107 cells)-1.s-1 (Figure 7.11A). The rate of 50 nM of 
[3H]-thymidine uptake for 3 minutes and 10 minutes incubation by the three cell 
lines was not completely inhibited by addition of 1 mM unlabelled thymidine 
(Figure 7.11A and B). The L. mexicana-Cas9ΔNT1 transport rate was observed, 
albeit, the points of saturation overlap the ΔNT1 uptake rate, this means that 
the little uptake observed by the strain of ΔNT1 could be considered negligible. 
As the linear uptake was expressed for a long period, checking the affinity of the 
nucleosides’ transporter would be the next step, as done in the next section. 









































































Figure 7.11: [3H]-Thymidine transport was by L. mexicana-cas9, L. mexicana-Cas9ΔNT1 and L. 
mexicana-Cas9ΔNT1+TcrNT2 over 3 and 10 minutes. 
A) Transport of 50 nM of [3H]-thymidine by L. mexicana-cas9 (●), L. mexicana-Cas9ΔNT1 (●) 
and L. mexicana-Cas9ΔNT1+TcrNT2 (●) was measured over 180 seconds in the presence or 
absent of 1mM unlabelled thymidine (○), (○) and (○) respectively. B) Transport of 50 nM of 
[3H]-thymidine by L. mexicana-Cas9ΔNT1 (●) and L. mexicana-Cas9ΔNT1+TcrNT2 (●) was 
measured over 10 minutes in the presence or absent of 1 mM unlabelled thymidine (○) and 
(○) respectively. Symbols represent the average of triplicate determinations in a single 
representative experiment and error bars represent ± SEM. P < 0.001 by F-test. 
The application of 25 nM of [3H]-thymidine and an incubation time of 6 minutes   
within the linear phase permitted characterisation of the uptake of the 
thymidine in L. mexicana-Cas9ΔNT1 expressing TcrNT2. Figure 7.12 shows 
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representative inhibition curves for the competition of 25 nM of [3H]-thymidine 
transport by unlabelled thymidine. Thymidine was a strong inhibitor. Based on 
the Michaelis-Menten saturation plots (Figure 7.12), the value of Km was 0.156 ± 
0.017 μM and Vmax was 0.023 ± 0.002 pmol. (107 cells)-1.s-1 for thymidine (n=4). 
The Hill slope was consistently very close to -1, indicating that it was likely 
performed by a single transporting mechanism in L. mexicana-Cas9ΔNT1 + TcrNT2 
cells. Therefore, TcrNT2 is a high-affinity thymidine transporter when expressed 
in L. mexicana-Cas9ΔNT1 cells. This result is identical to the previous 
characterisations of this TcrNT2 in a different cell line, the T. brucei Lister 427 
procyclic form, which also indicated that TcrNT2 has very high-affinity for 
thymidine (Km = 0.223 μM)(Campagnaro et al., 2018b). 



































































Figure 7.12: Km and Vmax measurement for TcrNT2 upon expression by L. mexicana-Cas9ΔNT1 
cell lines. 
L. mexicana-Cas9ΔNT1 cells expressing TcrNT2 were incubated with 25 nM of [3H]-thymidine 
in the presence of increasing concentrations of unlabelled thymidine and a dose-dependent 
inhibition curve with Hillslope near -1 (inset) was observed. Conversion of the data into a 
Michaelis-Menten plot yielded a Km of 0.156 ± 0.017 μM and Vmax of 0.023 ± 0.002 pmol. (107 
cells)-1.s-1 (n=4). The figure shows one representative out of four independent experiments 
and error bars represent ± SEM. 
In section 7.2.4.2 it was shown that the L. mexicana-Cas9ΔNT1+TcrNT2 cells are 
more sensitive to some adenosine analogues. Thus, it is important to test the 
rate of uptake of [3H]-thymidine in the presence of these inhibitors. The data 
showed low affinity of the T. cruzi NT2 transporter for the adenosine analogues 
(Ki of 804 ± 2 μM for tubercidin and  Ki of 740 ± 39 μM for TH1003 in competition 
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with just 25 nM of [3H]-thymidine), as compared to the high affinity for 
thymidine (Km of 0.156 ± 0.017 μM) (Figure 7.13A). The study of Finley et al. 
(1988) indicated that the decreased ability of laboratory-generated tubercidin-
resistant clones of T. cruzi to transport radiolabelled tubercidin was associated 
with a decrease in the transport of thymidine and uridine. Although our results 
showed that tubercidin possesses only a low-affinity for the TcrNT2 transporter, 
the expression of this transporter did significantly increase sensitivity to 
tubercidin and its analogues. The incubation of L. mexicana-Cas9ΔNT1 + TcrNT2 
cells with 25 nM of [3H]-thymidine in presence of increasing concentrations of 
other thymidine analogues (Figure 7.13B), revealed that TcrNT2 has a high 
affinity for 2-thiothymidine and 4-thiothymidine (Ki of 3.21 ± 0.25 μM and Ki of 
2.83 ± 0.14, respectively), whereas it has a much lower affinity for 3’-
deoxythymidine with a Ki value of 385.7 ± 42.8 (Table 7.3). 2-thiothymidine and 
4-thiothymidine displayed almost similar Ki values to thymidine. The conversion 
of Ki values of 2-thiothymidine and 4-thiothymidine to the Gibbs free binding 
energy (ΔG0), shows that the difference in binding energy (δ(ΔG0)) between 
these analogues is 0.4 kJ/mol (ΔG0 of -31.3 KJ/mol for 2-thiothymidine and -31.7 
KJ/mol for 4-thiothymidine). However, both analogues were found to have lost 
more than 7 kJ/mL in Gibbs free energy of binding relative to thymidine, 
showing that the two keto group are involved in medium-strength interactions 
with the transporter (Table 7.3). Moreover, the 3’-hydroxygroup seems to 
engage in an even stronger interaction, judging by the δ(ΔG0) of 19.4 kJ/mol of 
3’-deoxythymidine with thymidine. 






























































































Figure 7.13: Affinity of TcrNT2 for thymidine and adenosine analogues. 
A) and B) 1x107 L. mexicana-Cas9ΔNT1+TcrNT2 cells were incubated with 25 nM of [3H]-
thymidine in presence of increasing concentrations of thymidine, 2-thiothymidine, 4-
thiothymidine, 3’-deoxythymidine, tubercidin and TH1003. 2 mM ice-cold unlabelled 
thymidine was used as a stop solution. Figure shows a representative out of 2-3 
independent experiments and error bars represent ± SEM. 
To find out more about the specificity of TcrNT2, the assessment of the effects 
of uridine analogues was performed for inhibition of the uptake of 25 nM of [3H]-
thymidine. From table 7.3 it is clear that TcrNT2 has high affinity towards 5-
fluoro-2’-deoxyuridine and 5-iodo-2’-deoxyuridine (Ki of 1.42 ± 0.12 μM and Ki of 
0.180 ± 0.036, respectively), with ~7.8-fold difference. When comparing uridine 
with these, the transporter has negligible affinity towards uridine (Ki of 162.5 ± 
7.6), with 114.4-fold difference for 5-fluoro-2’-deoxyuridine and 903-fold for 5-
iodo-2’-deoxyuridine. Substitutions at position 5 of the pyrimidine ring (Fluoro 
and Iodo) appear to be slightly favoured by the TcrNT2 transporter, yet 5-
bromouridine displayed quite low affinity (Ki = 30.9 µM). The latter observation 
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clearly shows that the 2’-hydroxy group is detrimental to high affinity binding by 
TcrNT2, hence the large differential between thymidine and uridine. 
From table 7.3, due to the comparison of the Ki values obtained for 5'-
deoxyuridine (964.5 μM) and uridine (162.5 μM), it was found that the 
transporter favours a hydroxyl group at the 5’-position of the ribose ring of the 
pyrimidine analogues (δ(ΔG0 = 4.2) uridine versus 5’-deoxyUrd). In conclusion, L. 
mexicana-Cas9ΔNT1 promastigotes express a TcrNT2 with a broad specificity for 
2’-deoxypyrimidines over other pyrimidines, which was not observed for LdNT1 
(Aronow et al., 1987; Vasudevan et al., 1998). Binding involves interactions with 
the pyrimidine keto groups, and with the 3’ and 5’ hydroxy groups; the sum of 
the individual interactions adds up to -7.2 + -7.5 + -19.5 + -4.2 = -38.4 kJ/mol, 
which is an extremely close match for the experimental ΔG0 of thymidine, -38.8 
kJ/mol. This occurs under the standard in vitro laboratory conditions. 
Table 7.3: Ki for pyrimidine nucleosides and adenosine analogues on the transport of [3H]-
thymidine by TcrNT2 into L. mexicana-Cas9ΔNT1. 
IC50 values obtained were converted to Ki based on the Km of TcrNT2. ΔG° represents the 
change in Gibbs free energy and δ(ΔG°) represents the change in ΔG° of the respective 
analogues with respect to ΔG° of thymidine. All the averages and standard deviations are 
based on at least three independent experiments in triplicate ± SEM. 






Thymidine 0.156 ± 0.017 -38.8 -- 4 
3’-deoxythymidine 385.7 ± 42.8 -19.5 -19.4 3 
2-thiothymidine 3.21 ± 0.25 -31.3 -7.5 3 
4-thiothymidine 2.83 ± 0.14 -31.7 -7.2 3 
Uridine 162.5 ± 7.6 -21.6 -17.2 3 
5-fluoro-2’-deoxyUridine 1.42 ± 0.12 -33.4 -5.5 3 
5-iodo-2’-deoxyUridine 0.180 ± 0.036 -38.5 -0.3 3 
2-thioUridine 186.7 ± 24.0 -21.3 -17.6 3 
5-bromoUridine 30.9 ± 3.2 -25.7 -13.1 3 
4-thioUridine 165.9 ± 10.6 -21.6 -17.3 3 
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5’-deoxyUridine 964.5 ± 53.9 -17.2 -21.6 3 
Adenosine1 1560 ± 60 -15.75 -22.2 3 
Tubercidin 804.2 ± 1.9 -17.7 -21.2 2 
TH1003 740.2 ± 39.1 -17.9 -21.0 2 
    Value highlighted in bold represents the Km for thymidine. ΔG
0 was calculated at 37°C. 
      1. From Campagnaro et al. Biochim Biophys Acta 2018. 
 The heterologous expression of TcrNB2 in L. mexicana-
Cas9ΔNT1 
The study by (Campagnaro et al., 2018b) showed that four ENT genes TcrNB1, 
TcrNB2, TcrNT1 as well as TcrNT2 are encoded by T. cruzi. Despite getting the 
evidence of successfully cloning and characterising most of T. cruzi ENT 
transporters, the research reveals the failure in characterising the TcrNB2 
transporter’s activity. However, the research suggested, but based on 
phylogenetic analysis only, that TcrNB2 may function as a low affinity purine 
nucleobase transporter, given its sequence and predicted structural similarities 
to Leishmania NT4 transporters. Thus, this study, which is a follow-on of the 
previous work by (Campagnaro et al., 2018b), through cloning and functionally 
expressing TcrNB2 in L. mexicana-Cas9ΔNT1 cell lines and assesses its transporter 
activity. 
 PCR confirmation of the existence of TcrNB2 in L. mexicana-Cas9ΔNT1 
The T. cruzi putative nucleobase transporter TcrNB2 TcCLB.506773.50 was 
amplified by PCR from pHDK223 using HDK1537 as forward and HDK1538 reverse 
primers. The pNUS-HcN plasmid was used to express the TcrNB2 gene in L. 
mexicana-Cas9ΔNT1. BglII and XhoI restriction enzymes were used to digest the 
pNUS-HcN plasmid and the TcrNB2 gene and T4 DNA Ligase was used to perform 
the ligation, generating plasmid pHDK271 (Figure 7.14). The TcrNB2 gene 
integration into the pHDK271 was verified by a diagnostic restriction digest with 
restriction enzymes BglII and XhoI. As shown in figure 7.15A, TcrNB2 is 
represented by a band of ~1.4 kb, while ~6.2 kb represents the empty pHDK271 
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vector. Following the transfection of the episomal plasmid pHDK271 into L. 
mexicana-Cas9ΔNT1, PCR was applied in the verification of the presence of 
pHDK271 in positive clones, using HDK1537 as a forward primer for the TcrNB2 
gene and HDK340 as a reverse primer for the pNUS-HcN plasmid (Figure 7.15B). 
 
Figure 7.14: Plasmid map of pHDK271 vector for the expression of T. cruzi NB2 transporter 
(TcrNB2) in L. mexicana-Cas9ΔNT1 cell lines. 
 
Figure 7.15: Restriction digest products for pHDK271 plasmid and confirmation of the 
presence of TcrNB2 gene into L. mexicana-Cas9ΔNT1 cells after transfection. 
A) Restriction digest products for pHDK271 plasmid with BglII and XhoI to release TcrNB2 
gene. L: 1 kb DNA ladder (Promega); 1: Digested plasmid by BglII and XhoI to release 
TcrNB2 (1347 bp); 2: Undigested plasmid for pHDK271. B) Confirmation of the existence of 
TcrNB2 gene into L. mexicana-Cas9ΔNT1 strain after transfection by using HDK1537 as 
forward primer for TcrNB2 gene and HDK340 as a reverse primer for pNUS-HcN plasmid. L: 
1kb DNA Ladder (Promega); 1: Clone 1; 2: Clone 2; 3: Clone 3; 4: Non-transfected control 
(gDNA of L. mexicana-Cas9ΔNT1). 
 qRT-PCR and growth rate of TcrNB2 in L. mexicana-Cas9ΔNT1 
Three clones of the L. mexicana-Cas9ΔNT1+TcrNB2 and L. mexicana-Cas9ΔNT1, and its 
parental cell line (L. mexicana-Cas9), were assessed on their growth in HOMEM 
medium supplemented with 10% FBS and incubated at 25 ºC. The cell densities 
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were determined every 24 h (Figure 7.16). The study indicated that the knocking 
out of LmexNT1 in L. mexicana-Cas9 and the knocking in of TcrNB2 into L. 

































Figure 7.16: The growth rates of L. mexicana-Cas9, L. mexicana-Cas9ΔNT1 and three clones of 
L. mexicana-Cas9ΔNT1 expressing TcrNB2 on HOMEM medium supplemented with 10% FBS. 
The cells were seeded at a density of 1×105 cells/mL, and cell densities were determined 
every 24 h. Each data point in this result represents the mean of two similar independent 
repeats from separate cultures. 
To quantify the levels of expression of TcrNB2 gene in L. mexicana-Cas9ΔNT1 cells, 
qRT-PCR was undertaken compared to that in the control cells. All three clones 
expressing TcrNB2 in L. mexicana-Cas9ΔNT1 promastigotes increased the mRNA 
levels compared to the control L. mexicana-Cas9ΔNT1 (15-fold, 21.9-fold and 
18.9-fold; P < 0.001, respectively) (Figure 7.17). 





















































































Figure 7.17: The expression levels of TcrNB2 gene in L. mexicana-Cas9ΔNT1 compared to the 
control (L. mexicana-Cas9ΔNT1) determined by qRT-PCR. 
Levels were corrected against the expression level of the housekeeping gene (L. mexicana 
GPI8). The presented results are the average of 3 cDNA each performed in triplicates and 
error bars are ± SEM. *** P < 0.001. P values were measured by unpaired Student’s T-test. 
Through applying the Alamar blue drug sensitivity assay, the EC50 values of 
synthesised tubercidin analogues were determined by screening for their 
inhibitory action against the L. mexicana-Cas9, L. mexicana-Cas9ΔNT1 and L. 
mexicana-Cas9ΔNT1+TcrNB2. Pentamidine and tubercidin were used as controls. The 
results are presented in the table below. 
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 Drug sensitivity assay with adenosine analogues and 5-FU 
Table 7.4:The EC50 sensitivity values of L. mexicana-cas9, L. mexicana-Cas9ΔNT1 and L. mexicana-Cas9ΔNT1+TcrNB2 promastigotes to various adenosine analogues, 
obtained from drug sensitivity assay. EC50 are shown as averages in µM (± SEM) of at least 3 independent determinations. Pentamidine is a standard drug used 
as control in this assay. 
Adenosine 
analogues 
L. mexicana-Cas9 L. mexicana-Cas9ΔNT1 L. mexicana-Cas9ΔNT1+TcrNB2 
EC50± SEM (µM) EC50± SEM (µM) RF vs Cas9 P value vs Cas9 EC50± SEM (µM) RF vs ΔNT1 P value vs ΔNT1 
FH3141 0.834 ± 0.128 16.1 ± 0.70 19.3 P < 0.001 14.4 ± 3.36 1.12 P > 0.05 
FH3143 0.098 ± 0.015 1.07 ± 0.16 10.9 P < 0.01 1.18 ± 0.21 0.91 P > 0.05 
FH3147 9.30 ± 1.53 >100 ± 0.00 10.8 P < 0.001 >100 ± 0.00 1.00 P > 0.05 
FH3167 0.227 ± 0.094 9.95 ± 1.78 43.8 P < 0.01 10.1 ± 1.15 0.98 P > 0.05 
FH3169 0.345 ± 0.108 2.98 ± 1.02 8.64 P > 0.05 2.86 ± 0.47 1.04 P > 0.05 
FH8517 3.23 ± 0.679 10.6 ± 1.72 3.27 P < 0.05 13.3 ± 2.75 0.80 P > 0.05 
JB588 0.570 ± 0.07 9.24 ± 0.34 16.2 P < 0.001 8.41 ± 0.37 1.10 P > 0.05 
TH1003 0.166 ± 0.012 3.37 ± 0.13 20.3 P < 0.001 3.90 ± 0.48 0.86 P > 0.05 
FH8505 44.3 ± 1.5 51.8 ± 5.82 1.17 P > 0.05 38.1 ± 3.83 1.36 P > 0.05 
FH6367 1.27 ± 0.3 1.93 ± 0.32 1.52 P > 0.05 1.99 ± 0.82 0.97 P > 0.05 
FH7429-UP 9.31 ± 0.483 10.6 ± 0.41 1.14 P > 0.05 4.61 ± 0.89 2.30 P < 0.01 
Tubercidin 0.811 ± 0.295 37.7 ± 7.52 46.5 P < 0.01 27.6 ± 4.9 1.36 P > 0.05 
Pentamidine 0.861 ± 0.109 1.28 ± 0.18 1.49 P > 0.05 0.39 ± 0.0487 3.32 P < 0.01 
The P values show the level of significance of the sensitivity of the analogues have on the cell lines. The drugs in bold have a significantly different level of sensitivity 
on the cells. P values were determined by unpaired Student’s T-test: Not significant P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001. RF: resistance factor in comparison 
to Cas9 (L. mexicana-cas9) and ΔNT1 (L. mexicana-Cas9ΔNT1); SEM: standard error of mean. 
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In general, apart from FH7429-UP, the L. mexicana-Cas9ΔNT1+TcrNB2 cell lines did 
not indicate any difference in the EC50 values when compared to L. mexicana-
Cas9ΔNT1 cells (P > 0.05) (Table 7.4). In contrast, significant differences in the 
EC50 values of 5-FU and pentamidine were obtained in the assessment of L. 
mexicana-Cas9ΔNT1+TcrNB2 clonal derivatives when compared to the parental cells 
L. mexicana-Cas9ΔNT1 (Figure 7.18). The sensitivity of L. mexicana-Cas9ΔNT1+TcrNB2 
clone 2 and 3 to 5-FU significantly increased with mean an EC50 values of 9.96 ± 
0.36 µM and 12.8 ± 3.3 µM, respectively. However, there was no significant 
difference in the sensitivity of L. mexicana-Cas9ΔNT1+TcrNB2 clone 1 to 5-FU with 
mean an EC50 value of 17.7 ± 3.0 µM when compared to L. mexicana-Cas9ΔNT1, 
which displayed an EC50 value of 29.4 ± 3.5 µM. All clonal derivatives of L. 
mexicana-Cas9ΔNT1+TcrNB2 (clones 1-3) were significantly sensitised to 
pentamidine, compared with the parental cell lines. The link between TcrNB2 
heterologous expression and the LmexNT1 deletion impacts 5-FU and 
pentamidine efficacy against L. mexicana-WT is still unclear. However, NT1 is 
the main pyrimidine salvage transporter in L. mexicana, taking up uridine, 
thymidine and cytidine (Vasudevan et al., 1998)  and its deletion could well lead 
to an increase in the expresson other elements of pyrimidine salvage and/or 
biosynthesis. The data suggest that TcrNB2 might be able to mediate the uptake 
of 5-FU and pentamidine but if so, only small amounts, considering the very 










































































































































































































Ibrahim Abdullah Alfayez                               Chapter 7                                235 
 
Figure 7.18: Alamar blue drug sensitivity assay of expression of TcrNB2 in L. mexicana-
Cas9ΔNT1 clones 1-3 using 5-fluorouracil (A) and pentamidine (B). 
The mean of three independent repeats is shown ± SEM in µM. * P < 0.05 and ** P < 0.01 
were determined by unpaired Student’s T-test. 
 Transport studies with various substrates 
The transport assay of each substrate by L. mexicana-Cas9ΔNT1+TcrNB2 was 
investigated in order to determine which substrate TcrNB2 transports. The 
expression of TcrNB2 in L. mexicana-Cas9ΔNT1 did not change the rate of 50 nM of 
[3H]-adenosine transport in comparison to the parental cell lines L. mexicana-
Cas9ΔNT1 (P > 0.05 by F-test; n=1; Figure 7.19A). The addition of 1 mM unlabelled 
adenosine completely inhibited the uptake of [3H]-adenosine in all three cell 
lines, showing it is saturable. The uptake of 100 nM of [3H]-adenine by L. 
mexicana-Cas9ΔNT1+TcrNB2 cells was investigated to establish whether adenine is a 
substrate for the TcrNB2 transporter. [3H]-Adenine uptake was linear for 15 
seconds in L. mexicana-Cas9 promastigotes, with a rate of 0.082 ± 0.005 
pmol.(107 cells)-1.s-1 (r2=0.99; n=1; Figure 7.19B). The results show that there 
was no significant difference in the transport of 100 nM of [3H]-adenine between 
the L. mexicana-Cas9ΔNT1+TcrNB2 and L. mexicana-Cas9ΔNT1 strain (P > 0.05 by F-
test), with a rate of 0.062 ± 0.003 and 0.089 ± 0.007 pmol.(107 cells)-1.s-1, 
respectively; (n=1); in both strains [3H]-adenine transport was completely 
inhibited in the presence of 250 μM unlabelled adenine. 
In section 7.2.5.3, it was clear that introducing TcrNB2 transporter in L. 
mexicana-Cas9ΔNT1 promastigotes sensitised the cells to 5-FU when comparing it 
with the parental cells (n=3; P < 0.01). Therefore, to find out if introducing 
TcrNB2 can cause an increase in uracil transport, we investigated the uptake of 
0.1 μM of [3H]-uracil in L. mexicana-Cas9ΔNT1+TcrNB2. However, no difference was 
observed regarding the transport of 0.1 μM of [3H]-uracil between the L. 
mexicana-Cas9ΔNT1+TcrNB2 and L. mexicana-Cas9ΔNT1 cells (P > 0.05 by t-test; n=2; 
Figure 7.19C). The transport of 0.1 μM of [3H]-uracil was almost identical in L. 
mexicana-Cas9ΔNT1+TcrNB2 and L. mexicana-Cas9ΔNT1 cells, with a rate of 0.0011 ± 
0.00030 and 0.00099 ± 0.00026 pmol. (107 cells)-1.s-1 (n=2), respectively. 
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L. mexicana-Cas9 + 250µM ADE
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Figure 7.19: [3H]-Adenosine, [3H]-Adenine and [3H]-Uracil transport by L. mexicana-Cas9, L. 
mexicana-Cas9ΔNT1 and L. mexicana-Cas9ΔNT1+TcrNB2. 
A) Transport of 0.05 μM of [3H]-adenosine by L. mexicana-cas9 (●), L. mexicana-Cas9ΔNT1 (●) 
and L. mexicana-Cas9ΔNT1+TcrNB2 (●) was measured over 180 seconds in the presence or 
absent of 1 mM unlabelled adenosine (○), (○) and (○) respectively. B) Transport of 0.1 μM of 
[3H]-adenine by L. mexicana-cas9 (●), L. mexicana-Cas9ΔNT1 (●) and L. mexicana-Cas9ΔNT1 + 
TcrNB2  (●)  was measured over 15 seconds in the presence or absent of 250 μM unlabelled 
adenine (○), (○) and (○) respectively. C) Transport of 0.1 μM of [3H]-uracil by L. mexicana-
cas9 (●), L. mexicana-Cas9ΔNT1 (●) and L. mexicana-Cas9ΔNT1 + TcrNB2 (●) was measured over 
180 seconds in the presence or absent of 1 mM unlabelled uracil (○), (○) and (○) 
respectively. Symbols represent the average of triplicate determinations in a single 
representative experiment and error bars represent ± SEM. F-test was determined by 
GraphPad Prism 8. 
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 The introduction of the T. cruzi NB2 in Lmex-5FURes 
promastigotes 
In section 7.2.5.3, it was observed that introduction of TcrNB2 transporter in L. 
mexicana-Cas9ΔNT1 strain significantly increased the sensitisation to 5-
fluorouracil compared with the parental cells. It was therefore decided to 
transfect TcrNB2 transporter into 5-FU resistant cell lines of the L. mexicana 
promastigotes as well as determine the sensitivity of Lmex-5FURes cell lines 
expressing of TcrNB2 to 5-FU in vitro. 
 PCR and qPCR confirmation of the presence of TcrNB2 in in Lmex-
5FURes promastigotes 
A plasmid construct used to express the TcrNB2 gene in Lmex-5FURes, pHDK271 
(Figure 7.14) had been used previously for the expression of TcrNB2 in L. 
mexicana-Cas9ΔNT1. Following transfection of this episomal plasmid pHDK271, 
which was based on the pNUS-HcN plasmid, into the Lmex-5FURes strain, PCR 
was applied to verify the existence of pHDK271 in positive clones, using HDK1537 
as forward primer for the TcrNB2 gene and HDK340 as reverse primer for the 
pNUS-HcN plasmid (Figure 7.20). 
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Figure 7.20: Confirmation of the presence of TcrNB2 gene into Lmex-5FURes strain after 
transfection by using HDK1537 as forward primer for TcrNB2 gene and HDK340 as reverse 
primer for pNUS-HcN plasmid. 
L: 1kb DNA Ladder (Promega); 1: Clone 1; 2: Clone 2; 3: Clone 3; 4: Non-transfected control 
(gDNA of Lmex-5FURes). 
Quantitative RT-PCR was performed to quantify the levels of TcrNB2 gene 
expression in Lmex-5FURes cells compared to that in the control cell lines. All 
three clones 1, 2 and 3 of expressing of TcrNB2 gene in Lmex-5FURes 
significantly increased the expression levels compared to the control Lmex-





































































Figure 7.21: The expression levels of TcrNB2 gene in Lmex-5FURes and compared to the 
control (Lmex-5FURes) determined by qRT-PCR. 
Levels were corrected against the expression level of the housekeeping gene (L. mexicana 
GPI8). The presented results are the average of 2 cDNA each performed in triplicates, and 
error bars are ± SEM. *** P < 0.001 by unpaired student’s T-test. 
 Drug sensitivity assay with 5-FU,pentamidine and diminazene 
The sensitivity of the Lmex-5FURes and the three TcrNB2 clones in the Lmex-
5FURes parasites to 5-fluorouracil, pentamidine and diminazene aceturate was 
investigated using the usual Alamar blue assay (Figure 7.22). Pentamidine and 
diminazene were included as an unrelated control drug that does not act on the 
purine and pyrimidine system. Expression of TcrNB2 gene did not lead to 
increasing the sensitivity to 5-FU in the Lmex-5FURes+TcrNB2 clones 1-3 (n= 4; P > 
0.05). In contrast, the results a significant increase was observed in the 
sensitivity of Lmex-5FURes+TcrNB2 clones 1-3 to pentamidine in comparison with 
the Lmex-5FURes (by 2.3-fold, 2-fold and 2.2-fold, respectively; n=4). The 
expression of TcrNB2 in the three Tbb-5FURes clones also significantly increased 
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sensitivity to diminazene compared to Tbb-5FURes (6.8 ± 0.3 µM), with an 













































































































































































































































































Figure 7.22: Alamar blue drug sensitivity assay of expression of TcrNB2 gene in Lmex-
5FURes clones 1-3 by using 5-fluorouracil (A), pentamidine (B) and diminazene aceturate 
(C). 
The mean of four independent repeats is shown ± SEM in µM. ** P < 0.01 and *** P < 0.001 by 
unpaired student’s T-test. 
 The introduction of TcrNB2 transporter in the T. b. brucei 
B48 strain 
It has been previously shown that the introduction of TcrNB2 transporter in the 
L. mexicana-Cas9ΔNT1 and Lmex-5FURes lead to increasing the sensitisation to 
pentamidine (see section 7.2.5.3 and 7.2.6.2).  Thus, the purpose of this section 
was to examine the effect of expression of TcrNB2 in T. b. brucei clone B48 
parasites, a multi-drug resistant B48 cell lines, could cause changes to the 
sensitivity to pentamidine by the introduction of the TcrNB2 transporter. 
 PCR confirmation of the linearity of plasmid and integration of 
TcrNB2 in T. b. brucei B48 strain 
A plasmid construct used to express TcrNB2 genes in the T. b. brucei B48 strain, 
pHDK223 (Figure 7.23) had previously been generated by Dr. Gustavo 
Campagnaro (Prof Harry de Koning Lab, University of Glasgow). Following 
transfection of the NotI-linearised pHDK223 plasmid, based on pHD1336 plasmid 
(Biebinger et al., 1997), into the T. b. brucei B48 strain, PCR was applied to 
verify the linearisation of the circular pHDK223 vector and the integration of the 
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TcrNB2 gene in positive clones. The presence of the expected products, ~1.4 kb 
for the integration, and lack of band for the linearity of the circular pHDK223 
plasmid was confirmed by running the PCR products on 1% of agarose gel to be 
seen visually under UV light (Figure 7.24). 
 
Figure 7.23: Plasmid map of pHDK223 vector for the heterologous expression of TcrNB2 
gene in B48. 
 
Figure 7.24: PCR conformation for the linearisation of the circular pHDK223 plasmid and the 
integration of TcrNB2 gene into B48 strain after transfection. 
A) Confirmation of the integration of TcrNB2 gene into B48 strain after transfection by using 
HDK1409 as forward primer for TcrNB2 gene and HDK335 as reverse primer for pHD1336 
plasmid. L: 1kb DNA Ladder (Promega); 1: Clone 1; 2: Clone 2; 3: Clone 3; 4: Non-
transfected control (gDNA from B48 strain). B) Confirmation of the linearization of pHDK223 
vector into B48 strain after transfection by using HDK535 as forward primer for pHD1336 
plasmid and HDK1410 as reverse primer for TcrNB2 gene. L: 1kb DNA Ladder (Promega); 1: 
Clone 1; 2: Clone 2; 3: Clone 3; 4: Undigested PHDK223; 5: negative control (No gDNA). 
 qRT-PCR confirmation and growth rate of TcrNB2 in B48 strain 
The level of gene expression for B48+TcrNB2 clones 1-3 was analysed and compared 
to the control cell line by qRT-PCR (Figure 7.25). The results showed that TcrNB2 
expression in B48+TcrNB2 clone 2 was at 239-fold (P < 0.001), while the results in 
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B48+TcrNB2 clone 3 increased to 139-fold (P < 0.001) in relation to the control cell 
lines, but B48+TcrNB2 clone 1 recorded the highest expression level, amounting to 



























































Figure 7.25: The expression levels of TcrNB2 gene in B48 cells and compared to the control 
(B48) determined by qRT-PCR. 
Levels were corrected against the expression level of the housekeeping gene (T. b. brucei 
GPI8). The presented results are the average of 2 cDNA each performed in triplicates, and 
error bars are ± SEM. *** P < 0.001 by unpaired student’s T-test. 
Figure 7.26 shows the analysis of the growth of B48 parasites and B48+TcrNB2 
clones 1-3 was assessed in HMI-9 medium complemented with 10% FBS and cell 
densities were determined every 24 h. The result show that there was no effect 
on the growth of B48+TcrNB2 clones 1-3 when TcrNB2 genes was introduced in 
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Figure 7.26: The growth curve of B48 cell lines and B48 expressing TcrNB2 clones 1-3 on 
HMI-9 medium supplemented with 10% FBS. 
The cells were seeded at the density of 1×104 cells/mL, and cell densities were determined 
every 24 h. Cells were passaged every 48 h, when the growth had reached between 1.5 and 
2 x 106 cells/mL. Each data point in this result represents the mean of two similar 
independent repeats. Error bars are Standard Deviation; when not shown the bar falls within 
the symbol. 
 Drug sensitivity assay with pentamidine and diminazene 
As shown in Figure 7.27, the Alamar blue assay was used assess the susceptibility 
of the B48 resistant cell lines expressing TcrNB2. As expected and well-
documented (Bridges et al., 2007), the sensitivity of B48 parasites to 
pentamidine was strongly decreased (Resistance Factor (RF) = 104; n=4; P < 
0.0001)) compared to the Tbb-s427 wild-type. Results showed a small but 
significant increase in the sensitivity of B48+TcrNB2 clones 1, 2 and 3 to 
pentamidine (0.47 ± 0.04, 0.44 ± 0.03 and 0.50 ± 0.009 µM; respectively) 
compared with the parental cells (0.60 ± 0.02 µM; n=4; P < 0.001 by unpaired 
Student’s T-test). The susceptibility of clone 1, 2 and 3 to pentamidine was 
increased 1.25-fold, 1.35-fold and 1.18-fold, respectively. Bloodstream B48 
trypanosomes that expressed TcrNB2 exhibited a significant increase in the 
sensitivity to diminazene when compared to the parental cells. The B48+TcrNB2 
clones 1-3 displayed increased sensitivity to diminazene (2.2-fold, 3.1-fold and 
2.3-fold more sensitive to diminazene aceturate, respectively; n=4; P < 0.001) 































































































































Ibrahim Abdullah Alfayez                               Chapter 7                                243 
 
Figure 7.27: Alamar blue drug sensitivity assay of expression of TcrNB2 gene in B48 clones 
1-3, B48 strain and Tbb-s427WT by using pentamidine (A) and diminazene aceturate (B). 
The mean of four independent determinations is shown ± SEM. * P < 0.05; ** P < 0.01; *** P < 
0.001 by unpaired student’s T-test. 
 Discussion 
The activities of purine and pyrimidine transport have been characterised in 
detail, and the main observation is that all purine and pyrimidine transporters 
identified, to date, in protozoa are members of the ENT family, which has 
orthologues in many species ranging from prokaryotes to metazoa (De Koning, 
2007; Bellofatto, 2007; Acimovic and Coe, 2002; Baldwin et al., 2004; de Koning 
and Diallinas, 2000; De Koning et al., 2005; Ali et al., 2013a). However, the 
presence of other gene families has been suggested (De Koning, 2007; 
Campagnaro et al., 2018a; Balcazar et al., 2017; Bellofatto, 2007). For 
understanding the efficacy of anti-parasite chemotherapy the cloning and 
characterising of purine and pyrimidine transporters has been very important (de 
Koning and Jarvis, 1999; Alzahrani et al., 2017). The research carried out by 
Campagnaro et al. (2018b), involved characterising the four ENT family of T. 
cruzi. T. cruzi cannot synthesise its own purines and, hence, relies on the 
salvage from its hosts (Campagnaro and de Koning, 2020). This research study 
cloned four T. cruzi ENT genes: TcrNB1, TcrNB2, TcrNT1 and TcrNT2 in order to 
investigate the functionality of these transporters. The research showed that 
TcrNB1 had a high affinity for hypoxanthine and guanine (Km 0.093 μM and Ki 
0.122 μM, respectively). TcrNT1 displayed a high affinity in the transport of 
inosine and guanosine (Km 1.0 μM and Ki is 0.92 μM, respectively). Additionally, a 
high affinity for thymidine (Km of 0.223 μM) was exhibited by TcrNT2. T. cruzi 
NT2 transporter is the only known dedicated thymidine transporter in protozoa 
described to date. TcrNB2 remained an as yet uncharacterised transporter, as no 
substrate was identified. Notably, this was the first study to report the cloning 
of any T. cruzi purine and pyrimidine transporters (Campagnaro et al., 2018b). 
The five genes involved in the transport of purines and pyrimidines in Leishmania 
include, NT1.1, NT1.2, NT2, NT3 and NT4 (Campagnaro and de Koning, 2020). 
The function of Nucleoside transporter 1 (NT1) is to mediate the adenosine and 
pyrimidine nucleosides (uridine, thymidine and cytidine) uptake. Nucleoside 
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Transporter 2 (NT2) is involved in transporting the 6-oxopurine nucleosides 
inosine, guanosine and xanthosine (Boitz et al., 2012; Carter et al., 2001). More 
importantly, of the two L. major and L. mexicana NT1 sequences that are 
similar, NT1.1 and NT1.2, NT1.1 was recently shown by Alzahrani et al. (2017) to 
be more sensitive to inhibition by uracil. As a result, it was renamed uridine‐
uracil transporter 1 (UUT1); it was proposed that NT1.2 would carry the title of 
NT1 in the species. NT1 and NT2 transporters also serve as the main transporters 
for the transport of the adenosine analogue tubercidin and the inosine analogue 
formycin B, respectively (Landfear, 2013; Ortiz et al., 2007). Nucleobase 
transporter 3 (NT3) and nucleobase transporter 4 (NT4) transporters are purine 
nucleobase transporters (Landfear, 2011). NT3 is the main carrier for purine 
nucleobases at physiological pH and, consequently, displays high rates of 
adenine, guanine, xanthine and hypoxanthine transport (Ortiz et al., 2007; Ortiz 
et al., 2009a). Apart from NT4 being the main purine nucleobase transporter in 
intracellular amastigotes, it is also able to transport adenine, albeit with low 
affinity (Ortiz et al., 2007; Ortiz et al., 2009a). 
The technology of genome editing, particularly, by clustered regularly 
interspaced short palindromic repeats (CRISPR), has been developed for use in 
parasites such as L. mexicana (Beneke et al., 2017), L. donovani (Zhang and 
Matlashewski, 2015), L. major (Sollelis et al., 2015), T. brucei (Rico et al., 
2018), T. cruzi (Peng et al., 2015; Lander et al., 2015), T. gondii (Sidik et al., 
2016), Plasmodium spp. (Ghorbal et al., 2014; Zhang et al., 2014) and C. parvum 
(Vinayak et al., 2015). CRISPR-Cas9 is a system of new technology for precise 
cleavage of double stranded DNA (dsDNA) by a Cas9 nuclease with sequence-
specificity determined by a single-guide RNA (sgRNA)(Beneke et al., 2017; 
Beneke and Gluenz, 2019). In our study, we applied the system of CRISPR-Cas9 
that was successfully developed by Beneke et al. (2017) in L. mexicana 
promastigotes, to help in generating a double knockout of LmexNT1. The pNUS-
HcN plasmid was used to heterologously express TcrNT2 and TcrNB2 transporters 
in L. mexicana-Cas9 promastigotes and maintained episomally in the presence of 
G418 (neomycin) (Tetaud et al., 2002). We show that deletion of the LmexNT1 
locus in L. mexicana-Cas9 promastigotes by using CRISPR-Cas9 system completely 
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abolished adenosine and thymidine uptake. Moreover, it became highly resistant 
to tubercidin (and its analogues) and to 5-fluoro-2’-deoxyuridine. 
In a phylogenetic tree of T. cruzi ENT transporters with other trypanosomatids, 
TcrNT2 transporter was grouped close to the Leishmania NT1 transporter. As 
such, it would be most likely to transport pyrimidine nucleosides as well as 
adenosine due to possessing structural similarity to the Leishmania NT1 
(Campagnaro et al., 2018b). The uptake of thymidine in T. brucei BSF is 
mediated by P1-type transporters with moderate affinity (Ki = 44 µM) (de Koning 
and Jarvis, 1999; Ali et al., 2013a), while LmexNT1 transporter mediates the 
uptake of thymidine in L. mexicana and its more efficient to transport thymidine 
than the P1 carrier in T. brucei BSF (Km value of ~11 µM) (Alzahrani et al., 2017). 
We functionally characterised the transport activity of TcrNT2 in L. mexicana-
Cas9ΔNT1 promastigotes. The findings confirm that TcrNT2 has a very high affinity 
for thymidine with (Km of 0.156 ± 0.017 μM) and are almost identical to the 
previous characterisations of this TcrNT2 transporter in T. brucei procyclic 
TbNBT-KO cells, which likewise found that TcrNT2 possess a high-affinity for 
thymidine (Km of 0.223 ± 0.007 μM) (Campagnaro et al., 2018b). The T. cruzi 
parasites might need a very high affinity 2′‐deoxypyrimidines transporter with Km 
of 0.156 μM for thymidine in L. mexicana-Cas9ΔNT1 cells and Km of 0.223 μM for 
thymidine in T. brucei procyclic TbNBT-KO cells (Campagnaro et al., 2018b). 
Moreover, Caradonna et al. (2013) observe that T. cruzi may require salvage 
pyrimidines originating from the host. A decline in production of pyrimidine 
within the host cells disturbs the intracellular development of T. cruzi 
amastigotes challenges the overall idea of the inessentiality of pyrimidine 
salvage via the trypanosomatids (Ali et al., 2013b; Liu et al., 2006). Further, we 
kinetically identified the characteristics of the transport activity of the T. cruzi 
NT2 transporter in L. mexicana-Cas9ΔNT1 promastigotes. The outcomes show that 
2-thiothymidine and 4-thiothymidine displays almost similar Ki values (Ki of 3.21 
μM for 2-thiothymidine and Ki of 2.83 μM for 4-thiothymidine) to thymidine 
(Table 7.3). 
The Alamar Blue assay enabled the identification of a few nucleoside analogues 
with potent antiprotozoal activity. L. mexicana-Cas9ΔNT1 expressing TcrNT2 cells 
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was more sensitive to tubercidin (and its analogues) and 5-fluoro-2’-
deoxyuridine (pyrimidine analogue). Transport assay with radiolabelled 
thymidine and adenosine showed that the introduction of TcrNT2 in L. mexicana-
Cas9ΔNT1 restored [3H]-thymidine transport, whereas the uptake rate of [3H]-
adenosine did not change when compared to the parental cells (L. mexicana-
Cas9ΔNT1). Nevertheless, the cells were sensitive to the analogues of adenosine as 
well as tubercidin although the TcrNT2 transporter displayed only low affinity 
for them, with high Ki values (Ki 804 ± 2 μM for tubercidin and Ki 740 ± 39 μM for 
TH1003). At the C7 position, TcrNT2 transporter could not recognise any 
additional group of the purine since the low-affinity for tubercidin and TH1003 
were nearly identical. As a result, we conclude that the addition of halogens to 
the C7 position does not change the transporter interaction process, but the 
presence of a larger additional group may make it more unfit for transport owing 
to its size. Although previously it was thought that a thymidine transporter 
(TcrNT2) mediated the uptake of tubercidin (Finley et al., 1988), the low affinity 
of TcrNT2 for tubercidin analogues seems to make this unlikely. However, the 
expression of the TcrNT2 transporter did influence the sensitivity to tubercidin 
as well as its analogues in vitro. A previous report indicated the presence of at 
least three mechanisms of nucleoside transportation in T. cruzi: one for 
pyrimidines and tubercidin, one for thymidine with no affinity for tubercidin, 
and one for adenosine and inosine. Notably, the tubercidin-resistant T. cruzi 
strains used in that study were created by exposure of parasites to ionising 
radiation, which may have resulted in the mutations in other mechanisms of 
transportation as well (Finley et al., 1988; Nozaki and Dvorak, 1993). 
In addition to TcrNT2, the TcrNB2 transporter (TcCLB.506773.50) was cloned 
from T. cruzi and was studied through expression of the gene in L. mexicana-
Cas9ΔNT1 promastigotes. The advantage of using L. mexicana-Cas9ΔNT1 cells over 
the previous work in T. brucei PCF TbNBT-KO cells by Campagnaro et al. 
(2018b); L. mexicana-Cas9ΔNT1 cells has completely lost the adenosine transport 
activity by about ~98% while T. brucei PCF TbNBT-KO cells has still maintaining 
the adenosine transport activity especially via P1-type transporters. Transport 
assays with the TcrNB2-expressing cells used 3[H]-adenosine, [3H]-adenine and 
[3H]-uracil. Unfortunately, we are not able to determine the substrate for 
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TcrNB2 as there was no significant uptake of any of the three substrates. PCR 
and qRT-PCR techniques were used to confirm the presence as well as expression 
of TcrNB2 in the L. mexicana-Cas9ΔNT1 cell lines. There are four possible reasons 
for this outcome; firstly, TcrNB2 is an intracellular transporter. As a result, it 
transports substrates within the cell, and this cannot be measured by offering 
substrate to intact cells. Secondly, TcrNB2 is not a functional transporter. Next, 
it may be because of TcrNB2 is not correctly routed to the L. mexicana-Cas9 
cells plasma membrane, or unstable. Lastly, TcrNB2 does not transport purine or 
pyrimidine. According to Campagnaro et al. (2018b), they suggest that the 
similarities in sequence and structure of TcrNB2 and LmjNT4 indicates that 
TcrNB2 should be expected to have a medium-to-low affinity for purine 
nucleobases. Moreover, the high level of adenine transport in L. mexicana-
Cas9ΔNT1 cells could easily mask any adenine uptake mediated by the TcrNB2 
transporter, especially if TcrNB2 presents low affinity for its substrates. 
Therefore, we highly recommended the heterologous expression of TcrNB2 in the 
L. mexicana-Cas9ΔNT3 cell lines in order to determine whether adenine is a 
substrate for TcrNB2. The expression of a tagged version of TcrNB2 and its 
immunolocalization could show whether it is present in the cellular membrane 
or not and help to explain why we have been unable to identify its substrate. 
Nitroimidazole benznidazole and nitrofurane nifurtimox, the drugs that treat the 
Chagas’ disease, have been approved by the FDA to be the first-line drugs to 
suppress the parasite (Seebeck et al., 2011; Bern, 2015). The expression of 
TcrNT2 in L. mexicana-Cas9ΔNT1 significantly sensitised the cells to 5-fluoro-2’-
deoxyuridine (pyrimidine analogue), therefore, it indicates to be a good 
substrate. This indicates that the application of anticancer and antiviral 
thymidine analogues against T. cruzi should be explored. Moreover, if 
researchers can understand the nutritional requirements of T. cruzi, and the 
mechanisms that are applied to meet this requirement, this will assist in the 
discovery as well as the advancement of novel chemotherapeutics against 
Chagas’ disease (Campagnaro et al., 2018b). As a result, individuals will lead a 
healthy life and there will be a reduction in mortality rate. 
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8 General discussion 
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Kinetoplastida is a widespread order of flagellated protozoans with the primary 
feature that defines it as a group of parasites being the presence of large regions 
of mitochondrial DNA referred to as the kinetoplast (Stuart et al., 2008). In this 
order, the respective members have been reported to have the potential of 
parasitising several groups of plants and every group of animal (Maslov et al., 
2001). Some of these kinetoplastida include Leishmania spp, which causes 
leishmaniasis; T. brucei, which causes sleeping sickness, or HAT (Human African 
trypanosomiasis); and T. cruzi, which causes Chagas’ disease, or American 
trypanosomiasis. The WHO has designated these insect-transmitted infections as 
neglected parasitic diseases (Maslov et al., 2001; Barrett and Croft, 2012; Field 
et al., 2017). Parasitic trypanosomatids cause diseases that range from mild and 
self-curing, to fatal if untreated. The WHO has channeled numerous efforts 
towards addressing this problem, but these diseases still pose a severe threat to 
public health and present economic burdens to the poorest areas globally (Field 
et al., 2017; Krishna et al., 2020). 
There are limited options available for treatment. These options are also quite 
far from ideal because of their ineffectiveness to different stages of the disease 
or strains/subspecies of the parasites, high cost, and inconvenient drug 
administration routes (Field et al., 2017; Barrett and Croft, 2012; Ranjbarian et 
al., 2017; Kalel et al., 2017; P De Koning, 2020). Currently, besides the toxicity 
that has been associated with the difficulty in administering antiparasitic drugs, 
both the emergence and spread of parasites that are resistant to the drugs have 
been reported. For instance, resistance to eflornitine in T. b. rhodesiense 
infections (Vincent et al., 2010) and melarsoprol (Delespaux and de Koning, 
2007; Graf et al., 2013) for late stage HAT, and pentavalent antimonials for 
leishmaniasis (Sundar et al., 2008) have been reported, further limiting 
treatment options. Regarding the recent approval of fexinidazole, the cross-
resistance between fexinidazole and nifurtimox is of potential concern as any 
strains that survive fexinidazole monotherapy will also likely cause NECT failure 
(P De Koning, 2020). With the pathogens increasingly becoming resistant to most 
of the drugs being used currently, there is an urgent need for new therapeutic 
strategies. The development of vaccines, proven as a powerful approach to the 
management of disease, continues to be challenging and ineffective when it 
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comes to the trypanosomatid diseases since these parasites have been found to 
suppress and evade the host’s immune mechanisms. Examples are antigenic 
variation in African trypanosomes (Horn, 2014), and the intracellular locations of 
T. cruzi and Leishmania spp in the human host (Cardoso et al., 2016). The 
primary control strategy recommended is vector control, which is performed 
through screens and traps in combinations with insecticides and pesticides; early 
detection and treatment are also important, particularly in Chagas disease and 
sleeping sickness (Lidani et al., 2019; Legros et al., 2002). 
Drug combinations have been used for the treatment of a number of infectious 
diseases (such as tuberculosis, HIV and malaria) and are now being considered 
for treatment of neglected diseases like leishmaniasis and HAT. There exist two 
critical reasons for the need to establish combination therapies, delaying the 
possibility of resistance emergence for the protection of the few molecules 
available, and reducing the treatment length for compliance improvement (for 
instance, the miltefosine regimen requires the intake of drugs for 4 weeks two 
times a day) (Leprohon et al., 2015; Chakravarty and Sundar, 2010; Croft et al., 
2006). A combination therapy serves to improve drug efficacy and consequently 
result in a shortened course of treatment and reduced resistance. When sodium 
stibogluconate is administered along with paromomycin, it reported as safe and 
effective (Cobo, 2014; Croft and Coombs, 2003). 
Purines and pyrimidines are nucleotides that are intracellularly phosphorylated 
and are specifically significant for the functioning of all cells (De Koning et al., 
2005; Carter et al., 2008). Their significance ranges from the synthesis of nucleic 
acids such as DNA and RNA kinetoplastid parasites to metabolic processes of 
eukaryotic and prokaryotic cells (Carter et al., 2008). In contrast to the majority 
of mammalian cells in, protozoan parasites cannot synthesise the purine rings 
and are dependent on salvage mechanisms for the acquisition of these essential 
nutrients. Conversely, most protozoan pathogens have the ability to synthesise 
the pyrimidine ring, apart from the amitochondriate parasites T. vaginalis, T. 
foetus, and G. lamblia. Apart from Plasdmidium, most protozoa can salvage 
pyrimidines (De Koning et al., 2005; Carter et al., 2008; Campagnaro and de 
Koning, 2020; Hulpia et al., 2020a). Since purine and pyrimidine nucleobases 
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and/or nucleosides have a hydrophilic profile, their movement into the cell 
relies on the transportation through transmembrane proteins (Molina-Arcas et 
al., 2009; Carter et al., 2008). 
Membrane transport proteins are vital for moving most drugs in and out of cells, 
meaning that they are special intermediaries in both therapy and drug 
resistance. Therefore, generating and characterising drug resistant lines offers 
valuable information on resistance mechanisms and could possibly be used for 
identifying new drug transporters. For instance, multi-drug resistant T. b. brucei 
line B48 was generated in vitro by exposure to stepwise increasing 
concentrations of pentamidine until these cells lost the transport activity 
associated with high affinity pentamidine transport (HAPT1) (Matovu et al., 
2003; Bridges et al., 2007). Recently, the HAPT1 activity was found to be 
encoded by the gene TbAQP2 (Baker et al., 2012; Munday et al., 2014) Moreover, 
the identification of the genes encoding for adenosine/pyrimidine transporter 
(NT1) and inosine and guanosine transporter (NT2) were discovered in the 
promastigote form of L. donovani, using the TUBA5 and FBD5 resistant cell lines 
that were generated in vitro by adaptation to 20 µM tubercidin and 1 µM 
formycin B, respectively. The gene believed to encode TgAT1 (Toxoplasma 
gondii adenosine transporter 1) was identified from an adenine arabinoside 
(AraA) resistant cell line and characterized by expression in Xenopus oocytes, 
confirming it as a low-affinity high-capacity adenosine transporter (Iovannisci et 
al., 1984; Aronow et al., 1987; Vasudevan et al., 1998; Chiang et al., 1999). Up 
to this moment, only ENT genes are identified as encoding purine and pyrimidine 
transporters in protozoans (De Koning et al., 2005; Campagnaro and de Koning, 
2020), however, the involvement of other gene families has been proposed 
(Bellofatto, 2007; De Koning, 2007; Campagnaro et al., 2018a; Balcazar et al., 
2017). 
The analogues of pyrimidine and purine are used as drugs in the treatment of 
different infections and diseases. There is the use of some of these analogues 
against protozoa (pyrimethamine, allopurinol), viruses (penciclovir, acyclovir, 
brivudin, ganciclovir and many others), and malignant cells (e.g. thioguanine, 6-
mercaptopurine, 5-fluorouracil) (de Koning and Diallinas, 2000; Razonable, 2011; 
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Momeni et al., 2002; Kolb, 1997). 5-fluorouracil (5-FU) is a fluoropyrimidine that 
is classified as an antimetabolite. It works by inhibiting biosynthetic processes 
and through incorporating itself to macromolecules such as DNA and RNA and 
disrupting their normal function (Longley et al., 2003). Because of its 
functionality and aromatic structure, which is heterocyclic in nature, 5-FU was 
used as a chemotherapeutic drug for cancer. The F atom found on C5 instead of 
an H atom, makes it a toxic analogue of uracil and thymine (Zhang et al., 2008a; 
Longley et al., 2003; Yssel et al., 2017). Fluorinated pyrimidines such as 5-FU, 5-
fluoroorotic acid, 5-fluoro-2’deoxy- (uridine or cytidine) and 5-chloro-
2’deoxyuridine displayed anti-trypanosomal activity in the micromolar range 
(Ali, 2013). Fluorinated pyrimidines have recently been reported as an 
innovative series of 5’-norcarbocyclic uridine analogues against L. mexicana and 
T. b. brucei, with some their compounds exhibiting similar activities against 
Leishmania and Trypanosoma, which consequently make them ideal leads for 
structure optimization (Alzahrani et al., 2017). 
While 5-FU is widely used to treat a wide array of cancers which include 
colorectal cancer and breast cancer (Longley et al., 2003), there is still need for 
a deeper understanding of how 5-FU induces cytotoxicity and cell death; not just 
in cancer cells but in protozoa such as T. b brucei as well as L. mexicana 
species. Munday et al. (2015) noted that drug resistance in protozoa such as T. b 
brucei is a result of changes to the ‘transportome’ of the parasites. 5-FU uses 
the same mechanism to enter cells as the uracil transport mechanism, and once 
in the cells, there is conversion of 5-FU to several active metabolites such as 5-
fluorodeoxyuridine monophosphate (5F-dUMP), 5-fluorodeoxyuridine 
triphosphate (5F-dUTP) and fluorouridine triphosphate (5F-UTP). 5F-dUTP and 
5F-UTP are incorporated into DNA and RNA and causes an impairment in their 
function and maturation. F-dUTP triggers DNA mutations considering that there 
is the pairing of 5-FU with guanine at the expense of adenine, and the cell’s 
attempts at repairs result in double or single breaks in the strand. .5F-dUMP is 
an inhibitor of thymidylate synthase that cannot be reversed; this causes a 
deprivation of thymidine monophosphate (TMP) deprivation that subsequently 
disrupts DNA synthesising. This means that the drugs bind to the protein 
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inhibiting irreversibly (Longley et al., 2003; Galmarini et al., 2002; Yssel et al., 
2017). 
5-FU was found to be an excellent substrate for all the kinetoplastid uracil 
transporters; LmexU1 in L. mexicana and LmajU1 in L. major (Papageorgiou et 
al., 2005; Alzahrani et al., 2017) as well as TbU1 in T. b. brucei PCF and TbU3 in 
T. b. brucei BSF (de Koning and Jarvis, 1998; Ali et al., 2013a; Campagnaro and 
de Koning, 2020). Therefore, it may be possible to develop a new chemotherapy 
for kinetoplastid parasites based on the efficiency of 5-FU against Leishmania 
and Trypanosoma species in vitro (Gudin et al., 2006; Papageorgiou et al., 
2005), although host toxicity of this antimetabolite might be a limiting factor. 
Unlike the transporters for the therapeutically active nucleoside analogues and 
allopurinol, the transporter for 5-FU has not been identified. However, by the 
method of exclusion, it can concluded that the 5-FU transporter in Trypanosoma 
and Leishmania species is not an ENT transporter, as all their ENT transporters 
have been cloned and at least partially characterised (De Koning, 2007; Ali et 
al., 2013a; Campagnaro and de Koning, 2020). 
As such, we are highly interested in identifying the pyrimidine transporter gene 
family of kinetoplastids using the antimetabolite 5-FU as a probe, which we 
anticipate will not be of a gene family previously associated with this activity 
(Domin et al., 1993; de Koning and Diallinas, 2000; De Koning, 2007; Bellofatto, 
2007). For that reason, resistance to 5-FU was generated in both T. b. 
brucei s427-WT BSF and L. mexicana promastigotes, producing clonal lines Tbb-
5FURes and Lmex-5FURes, respectively (Ali et al., 2013a; Alzahrani et al., 2017). 
Uracil/5-FU transport rates in these cell lines are strongly reduced, particularly 
in the L. mexicana cell line. 
The fast identification of transporters and new pathways is facilitated by the 
current genomic technologies, particularly in the protozoan parasites for which 
these techniques are most advanced. Multiple lines of investigation have been 
followed to date to try to identify the gene(s) coding for kinetoplastid 
pyrimidine transporters. The BLAST searches for pyrimidine transporter genes 
using fungal, yeast and prokaryote sequences have, until this day, not produced 
a single candidate gene from any of the available protozoan genomes, leading us 
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to conclude that no genes can be identified by homology to known pyrimidine 
transporter genes. Therefore, previous work in our laboratory undertook whole 
genome sequencing, RNA-seq and RIT-seq as a way of finding the pyrimidine 
transporter genes of T. b. brucei and L. mexicana promastigotes (Ali, 2013; 
Alzahrani, 2017). 
RNA sequencing (RNA-seq) is considered to be a powerful technique, utilisasing 
deep-sequencing technologies in sequencing RNA for the determination of 
differential gene expression under different environmental and physiological 
conditions (Wang et al., 2009; Kukurba and Montgomery, 2015). Siegel et al. 
(2010)  showed that there was differential expression of 6% of genes in T. b. 
brucei between the two stages of life cycle (BSF and PCF) using RNA-seq. 
Therefore, comparative sequencing of the resistant and parental strains through 
the use of RNA-seq in the analysis of the differences in transcription within 
resistant and sensitive parasites was carried out with the aim of identifying the 
pyrimidine transporter genes. From RNA-seq data, the aim was to find the down-
regulated genes both in the resistant lines of L. mexicana and T. b. brucei that 
constituted of at least three trans-membrane domains. Such candidate 
transporters were subsequently overexpressed in the resistant strain to allow a 
fast confirmation by resistance reversal. 
A very strong technique for genetic screens for genes to be linked to function 
and precise phenotypes, where knockdown confers resistant populations, is the 
genome-wide RNA interference (RNAi) library screen. The first organism utilised 
in the application of this technique is T. b. brucei PCF (Alsford et al., 2012; Mohr 
and Perrimon, 2012; Chou et al., 2015; Morris et al., 2002). The utilisation of 
RNAi library screening helped to identify novel trypanosomal drug transporters in 
the last few years, including TbAQP2 as a determinant of pentamidine sensitivity  
(Baker et al., 2012; Munday et al., 2014), the aminopurine transporter TbAT1 as 
the carrier for melarsoprol (Burkard et al., 2011) and amino acid transporter 
TbAAT6 as the carrier for eflornithine (Baker et al., 2011; Burkard et al., 2011). 
RNA-seq results show that three CAT transporters were significantly down-
regulated in the Tbb-5FURes strain (Alzahrani, 2017). However, in chapter 3 of 
this thesis it is shown show that there was no significant difference in the 
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sensitivity to 5-FU and 6-AU pyrimidine analogues and uracil transport through a 
single knockout of the Tbb CAT1-4 genes in T. b. brucei BSF s427-WT, although 
mRNA levels in some sKO clones was halved. We also showed that the transport 
rate of [3H]-uracil in Tbb-5FURes was only partly reduced from the wild-type 
levels, as it entails the problem of high background generated by transport via 
TbU3. However, this outcome does not mean that Tbb-CAT1-4 genes are not 
involved in the 5-FU sensitivity or transport, for the reason that the first allele 
of these genes was deleted while the second allele still exists in the genome of 
hemizygous knockout cells. Unfortunately, we were unable to make a full double 
knockout for the Tbb-CAT1-4 genes, as this led to the death of the cells, showing 
that their function is essential for the growth of the T. b. brucei. Also, Alzahrani 
(2017) proved that the genes encoding CATs are essential for the viability of T. 
b. brucei BSF cells, as RNAi-mediated the downregulation of Tbb-Cation1-4 
genes showed that the genes are essential for the survival of T. b. brucei BSF, a 
severe growth defect noticed after inducing expression of the RNAi construct 
with tetracycline. The potential utility of this system is the investigation of the 
connection between the uptake of uracil/5-FU and Tbb-CAT1-4 proteins within 
the T. brucei.According to a Pfam analysis (https://pfam.xfam.org) Tbb-CAT1-4 
protein can be part of the Zip Zinc transporter family (PF02535). Thus, it is 
possible that the double knockout effect of the Tbb-CAT1-4 genes would disrupt 
intracellular ion distribution in T. brucei. Consequently, it is possible that these 
CATs are belong to Zip zinc transporter family, and iron ions are very important 
in mitochondrial metabolism, as they are essential to the function of 
cytochromes and of Trypanosome Alternative Oxidase (TAO) (Saimoto et al., 
2013; Shiba et al., 2013). However, this appears to rule out the possible 
involvement of CAT transporters in uracil uptake as we have reason to believe 
that the uracil/5-FU transporters are not essential when it comes to T. b. brucei 
and L. mexicana parasites although they are important when it comes to 5-FU 
anti-protozoal activity (Alzahrani et al., 2017). We firmly believed that the 
pyrimidine transporter gene is not likely to be essential in T. b. brucei BSF 
because of the following two reasons. 1) The ability of pyrimidine prototrophic 
T. b. brucei cells to grow in pyrimidine-free HMI-9 media (Ali et al., 2013b). 2) 
There was a reduction of [3H]-5-FU uptake rate by greater than 65% when T. b. 
brucei WT adapted to high levels of 5-FU (Tbb-5FURes) (Ali et al., 2013a). 
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Additionally, a similar experiment was done using L. mexicana promastigotes 
almost completely eliminated (94.5%) [3H]-5-FU transport in the Lmex-5FURes 
(Alzahrani et al., 2017), demonstrating that the uracil/5-FU transporters are 
non-essential in this organism. 
Another class of genes highlighted in the 5-FU resistance analyses leading up to 
the work reported in this thesis are the fatty acid desaturases (FADs). FADs are 
categorized into three classes observed in Kinetoplastid parasites. The first class 
is Delta ‘Δ’ desaturases, which introduces the double-bond x-carbons from the 
carboxyl end. The second class is Omega ‘ω,’ which comprises of enzymes that 
introduce double-bond x-carbons from the methyl end. The third class is Chi and 
nu ‘v + x’ desaturases, which add double-bond x-carbons from the existing 
double bond (Alloatti and Uttaro, 2011; Petrini et al., 2004). L. mexicana and T. 
brucei cells have the ability of taking up lipids from the host environments 
through the receptor-mediated endocytosis of lipoproteins or transportation of 
protein-bound fatty acid. In addition they have the ability to synthesize their 
own fatty acids de novo via mitochondrial type II (prokaryotic-type) pathways 
(Smith and Bütikofer, 2010; Zhang and Beverley, 2010). 
RNA-seq and RIT-seq data revealed FAD as one of the most prominent hits to be 
linked to 5-FU resistance in T. b. brucei BSF. Tbb-FAD gene showed significant 
decreases in the transcription in Tbb-5FURes with a log2 fold-change of -0.68 (P 
≤ 0.01)  (Ali, 2013; Alzahrani, 2017). Moreover, RNA-seq also showed that FAD is 
an interesting hit also connected to 5-FU resistance in L. mexicana 
promastigotes. Lmex-FAD gene was downregulated in the Lmex-5FURes with a 
Log2 fold-change of -0.32 (P ≤ 0.01) (Alzahrani, 2017). The results in chapter 4 
show that overexpression of the Tbb-FAD gene in Tbb-5FURes and Lmex-FAD 
gene in Lmex-5FURes do not cause an increase in the sensitivity to 5-FU in vitro 
as well as did not change the transport rate of [3H]-uracil. Therefore, it is still 
not clear how FAD determines sensitivity to pyrimidine nucleobases or transport 
in L. mexicana and T. b. brucei. However, while it is clear that the regular 
expression of the FAD gene is not limiting the sensitivity to 5-FU, it appears that 
a strong reduction in expression may cause resistance, hence the observation 
that overexpression did not change susceptibility to 5-FU, but RNAi-mediated 
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downregulation (RITseq) did. If time had allowed, we recommend functional 
characterisation of Tbb-FAD gene in T. brucei using RNAi technique to study FAD 
knockdown phenotypes. We also recommend tagging Tbb-FAD gene with GFP and 
transfecting the tagged gene in T. brucei. Then, immunofluorescence assay 
could be performed to determine the localization of the protein. 
It has been determined that uracil transporter mutants are resistant to 5-FU in 
several instances (Palmer et al., 1975; Jund et al., 1977; Andersen et al., 1995; 
Amillis et al., 2007; Stoffer-Bittner et al., 2018). For instance, it has been 
identified by previous studies that deleting the uracil transporter FurD from A. 
nidulans is responsible for contributing to full resistance to 5-FU and a reduced 
uptake rate of [3H]-uracil (Amillis et al., 2007). However, protozoan genomes do 
not contain any FurD homologues and the uptake of uracil is required to be 
mediated by a transporter from different gene families. For that reason, we 
functionally expressed FurD in the 5-FU resistant cell lines (Tbb-5FURes and 
Lmex-5FURes) in order to investigate whether the sensitivity to 5-FU in vitro 
resistant strains could be restored by the introduction of a confirmed uracil/5-
FU transporter. This would allow a functional screening of potential transporter 
genes. 
We found no significant differences in the EC50 values of 5-FU of resistant and 
expressing cell lines. It was, however, revealed that the expression of FurD in 
Lmex-5FURes caused high levels of [3H]-5FU/uracil uptake, to a level that is 
considerably above the wild type activity. We characterised the transport 
activity of FurD in Lmex-5FURes promastigotes and found FurD to be a highly 
selective and high-affinity transporter for uracil, as originally reported in 
Aspergillus nidulans (Amillis et al., 2007), and confirmed that 5-FU was also a 
good substrate for FurD. As the resistance was induced, stepwise, to a very high 
concentration of 5-FU in Lmex-5FURes, it is possible that the cells developed 
defects in both the uptake and the metabolism of the 5-FU, making them fully 
resistant to 5-FU, whether it enters the cells or not. Therefore, a metabolic 
adaptation appears to have rendered the Lmex-5FURes cells insensitive to 
intracellular 5-FU. Therefore, we highly recommended to assess the metabolism 
of 5-FU, using metabolomic assessments of L. mexicana clonal lines adapted to 
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high concentrations of 5-FU, the sensitive L. mexicana-WT and 5-FU resistant 
cell lines expressing FurD. 
Many Trypanosoma and Leishmania protists including L. mexicana and T. brucei 
species, possess hexose transporters that are related in sequence to the 
mammalian GLUT1, an equilibrative glucose transporter and is a member of the 
major facilitator superfamily (MFS) (Dean et al., 2014; Deng et al., 2014). In L. 
mexicana, three transport proteins are designated to transport hexoses such as 
glucose, ribose, and amino sugars. These permeases are LmexGT1, LmexGT2 and 
LmexGT3 and while they close related, they differ in functionality and biological 
properties, including aspects such as differential localisation, substrate 
specificity, and developmental stage expression (Burchmore et al., 2003a; 
Rodriguez-Contreras et al., 2007). 
In comparison to LmexGT2 and LmexGT3, LmexGT1 displays a lower affinity 
towards hexoses and serves only as a signal transducer and glucose sensor. 
LmexGT1 functions by promoting the transition from the exponential phase of 
growth to the stationary phase when there is low glucose level, and is thus is 
needed in the survival and adaptation of the promastigote (Akpunarlieva and 
Burchmore, 2017). In contrast, LmexGT2 and LmexGT3 are high affinity hexose 
permeases specifically localized on the plasma membrane (Akpunarlieva and 
Burchmore, 2017). LmexGT1, LmexGT2 and LmexGT3 belong to the SLC2 or 
GLUT transporter family (Pereira and Silber, 2012; Augustin, 2010). 
One of the most striking results to emerge from our data is that glucose 
transporter genes showed up in both our RNA-seq and RIT-seq data. 
Determination of sensitivity of glucose transporter genes to 5-FU was achieved 
by a full knockout of these genes in L. mexicana (Burchmore et al., 2003a). This 
revealed a significant reduction in the sensitivity of the LmexGT1-3 double 
knockout to 5-FU when compared to the wild type cell lines. The result also 
showed that there is no longer any accumulation of 5-FU and uracil by the Lmex-
GT1-3 KO cells. Yet, there were no measurable effects of uracil and 5-FU on the 
transportation of glucose by LmexGT1, LmexGT2, and LmexGT3. 
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Although, there was a significant increase in the sensitivity to 5-FU from the re-
expression of individual LmexGT transporters in Lmex-GT1-3 KO cells, ultimately 
the results of our study indicate that uracil/5-FU and glucose do not share the 
same transporters. Considering that both 5-FU and uracil are pyrimidines, it 
could be speculated that the metabolism of glucose regulates the uptake of 
uracil and 5-FU, as the pathways overlap in the process of glycosylation (e.g. 
UDP-glucose, UDP-galactose and UDP-N-acetylglucosamine) and/or lipid 
biosynthesis (CDP-ethanolamine, CDP-choline). However, the presence of 
glucose in the medium did not affect the uptake rate of uracil or 5-FU, or 
sensitivity to 5-FU, so we are left with the conclusion that although the presence 
of glucose transporters is essential for uracil uptake in Leishmania, the uptake of 
glucose is not. The mechanism for this is currently unclear but could conceivably 
be related to a complexing of different membrane proteins including LmexGTs, 
necessary to enable uracil transport. 
The possibility of the use of L. mexicana-Cas9ΔNT1 promastigotes as surrogate 
systems for expressing TcrNB2 and TcrNT2 transporters of T. cruzi was also 
tested. We found TcrNT2 to be a high-affinity thymidine transporter, confirming 
and elaborating on the results obtained by former phD student Gustavo 
Campagnaro (Campagnaro et al., 2018b). TcrNT2 transporter is the only known 
dedicated thymidine transporter in protozoa described to date. It was not 
possible to perform the biochemical characterization of TcrNB2, however, 
although it had structural and sequence similarities to the Leishmania NT4 
transporters, indicating that it might possibly be a low-affinity purine 
transporter (Ortiz et al., 2009a; Campagnaro et al., 2018b). The high level of 
adenine transport in L. mexicana-Cas9ΔNT1 cells could easily have masked any 
adenine uptake mediated by the TcrNB2 transporter, especially if TcrNB2 
presents low affinity for its substrates. Thus, we highly recommend the 
heterologous expression of TcrNB2 in L. mexicana-Cas9ΔNT3 cell lines in order to 
determine whether adenine is a substrate for TcrNB2. The expression of a tagged 
version of TcrNB2 and its immunolocalization could show whether it is present in 
the cellular membrane or not and help to explain why we have been unable to 
identify its substrate. 
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To date, the gene family responsible for the encoding of pyrimidine transporters 
in kinetoplast parasites has not been discovered. In the dataset of RNA-seq and 
RIT-seq experiments, the reverse genetic validation of top hits has not yet 
resulted in the identification of the protozoan pyrimidine transporter genes 
(PPTs) in Trypanosoma and Leishmania species. Though there is still need for 
much to be done, good progress has been achieved when it comes to identifying 
the PPTs. The identification of these genes will serve to improve the 
understanding of nutrient and drug transporters as well as increase the insights 
into nucleotide metabolism and pyrimidine salvage processes of kinetoplast 
parasites. Finally, the knowledge obtained herein will be of importance in 
providing a foundation for conducting further studies on the developing and 
complex universe that pertains to the nutrient transporters of protozoa. 
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Appendices 
Appendix 1: Preparation of culture medium. 
A) Standard HMI-9 Media  
1 tub HMI-9 powder 
15 g NaHCO3 
4.5 L ddH2O (+ more to 5 L) 
71.5 µL 13.4M β-mercaptoethanol 
HCl / NaOH 
1. Put tub of HMI-9 powder into 5 L flask, add 15 g NaHCO3.   
2. Add 4.5 L of ddH2O, rinsing out tub with some of the water. 
3. Add 71.5 µL 13.4 M β-mercaptoethanol 
4. Stir flask overnight in coldroom. 
5. Add 1 bottle of 500 mL of Heat Inactivated Fetal Bovine Serum(FBS) 
6. Adjust the pH to 7.4 
7. Filter sterilise through 0.22 µm filter units, into sterile bottles 
8. Store in cold room 4°C. 
B) SDM 79 without glucose media 
Compounds For 1 Liter 
NaH2PO4 157 mg 
NaCl 6.8 g 
MgSO4 100 mg 
KCl 400 mg 
CaCl2 200 mg 
L-Arginine 100 mg 
L-Methionine 70 mg 
L-Phenylalanine 80 mg 
L-Threonine 350 mg 
L-proline 600 mg 
L-Tyrosine 100 mg 
Taurine 160 mg 
L-Alanine 200 mg 
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L-Asparagine 13,2 mg 
L-Aspartate 13.3 mg 
L-Glutamate 14.7 mg 
L-Glutamine 200 mg 
Glycine 7.5 mg 
L.Serine 60 mg 
HEPES 8 g 
MOPS 5 g 
NaHCO3 2.2 g 
Pyruvate 220 mg 
Mercatoethanol 0.1 M 2 mL 
Hypoxanthine 14 mg 
Thymidine 4 mg 
Vitamins 100 X 10 mL 
Essential amino acids 50 X 20 mL 
Phenol Red 4 mL 
Hemin (2.5 mg/mL) 2mL 
Add 50 mL of Heat Inactivated Fetal Bovine Serum (FBS). Make up to 1 Liter. 
Adjust the pH to 7.4. Filter sterilise through 0.22 µm filter units, into sterile 
bottles. Store in cold room 4°C. 
C) HOMEM without glucose media 
Compounds For 5 Liter 
SOD DIHYD PHOS 2H2O EP 7.9 g 
MAG SULPHATE 7H2O EP 1 g 
SODIUM CHLORIDE EP 34 g 
POTASSIUM CHLORIDE EP 2 g 
SODIUM PYRUVATE 0.55 g 
MEM A/A (x50) 150 mL 
200mM L-GLUTAMINE (x100) 50 mL 
MEM NEAA (x100) 50 mL 
MEM VIT (x100) 50 mL 
D-BIOTIN EP 0.0005 g 
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P-AMINOBENZOIC ACID 0.005 g 
PHENOL RED NA SALT 0.05 g 
HEPES  29.7875 g 
SODIUM BICARBONATE EP 1.5 g 
Add 500 mL of Heat Inactivated Fetal Bovine Serum (FBS). Make up to 5 Liter. 
Adjust the pH to 7.4. Filter sterilise through 0.22 µm filter units, into sterile 
bottles. Store in cold room 4°C. 
Appendix 2: Prepration of general buffers and solutions. 
A) Luria Bertani (LB) broth (pH 7) 
LB powder (Sigma-Aldrich) 12.5 g 
Distilled water  500 mL 
B) LB Agar 
Luria Agar (Sigma-Aldrich) 17.5 g 
Distilled water  500 mL 
C) Cytomex buffer (pH 7.6) 
KCl 120 mM 
HEPES pH 7.6 25 mM 
MgCl2.6H2O 5 mM 
K2HPO4/KH2PO4 pH 7.6 10 mM 
EGTA pH 7.6 2 mM 
CaCl2 150 µM 
Glucose 0.5% 
Albumin, bovine serum 100 µg/mL 
Hypoxanthine 1 mM 
Appendix 3: Transformation of XL1 blue E. coli cells with plasmid DNA 
1. Defrost aliquot of XL1 blue cells on ice. 
2. Put 5 µL of ligation into Eppendorf tube. 
3. Add 50 µL of XL1 blue cells. 
4. Incubate on ice for 30 min. 
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5. Heat shock at 42°C for 45 s. 
6. Incubate on ice for 2 min. 
7. Add 100 µL SOC media or LB broth. 
8. Incubate at 37°C for one hour with shaking. 
9. Spread cells on LB agar containing ampicillin (100 µg/mL). 
10. Incubate at 37°C overnight. 




Ibrahim Abdullah Alfayez                          Appendices                                   265 
     
Appendix 5: The multiple sequence alignment result of the Tbb-CAT1, Tbb-
CAT2, Tbb-CAT3 and Tbb-CAT4. Alignments were performed using CLC Genomics 
Workbench version 7.0 software package. 
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Appendix 6: Kinetoplastid Tbb-FAD and Lmex-FAD genes sequence alignment. 
Alignments were performed using CLC Genomics Workbench version 7.0 software 
package. 
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Appendix 7: Amino acid sequence alignment of the four different uracil 
transporters in A. nidulans, S. cerevisiae, E. coli and P. larvae organisms. 
Alignments were performed using CLC Genomics Workbench version 7.0 software 
package. 
 
Ibrahim Abdullah Alfayez                          Appendices                                   268 
     
Appendix 8: The amino acid sequences alignment of three glucose transporter 
genes (LmexGT1, LmexGT2 and LmexGT3) in L. mexicana promastigotes. 
Alignments were performed using CLC Genomics Workbench version 7.0 software 
package. 
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Appendix 9: The multiple sequence alignment result of the NT1.1 and NT1.2 
genes in L. mexicana promastigotes. Alignments were performed using CLC 
Genomics Workbench version 7.0 software package. 
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